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Thesis title: Data sharing and transparency: the impact on evidence synthesis 
Introduction and aims 
The use of individual participant data (IPD) for evidence synthesis is widely regarded as the 
‘gold standard’ approach to analysis, in particular for clinical outcomes of a ‘time to event’ 
(TTE) nature. However, the undertaking of IPD syntheses can be methodologically complex, 
time consuming and open to sources of bias if not conducted rigorously.  
The aim of this thesis is to investigate and document the practical aspects and challenges of 
conducting IPD syntheses. Such challenges are of particular relevance in the current research 
environment with changing functionalities of and attitudes towards data sharing.  
Methods 
This thesis reports two novel systematic reviews regarding the reporting of aggregate TTE 
outcomes and analyses in epilepsy monotherapy trials published to 2012 and regarding data 
retrieval rates and characteristics associated with a high proportion of data retrieved for all 
published IPD meta-analyses (IPD-MAs) from 1987 to 2015. This thesis also presents the 
results of an IPD-network meta-analysis (NMA) of antiepileptic drug therapy including 
detailed documentation of the statistical methodology of the IPD-NMA, IPD requesting and 
preparation processes, and methods for incorporating summary statistics with IPD for NMA. 
Results 
The first systematic review of reporting in epilepsy monotherapy trials showed concerning 
reporting inadequacies relating to definitions, analysis and reporting of TTE outcomes in 
these trials, suggesting that an IPD approach synthesis is the only feasible option for this 
topic. The systematic review of 760 published IPD-MAs using systematic methods to identify 
eligible studies showed that only 25% of these IPD-MAs have had access to all IPD and that 
IPD-MAs that included only randomised trials, had an authorship policy, included fewer 
eligible participants and were conducted outside of the Cochrane Database of Systematic 
Reviews were associated with a high or complete IPD retrieval rate.  
IPD was provided for a total of 12,391 out of a total of 17,961 eligible participants (69% of 
total data) from 36 out of the 77 eligible trials (47%) for the IPD-NMA of antiepileptic drug 
therapy. This reflects a decline in the IPD retrieval rate from requests made by the Cochrane 
Epilepsy Group from 1995-2005 to requests made in 2012-2015. 
A range of methodological approaches to modelling the relationship between treatment-
effect and epilepsy type within the NMA and for including AD with IPD in NMA show that 
incorporation of the small amount of additional AD available with the IPD in NMA had a 
negligible impact on results. However, the methodological approach to the relationship 
between treatment and epilepsy type did impact on numerical results and conclusions.  
Conclusions 
The work of this thesis has provided a detailed insight into the conduct of an IPD-NMA in 
epilepsy and highlighted many inadequacies of the conduct and reporting of AD and IPD 
syntheses across a wide range of clinical disciplines.  The work of this thesis was undertaken 
during a time of great change within the research community regarding how clinical trial data 
is shared for secondary research and has identified some of the early benefits and 
importantly challenges and restrictions of new methods of sharing clinical trial data. Unless 
emerging limitations are addressed with urgency, new methods of data sharing, intended to 
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Chapter 1: Introduction 
1.1  Evidence synthesis 
Evidence synthesis is a general term used to describe techniques to combine sources of 
quantitative evidence. The formulation of the research question of interest in a clinical 
setting for any evidence synthesis requires careful attention; a research question must be 
specific enough for results to be clinically useful but not too specific so that inadequate 
amounts of evidence are available [1]. A commonly applied analogy to this decision is the 
choice of whether to ‘lump’ or to ‘split’ [2]; in other words, whether to take a broad approach 
to a wide variety of settings and participant groups or whether to narrow a research question 
into a homogenous evidence base [3].  
In a clinical setting, where interventions and treatment effects are of interest, clinical 
assumptions underlying a synthesis must be considered as closely as statistical assumptions 
[4]. It is unlikely that a treatment effect would be replicated exactly in two clinical studies 
due to variations in participant populations and settings. However if an intervention does 
provide true benefit over another then one would expect the direction of effect to be the 
same in a range of heterogeneous situations [5]. This true direction of treatment effect is 
more likely to stand out in a synthesis when a number of studies are considered together. 
The techniques of evidence synthesis of relevance to this thesis are systematic review, meta-
analysis and network meta-analysis which are introduced in the following sections. 
1.1.1 Systematic reviews and meta - analysis   
Systematic reviews are commonly used as a means of summarising the results of all 
independent sources of evidence which address the same or similar questions in a systematic 
way [6, 7]. Systematic reviews of randomised controlled trials are widely accepted to provide 
the highest quality inferences in evidence based medicine [8]. However the quality of a 
systematic review or any synthesis is dependent on the completeness of the evidence [1].  
Meta-analysis is a statistical technique used to synthesise the results of each study included 
in the systematic review to obtain a single pooled result which gives an overall relative 
treatment effect of one treatment to another [9]. The application of this technique increases 
sample size and may increase precision and power, minimising the likelihood of a chance 
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result and providing more information regarding treatment effects which single studies do 
not have the power to detect [7, 10]. 
In general terms, meta-analyses can be performed with fixed-effects assuming a baseline risk 
of 𝜇𝑖  and a common fixed underlying treatment effect 𝛿 across all 𝑖 studies and within-study 
error 𝜀𝑖   or with random-effects assuming the same baseline risk 𝜇𝑖  and within-study error 𝜀𝑖  
of the fixed-effects model but random systematic differences 𝛿𝑖  in between trial results due 
to study heterogeneity 𝜏2. In other words, pooled treatment effect 𝑌 can be estimated as:  
Fixed-effects:   𝑌 = 𝜇𝑖 + 𝛿 + 𝜀𝑖    (Equation 1) 
Random-effects   𝑌 = 𝜇𝑖 + 𝛿𝑖 + 𝜀𝑖  𝛿𝑖~(𝛿, 𝜏
2)  (Equation 2) 
where 𝛿𝑖  is sampled from a distribution with mean 𝛿  and variance 𝜏
2 . A comprehensive 
guide to meta-analytic methods for different data types and in both Frequentist and Bayesian 
settings is provided by Sutton et al [11]. 
Origins of heterogeneity in meta-analysis include variation in  study design and methodology, 
clinical settings and participant characteristics including baseline risk between trials within 
the meta-analysis leading to variation in sampling error [11, 12]. More specifically, within a 
time-to-event context (see Chapter 1.1.4 for further details of time-to-event data), sources 
of heterogeneity include time-dependent (non-constant) treatment effects and variation in 
length of follow-up time across trials [13]. 
1.1.2  Indirect comparisons and network meta - analysis   
The framework of a traditional ‘pairwise’ meta-analysis can consider only two interventions 
(or classes of interventions) head-to-head. However, within clinical settings for which a large 
range of intervention options are available, some of which may never have been compared 
directly in a clinical trial, pairwise meta-analysis cannot provide an adequate estimate of the 
relative effectiveness of all interventions of interest to aid medical decision making [14]. 
Network meta-analysis (also referred to a multiple treatment meta-analysis or mixed 
treatment comparison; referred to as ‘network meta-analysis’ (NMA) herein for consistency 
of terminology) provides a framework for the synthesis of direct evidence for interventions 
A and B from their head-to-head comparison within clinical trials and indirect evidence for 
the same interventions A and B deduced via a direct comparison to a common intervention 






Figure 1: Direct and indirect evidence from the network of interventions A, B and C 
In other words, if 𝑌𝐴𝐶
𝐷   and 𝑌𝐵𝐶
𝐷   denote the pooled estimates from the synthesis (via fixed or 
random-effects analyses) of all direct evidence of A versus C and B versus C respectively, the 
indirect estimate for A versus B (𝑌𝐴𝐵




𝐷    (Equation 3) 
An additional benefit of indirect comparison under the framework of a connected ‘network’ 
of interventions, such that each intervention in the network has been compared to at least 
one other intervention in the network directly, is that an estimate for every pairwise 
comparison within the network can be calculated via a combination of direct and indirect 
evidence without the necessity for a common ‘control’ intervention (e.g. direct evidence for 
each intervention versus placebo) across all trials [16, 17]. 
Indirect comparisons are also valuable where a limited amount of data is available to inform 
a direct comparison or where evidence informing a direct comparison is of poor 
methodological quality. The power and precision of a treatment effect estimate can be 
increased by “borrowing strength” from the indirect evidence within the network [15]. 
An underlying assumption of indirect comparisons and NMA is that any intervention effect is 
‘exchangeable’ across all included trials [14]; in other words, the indirect comparison 
between two interventions is a feasible one to make (known as the transitivity assumption) 
and that the indirect evidence is consistent with the direct evidence where a comparison 
exists (known as the consistency assumption). Transitivity requires that all treatments are 
“jointly randomisable;” in other words, all interventions within a network could feasibly be 
randomised in the same trial and those which are not treatment arms in any given trial are 
“missing at random”[17]. Such an assumption cannot be formally tested statistically; 
transitivity must be judged by careful consideration of trial settings and characteristics, 
treatment mechanisms and participant demographics to investigate if any differences would 













The consistency assumption can be evaluated statistically over a closed ‘loop of evidence’ 
where both direct and indirect evidence exists for a comparison. Inconsistency may be 
present in NMA for a number of reasons [18]; a common source of inconsistency is thought 
to be an imbalance in treatment effect modifiers across comparisons as randomisation does 
not hold across a network of studies [19, 20]. Inclusion of treatment-covariate interaction 
terms within NMA models may reduce this confounding bias and in turn reduce inconsistency 
within the network [19-21]. 
Further statistical concepts and models for NMA, including models to account for 
inconsistency are discussed in Salanti et al [3] and Efthimiou et al [18].  
1.1.3  Aggregate data and individual participant data synthesis 
The most common approach to quantitative synthesis is undertaken using aggregate data 
(AD); an approach where summary statistics such as mean differences, event counts, risk 
ratios, odds ratios, hazard ratios etc. are extracted from published literature and can be 
supplemented with unpublished information provided by the original trialists. 
The alternative approach, an individual participant data (IPD) analysis, where participant-
level data containing detailed demographic, baseline and outcome data is retrieved and re-
analysed, is widely regarded as the gold standard approach to the synthesis of study results 
[22, 23]. Analysis of participant-level data has many advantages over traditional AD meta-
analysis (AD-MA); allowing a more standardised, comprehensive and potentially more 
methodologically complex approach to target clinical questions within participant subgroups 
via treatment-covariate interactions [24, 25]. Theoretically, an IPD approach should also 
reduce publication, reporting and ecological biases often associated with AD-MA [26-28]. IPD 
meta-analyses (IPD-MAs) have been shown to directly influence the design and conduct of 
clinical trials [29] and in some contexts to impact upon clinical practice guidelines [30].  
Furthermore in some settings, particularly where the necessary published information to 
perform AD-MA is not reported or is reported inconsistently [6, 31], a re-analysis of IPD may 
be the only feasible approach to synthesis (see Chapter 3 for further discussion).  
IPD syntheses have been performed since the 1980s [23], with most early IPD-MAs limited in 
their statistical methodology to estimation of overall treatment effect [32]. Recent years 
have shown a sharp increase in the number of IPD-MAs [33-35], with an average of 49 
published per year between 2005 and 2009 [34] and  recent estimates suggest an increase 
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of around four published IPD-MAs per year [35]. Development of methodology for the 
synthesis of IPD has also increased [36].  For example, in addition to models for the 
estimation of overall treatment effect with and without treatment covariate interactions 
[24], methodology is now available to explore heterogeneity within and between studies 
[37], examine within-study and across-study associations[25], to combine IPD with AD [38-
41] and to perform prognostic or diagnostic modelling [42]. 
AD-MA make up the vast majority of the meta-analysis literature. Previous work has 
indicated that up to 2004, less than 10% of published meta-analyses per year used IPD (in 
fact, for most years the figure was less than 5%) [43]. An IPD approach is also still relatively 
rare within NMA compared to an AD approach [18, 19, 44-48]. A basic MEDLINE search 
conducted in August 2016 by SJN found that out of 71539 records indexed as ‘meta-analysis,’ 
only 1073 (1.5%) included ‘individual patient data’ or ‘individual participant data’ from a title, 
abstract and keyword search. This figure should be treated as approximate; but it does imply 
that up to 2016, despite the increase in the number of published IPD-MAs, such an approach 
is still only used in a very small proportion of the meta-analysis literature. 
The aim of any systematic synthesis is to obtain all relevant information from all eligible 
participants. However in practice for an IPD approach to synthesis, retrieving all participant 
data can require a considerable amount of time, cost and personnel and can be 
computationally intensive in the case of large individual participant datasets [22, 49]. 
Furthermore, statistical expertise will often be required to perform more methodologically 
complex analyses proposed in IPD-MAs. Lack of time, resources and statistical expertise may 
explain the apparent preference for an AD approach to meta-analysis over an IPD approach; 
interface based meta-analysis software, such as Review Manager from the Cochrane 
Collaboration [50], facilitates AD-MA techniques for non-statisticians while undertaking an 
IPD-MA is likely to require some level of statistical programming.  
Additionally, retrieval of all relevant data is not always possible. IPD may have been 
destroyed or lost, trialists may be unwilling to collaborate due to confidentiality of data etc. 
and only a proportion of IPD is available for re-analysis. Synthesis with published AD may be 
required for a complete analysis or studies may have to be excluded from synthesis entirely 
[38-40, 44-46, 51]. Conversely, combining IPD with AD estimates in a synthesis may not be 
deemed acceptable to trialists who put in effort to provide IPD [22], but excluding studies 
which do not provide IPD violates a major assumption of systematic syntheses that all 
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relevant evidence has been included. Further discussion of retrieval of IPD for evidence 
synthesis and the impact of missing IPD on analysis is described in Chapters 4 to 7. 
Previous work has demonstrated that meta-analyses based on aggregated results from 
published literature can give different results to meta-analysis using IPD from the same 
studies [23, 43, 52-54]. IPD and AD approaches to meta-analysis, when based on identical 
data from homogeneous studies, should produce theoretically identical results [55, 56], 
however it is unlikely the data used for each approach would be identical and factors 
contributing to any observed differences in results are publication bias, patient exclusions, 
length of follow-up and method of analysis. Conclusions of previous work recommend that if 
IPD-MA and AD-MA can be shown to be mathematically equivalent, and adequate AD is 
available, the resource savings associated with an AD-MA would make this the approach of 
choice [52, 53], but in all other settings, wherever possible an IPD approach is favourable and 
will provide the least biased and most reliable means of addressing the clinical question [23]. 
1.1.4  Time-to-event data 
Time-to-event (TTE) data, also referred to as survival data (often within an oncology setting) 
or failure-time data (often within an engineering setting), arise when interest lies not only in 
whether an event of interest occurs but also the time taken for that event to occur from a 
well-defined time origin. Examples of outcomes measured using TTE data include time-to- 
death following diagnosis of cancer, time-to-remission of epileptic seizures after 
randomisation into a clinical trial and time-to-conception following fertility treatment.  
Specific statistical methodology is required for the analysis of TTE data for two reasons. 
Firstly, TTE data is non-symmetrical, usually positively skewed, therefore methodology for 
continuous data which assumes a normal approximation is violated. Secondly, TTE data is 
frequently censored in that an event is not observed for an individual therefore they cannot 
contribute an event time towards an analysis; however a censoring time (i.e. the length of 
time that individual was known to be event free for) can contribute to analysis.  
Theoretically, the survival and hazard functions are used in the statistical analysis of TTE data. 
The hazard function ℎ(𝑡) is defined as the instantaneous risk of an event at time 𝑡, given that 
an individual has been event free up to time 𝑡 , 𝐻(𝑡)  is the cumulative hazard function, 
defined as the sum of instantaneous hazards up to time 𝑡,  and the survival function 𝑆(𝑡) 
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describes the probability of being event-free up to time 𝑡, essentially a cumulative history of 
events. The functions are directly linked as follows (where 𝑇 represents the event time) [57]: 
𝑆(𝑡) = Pr(𝑇 > 𝑡) = exp[−𝐻(𝑡)] = exp [−∫ ℎ(𝑢)𝑑𝑢
𝑡
0
]  (Equation 4) 
The hazard functions ℎ𝑇(𝑡) and ℎ𝐶(𝑡)  and the corresponding survivor functions 𝑆𝑇(𝑡) and 
𝑆𝐶(𝑡)  of the treatment (T) and control (C) groups respectively are linked by the hazard ratio 
parameter 𝜃: 
ℎ𝑇(𝑡) = 𝜃ℎ𝐶(𝑡)       (Equation 5)
 𝑆𝑇(𝑡) = 𝑆𝐶(𝑡)
𝜃     (Equation 6) 
The nature of the hazard function makes it more flexible for modelling than the survival 
function [57]. The hazard function can be related multiplicatively to participant 
characteristics via a semi-parametric proportional hazards model as follows for 𝑖 individuals, 
with common baseline hazard ℎ0(𝑡), 𝑥1… 𝑥𝑛 characteristics and 𝛽1… 𝛽𝑛  as follows [58]: 
ℎ𝑖(𝑡) = ℎ0(𝑡)𝑒𝑥𝑝(𝛽1𝑥1 + 𝛽2𝑥2 +⋯+ 𝛽𝑛𝑥𝑛)  (Equation 7) 
A comprehensive guide to modelling of TTE data in parametric, semi- and non-parametric 
settings, under the assumptions of proportional or time dependent hazards is provided by 
Collett [57] and further details of synthesis methods for TTE data are presented in Chapter 2. 
1.2  Individual participant data meta-analyses and network meta-
analyses in Epilepsy 
To date, the Cochrane Epilepsy Group have performed nine IPD-MAs of antiepileptic drug 
(AED) monotherapy trials [59-67] and an IPD-NMA of 10 different AEDs [68, 69].   
1.2.1  Clinical Setting  
Epilepsy is a common neurological condition in which recurrent, unprovoked seizures are 
caused by abnormal electrical discharges from the brain. Epilepsy is a disorder of many 
heterogeneous seizure types and accounts for approximately 0.75% of the global burden of 
disease [70].  It is believed that with effective drug treatment, up to 70% of individuals with 
active epilepsy have the potential to become seizure-free and go into long-term remission 
shortly after starting drug therapy and that around 70% of these individuals can achieve 
seizure-freedom using a single AED in monotherapy [71]. 
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Cochrane IPD reviews have considered two epilepsy types for which monotherapy is 
indicated: generalised-onset (generalised tonic-clonic) seizures in which electrical discharges 
begin in one part of the brain and move throughout the brain, and partial-onset seizures in 
which the seizure is generated in and affects one part of the brain (the whole hemisphere of 
the brain or part of a lobe of the brain). The reviews examine ten AEDs which are currently 
licensed and used in clinical practice for use as monotherapy for partial and generalised 
seizures in at least one country [72, 73]:  
Carbamazepine (CBZ), Phenytoin (PHT), Phenobarbitone (PHB), Sodium Valproate (VPS), 
Lamotrigine (LTG),  Oxcarbazepine (OXC),  Topiramate (TPM), Gabapentin (GBP), 
Levetiracetam (LEV),   Zonisamide (ZNS). 
Current guidelines from the National Institute for Health and Care Excellence (NICE) for adults 
and children recommend carbamazepine or lamotrigine as first-line treatment for partial-
onset seizures and valproate for generalised-onset seizures, on the condition that females of 
childbearing age are made aware of the potential teratogenic effects of the drug [74, 75]. 
Clinical profiles and mechanisms of action of these ten drugs are detailed in the Cochrane 
Epilepsy IPD-NMA [68, 69]. 
1.2.2  Rationale for individual participant data approach  
With evidence that up to 70% of individuals with active epilepsy have the potential to go into 
long-term remission of seizures shortly after starting drug therapy [71], the correct choice of 
first-line AED therapy for individuals with newly diagnosed seizures is of great importance. 
There are currently over 30 drugs (over 50 generic and branded formulations) available 
worldwide for the treatment of various seizure types [76], therefore it is important that the 
choice of AEDs for an individual is made using the highest quality evidence regarding 
potential benefits and harms of treatments appropriate to given seizure types. 
The design and choice of outcome for epilepsy monotherapy trials is discussed at length in 
Chapter 3.1.2. In summary, the important efficacy outcomes defined in epilepsy 
monotherapy trials and used in Cochrane reviews of epilepsy monotherapy often require 
analysis of TTE data (for example, time-to-first seizure after randomisation or time-to-
withdrawal of allocated treatment).  
Methods have been developed to synthesise TTE data using summary information [6, 13] 
(also see Chapter 2.3.2 for further discussion of these methods); however, the appropriate 
9 
 
statistics to perform a direct synthesis or indirect estimation are not commonly published in 
epilepsy monotherapy trials (see Chapter 3 for further discussion).  
Furthermore, although seizure data have been collected in most epilepsy monotherapy trials, 
there is little uniformity in the definition and reporting of outcomes (see Chapter 3 for further 
details). For these reasons, an IPD approach has been taken for pairwise meta-analysis and 
proposed for network meta-analyses in Cochrane reviews of epilepsy monotherapy. This 
approach helps to overcome issues around inconsistent reporting in trials and is considered 
to be the ’gold standard’ approach to synthesis of TTE data [6].  
Each Cochrane pairwise meta-analysis provides high quality evidence for each pair of drugs 
but does not inform a choice between the whole evidence base of appropriate drugs for 
decision makers, clinicians or individuals with epilepsy. Furthermore, direct evidence from 
randomised controlled trials (RCTs) is not available between some of the commonly used 
AEDs (such as between OXC and PHB) and due to current first-line treatment 
recommendations, it is unlikely that an RCT will be designed in the future that will make a 
direct comparison between such drugs [74], so it is not possible to make pairwise 
comparisons of treatment effects between all drugs.  
Use of NMA allows for indirect pairwise comparison of all drugs in the network, in other 
words indirect treatment effect estimates can be calculated for all 45 pairwise comparisons 
of the ten AEDs of interest in the Cochrane reviews of epilepsy monotherapy.  Indirect 
evidence from the network can also increase the power and precision of direct treatment 
effect estimates as discussed in Chapter 1.1.2. 
1.3  Individual participant data sharing: recent initiatives 
Recent years have seen change in attitudes to sharing of clinical trial data with many calls for 
improved data transparency and data sharing initiatives introduced across the research 
community as a whole [77-83], in addition to the publication of data transparency policies by 
the Institute of Medicine [84], the European Medicines Agency [85], and the International 
Committee of Medical Journal Editors [86, 87]. Support of clinical trial data sharing seems to 
be improving in recent years, with a reported increased willingness of authors of published 
trials to share data in surveys conducted in 2011 [77, 88] compared to an empirical study 
conducted in 2009 [89]. A recent survey of patients within a U.S. emergency department has 
also shown that the majority of patients were in favour of de-identified clinical trial data 
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sharing in general, however 25% of patients indicated that they would be less likely to 
participate in a clinical trial if data were shared, demonstrating the increased importance of 
the informed consent process during trials [90].  
The launch of the first data sharing platform, led by GlaxoSmithKline (GSK) in May 2013 [80], 
marked the beginning of a new era of data transparency within the Pharmaceutical Industry. 
At the time of writing (July 2017), thirteen pharmaceutical sponsors have committed to the 
sharing of IPD from nearly 3500 of their trials with independent researchers via multi-sponsor 
platform Clinical Study Data Request (CSDR)[91]. CSDR provides a structured format for 
requesting data, including a step-by-step diagram, user guide, supporting guidance videos 
and the opportunity to communicate with the sponsor throughout the process. The data 
sharing process for requests submitted to CSDR is as follows: 
 Selection of studies of interest from a list by the sponsor(s) or submit an enquiry for 
any studies of a relevant sponsor not currently listed. Multiple studies from a single 
sponsor or from different sponsors can be included in a single request (single sponsor 
request or multi-sponsor request). 
 Submission of a research proposal for the studies required for the research, including 
statistical analysis plan, publication plan and conflicts of interest for review by an 
independent review panel. 
 Signing of data sharing agreements by the researcher and sponsor for approved 
proposals. 
 Sponsor undertakes the de-identification of participant-level data and related 
documentation (e.g. protocols, case report forms) in preparation for sharing of data 
(see Hrynaszkiewicz et al [92] for a summary of the principles of data de-
identification). 
 Remote access to requested de-identified datasets and all related documentation is 
provided via a secured SAS analytic environment. 
Other sponsors have opted for a single sponsor environment in contrast to the multi-sponsor 
format of CSDR. For example, Johnson & Johnson (J&J) announced an agreement with Yale 
University School of Medicine’s Open Data Access (YODA) project in January 2014 in which 
YODA acts as an independent review panel for research proposals requesting access to 191 
J&J datasets (correct to July 2017) in a similar format to CSDR [93, 94]. More recently in 2016, 
Bristol Myers Squib announced a collaboration with the Clinical Research Institute of Duke 
University for the Supporting Open Access to Researchers (SOAR) initiative, a similar data 
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sharing model to the YODA process [95]. Both CSDR and YODA provide metrics related to 
submitted research proposals on their respective websites [91, 93]; see Chapter 5.5.2 for 
further discussion of these metrics. 
These changes and initiatives may go some way to reducing some barriers to conducting IPD-
MAs (as described in Chapter 1.1.3 and further discussed in Chapters 4 to 7).  However, 
concerns have been raised regarding practical challenges of data sharing and the potential 
impact of data sharing on clinical trial participation [96] and recent editorials have suggested 
that current initiatives do not go far enough in the commitment to data sharing [97, 98].   
However, the benefits and impact of such initiatives and reported changes in attitude 
towards data sharing on IPD analyses may not become clear for some time; a recent study 
has shown that out of over 3000 trials available for data request via CSDR, YODA or SOAR, 
only 15.5% of these studies have been requested by a limited number of researchers [99]. 
Furthermore, at the time of writing, out of over 350 research proposals submitted to and 
reviewed by CSDR and YODA up to July 2017, results from only ten data requests have been 
published to date [69, 100-108]. This slow publication rate may reflect the originality and 
complexity of the research hypotheses proposed. While the provision of access to original 
datasets may have previously been associated with re-analysis to confirm validity of trial 
results [109], the focus of the majority of approved research proposals seems to be original 
research. Published titles of approved CSDR and YODA research proposals range from IPD-
MAs, development of prognostic, pharmacokinetic and genetic models, the development of 
novel statistical methodology, investigation of adverse drug events and the design of new 
randomized controlled trials. Such projects are likely to take several years to reach final 
publication stage.  
Furthermore, the researcher’s perspective of using CSDR has received mixed reviews 
highlighting that access to IPD could be taking longer due to the additional safeguards that 
have been put in place [96, 110-113]. Restrictions relating to the remote analysis of IPD has 
prevented the completion of some projects, as highlighted via the reported metrics of the 
status of data requests of the YODA project [93]. The full extent of such restrictions and the 
impact of the provision of highly de-identified data on the range of clinical questions that can 
be addressed and statistical methodology which can be employed within data sharing 
platforms is currently unknown [114]. 
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1.4  Thesis objective and structure 
Evidence syntheses are commonly used and highly regarded techniques for the quantitative 
summary of evidence from a number of sources [8, 34]. The undertaking of an IPD synthesis 
can be methodologically complex, time consuming and open to sources of bias if not 
conducted rigorously [51]. While IPD syntheses published as journal articles will present 
clinical results and implications and some level of detail regarding methodology, it is difficult 
to translate the complete rationale and the practical challenges of such an approach to 
synthesis within the structure and word limit of a journal manuscript.  
The aim of this thesis is to document the practical aspects and challenges of conducting IPD-
MAs and an IPD-NMA of AED monotherapy and to provide a wider context to these syntheses 
in the literature of AD and IPD evidence synthesis. Such experiences and challenges are of 
particular relevance in current research environment with changing functionalities of and 
attitudes towards data sharing. 
Chapter 2 summarises methodology for meta-analysis of TTE data from both an AD and IPD 
perspective. Chapter 3 summarises previous reviews of the reporting of TTE data in the 
published literature and presents a novel systematic review of the reporting of aggregate TTE 
outcomes and analyses specifically in epilepsy AED monotherapy trials published to 2012.  
Chapter 4 then presents a novel systematic review of previously conducted IPD-MAs to 
explore data retrieval rates and characteristics associated data retrieved for all published 
IPD-MAs from 1987 to 2015. Chapter 5 then reflects upon the experiences of the Cochrane 
Epilepsy Group in previous data requests made between 1995 and 2005 compared to data 
requests made for current projects between 2011 and 2015; a time frame which has seen 
substantial changes to the way clinical trial data, particularly pharmaceutical sponsored trial 
data, is shared with independent researchers. 
Chapter 6 presents statistical methodology and results of several approaches to modelling 
the association between treatment effect and epilepsy type in the IPD-NMA and Chapter 7 
then presents further results and clinical implications of the Cochrane IPD-NMA of AED 
monotherapy described in Chapter 1.1.2. Chapter 8 then presents statistical methodology, 
for combining published AD with IPD in NMA as well as results and clinical implications of 
incorporating additional published AD with IPD in this example of AED monotherapy. 
The final chapter summarises the findings of the previous chapters, reflects upon the 
implications of these findings in the clinical context and in the context of IPD and AD evidence 
synthesis and provides discussion of further research needed.    
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Chapter 2: Meta-analysis of time-to-event data: a 
methodology review  
2.1  Introduction 
As introduced in Chapter 1.1.4, in many clinical settings, the outcome of interest is the time 
to an event. The use of time-to-event (TTE) outcomes is particularly common in the field of 
oncology, where the aim of a clinical trial is often to detect a modest treatment effect [1, 4, 
115]; so unless a single study is very large in sample size, it is unlikely to detect the small 
treatment effect due to insufficient statistical power. As cancer is a relatively common 
condition, a moderate treatment effect could have substantial benefit for public health. 
Meta-analyses are commonly used in the field of oncology. For example, the Early Breast 
Cancer Trialists Collaborative Group have collected IPD from over 450,000 women from 400 
randomised trials from the last 30-40 years and found modest but highly significant survival 
benefit for a range of chemotherapy, hormonal and radiotherapy regimens [4, 116, 117]. 
Meta-analysis of TTE data is also important in other settings; as outlined in Chapter 1.2, the 
Cochrane Epilepsy Group have performed or are in the process of performing nine IPD-MAs 
and an NMA of AED monotherapy trials [59-67, 69], within which important efficacy 
outcomes such as ‘time-to-withdrawal of allocated treatment’ and ‘time-to-12-month 
remission from seizures’ required the analysis of TTE data. 
A range of methods for the meta-analytic synthesis of TTE data have been proposed over 
several decades, with the applicability of specific methods depending on the clinical question 
of interest, the assumed hazard distribution and the type of data available for each study for 
meta-analysis [11].  
The objective of this Chapter is to provide a summary of existing methodology developed for 
meta-analysis of TTE data with a particular focus on the level of data (individual level or 
aggregate-level) required for that method. Where possible, applications of developed 
methods (via illustrative examples or simulation studies) will also be discussed to highlight 






2.2  Analysis of TTE data in a single trial  
2.2.1  Direct calculation of the Hazard Ratio 
Chapter 1.1.4 introduces the theoretical concepts in the analysis of TTE data of the survival 
and hazard functions which are linked by a parameter known as the Hazard Ratio (HR). The 
HR can be directly calculated in two general approaches and several methods have been 
suggested for the indirect estimation of HRs; see Chapter 2.3.2 for further discussion. The 
first direct approach, via comparison of observed and expected numbers of events across 
treatment groups, defines the log hazard ratio (ln (𝐻𝑅)) as [6, 118]: 
ln (𝐻𝑅) = ln (
𝑂𝑇 𝐸𝑇⁄
𝑂𝐶 𝐸𝐶⁄
)     (Equation 8) 
And the associated variance of this log hazard ratio (𝑣𝑎𝑟(ln (𝐻𝑅))) is defined as: 






    (Equation 9) 
Where 𝑂𝑇 = Observed number of events in the treatment group.  
𝑂𝐶 = Observed number of events in the control group.  
𝐸𝑇 = Log-Rank Expected number of events in the treatment group (under null hypothesis).  
𝐸𝐶 = Log-Rank Expected number of events in the control group (under null hypothesis).  
An alternative direct calculation of ln (𝐻𝑅), where 𝑂𝑇 and 𝐸𝑇 are defined as above and 1/𝑉𝑇 
is the Mantel Haenszel (log-rank) variance of ln(𝐻𝑅), is [6, 118, 119]:  
    ln (𝐻𝑅) =
𝑂𝑇−𝐸𝑇
𝑉𝑇
     (Equation 10) 
And the associated variance of this log hazard ratio (𝑣𝑎𝑟(ln (𝐻𝑅))) is defined as: 
𝑣𝑎𝑟(ln (𝐻𝑅) ) =
1
𝑉𝑇
     (Equation 11) 
HRs derived from either of the above calculations are often referred to as ‘log-rank’ HRs due 
to the use of log-rank methodology in the calculation of expected number of events [10, 118]. 
The two ln (𝐻𝑅)  estimates from Equation 8 and Equation 10 (and their respective variances) 
are approximately equivalent, and will only differ markedly if the total number of observed 
events in a trial is small [6, 120]. 
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Secondly, the coefficient of a treatment indicator variable from a proportional hazards (PH) 
regression model provides a direct estimate of ln (𝐻𝑅). For example, given the PH model 
(Equation 7) defined in Chapter 1.1.4, hazards ℎ𝑇 𝑎𝑛𝑑 ℎ𝐶  in the treatment and control 
groups respectively and coefficient 𝜃 associated with treatment indicator variable 𝑥 [7]: 
ln(𝐻𝑅) = 𝜃 =  ln (
ℎ𝑇(𝑡)
ℎ𝐶(𝑡)
)    (Equation 12) 
The variance (𝑣𝑎𝑟(ln (𝐻𝑅) ))  is provided by the associated variance of the regression 
coefficient. If the treatment indicator is the only variable included in the regression model, 
the ‘unadjusted’ ln (𝐻𝑅)  derived from the regression coefficient can be considered 
conceptually equivalent to the ln(𝐻𝑅) derived from log-rank methods as described above. 
However, often regression modelling is performed due to the desire to adjust for potential 
confounders of interest, the coefficient associated with the treatment indicator variable will 
be ‘adjusted’ for the additional variables. Therefore the difference between the ‘adjusted’ 
and ‘unadjusted’ HRs will depend on the influence of any confounding variables. While in a 
meta-analytic context, combination of adjusted and unadjusted estimates is likely to 
introduce bias into pooled effect estimates [121], methodology has been developed which 
allows the combination via meta-regression of Cox proportional hazards models with 
different covariate adjustment or no covariate adjustment [122]. 
HRs derived from regression models are often referred to as ‘Cox’ HRs, in reference to the 
semi-parametric Cox PH model commonly used for the analysis of TTE data[58]. It should be 
noted that HRs from parametric PH models (such as Weibull or Exponential PH models) also 
provide a direct estimate of ln (𝐻𝑅) and associated variance as described above. 
It has been shown that the ‘log-rank’ and ‘Cox’ HRs are approximately equivalent for modest 
treatment effects and fairly balanced treatment arms; for larger treatment effects, the ‘log-
rank’ approach becomes biased and confidence intervals show a lack of coverage [123-125]. 
2.2.2  Use and interpretation of the Hazard Ratio 
The HR, or ln(𝐻𝑅),  and associated variance are considered, generally under the PH 
assumption, to be the most appropriate summary statistics to present when reporting on 
randomised TTE data as the HR is the only summary statistic which takes account of both the 
proportion of individuals experiencing an event in question and the time at which the event 
occurs (or the censoring time for individuals not experiencing the event in question) [6, 118]. 
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The HR is mathematically linked to the two well-known summary statistics used to express 
the relative difference of a dichotomous outcome at a fixed point in time (e.g. the end of a 
clinical trial); the Odds Ratio (OR) or Relative Risk (RR). In fact, in the absence of censoring, 
the HR and RR can be considered to be mathematically equivalent [118]. In the presence of 
censoring, it has been demonstrated that approaches such as comparing the number of 
events across patient subgroups or calculating the odds of an event at fixed time points 
across follow-up are inefficient and could lead to inappropriate conclusions [6, 23, 126, 127], 
especially among trials with varying lengths of follow-up and therefore variable stages of 
maturity [128, 129]. In a meta-analytic context, such methods could introduce bias into meta-
analysis if fixed time points are selectively chosen by trialists to demonstrate a maximal or 
minimal difference between treatment groups [128]. Appropriate adjustment for censoring 
in meta-analysis of TTE data is essential; censored patients provide less information than 
those who experience an event to the overall distribution of event times, therefore the 
extent of censoring will affect the variance of survival proportions, hence the relative weights 
of individual results in meta-analysis and the precision of combined estimates [130]. 
The HR is often interpreted in a similar way to the RR due to the similarities between the 
notions of hazard and risk. It must be noted for the interpretation of this measure that 
‘hazard’ is a conditional and dynamic measure which may change continuously (e.g. an 
individual’s hazard of death increases as they cross the road), while ‘risk’ is assumed to 
remain fairly constant across the follow-up period of a study [121]. It has been argued that 
the HR doesn’t have an intuitive interpretation for non-statisticians and is easily 
misinterpreted [131, 132] and that ORs or RRs are more commonly presented in clinical trial 
publications due to perceived statistical complexity related to HRs [128, 133].  
2.3  Meta-analysis of TTE data 
2.3.1  Literature review methods 
A literature review was conducted to identify methodological publications (whether full-text 
articles, abstracts or conference proceedings published in English) describing meta-analytic 
methods developed for or applied to TTE data. MEDLINE electronic database (from the 
earliest date up to January 2017) and Cochrane Methods Methodology Register (from the 
earliest date up to the last update of the register in July 2012) were searched using keywords 
such as ‘meta-analysis,’ ’time-to-event,’ ’survival,’ ’failure time’ and ‘statistical methods.’ See 
Appendix 1 for search strategies of the two electronic databases.   
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Electronic searches were constructed and carried out by SJN, with advice from an information 
specialist (GC). References of relevant publications were also consulted and methodological 
journals (Statistics in Medicine, Statistical Methods in Medical Research, BMC Research 
Methodology and Research Synthesis Methods) were hand-searched using the keywords as 
described above via the ‘Search’ or ‘Advanced Search’ function of the journal website. 
The inclusion criteria of this methodological review were broad; publications describing a 
novel methodology for meta-analysis of TTE data or publications describing the application 
of existing methods (with methodological discussion) were considered. Publications 
describing methodology for meta-analysis in general, for TTE in general or publications 
describing an application only without methodological discussion were not considered.  
Over 100 methodological publications were identified by the search methods described 
above. A list of references of all publications identified from the searches is available in 
Appendix 1. This methodological review was not intended to be systematic and the results 
section of this Chapter focus on the methodology related to the topic of this thesis; 
particularly on methods developed for AD and for IPD of TTE outcomes. This review was also 
not intended to ‘compare’ methods; as outlined in Chapter 2.1, the applicability of most of 
the methods is dependent on many factors. Rather, the relative advantages and 
disadvantages of specific methods within given contexts are discussed where appropriate. 
2.3.2  Methods for aggregate data 
Whitehead and Whitehead [7] were among the earliest authors to develop a general 
comprehensive methodological framework for the meta-analysis of RCTs including those 
with censored TTE data.  The methodology involves combining efficient score statistics for 
the HR estimates based on the efficient score statistics and Fisher Information of an assumed 
PH model.  
Assuming that for K trials, an estimate of ln (𝐻𝑅𝑖) and 𝑣𝑎𝑟(ln(𝐻𝑅𝑖)) for each trial 𝑖 = 1…𝐾  
is available; a pooled ln (𝐻𝑅)  and its variance (𝑣𝑎𝑟((ln(𝐻𝑅))) can be calculated by the 



















   (Equation 14) 
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Meta-analysis of relative effects (i.e. ratios) via an inverse-variance approach is performed 
on the natural logarithm of the effect size and variance due to the beneficial mathematical 
properties for meta-analysis of converting ratios to differences when a log scale is applied. A 
further benefit for TTE data and the HR is that the additive difference in log hazards of two 
treatments does not depend on the observation times and is therefore more appropriate 
when combining studies with different lengths of follow-up in meta-analysis [134-136]. 
Even at this early stage of methodological development, Whitehead and Whitehead [7] 
express doubt over the chances of finding sufficient details, of adequate quality, in study 
publications to allow meta-analysis. The authors also warn of potential variability in 
conventions and terminology used across the published literature, which may make 
identification of the appropriate statistics difficult.  
As introduced in Chapter 1.1.3, the use of IPD is widely regarded as the ‘gold-standard’ 
approach to synthesis; however, in the event that IPD is not available for a proportion of 
eligible studies and the required effect size is not reported in the published literature, these 
studies may have to be excluded from analysis.  
A potential solution as an alternative to excluding studies from meta-analysis entirely is to 
make use of the summary statistics available in the published literature. This can be done in 
two ways. Firstly by pooling an alternative statistic to the HR, where HRs are not available (a 
summary of some methods taking this approach is outlined in Chapter 2.3.4.2). Secondly, and 
arguably more appropriately [6, 13, 128], a range of methods have been developed which 
allow the indirect estimation of HRs and their associated variances from commonly published 
summary statistics such as p-values, numbers of events and from published survival curves 
[6, 13, 128, 137-139]. 
2.3.2.1  Indirect estimation methods: numerical 
Parmar et al [6], Williamson et al [13] and Tierney et al [128] provide full derivation and 
illustrative examples of commonly used indirect estimation methods; the latter online 
publication also providing a macro-enabled Excel Spreadsheet to facilitate the indirect 
calculation of HRs and associated variances. In summary, the indirect methods outlined 




1) Indirect estimation of variance 𝒗𝒂𝒓(𝒍𝒏(𝑯𝑹)) 
The following methods assume that 𝐻𝑅 or ln (𝐻𝑅) is reported and 𝑣𝑎𝑟(𝑙𝑛(𝐻𝑅)) must be 
estimated. Note that for indirect methods b to d, 𝑣𝑎𝑟(𝑙𝑛(𝐻𝑅))  is the inverse of  𝑉𝑇  as 
outlined in Equation 11. 









    (Equation 15) 
where LCI and UCI are the lower and upper bounds of the confidence interval (CI) 
respectively, 𝛼 is the significance level (usually 5% corresponding to a 95% CI)  and  Φ is the 
cumulative distribution function of the Normal distribution (Φ−1 (1 −
𝛼
2
) = 1.96 if 𝛼 = 5%). 
b. Total number of events in both groups reported (randomisation ratio 1:1) 
𝑉𝑇 ≈ (𝑂𝑁)/4      (Equation 16) 
where 𝑂𝑁 is the total number of events in both treatment groups.  
c. Number of events in each group reported (randomisation ratio 1:1) 
𝑉𝑇 ≈ (𝑂𝑇 𝑂𝐶)/𝑂𝑁     (Equation 17) 
where 𝑂𝑇, 𝑂𝐶  and 𝑂𝑁 are the observed number of events in the treatment group, control 
group and total number of events respectively.  
d. Total number of events in both treatment groups and number randomised to 




     (Equation 18) 
Where 𝑂𝑁  is the total number of events in both treatment groups, 𝑅𝑇  and 𝑅𝐶  are the 
number of participants randomised to treatment and control groups respectively.  
2) Indirect estimation of 𝒍𝒏 (𝑯𝑹) and 𝒗𝒂𝒓(𝒍𝒏 (𝑯𝑹)), see also Equation 10 
e. Log-rank p-value and total number of events in both treatment groups 
reported (randomisation ratio 1:1) 
𝑂𝑇 − 𝐸𝑇 ≈ 
1




)   (Equation 19) 
f. Log-rank p-value and number of events on each treatment group reported 
(randomisation ratio 1:1) 








g. Log-rank p-value, total number of events in both treatment groups and number 
randomised to each group reported (randomisation ratio not 1:1) 
𝑂𝑇 − 𝐸𝑇 ≈ √
𝑂𝑁  𝑅𝑇 𝑅𝐶 
𝑅𝑇+𝑅𝐶
 × Φ−1 (1 −
𝑝
2
)    (Equation 21) 
Where for indirect methods e to g: 
  𝑂𝑇 = Observed number of events in the treatment group.  
𝑂𝐶 = Observed number of events in the control group.  
𝑂𝑁 = Observed number of events in both treatment groups.  
𝐸𝑇 =  Log-Rank Expected number of events in the treatment group (under null 
hypothesis).  
𝑅𝑇 = Number randomised in the treatment group.  
𝑅𝐶 = Number randomised in the control group.  
Φ = Cumulative distribution function of the Normal distribution. 
𝑝 = Two-sided log-rank p-value (or Cox regression p-value as an alternative if log-
rank p-value is not reported [128]). 
Note that 𝑉𝑇 can be estimated using any of indirect methods b to d, then ln(𝐻𝑅) can be 
estimated using Equation 10.   
Indirect variance estimation methods b to g are derived from the 𝜒2 statistic of the log-rank 
test and have been shown to provide reasonable estimates of variance when treatment 
effect ‘is not too large’ [134, 140]. Illustrative examples have shown reasonably good 
agreement between these indirect estimates and also between these indirect estimates with 
direct estimates in a range of clinical settings [6, 141-144]. However, a simulation study has 
shown that indirect method 2 (Equation 16), may systematically overestimate the true log-
rank variance and all three approximations improve as the proportion of censoring increases 
[142]. Therefore, in the context of oncology trials where treatment effects are likely to be 
modest and event rates low these indirect methods are likely to perform well, however for 
other contexts where diseases have a poor prognosis and therefore a high event and low 




2.3.2.2  Indirect estimation methods: Survival curves 
Survival curves (usually Kaplan-Meier (KM) curves) are commonly presented graphical 
representations of TTE data; previous reviews examining studies with TTE outcomes have 
shown that around 90% presented at least one survival curve (see Chapter 3.1.1  for further 
details and references). Given the popularity of such graphical figures, many methods have 
been proposed for extracting and combining data from published KM curves in the context 
of meta-analysis. Such methods generally aim to reconstruct or estimate trial-specific or 
pooled survival functions, rather than to estimate ln(𝐻𝑅)  and associated variance 
specifically [6, 13, 126, 130, 145-155]. 
Earle et al [126] present an overview and comparison of five of these techniques [145-149]. 
Firstly, two similar methods which make use of the published survival curve to iteratively 
estimate the survival function via iterative Generalised Least Squares and iteratively 
reweighted least squares algorithms respectively [145, 147].  Also, two methods which derive 
‘Log RR’ and ‘Weighted Log RR’ indices respectively as parameters to represent long-term 
survival from the survival curves of a selection of trials [126, 146]. These pooled indices can 
then be back transformed to pooled survival functions [149]. Finally, a method for combining 
data from survival curves while adjusting variability participant covariates across studies to 
produce an effect estimate which represents the variability in participant subgroups [148]. 
This method does rely on published results being stratified by the covariates of interest so 
may not be feasible in practice [126]. Earle et al [126] assess the accuracy of the five 
techniques by comparison of a reconstructed pooled curve to a curve constructed using IPD 
and show no more discrepancy from the IPD curve is present than would be expected by 
chance alone. The authors conclude that while not every technique would be appropriate for 
every context, in general, all five techniques could accurately reproduce summary survival 
curves from published literature and the choice of technique would depend on data 
characteristics the context and the aim of analysis. 
Parmar et al [6] present a method for estimating ln(𝐻𝑅)  and associated variance from 
published survival curves. A summary of this method is as follows:  
 Split the time axis into 𝑇 arbitrary non-overlapping intervals,  
 Estimate ln(𝐻𝑅) for each interval based on estimated numbers at risk in the time 
interval (assuming uniform censoring across the entire follow-up period) and 
numbers of events in the time interval. Such information may be read directly from 
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the curve or using additional published information where provided (e.g. numbers of 
participants remaining in the trial at various time points). 
 Combine estimates over the intervals in a stratified way to obtain an overall ln(𝐻𝑅) 
for the trial.  
The full derivation of this method is provided in Parmar et al [6]. An illustrative example 
performed by the authors using their derived method shows that the assumption of uniform 
censoring is somewhat ‘idealized’ and underestimates the true variance of the estimate, 
resulting in the trial being given too much weight in meta-analysis. It has been shown that 
the assumptions made regarding censoring in a meta-analysis of TTE data can change pooled 
effect sizes by between 1-9% and often has an impact on statistical heterogeneity [156]. 
Williamson et al [13] propose an extension to the Parmar et al [6] methods following an 
actuarial approach that assumes the rate of censoring is constant within each interval but 
can vary across intervals, with the aim of improving variance estimates. These methods also 
extend to examining differences in treatment effect over time (i.e. non-proportional hazards) 
as a source of heterogeneity in meta-analyses of trials with variable lengths of follow-up. The 
methods assume that if the PH assumption holds, then ln (𝐻𝑅)  estimates should be 
approximately constant across time intervals.  
More recently developed methods have made use of digital software to extract data from 
KM curves at selected time intervals or, where possible, entire curves in an attempt to 
reconstruct IPD via iterative algorithms [157-159].  In theory, such methods allow a better 
determination of censoring distributions, avoiding the assumptions regarding censoring 
made in the methods of Parmar et al [6] and Williamson et al [13] and therefore producing 
more accurate results than any previous method [157]. Use of reconstructed IPD also allows 
the use of more advanced methods for further analysis; illustrative examples include 
modelling of fractional polynomials and flexible parametric modelling to account for non-
proportional hazards in pairwise and network meta-analysis [158, 159]. Guyot et al [157] 
have demonstrated a high degree of reproducibility and accuracy for survival probabilities 
and median survival time, even in the absence of additional information regarding numbers 
at risk and numbers of events; however HR estimates became less accurate as less 
information was available to inform censoring patterns to becoming ‘unusable’ when no 




2.3.2.3  Reliability of indirect methods 
Many studies have investigated the reliability and practicality of applying indirect estimation 
methods [6, 126, 141-144, 160-163], particularly the methods of Parmar et al [6].  
It must be emphasised that the reliability of these estimations, particularly graphical 
estimations, are dependent on the quality of the published survival curves and the precision 
of other published information [6, 13]. It has also been shown that estimating the number of 
events from a published KM curve is often an overestimation of the true number of events 
and the extent of overestimation increases as an increasing number of patients are censored 
[164, 165]. Further, an illustrative example shows that the graphical methods of Parmar et al 
[6] , which were developed within the context of randomised clinical trials, may produce 
biased estimates when applied to survival curves of non-randomised data, particularly where 
non-randomised data has been adjusted in analysis to account for confounding or selection 
bias [162]. Further discussion of analytic methods for non-randomised and observational TTE 
data and the implications for meta-analysis are discussed by Bennett [166]. 
Parmar et al [6] also discuss the difficulty in selecting the best time intervals such that the 
event rate within each time interval is appropriate. Their suggested rule of thumb is that the 
event rate within each time interval should be no more than 20% of those at the beginning 
of the time interval. However, this is dependent on the event rate and follow-up time of an 
individual trial and a simulation study has shown that treatment effect may be under-
estimated in trials with small sample sizes and/or low event rates [144]. 
A general recommendation from all work within this area is that as much summary 
information should be extracted from published literature as possible so that several indirect 
estimates can be calculated and compared [6, 128, 141]. Due to the assumptions involved 
(e.g. choice of time intervals, censoring rate), estimation from survival curves should only be 
used in the absence of sufficient information for the direct or indirect methods [6]. However, 
if multiple estimates can be calculated, it may be reasonable to take an average of these 




2.3.3  Methods for individual participant data (IPD) 
Two approaches can be taken when conducting an IPD-MA, either a one-stage or two-stage 
approach [32, 34, 36, 167-169]. Two-stage methods reduce IPD to study-specific treatment 
effect estimates, allowing use of standard meta-analytic methodology to obtain a pooled 
treatment effect estimate. Such methods are commonly used in practice and are considered 
conceptually less complicated than one-stage methods [32, 36, 123].  
One-stage methods simultaneously analyse IPD from all studies, while accounting for the 
separate trials within the one-stage model, to obtain estimates of pooled treatment effect 
and between-study heterogeneity by fitting a single hierarchical (fixed, random or mixed 
effects) statistical model. Such models, while more computationally complex, offer additional 
flexibility to incorporate covariates, interaction terms or heterogeneity parameters [32, 37, 
169]. Generally within meta-analysis, heterogeneity between trials may arise from the 
treatment effects themselves; i.e. the intervention may have worked better in some trials 
than others, and treatment-by-trial interactions may arise due to differences in 
implementation of treatment protocols (i.e. treatment doses, dose scheduling etc.), study 
participant characteristics and their individual baseline risks [136], which may be interpreted 
as unmeasured characteristics [170]. One-stage approaches allow for simultaneous or 
separate modelling of heterogeneity of treatments effects and of baseline risk.  Baseline risk 
may be measured on a trial level and modelled as a fixed-effect or the addition of a random-
effect to a hierarchical model (also referred to as a frailty parameter within a TTE setting 
[171]) can account for the level of risk associated with an individual which could account for 
heterogeneity among individuals not explained by the covariates [37, 172].  
Specifically within a TTE setting, advantages of the availability of individual TTE data for meta-
analysis include a more thorough and flexible investigation of treatment effect over time 
[135], treatment-covariate interactions [13, 173] and patient characteristics and clinical 
factors as potential causes of statistical heterogeneity between trials in a meta-analysis [37, 
174]. Specific sources of heterogeneity in TTE data include time-dependent (non-constant) 
treatment effects and variation in length of follow-up time across trials [13, 37]. Methodology 




2.3.3.1  One-stage IPD-MA 
A simple assumption in IPD-MA of TTE data from RCTs would be that the hazard function 
differs only by the allocated treatment, with all other risk factors potentially influencing the 
hazard balanced by randomisation [135]. To achieve a better insight into potential treatment 
effect modifiers, this assumption can be relaxed via stratification of baseline hazard by trial 
[37], or by the addition of a treatment-study or treatment-time interaction [135, 176, 177].  
Tudur-Smith et al [37] present a series of one-stage hierarchical Cox PH regression models 
designed to explore heterogeneity in meta-analysis and examine the relationship between 
participant-level covariates and TTE data via the addition of a treatment-study interaction 
indicator variable to each model for use in IPD meta-analysis.  
Without stratification by study, it is assumed that the hazards within each study are 
proportional to a single fixed baseline hazard function, common to all studies within the 
meta-analysis. Stratification of the model allows for different baseline hazard functions for 
each study (assuming that hazards are proportional within each study), a less restrictive 
assumption when synthesising studies of variable settings and participant populations. The 
models can extend to either fixed or random treatment effects [172, 178-180] and to either 
a Frequentist or Bayesian hierarchical framework [181, 182]. Furthermore, Bennett et al 
[183] provide a comparison of three Cox PH based approaches to meta-analysis of TTE data, 
two from a frequentist framework and one from a Bayesian framework, with an additional 
consideration of the performance of such methods in the context of low event rates. 
The general form of one-stage hierarchical Cox PH models are as follows; for the 𝑖𝑡ℎ 
participant, 𝑖 = 1…𝑛𝑗 , in the 𝑗
𝑡ℎ  study, 𝑗 = 1… 𝐽 , the following models for the hazard 
function at time 𝑡 (without participant-level covariates) are proposed [37] :   
a. Fixed treatment effects with fixed (proportional) study effects 
ℎ𝑖𝑗(𝑡) = ℎ0(𝑡)exp (𝛽0𝑗 + 𝛽1𝑥𝑖𝑗)  (Equation 22) 
ℎ0(𝑡)  is the baseline hazard function in the reference study (e.g. study 𝑗 = 1  so 𝛽01  is 
constrained to be zero), 𝛽0𝑗 is the proportional effect on the baseline hazard due to the 𝑗
𝑡ℎ 
study, 𝑗 = 2… 𝐽, 𝑥𝑖𝑗  is the treatment group indicator and 𝛽1 is the ln(𝐻𝑅) for the treatment 
group compared to control group, assumed constant (fixed-effects) across all studies. 
b. Fixed treatment effects with baseline hazard stratified by study 
ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡)exp (𝛽1𝑥𝑖𝑗)   (Equation 23) 
ℎ0𝑗 is the baseline hazard function in the 𝑗




c. Random treatment effects with fixed (proportional) study effects 
ℎ𝑖𝑗(𝑡) = ℎ0(𝑡)exp (𝛽0𝑗 + 𝛽1𝑗𝑥𝑖𝑗)  (Equation 24) 
𝛽1𝑗 = 𝛽1 + 𝑏1𝑗  𝑏1𝑗 ~ 𝑁(0, 𝜏
2) 
𝛽1  is now interpreted as the mean ln(𝐻𝑅) for a distribution of treatment effects with a 
deviation from the population mean of 𝑏1𝑗 in the 𝑗
𝑡ℎ study, assuming deviations 𝑏1𝑗 follow a 
Normal distribution with mean zero and variance 𝜏2 (where 𝜏2 represents between-study 
heterogeneity). Other parameters are defined as in Equation 22 and Equation 23. 
d. Random treatment effects with baseline hazard stratified by study 
ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡)exp (𝛽0𝑗 + 𝛽1𝑗𝑥𝑖𝑗)   (Equation 25) 
𝛽1𝑗 = 𝛽1 + 𝑏1𝑗  𝑏1𝑗 ~ 𝑁(0, 𝜏
2) 
All parameters are defined as in Equation 22, Equation 23 and Equation 24. 
e. Random treatment effects and random study effects 
ℎ𝑖𝑗(𝑡) = ℎ0(𝑡)exp (𝑏0𝑗 + 𝛽1𝑗𝑥𝑖𝑗)  (Equation 26) 
𝛽1𝑗 = 𝛽1 + 𝑏1𝑗  𝑏1𝑗 ~ 𝑁(0, 𝜏
2)   
𝑏0𝑗 ~ 𝑁(0, 𝜎
2)  𝑐𝑜𝑣(𝑏0𝑗, 𝑏1𝑗) = 0  
𝑏0𝑗 is the deviation of the 𝑗
𝑡ℎ study from the overall baseline risk, assuming deviations 𝑏0𝑗 
follow a Normal distribution with mean zero and variance 𝜎2. Other parameters are defined 
as previously.  
Tudur Smith et al [174] compare these hierarchical Cox regression models with participant-
level covariates to meta-regression models with aggregate-level covariates on an empirical 
dataset. Results show that the stratified models with random-effects estimate a larger 
standard error of treatment effect and adding participant-level covariates and interactions 
into the models helps to explain variation and decreases the levels of between-study 
heterogeneity than those with fixed-effects only. Previous work has also demonstrated the 
benefit of random trial effects in a TTE setting from the sharing of information (‘borrowing 
strength’) across all trials [171, 178, 184], particularly when combining a large number of 
trials with treatment groups of small sample size [171].   
Tudur Smith et al [174] also show that evidence of treatment-covariate interaction is weaker 
in the aggregate meta-regression models than the IPD models. Also within these aggregate-
level models, effect sizes seem to be dependent on the estimation approach, precision of 
estimation is poor and there is scope for the identification of false treatment-covariate 
associations due to multiple testing potential correlations between aggregate variables. The 
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authors conclude that meta-regression with AD can be accurate if there is evidence for a 
within-study treatment-by-covariate interaction and sufficient between-study variation for 
the aggregate value of the covariate, however such information is unlikely to be reported in 
practice and the stratified IPD approach is preferred. More recent work emphasises the 
importance of the appropriate specification of one-stage IPD models with treatment-
covariate interactions by separating within-study and across-study interactions to avoid 
inadvertent ecological bias [25, 38, 41, 185], particularly within a TTE setting [25]. 
Michiels et al [186] also propose Cox PH regression models, which can be fitted in both 
Frequentist and Bayesian frameworks, to investigate heterogeneity from both variation in 
treatment effect and from difference in baseline hazard rates with via random (frailty) 
effects. The method applies random treatment-trial interaction terms and with adjustment 
for study variations such as region or population variability across studies. An assumption of 
a common baseline hazard function shape is made across the trials, allowing for varying 
magnitude of the hazard function due to systematic variation across trials. The authors apply 
their models to a large meta-analysis of 65 trials, originally analysed using a two-stage 
approach (with methods developed by Peto et al [187] for TTE data), with results showing a 
beneficial treatment effect with significant heterogeneity present.  Application of the new 
models to the meta-analysis resulted in similar pooled HRs and the addition of between-trial 
variance increased the relative weight of small trials for the overall pooled result.  
Katsahian et al [188] compare the performance of four one-stage Cox PH models; fixed-
effects, random-effects (frailty), stratified and marginal. The fixed-effects, frailty and 
stratified models are all modelled on trial-specific hazard functions which can incorporate 
heterogeneity (conditional models). The marginal model assumes a multivariate structure 
with the advantage of allowing estimation of a population averaged treatment effect [189], 
a benefit for studies of varying sample size, but  this model cannot incorporate heterogeneity. 
The authors perform a simulation study based on three separate assumptions; no 
heterogeneity present, heterogeneity in baseline risk present, heterogeneity in baseline risk 
and treatment effect present. The results of the simulation study show that standard errors 
are consistently underestimated by the marginal model, particularly for a small number of 
trials in a meta-analysis. Results also show that if heterogeneity in treatment effect is 
present, models without a random treatment-trial interaction perform poorly and the 
models with interactions tend to perform better with large numbers of trials and large 
sample sizes. The authors note that population averaged treatment effect may be of value 
where substantial heterogeneity is present in meta-analysis. 
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Rondeau et al [136] present a one-stage additive Cox model, similar to the model of Vaida 
and Xu [190] for clustered data, to jointly account for heterogeneity in meta-analysis of both 
treatment effects and baseline risk via a random treatment effect and a random interaction 
between trial and treatment effect. The authors also investigate the relationship between 
the two random-effects under the assumption that magnitude of effect is related to 
underlying risk. Rondeau et al [136] perform a simulation study, using a semi-parametric 
penalised likelihood approach to model fitting, and show that most accurate results are 
obtained for meta-analyses with large numbers of trials or large sample sizes and when a 
non-zero covariance of the two random-effects is specified (i.e. a value for the correlation 
between the two random-effects is assumed).  
The complexity of one-stage random-effects models, particularly the semi-parametric form 
of the stratified Cox models proposed by Tudur-Smith et al [37] can lead to computational 
difficulties and problems with convergence [49, 172, 185, 191], making their use within 
practice difficult [123]. To allow the implementation of these random-effects models in 
standard statistical software, Simmonds et al [191] propose an approach  which treats the 
random-effects as missing data. The authors apply the expectation-maximisation algorithm, 
approximating the expected values of the random-effects in the expectation step using 
shrinkage estimators. A simulation study and application to an example of post-operative 
radiotherapy for non-small-cell lung cancer show that this approach can provide estimates 
of random-effects without bias or loss of precision.  
Crowther et al [49] propose an alternative flexible modelling approach for hierarchical 
models a to d above using Poisson generalised linear models via a piecewise exponential 
model. Such models extend to a Frequentist or Bayesian framework, can incorporate 
treatment-covariate interactions and non-proportional hazards. Massonnet et al [192] also 
remark that frailty models are often likelihood based and such a model structure can be 
reformulated into a linear mixed model assuming clustered data structure with a random 
cluster effect and random treatment effect. This transformation is applicable to meta-
analysis under the assumption that clusters are analogous to studies. Such alternative 
methods are practical as linear mixed-effects models is more accessible in standard statistical 
packages than procedures for fitting conditional random-effects to TTE models [49, 192]. 
A simulation study shows that this Poisson approach proposed by Crowther et al [49]  
produces near identical estimates to the hierarchical Cox approach, including for all 
parameters when covariates are added to the model and the method is extremely 
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computationally efficient with coverage of Poisson models taking between 5-65 seconds 
compared to up to 29 hours for the stratified Cox models [37]. A further simulation study (on 
a cluster level) shows that model parameters (treatment effect and heterogeneity) are well 
estimated following transformation to linear mixed-effects for large numbers of clusters and 
large sizes of clusters. However this simulation was conducted assuming equal cluster sizes; 
an assumption which may not translate to meta-analysis (i.e. equal study sizes).  
Crowther et al [193] present a series of multilevel mixed effects parametric models as an 
alternative, flexible approach to previous hierarchical semi-parametric Cox model 
approaches. The authors extend parametric frailty PH models and accelerated failure time 
models, in addition to the flexible parametric model of Royston and Parmar [194], to 
incorporate any number of normally distributed random-effects estimated via adaptive or 
nonadaptive Gauss–Hermite quadrature. The authors demonstrate the application of these 
models to IPD-MA via a simulation study and a re-analysis of a previous IPD-MA in breast 
cancer, showing similar results to their previous work [49]. 
See a recent review by Debray et al [36] for an additional summary of IPD-MA methodology 
for all data types; including TTE data. 
2.3.3.2  Two-stage IPD-MA and comparison to one stage IPD-MA 
Burke et al [169] provide a tutorial of key statistical methods for two-stage IPD-MA and one-
stage IPD-MA and note that most differences between the approaches arise due to different 
modelling assumptions, rather than the choice of one-stage or two-stage itself. While two-
stage methods for IPD-MA generally allow use of ‘standard’ methodology; i.e. ‘standard’ 
methods of analysing TTE data and ‘standard’ methodology for meta-analysing study-specific 
treatment effects, a wide variety of approaches within these two stages may still be used 
[195]. A review of IPD-MAs by Simmonds et al [32, 195] found use of methods developed by 
Peto et al [187], log-rank methods [196] and Cox PH regression methods [58]. The review 
authors also discuss further methodology which could be used in two-stage IPD-MA such as 
modelling via interval censored logistic models [32]. An additional application of a two-stage 
approach is the derivation and synthesis of risk prediction models as described by Pennells 
et al on behalf of the Emerging Risk Factors Collaboration [197]. 
Haines and Hill [53] question whether it is ever appropriate to combine summary results 
produced by a variety of methods given that differences in methodology are generally 
reflective of different aims of analysis.  The authors provide an illustrative example of meta-
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analysis of repeated measures survival data of accidental falls where a range of analysis 
approaches were taken; Cox PH regression models, Andersen – Gill recurrent events models 
[198], negative binomial regression, linear regression or by reducing IPD to dichotomous 
data. The authors also make an empirical comparison to AD-MAs of published summary 
statistics only. Results show that estimated SEs seemed to be dependent on the methodology 
used, therefore by combining estimates from these different methods, the relative 
weightings in meta-analysis would be influenced by the methodology used in the studies 
rather than the actual precision of the effect estimate, resulting in biased pooled effects. 
Tudur Smith and Williamson [125] compare three methods of fixed-effects meta-analysis for 
TTE outcomes; stratified log-rank analysis (two-stage), inverse-variance weighted average of 
Cox model estimates (two-stage) and stratified Cox regression (one-stage). Theoretically, the 
three methods should produce similar estimates of the pooled ln (𝐻𝑅) and its variance when 
the underlying treatment effect is close to the null and the degree of heterogeneity is 
minimal. Also, the stratified log-rank analysis should in theory have the maximal statistical 
sensitivity for the detection of modest treatment effects. Both the simulation study and an 
illustrative example show that the methods are approximately equivalent for modest 
treatment effects and low levels of heterogeneity and for large treatment effects, the 
stratified log-rank analysis overestimates and the inverse-variance weighted average 
underestimates treatment effect. The stratified Cox regression model is the most consistent 
for varying levels of effect size and heterogeneity. The authors conclude that in practice the 
choice of the most appropriate method depends on study size, meta-analysis size, censoring 
distributions and deviation from PH assumptions.  
Bowden et al [123] compare the performance of two-stage approaches combining ‘log-rank’ 
and ‘Cox’ HRs respectively (see Chapter 2.2.1 for further details) via DerSimonian and Laird 
random-effects method [12] to a one-stage random-effects Cox model [172] fitted using 
Restricted Maximum Likelihood [199]. Via a simulation study and illustrative example, 
Bowden et al [123] demonstrate a small amount of bias in the pooled ‘log-rank’ HR as 
magnitude of treatment effect increases compared to negligible bias in two-stage and one-
stage Cox model estimates. However in absolute terms, the estimates of the two-stage and 
one-stage methods are very similar. The authors also demonstrate decreased model 
coverage and more conservative effect estimates with increasing sample size in all three 
methods due to increased HR variance under the random-effects model; an effect which 
would not be observed in fixed-effects analyses [125]. 
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2.3.4  Other meta-analytic methods 
2.3.4.1  Multivariate and network meta-analysis  
Data reported at a series of time points or over multiple correlated outcomes has a 
multivariate structure [200, 201]. In general, the methods described above in Chapters 2.3.2 
and 2.3.3 make the assumption of non-informative censoring; in other words, that an 
individual’s time-to-event is independent of any mechanism leading to censoring. However, 
where two-or-more outcomes of interest are correlated, it is likely that the censoring 
distributions of the outcomes will also be correlated; violating the assumption of non-
informative censoring [202]. For example, in the context that disease progression within a 
randomised trial is defined as a treatment failure; measured outcomes of ‘time-to-treatment 
failure’ and ‘time to progression’ would be correlated and the censoring of an individual for 
one of these outcomes would inform the other outcome.  
Multivariate meta-analysis allows the joint synthesis of correlated endpoints from multiple 
trials, taking account of both between-study correlation (i.e. association between the within-
study estimates of underlying effect sizes between studies due to differences in individual-
level and study-level characteristics) and within-study correlation (i.e. association between 
the outcomes in question) [170, 203-206]. The benefits of such a joint approach to synthesis 
have been widely discussed [145, 170, 202-206]. A particular advantage in the context of TTE 
data is the use of multivariate meta-analysis to identify and validate surrogate markers such 
as progression-free survival as a surrogate marker of overall survival [202, 207-212]. 
Arends et al [170] present a general linear mixed model for the joint analysis of two-or-more 
TTE outcomes in random-effects meta-analysis with an illustrative comparison of their 
multivariate analysis to the results of separate univariate meta-analyses. The authors 
demonstrate that multivariate meta-analysis has advantages over univariate analysis such as 
investigating associations between event-free survival and length of follow-up (short or long-
term) and investigating how both treatment difference and heterogeneity are influenced by 
population baseline risk. 
The use of multivariate models in meta-analysis will generally require a substantial amount 
of information regarding the correlation structure of the outcomes which may not be 
provided in sufficient detail within published studies [145, 201, 213] so an IPD approach may 
need to be taken [208, 214]. However, methods have been developed [145, 155, 170, 215-
217] which make use of published or indirectly estimated aggregate TTE data in multivariate 
meta-analysis (see Chapter 2.3.2 for further discussion of indirect estimation). 
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Dear [145] presents an iterative generalised modified least-squares algorithm for the joint 
fixed-effects meta-analysis of a single TTE outcome reported repeatedly over time in several 
trials, while allowing a different set of between-trial and within-trial covariates to be 
modelled for each outcome. However, in the absence of IPD, the algorithm requires standard 
errors of survival probabilities are published (or reconstructed indirectly) and that sufficient 
information regarding the correlation structure of the data is published.  
Arends et al [155]  present a model for multivariate aggregate TTE data which generalises the  
fixed-effects models of Dear [145] and a random-effects model proposed by Berkey et al 
[218] which reduces to random-effects meta-analysis model of DerSimonian and Laird [12] 
for a fixed time point. The generalised model also allows extensions to include proportional 
or non-proportional hazards and time, trial and treatment interactions.  
Fiocco et al [215-217] take a different, hazard based approach to the multivariate meta-
analysis of published survival curves under the assumption of heterogeneity between 
studies.  Using extracted or indirectly estimated information on number of events, 
proportion censored and effective numbers at risk within given time intervals, the authors 
construct piecewise hazard functions by treatment arm, constant within time intervals, via a 
Poisson correlated gamma frailty model assuming negative binomial marginal distributions 
and that the correlation structure is described by a multivariate gamma process derived by 
the authors [217]. The methodology can be used to estimate mean survival, correlation over 
time, within-studies, within and between treatment arms and the degree of heterogeneity 
between trials. The methods can be extended to incorporate study-level covariates to explain 
heterogeneity via meta-regression and can accommodate PH or non PH.   
Jackson et al [219] propose an alternative multivariate approach to AD-MA of TTE outcomes 
which models the probability of the event at multiple time points using exact binomial within-
study distributions, thus avoiding assumptions regarding hazard functions. The approach also 
extends to modelling covariates and accounting for censoring and the authors provide an 
application to an AD meta-analysis of critical leg ischemia data. 
Multivariate meta-analysis methods extend also to NMA [220]; see Chapter 1.1.2 for an 
introduction to NMA and Efthimiou et al [18] for a review of methodology for NMA. Within 
a TTE setting, tutorials have been provided on performing NMA on a ln (𝐻𝑅) scale or using 
other summary statistics such as mean or median time-to-event [221, 222]. Additionally, 
methodology has been developed to investigate the impact of non PH, parametric modelling 
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of the survival function, and extension to study-level covariates on the consistency of NMA 
results [20, 158, 159, 223]. Methodology has also been developed for the simultaneous 
synthesis of IPD and AD in a Bayesian framework [45]; this methodology also extends to the 
synthesis of IPD (censored TTE data) with summary-level count data (event count within a 
given follow-up time) where published summary TTE statistics are not available [44].  
2.3.4.2  Alternatives to the hazard ratio 
As introduced in Chapter 2.2.2, the HR is recommended as the most appropriate relative 
summary statistic of TTE data under the PH assumption and the use of RRs or ORs as an 
alternative or approximation to the HR can result in inappropriate conclusions. However, 
when the PH assumption is violated, the HR is dependent on the length of participant follow-
up and may not necessarily have an intuitive interpretation [132, 224, 225]. Furthermore, it 
has been demonstrated that even if PH violations are not a concern within individual trials, 
the PH assumption may still be violated in meta-analysis across multiple trials, which has 
implications for the interpretation of a pooled HR [224]. Various alternatives to the HR have 
been proposed which may be more appropriate under non PH such as the ratio or difference 
of medians [132, 226, 227], percentiles of survival [228, 229], survival rates [229], and most 
recently difference in restricted mean survival time (RMST) [224, 225, 229-231].  
In a meta-analytic context, Simes et al [226] proposed the pooled log ‘median ratio’ 
(𝑙𝑜𝑔 (𝑀𝑅)) by taking an average of median survival times weighted by the sample size in 
each treatment arm. However, via an empirical comparison using IPD, Michiels et al [160] 
demonstrate that this 𝑙𝑜𝑔 (𝑀𝑅)  can over or under-estimate treatment effect, with 
discrepancies mainly occurring at trial level with even more pronounced biases for low event 
rates. The authors argue that use of published median values only to calculate 𝑙𝑜𝑔 (𝑀𝑅) is 
likely to reduce in further biases and lack of statistical power where participant-level 
information regarding attrition is not available and the authors do not recommend the use 
of 𝑙𝑜𝑔 (𝑀𝑅) as a surrogate for 𝑙𝑛(𝐻𝑅).    
Moodie et al [232] present a non-parametric procedure for the evaluation of treatment 
effect in the meta-analysis of TTE which uses the log (-log) survival function difference, as an 
alternative measure when published HRs are not available. The resulting pooled effect 
estimate is interpreted as the ‘weighted average on the natural log scale of hazard ratios 
within interval [0, 𝑡] in a trial.’ The authors also discuss various weighting schemes for meta-
analysis of log (-log) survival function difference to account for precision of study-specific 
estimates and for study quality. 
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Siannis et al [228] argue that the imposition of the PH assumption across multiple trials in 
the context of meta-analysis is particularly restrictive and a more flexible parametric 
representation of treatment effects allowing for shape parameters to vary between trials 
may be preferable. The authors propose use of the pooled ‘percentile ratio’ (a continuous 
function of survival percentile) which reduces to the ‘median ratio’ for the 50th survival 
percentile, estimated via a parametric accelerated failure time model as an alternative to the 
semi-parametric PH model. Such a model would be fitted in a one stage-approach (see 
Chapter 2.3.3.1) to IPD-MA and can be fitted with fixed or random-effects in a Frequentist or 
Bayesian framework. Barrett et al [233] extend this method to the two-stage estimation of 
pooled percentile ratios using only KM estimates of the survival function, removing the need 
to make any distributional assumptions. 
Most recently, the difference in RMSTs, defined as the difference in areas under two survival 
curves to time 𝑡, has been proposed as an alternative to HR [224, 225]. Such a measure has 
direct applications to cost-effectiveness analysis [230] and the attractive properties of not 
requiring an assumption of PH and is interpreted on the scale of the time-to-event which is 
arguably a more intuitive interpretation than that of relative hazards [224, 225]. Wei et al 
[224] present three parametric and non-parametric estimation methods of RMST and 
describe the calculation of the effect size difference in RMST and associated variance as an 
alternative to HR for two-stage IPD meta-analysis of TTE outcomes. The authors compare 
different estimation methods via a simulation study and conclude that the three methods of 
estimating RMST perform similarly well.  
Lueza et al [225] extend the methods of Wei et al [224] to consider the use of difference in 
RMST in meta-analysis from addition estimation methods and across a wider range of 
simulated meta-analysis parameters such as variations in heterogeneity in baseline risk and 
treatment effect, fixed or random-effects, number of trials and number of participants. The 
authors conclude that pooling of trial-specific KM curves under DerSimonian-Laird random-
effects [12] provides the best compromise across all scenarios of estimating difference in 
RMST for an IPD-MA. Both Wei et al [224]  and Lueza et al [225] also demonstrate the use of 
RMST in meta-analysis via reanalysis of IPD-MA in cancer and both author groups conclude 
that that difference in RMST is a useful and interpretable effect measure for IPD-MA.    
Combescure et al [234] note that interest may not always lie in a relative comparison of two 
interventions and the authors propose an approach for the meta-analysis of the published 
survival curves of single treatment arms to obtain a distribution free summary survival curve 
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assuming random-effects via product-limit estimation. The method allows for the estimation 
of pooled mean and median survival times, as well as estimates of heterogeneity between 
the published survival curves. The authors demonstrate the method via a simulation study 
and an application to an AD-MA of graft survival following kidney transplant. 
2.4  Discussion 
Meta-analyses of TTE data are commonly performed, particularly in the field of oncology. A 
range of methods have been developed to allow synthesis of TTE data depending on the type 
of data available (IPD or summary (AD) level only), use of fixed or random-effects, the desire 
to explore heterogeneity of treatment effect or baseline risk via the addition of participant-
level or study-level covariates or treatment covariate interactions and whether the 
proportional hazards can be assumed. Many such meta-analytic methods also extend other 
synthesis approaches such as multivariate and network meta-analysis. 
This chapter presents a methodological review of many important methods used in the 
synthesis of TTE data as well as a summary of the reliability and applicability of many of these 
methods in practice. 
It is widely accepted that an IPD approach to meta-analysis is the ‘gold-standard’[24]; 
particularly for TTE data [6]. This is reflected in many methods which have been developed 
in the last decade require an IPD approach, particularly the development of one-stage 
approaches allowing clinical questions of growing complexity to be addressed via the 
addition of random trial and participant effects or by participant-level covariates and 
treatment by covariate interactions [36]. The practical use of some of these methods has, 
however, been questioned due to the complexity of some modelling assumptions leading to 
problems with convergence and various alternative, more accessible, approaches have been 
suggested [49, 123]. 
It must not be forgotten that within many settings, a complete IPD approach to synthesis 
may not be feasible and a partial or complete AD approach to meta-analysis may be required 
[6]. It is also well documented that within a TTE setting, summary statistics required for meta-
analysis are rarely published (see Chapter 3 for further discussion), therefore a range of 
methods have been developed which make use of more commonly reported summary 
statistics and published survival curves to indirectly estimate hazard ratios and associated 
variances. The methods proposed by Parmar et al [6], later translated into ‘plain language’ 
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and implemented to a macro enabled spreadsheet for use by non-expert users by Tierney et 
al [128], are perhaps the best known of these methods. While such methods are theoretically 
useful and accessible to statisticians and non-statisticians alike, it has been questioned 
whether such methods are useful in practice as often the summary statistics required to 
make use of such methods aren’t reported either, or published graphical figures are of too 
poor quality to adequately make use of graphical estimation methods [6, 141, 144].  
Furthermore, some applications including simulation studies have shown that some of the 
indirect estimation methods proposed become biased in certain scenarios and if used, would 
introduce bias into meta-analysis [6, 141, 142]. 
The information presented within this chapter is a review of methodological literature with 
relevance to this thesis, rather than a systematic review of all methods developed for meta-
analysis of TTE. While this is a limitation, the search techniques employed to inform this 
methodological review were broad (see Chapter 2.3.1), therefore it is unlikely that any 
important methodology in relation to this thesis was missed. 
In summary, meta-analytic techniques of TTE data have been proposed for and applied to a 
wide range of clinical and methodological scenarios. While the availability of IPD allows for 
more complex meta-analytic modelling of TTE data and a wide variety of indirect methods 
have been suggested where IPD and published AD are not available, it is important that as 
this research field continues to develop, the applicability and accessibility of new 
methodology is kept in mind. 
Chapter 3 and Chapter 8 of this thesis make an assessment of published summary statistics 
for TTE outcomes epilepsy monotherapy trials and demonstrates the applicability of these 
indirect methods within this setting. Chapter 6 and Chapter 7 present the methodology and 




Chapter 3: Aggregate time-to-event (TTE) data: a 
systematic review of reporting of outcomes and 
statistical analyses in epilepsy monotherapy trials 
3.1  Introduction 
An individual participant data meta-analysis (IPD-MA) is considered to be the ‘gold-standard’ 
approach to data synthesis for many reasons (see Chapter 1.1.4 for a more detailed 
discussion) [23, 24]. These reasons include the ability to comprehensively undertake time-to-
event (TTE) analyses and the standardisation of outcomes and analyses across studies. 
Inconsistency of definitions, reporting and presentation of outcomes, effect sizes and 
statistical analyses for TTE outcomes have been documented since the early 1990s [31, 144, 
160, 235-237].  Due to this inadequate reporting, an IPD analysis is often the only approach 
that can be taken for TTE data. The consistency and quality of reporting of TTE data is 
particularly important in an evidence synthesis context where aggregate data meta-analyses 
(AD-MA) can only use published information.  As earlier outlined in Chapter 2.3.2, methods 
have been developed for the indirect estimation of TTE measures required for AD-MA from 
other published statistics [6, 13]. However, in practice, it is uncommon for the statistics 
required for indirect estimation to be reported either [141, 144, 160, 161]. 
This chapter summarises previous work on the reporting of aggregate TTE data and extends 
this methodology to a systematic review of the reporting of TTE outcomes and associated 
statistics in epilepsy monotherapy studies.  
3.1.1  Summary of previous reviews of aggregate TTE data 
Table 1 and Table 2 summarise the findings of previous reviews of aggregate TTE data. 
The first review to investigate the reporting of TTE analyses was conducted in the 1990s [31]. 
The authors considered 132 studies with TTE endpoints published in five oncology journals.  
In summary, 11 out of the 132 (8%) papers failed to state how many participants were 
analysed, almost half of the papers (48%) did not give any summary of length of follow-up 
and in 62% of papers at least one end point was not clearly defined.  Results were often 
reported with p-values only; 63 out of 84 papers performed log-rank analyses (75%) and 22 
out of 47 (47%) performed ‘multivariate’ analyses reported p-values. Less than a sixth of 
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papers using log-rank analyses (10 out of 84, 12%) and only half of those using ‘multivariate’ 
analyses (25 out of 47, 53%) reported a survival estimate or effect size such as hazard ratio 
(HR) or odds ratio (OR) and even fewer reported an associated measure of precision such as 
a standard error or confidence interval.  
Survival plots were presented in 95% of the papers; however, the quality of survival plots was 
deemed poor in 42 out of 117 (37%) papers with the most common issues being censored 
observations not marked, poor or unhelpful numerical axis, survival curves of two groups for 
comparison not clearly distinguished, inadequate or no legend reported and inconsistency 
between curves and other reported results.   
Overall, the presentation of analyses and graphs was deemed adequate in only 21% of papers 
(28 out of 132) of [31]. The authors report an appendix of guidelines for the reporting of 
survival analyses and a later series of tutorial papers for the conduct of such analyses [31, 
238-240]. 
Table 1: Characteristics of previous reviews on the reporting of aggregate TTE data and 
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Table 2: Summary of the reporting of TTE outcomes and statistical analysis; previous work and current systematic review of epilepsy  
monotherapy studies 
Information or summary statistic 
Review Number1  























Median follow-up time reported 
39% NR 60% NA 57% 26% 41% 78% NA 13% 
Minimum and maximum follow-up time reported 
NR NR 25% NA NR 6% 2% NR NA 19% 
Any summary of follow-up time reported 
55% NR NR NA 57% 69% 76% 91% NA 76% 
Method for calculating the median follow-up reported 
12% NR NR NA 2% NR NR NR NA 0% 
Sample size calculation reported 
93% NR NR NA 78% 14% 28% NR NA 50% 
Outcome(s) clearly defined 
38% NR NR 42% 52% NR NR 66% 49% 55% 
Time origin clearly defined 
52% NR NR 76% 78% NR NR NR 60% 65% 
Event of interest clearly defined 
NR NR NR 70% 79% NR NR NR 87% 78% 
Censoring clearly defined 
NR NR NR 47% 58% 30% 39% NR 49% 55% 
Analysis methods for losses to follow-up reported 
26% NR NR NR NR NR NR NR 48% 56% 
Number of participants analysed 
92% NR NR NR NR 100% 99% NR 95% 93% 
Number of events reported 
45% NR 74% 65% 72% 71% 75% 72% 73% 63% 
Observed and expected number of events 
NR NR 1% NR NR NR NR NR 0% 0% 
Multivariable analysis used 
36% NR NR NR NR NR NR 59% 45% 65% 
Cox regression used 






Hazard Ratio presented 
NR 3% 52% NR 52% NR NR 87% 32% 31% 
Hazard Ratio and CI presented 
NR NR 51% NR NR NR NR 87% 32% 31% 
Any effect size presented 
NR NR NR 93% 95% NR NR NR 45% 44% 
Any effect size and CI presented 
NR NR NR 61% 67% 53% 94% NR 45% 44% 
Adjusted effect size presented (from a multivariable analysis) 
12% NR NR NR NR NR NR NR 21% 31% 
Adjusted effect size and CI presented (from a multivariable 
analysis) 
19% NR NR NR NR NR NR NR 21% 31% 
Log-rank p-value presented 
57% 37% 97% NR NR NR NR NR 40% 48% 
Cox model p-value presented 
27% NR NR NR NR NR NR NR 14% 15% 
Median survival presented 
2% 73% 59% NR 46% NR NR NR 19% 26% 
Subgroup analyses presented 
52% NR NR NR NR NR NR 56% 30% 39% 
Survival probability presented 
2% 43% 71% NR NR NR NR NR 61% 72% 
Survival curve presented 
95% NR 94% NR 92% 95% 86% 100% 76% 93% 
Number at risk presented 
8% NR 38% 45% 53% NR NR 66% 22% 17% 
Abbreviations: CI – Confidence Interval; NA – not applicable (items are applicable only to study-level reporting); NR – Not reported 




Pocock et al [241] have also made recommendations regarding the presentations of survival 
plots in published literature. The authors emphasise the difference in graphical 
interpretation depending on the direction of the survival curve and event rate in terms of 
absolute and relative treatment difference. Pocock et al [241] also argue that an effect size 
and related measure of precision should be presented alongside a survival curve to aid with 
visual interpretation. 
A literature review of 131 comparisons of chemotherapy drugs in metastatic lung cancer 
conducted by Michels et al [160] shows the median survival time to be the most commonly 
reported summary statistic (73% of studies). In their review, only 3% of studies reported a 
HR, 37% reported a p-value and 43% reported one year survival in the text of the published 
report or clearly on a survival plot. 
Mathoulin-Pelissier et al [236] and Arkenau et al [237] conducted systematic reviews of 125 
and 144 oncology RCTs respectively and noted inadequacies in relation to the definitions and 
reporting of important recommended TTE outcomes such as overall survival and progression 
free survival. Arkenau et al [237] note that binary response rates are reported more 
frequently than TTE outcomes (i.e. proportion surviving rather than survival time) and note 
on a lack of standardisation of definition of TTE intervals. For example, from the colorectal 
cancer studies included in their review, time origin for survival time was defined as date of 
disease diagnosis, date of enrolment into trial or date of first visit to oncologist.  Arkenau et 
al [237]  note that a lack of a uniform definition could potentially impact on the ability to 
combine trials with differently defined endpoints in meta-analysis.   
Mathoulin-Pelissier et al [236]  also assessed several areas related to reporting of TTE 
outcomes and statistics. Out of 125 oncology studies; time origin was defined in 98 (78%), 
the event of interest was defined in 99 (79%) and the number of events were reported in 90 
(72%), censoring events were defined in 73 (58%) and the number of patients at risk were 
reported in 66 (53%). Further, median follow-up was reported in 71 (57%) and an estimation 
of survival or effect size was reported in 119 (95%); HR in 65 (52%) of studies and difference 
in median survival in 57 (46%) and survival curves were presented in 115 (92%). Mathoulin-
Pelissier et al [236] conclude that standardised definitions of survival endpoints, events, 
censored events and follow-up should be developed to improve the reporting and 
interpretation of results in cancer clinical trials. 
Hirooka et al [144] performed a similar review to that of Altman et al [31], of phase III RCTs 
published between January 2004 and December 2005 from two oncology journals with the 
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objective of determining whether the indirect estimation methods of Parmar et al [6] could 
be used in practice (see Chapter 2.3.2 for further details).  From 129 included articles, only 
66 (51%) reported a HR and confidence interval that could be directly used in an AD-MA. Only 
2 studies (1%) reported observed and expected numbers of events required for use of the 
direct Peto method [10]. While 125 studies (97%) reported log-rank p-values and 96 studies 
(74%) report the number of events, only 35 (27%) reported both statistics required for 
indirect estimation [6]. Also while 121 (94%) of the studies presented KM plots only 49 (38%) 
provided the numbers at risk required for the estimation method of Williamson et al [13] and 
only 32 (25%) provided minimum and maximum follow-up times required for the Parmar et 
al [6] indirect estimation method.  Hirooka et al [144] note that median survival time is the 
most common effect size reported in 76 studies (59%). 
More recent work conducted by Abraira et al [242] comparing survival analyses published in 
1991 to those published in 2007 in 13 high impact internal medicine, cardiology, nephrology 
and oncology journals has shown a large increase in the number of published analyses but 
little improvement in the quality of reporting in these analyses between 1991 and 2007. 
Abraira et al [242] emphasise the lack of reporting of numbers of events and follow-up time 
in around 30% of studies and highlight the lack of articles reporting any checks or validations 
of important statistical assumptions, such as the PH assumption [58]. Batson et al [243] also 
highlight the lack of details reported in oncology trials published in 2015 regarding validation 
of the statistical models in terms of the PH assumption and the potential impact on the 
interpretation of such unvalidated data for meta-analysis, NMA and health technology 
assessment. Both author groups call for recommendations to improve the reporting of 
survival analyses in journal articles and Abraira et al [242] propose an appendix of minimum 
requirements for the reporting of survival analyses. 
While some reviews of this topic [31, 160] were conducted and published before the 
introduction of the CONSORT statement for improving the quality of reporting of randomised 
controlled trials first published in 1996 [244],  revised in 2001 [245] and updated in 2010 
[246]; more recent work published after 2008 [144, 236, 237, 242, 243] demonstrates levels 
of reporting similar to that reported over 10 years earlier.  
Variability of outcomes and reporting is not restricted to single studies. Floriani et al [235] 
reviewed 15 AD-MAs of comparative cancer studies published after 1985 and found a large 
variation in the summary statistics reported and methods used for outcome evaluation. Four 
of the meta-analyses evaluated the total number of deaths, five compared survival at a single 
fixed time point, three compared survival at multiple time points, two compared median 
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survival time and three compared the hazard rate. In terms of pooled summary statistics 
reported, nine used an OR, three used HR, two used RR, one used risk difference, and two 
used difference in log median survival. Only four of the 15 reviews accounted for censoring 
in analysis. Floriani et al [235] raise their concerns over this heterogeneity of reporting which 
may compromise the reliability and interpretation of results. 
Guyot et al [157, 247] argue that the poor reporting of studies and reviews with TTE 
outcomes may be due to lack of clarity in guidelines of what should be reported. The 
Cochrane Handbook of Systematic reviews [248] advises that effect size should be expressed 
as a HR and the CONSORT statement recommends that “the measure could be the HR or 
difference in median survival time.” [245] 
Neither recommends the reporting of a measure of precision (standard error, variance, 
confidence interval) which is required for meta-analysis even though the CONSORT 
statement recommends the reporting of a measure of precision for continuous and 
dichotomous outcomes.  Furthermore, the HR or difference in median survival gives no 
indication of average prognosis in each trial arm which is generally required for cost-
effectiveness analysis. Guyot et al [157, 247] also recommend the reporting of numbers of 
events and effective numbers at risk (potentially in the form of a life table) to facilitate 
evidence synthesis and economic evaluations of TTE event data. 
3.1.2  TTE outcomes in published epilepsy monotherapy trials  
Previous reviews of the reporting of TTE analyses have mainly considered trials in the field of 
oncology where the focus of the trials is usually ‘survival’ (i.e. time-to-death) [31, 144, 160, 
235-237]. As outlined in Chapter 1.1.4, there are other clinical areas where important 
outcomes require the analyses of TTE data; one of these conditions is epilepsy. 
The majority of people with epilepsy can achieve remission of seizures following treatment 
with a single antiepileptic drug (AED monotherapy) [71, 249] and recruitment populations 
for such a design include newly diagnosed patients, patients previously intolerant to or 
inadequately treated with a single drug, and patients previously successfully treated who 
relapse on discontinuation of their previous regimen [249]. 
A monotherapy trial has one of two designs; a ‘complete’ monotherapy in which all 
participants are AED naïve and receive only the allocated drug throughout the whole trial 
period or a withdrawal / conversion to monotherapy design in which any pre-study AEDs are 
discontinued before randomisation and then all participants receive only the allocated drug 
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throughout the whole trial period. The conversion to monotherapy design is thought to be 
useful as a proof-of-principle investigation (i.e. proof of efficacy) but of limited use in routine 
clinical practice with a complete monotherapy design being more pragmatic [250, 251]. 
Epilepsy monotherapy trials are usually designed to measure efficacy, tolerability and overall 
effectiveness of AEDs [249]. The Commission on AEDs of the International League Against 
Epilepsy (ILAE) [249, 252, 253]  defines ‘efficacy’ as the ability of a medication to produce 
seizure-freedom and ‘tolerability’ is related to the ‘incidence, severity and impact’ of AED-
related adverse events, most importantly those which lead to the discontinuation of a drug. 
It is recommended that ‘retention time,’ defined as time-to-withdrawal of allocated 
treatment after randomisation due to inadequate efficacy and/or poor tolerability [249] over 
a “long-term” treatment period of at least 48 weeks [252, 253], should be used as the primary 
outcome for monotherapy trials as this is a combined ‘effectiveness’ outcome reflecting both 
efficacy and tolerability. This is the outcome of greatest clinical utility and relevance [254] 
and retention is an outcome to which the individual makes a contribution. This is the 
outcome adopted as the primary outcome for systematic reviews of monotherapy studies 
performed by the Cochrane Epilepsy Group [59-67, 69]. It is also recommended that the 
primary ‘effectiveness’ outcome should also be supported by secondary outcomes of efficacy 
and/or tolerability [249, 251, 254]. The secondary efficacy outcomes adopted in Cochrane 
Epilepsy reviews of monotherapy studies are time-to-12-month remission, time-to-6-month 
remission and time-to-first seizure, in addition to a summary of the tolerability of the 
treatments in terms of reported adverse events [59-67, 69]. 
Guidelines proposed by the European Medicines Agency Committee for Proprietary 
Medicinal Products (CPMP) in 2000 [255] and updated in 2010 [251] make generally similar 
recommendations to those of the ILAE guidelines [249, 252, 253], but some differences 
relating to recommended outcomes in monotherapy studies. These guidelines recommend 
that for epilepsy monotherapy studies [251, 255]: 
“…in newly diagnosed patients the primary efficacy variable should be based on the 
proportion of patients remaining seizure-free for at least six months (excluding the 
dose escalation period). However the trial should have a minimum duration of one 
year in order to assess safety and maintenance of efficacy…” 
and that possible secondary efficacy variables may concern; 
“…a treatment retention time, measuring the combination of failed efficacy and 
tolerability, enables to assess the global clinical effectiveness of the drug.” 
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Despite guidelines from the ILAE [249, 252], International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use [254] and European Medicines 
Agency [251, 255] that a primary outcome of effectiveness or efficacy should be clearly 
defined in monotherapy trials, little uniformity in the definition of outcomes has been shown. 
For example, while the majority of trials will measure and report an efficacy outcome relating 
to seizures, some trials will record time-to-first seizure following randomisation [256] while 
others will record seizure-freedom at a specific time point (e.g. 12 months after 
randomisation) [257] or change in seizure frequency over a period of time [258].  
There is also a lack of uniformity of statistical analyses performed and reported in 
monotherapy trials. While the majority of monotherapy trials aim to compare one AED 
compared to another in terms of efficacy and tolerability, statistical analyses performed in 
trials range from reporting counts of seizure and adverse event frequency only [259], to 
multivariable Cox regression modelling to adjust for relevant prognostic factors [260], to 
complex and innovative trial designs to demonstrate non-inferiority of a newer AED 
compared with a “standard” treatment [261, 262]. 
An ILAE investigation [252]  of epilepsy monotherapy RCTs and systematic reviews conducted 
up to 2006 and updated in 2013 [253] concluded a paucity in high quality evidence due to 
“alarming lack of well-designed, properly conducted epilepsy RCTs,” and therefore 
insufficient information to “answer important clinical questions” and better inform 
treatment policy. However, this investigation places a high level of importance on the 
blinding of studies which some investigators believe may not be possible or ethical in epilepsy 
monotherapy and not representative of pragmatic clinical practice [256, 263-265] despite 
previous ILAE guidelines recommending that comparative monotherapy studies “should aim 
to replicate usual clinical practice as closely as possible [249].” The investigation is also critical 
of studies conducted for “regulatory and marketing-driven” purpose with protocol driven 
endpoints and populations that may “bias the results in favour of the sponsors’ product” and 
would not  “reflect routine clinical care, meaning that results may not be fully generalizable 
to routine practice [252].” 
Less emphasis is given in the investigation to the accuracy and quality of statistical analysis 
and reporting in studies; these aspects are essential for the synthesis of trial results to inform 
clinical practice and future research. The investigation concludes that demonstrating 
differences statistically between drugs in terms of efficacy and tolerability “has been very 
hard to show, except in a few studies [252],” and furthermore it has not been possible to 
demonstrate many convincing differences between AEDs in systematic reviews and meta-
 46 
 
analysis conducted by the Cochrane Epilepsy Group [59-67]. However, it is difficult to know 
whether this apparent lack of convincing differences between AEDs is due to a true absence 
of differences between treatments or whether individual results may been biased due to 
inappropriate study designs and analysis of “methodologically flawed” studies. 
The choice of study design in epilepsy has also been widely debated in the literature. An 
argument against the superiority design [252] if a study fails to show significant differences 
in seizure control between treatments is that seizure remission rates could be related to the 
natural history of the disease rather than efficacy of administered drugs, particularly in newly 
diagnosed individuals [71, 266]. Therefore in order to obtain a licence for monotherapy, it is 
now necessary to demonstrate non-inferiority of an experimental drug to an established 
comparator at its optimum dose [251, 267]. However, a finding of equivalence or non-
inferiority does not exclude that in the particular population and under the specific 
conditions in which the trial was undertaken, both treatments could have been similarly 
ineffective [250], particularly if trials of a statistically complex non-inferiority or equivalence 
design have not been adequately powered or results and conclusions interpreted 
appropriately under the assumptions of equivalence or non-inferiority [252, 253]. 
The variation in the designs, definitions and type of outcome reported as well as variable 
approach to statistical analysis makes undertaking a meta-analysis of epilepsy monotherapy 
trials difficult without performing an IPD review. While such an approach is considered ‘gold-
standard’ for TTE outcomes [23, 24], obtaining and re-analysing IPD is time consuming and 
resource intensive. Often, potentially relevant information has to be excluded from meta-
analysis if IPD is not available and summary information for an outcome has not been 
reported adequately or not reported at all [59-67, 69].  Some updates of Cochrane reviews 
have taken many years to complete or updates are still ongoing [67], due to the time required 
to obtain, prepare and analyse IPD (see Chapter 5 for further discussion).  
The choice of initial AED for an individual should be based on the highest quality evidence 
from randomised controlled trials and systematic reviews regarding the potential benefits 
and harms of all available treatments. If potentially important evidence is excluded from the 
evidence base of a systematic review due to lack of standardisation of outcome reporting 
across trials or insufficient, inadequate quality of outcome and statistical reporting, 
implications for clinical practice and medical decision making are inevitable.  
At the time of writing, we are not aware of a review which systematically considers the 
reporting of TTE data in all trials within a context outside of oncology or within a context of 
TTE data without a ‘survival’ focus.  
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Therefore, the aim of this chapter was to extend previous work described in Chapter 3.1.1 by 
systematically reviewing all epilepsy monotherapy trials, with a particular focus on the 
definitions and reporting of primary outcomes and the use of TTE analyses when making 
treatment comparisons, in order to better inform and improve reporting standards for future 
RCTs, systematic reviews and evidence synthesises and therefore clinical practice. 
3.2  Methods 
3.2.1  Systematic Search  
In order to identify all epilepsy monotherapy trials, a systematic search of the Cochrane 
Epilepsy Group’s specialised register was carried out by the group’s information specialist 
(GC, see Appendix 2 for the search strategy). 
3.2.2  Eligibility Criteria 
3.2.2.1  Inclusion criteria 
 Randomised, controlled trials of adults and/or children of all parallel designs (e.g. 
superiority, non-inferiority, equivalence etc.) reported in a full-text journal article. 
 Study participants with epileptic seizures of any kind except those requiring emergency 
treatment in hospital settings (see Exclusion criteria). 
 Monotherapy design studies with drug naive participants and withdrawal/conversion to 
monotherapy studies (e.g. all participants current AED treatment tapered off during 
titration phase of study) are included if all participants are converted to monotherapy 
without an add-on treatment period of any length.  
 Two-or-more active treatments are compared, dose-controlled or placebo-controlled 
designs. ILAE guidelines debate ethical issues in the use of placebo controls [249, 252]. 
However, such designs provide the majority of the evidence base for some epileptic 
syndromes of childhood (such as benign epilepsy of childhood with centro-temporal 
spikes (BECTS))[252], therefore studies of a placebo-controlled design were included.  
3.2.1.2  Exclusion criteria 
 Non-randomised or observational studies or report which is not a study such as letters, 
comments on journal articles, clinical summaries, book chapters etc. 
 Cross-over studies; such a design cannot adequately measure long-term TTE outcomes 
of interest and do not replicate routine clinical practice in monotherapy treatment [249]. 
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 Full-text not originally published in English to allow for an assessment of outcome and 
statistical reporting by English speaking reviewers. 
 Studies with an add-on or poly-therapy phase of any length. 
 Withdrawal of monotherapy comparisons (withdrawal of treatment to no treatment) as 
such a design does not aim to evaluate AED efficacy. 
 Pharmacokinetic studies (e.g. comparison of two preparations of the same drug) as such 
studies consider the chemical effect of the drug rather than medical effect. 
 Studies in which the randomised comparison made is not between AED treatments (e.g. 
randomisation of methods of treatment delivery (fast vs. slow titration)). 
 Studies of emergency IV treatment with AEDs (e.g. status epilepticus, infantile spasms) 
as such studies are too short-term to measure TTE outcomes of interest.  
 Other types of non-epileptic seizures (e.g. post traumatic, alcohol withdrawal, febrile). 
 Studies with healthy controls (no epilepsy) or participants with a single seizure (epilepsy 
is defined as the occurrence of two-or-more unprovoked seizures)[268]. 
3.2.3  Screening of Studies  
All studies identified in the systematic search of the Cochrane Epilepsy Group Specialised 
Register were screened for eligibility by SJN. Title and abstract screening was first performed, 
followed by full-text screening and reference lists of included studies were also screened for 
further eligible studies. If a full-text manuscript of an abstract could not be found, the 
abstract was excluded.  Any uncertainty over eligibility of studies was discussed with AGM 
and CTS and a decision was made whether to include or exclude the study. Secondary 
analyses or multiple publications of the same subset of participants were included if different 
outcomes were measured and treated as separate ‘studies’ (i.e. data extraction for each 
study was performed using only information from a single publication; any online 
supplementary material linked to the single publication was considered but no external 
information from related publications was used). 
3.2.4  Data Extraction 
Data extraction was performed in four stages using a piloted data extraction form (see 
Appendix 3) converted into a Microsoft Access database which was used to create a database 
of all extracted data. A screenshot of the database is provided in Appendix 4. 
The content of the data extraction form was based on the recommendations for the 
reporting of outcomes in epilepsy monotherapy studies from the ILAE [249, 252], guidelines 
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for the reporting of survival outcomes and analyses in Altman et al [31], recommendations 
for the presentation of survival plots in published literature from Pocock et al [241] and the 
summary statistics required to use the indirect estimation methods for TTE analyses as 
described by Parmar et al [6] and Williamson et al [13]. Data extraction was performed on all 
studies by SJN and LS independently extracted from a subset of 10% of studies.  Agreement 
between extractions was good and any discrepancies were resolved by discussion.  
The first stage of data extraction was performed on all eligible studies identified in the search. 
This stage of data extraction included a question which acted as an indicator variable; “Is at 
least one time-to-event outcome reported?” with possible responses Yes, No or Unclear. If it 
was clear that no TTE outcomes were reported for the study, data extraction was considered 
complete. If a study did report at least one TTE outcome or if it was unclear whether a TTE 
outcome had been reported from the definition of all reported outcomes, further data 
extraction was performed including study design and characteristics, definition of outcomes, 
statistical analyses and presentation of results for each reported TTE outcome of the study.  
It was anticipated that the following TTE outcomes would be reported in the studies: time-
to-withdrawal of allocated treatment, time-to-first seizure, time-to-6, 12 or 24 month 
remission of seizures and time-to-exiting the study. Extraction was performed according to 
the definition of the outcome as described in the study publication and TTE outcomes were 
classified as meeting the definition of one of the pre-defined outcomes above or other. 
3.2.5  Data analysis and presentation of results 
Numerical results are presented as medians and ranges or numbers and percentages as 
appropriate. No formal statistical analyses were conducted. 
3.3  Results  
3.3.1  Results of the search 
From an electronic search outlined in Chapter 3.2.1 and conducted on 14th September 2012, 
1007 references were identified and downloaded into Endnote Software. Applying inclusion 
and exclusion criteria outlined in Chapter 3.2.2, 822 references were excluded from title and 
abstract screening and 185 full-text articles were screened for inclusion in the review. Full-
text screening included fifteen conference abstracts which were linked to full-text articles 
that were not found in the search. Seventy-seven full-text articles were excluded resulting in 
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108 full-text epilepsy monotherapy studies for eligible for inclusion in the review. See Figure 
2 for a study flow diagram of the screening process, including reasons for exclusion at each 
screening stage and see Appendix 5 for a reference list of the 108 included studies. 
The 108 eligible studies were published between 1978 and 2012. The majority of studies (91 
out of 108 studies, 84%) were published in speciality Epilepsy or Neurology journals such as 
Epilepsia (21 out of 108 studies, 19% of total studies), Neurology (13 studies, 12%), Epilepsy 
Research (12 studies, 11%) and Epilepsy & Behaviour (11 studies, 10%). The remaining 17 
studies were published in general (and some high impact) medical journals such as the 
Lancet, the British Medical Journal and the New England Journal of Medicine. See Table 31 
and Table 32 in Appendix 6 for further details of publication dates and journals.  
3.3.2  Outcomes reported in Epilepsy Monotherapy studies  
Considering all outcomes of any data type (TTE or otherwise), the 108 studies reported a 
median of 4 outcomes per study (range 1 to 9 outcomes per study). Fifty-four studies out of 
the total 108 eligible studies (50%) were deemed as not reporting a TTE outcome and data 
extraction was therefore complete. Outcomes (as reported in study publications) are listed 
for the 54 studies without a TTE outcome in Table 31 (Appendix 6). No further data extraction 
was performed for these 54 studies. 
Forty-six out of 108 studies (43%) clearly reported at least one TTE outcome and for eight 
studies (7%), it was unclear whether a TTE outcome had been reported.  Uncertainty arose 
for two reasons:  
1. In six studies the definition of the outcome implies a categorical nature (i.e. the outcome 
is defined as a percentage, rate etc.) or the statistical analysis section of the paper states 
or implies that the outcome is to be analysed with statistical methods for categorical data 
(chi-squared test, Fisher’s exact test, logistic regression etc.). No statistical methods 
relating to TTE analyses are described for this outcome, however in the results section a 
KM curve (or unnamed “survival” plot) is presented for the outcome. As the definition of 
the outcome is unclear and no time-to-event statistical analyses have been specified, it 
is unclear whether the censored nature of the data has been properly taken into account 
and whether the outcome has been analysed appropriately as a TTE outcome.  
2. Two studies report the “Mean time-to-withdrawal.” The use of ‘mean’ in relation to TTE 
data is considered inappropriate due to the likely skewed nature of the data (see Chapter 
1.1.4). Therefore it is unclear whether censoring has been taken into account properly in 
the analyses of these outcomes or if they have been analysed as continuous outcomes.  
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Outcomes (as reported in study publications) for the 46 studies with at least one TTE outcome 
and the 8 studies in which a TTE outcome may have been reported (unclear) are listed in 
Table 32 (Appendix 6). Some of the outcomes reported in the 54 studies were vague in 
definition such as ‘overall assessment of efficacy and tolerability,’ ‘seizure rating score,’ 
seizure control’ and ‘adverse events reports.’ Further data extraction was conducted on 
these 54 studies; for this purpose, the ‘unclear’ outcomes in eight studies (see Table 32 
(Appendix 6) for details) were treated as TTE outcomes. 
3.3.3  Characteristics of Epilepsy Monotherapy studies reporting at least 
one time-to-event outcome 
See Table 1 and Table 2 for a summary of the reporting of outcomes and statistical analyses 
in the 54 epilepsy monotherapy studies.  
3.3.3.1  Study and Participant Characteristics 
See Table 3 for a summary of the study and participant characteristics. Out of the 54 studies, 
42 had two treatment arms (78% of total), five had three arms (9%), six had four arms (11%) 
and one had five arms (2%).  
Forty-one studies (76%) followed a monotherapy design and the other 13 studies (24%) 
followed a withdrawal or conversion-to-monotherapy design (see Chapter 3.1.2 for 
definitions of designs). Twenty-eight studies (52%) recruited AED-naive individuals with 
newly diagnosed seizures only, seventeen studies (31%) recruited both AED-naïve newly 
diagnosed participants and currently untreated participants who had failed a previous AED 
or with relapsed seizures after remission and nine studies (17%) recruited individuals with 
refractory / drug resistant seizures only. 
The majority of studies (41 studies, 76%) had an active comparator design comparing two-
or-more antiepileptic drugs (AEDs), six studies (11%) had a dose-controlled design (i.e. 
comparing doses of the same AED), four studies (7%) had both a dose-controlled and active 
comparator design and three studies (5%) were placebo-controlled. 
The majority of the studies (42 studies, 78%) were of a superiority design.  Seven studies 
(13%) were of a non-inferiority design and three studies (5%) were of an equivalence design; 
however, three of these studies did not describe a sample size calculation or statistics relating 
to an appropriate non-inferiority boundary or equivalence range. One study was of a ‘double 
triangular sequential’ design (2%) and the sample size calculation for this design was 
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described and one study (2%) reported that “the study was not powered to detect statistical 
differences in efficacy.” 
Table 3: Study designs and participant characteristics of 54 epilepsy monotherapy studies 
Design or characteristic 
Number of studies 
 (% of 54 studies) 
Therapeutic Design 
Monotherapy 41 (76%) 
Conversion / withdrawal to monotherapy 13 (24%) 
Participant population 
Antiepileptic drug (AED) naïve participants only 28 (52%) 
AED naïve and currently untreated participants 17 (31%) 
Refractory / drug resistant seizures 9 (17%) 
Type of control 
Active comparator 41 (76%) 
Dose-controlled 6 (11%) 
Active comparator and dose-controlled  4 (7%) 
Placebo-controlled 3 (5%) 
Statistical Design 
Superiority 42 (78%) 
Non-inferiority 7 (13%) 
Equivalence 3 (5%) 
Double triangular sequential 1 (2%) 
Descriptive only 1 (2%) 
Blinding 
Double-blind 36 (67%) 
Single-blind 2 (4%) 
Open label 13 (24%) 
Unclear or not stated 3 (5%) 
Funding 
Pharmaceutical funded 29 (54%) 
Public funding 9 (17%) 
Pharmaceutical and Public funded 5 (9%) 
No funding source stated 11 (20%) 
Role of the funding source 
Funding source involved 6 (11%) 
Funding source not involved 4 (7%) 
Funding source involvement not stated 44 (82%) 
 
Thirty-six studies (67%) described a double-blind design, however only 15 of these studies 
provided any details of who was blinded and how the blinding was achieved. Two studies 
(4%) described a single-blind design of outcome assessors and 13 studies (24%) had an open-
label design. Out of the remaining three studies, one made no mention of blinding and two 
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described ‘partially’ blinded designs due to variation in titration periods of the study drugs; 
it was unclear exactly how this blinding was achieved.   
Twenty-nine studies (54%) were described as funded, sponsored or supported by a 
pharmaceutical industry; specifically, the manufacturing industry of the investigational AED 
in the trial. Nine studies (17%) were completely publically funded; funding sources were 
Department for International Development (UK), the Wellcome Trust (UK), International 
League against Epilepsy (worldwide), National Institute of Health (US) and Veterans 
Administration Medical Research Service Cooperative studies program (US). Five studies (9%) 
were part-publically funded and part-industry funded (9%); as above industry funding was 
provided from the manufacturer of the investigational AED in the trial and public funding 
sources were the Medical Research Council (UK), the Health Promotion Trust (UK), the 
Wellcome Trust (UK), the Health Technology Assessment programme (UK) and the Royal 
Melbourne Hospital Neuroscience Foundation (Australia).    
For the remaining eleven studies (20%), no source of funding was disclosed. For eight of these 
studies, at least one author was affiliated to the manufacturing industry of the investigational 
AED suggesting pharmaceutical involvement in the trial.  Regarding the design, data 
collection and analysis of the trial, six studies (11%), all pharmaceutical funded, reported that 
the funding source was directly involved in at least one area and four studies (7%), all 
publically funded, reported that the funding source had no involvement. The remaining 44 
studies (82%) did not describe any involvement of the funding source. 
3.3.3.2  Disposition of participants in the study  
Twenty-five out of 54 studies (46%) presented a flow diagram of disposition of participants 
throughout the study. All except one study (98%) stated how many participants were 
randomised to each treatment arm; the single study reported the number of participants 
included in analysis but not the number originally randomised to each treatment arm.  
Forty-two studies (78%) stated how many randomised participants completed the study and 
35 studies (65%) specified the number of participants completing by treatment arm. The 
remaining 12 studies (22%) did not state how many participants completed the study, 
however six of these studies had long-term follow-up and no fixed duration, therefore it 
would be difficult to quantify how many participants actually “completed” the study. 
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Frequently, different populations (e.g. intention to treat, per-protocol, safety) were included 
in analyses but it was not always clear how such populations were defined and how many 
participants were included in each population. Thirty-four studies (63%) reported that 
participants were excluded from one-or-more analyses in the study and 25 studies (46%) 
reported exclusions made by treatment arm. The remaining 20 studies (37%) did not report 
any exclusion from analyses.  
There were inconsistencies in participant numbers throughout different sections of the study 
publication for three studies (5%). In nine studies (17%), the numbers or statistics presented 
in at least one of tables didn’t correspond with results specified in the text. 
3.3.3.3  Time frame of the study and extent of follow-up 
Thirteen out of 54 studies (24%) reported a diagram of study periods or phases and their 
respective lengths.  Twenty-eight studies (52%) reported the length of the period in which 
participants were recruited into the study and 20 studies (37%) reported the length of a pre-
randomisation baseline or screening phase. Post – randomisation, 41 studies (76%) reported 
a titration or dose-escalation period and 34 studies (63%) reported a maintenance period 
and their lengths in the design. Sixteen studies (30%) reported an open label or double-blind 
extension phase of the study; however only three of these 16 reported the length of 
extension phase. Forty-five out of 54 studies (83%) reported the frequency and/or times of 
scheduled follow-up visits during the study. 
Forty-seven out of 54 studies (87%) reported the duration of the study; 37 of these studies 
had a fixed duration (ranging from 28 days to 4.5 years), ten studies reported a maximum 
study duration (ranging from one to seven years). Four studies (7%) reported that the 
duration was ‘variable’ or ‘approximate’ and three studies (6%) did not report any details 
regarding study duration. 
Twelve studies (22%) reported the minimum length follow-up of the participants in the study, 
38 studies (70%) reported the maximum follow-up and 10 of these studies (18.5%) reported 
both the minimum and maximum follow-up. Seven studies (13%) reported mean follow-up 
and seven studies (13%) reported median follow-up time. Thirteen studies (25%) reported 
no extent of follow-up at all. Frequently, it was not clear if extent of follow-up was 
summarised for all participants or for those completing the study only and summary values 
of follow-up were rarely reported by treatment arm. 
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There were inconsistencies in the described time frame or extent of follow-up throughout 
different sections of the study publication for 8 studies (15%), mainly where follow-up time 
indicated on a survival plot was different to the extent of follow-up described in the text of 
the publication (see Chapter 3.3.4.4 for further details). 
3.3.3.4   Time-to-event and primary outcomes 
In total, 98 time-to-event outcomes were reported in the 54 studies; 23 studies (43%) 
reported one time-to-event outcome, 22 studies (41%) reported two outcomes, five studies 
(9%) reported three and four studies (7%) reported four.  
According to pre-specified definitions of outcomes of interest for this review (see Chapter 
3.2.4), the TTE outcomes reported in the studies were time-to-withdrawal of allocated 
treatment (reported by 35 studies, 65%; one study reports this outcome twice with slightly 
different definitions), time-to-first seizure (reported by 27 studies, 50%), time-to-exiting the 
study (reported by 10 studies, 19%), time-to-withdrawal of allocated treatment due to 
adverse events (reported by 8 studies, 15%), time-to-6-month remission (reported by five 
studies, 9%), time-to-12-month remission (reported by seven studies, 13%) and 24-month 
remission (reported by 5 studies, 9%). Further definitions of these outcomes are discussed in 
Chapter 3.3.4 and see Table 32 (Appendix 6) for other non TTE outcomes reported.  
Thirty-five studies (65%) defined a single primary outcome; 16 of which were TTE outcomes 
(time-to-exit in seven studies, time-to-withdrawal of allocated treatment in five studies and 
time-to-first seizure in four studies, see Table 32 (Appendix 6) for other primary outcomes). 
Four studies defined two primary outcomes, all of which were TTE outcomes (time-to-
withdrawal of allocated treatment and time-to-12-month remission for all studies) and three 
studies defined three primary outcomes, two of which in each study were TTE outcomes 
(time-to-withdrawal of allocated treatment and time-to-withdrawal of allocated treatment 
due to adverse events).  
Out of 35 studies which define a single primary outcome, 27 studies (77%) described a sample 
size calculation relating to the primary outcome and for the seven studies defining more than 
one primary outcome the sample size related to all primary outcomes. Three studies 
reported a sample size calculation relating to one-or-more outcomes other than the defined 
primary outcome and three studies without a defined primary outcome report a sample size 
calculation relating to ‘all outcomes.’ 
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The primary recommended outcome for epilepsy monotherapy studies from ILAE guidelines 
first published in 1998 [249] originates from the outcome of ‘retention time’ defined in 
Mattson et al 1985 [269] and Mattson et al 1992 [270]. Therefore, the reference lists of all 
studies published after 1985 (53 out of 54 studies, one study was published in 1981 [271]) 
were checked for reference to either of the Mattson et al studies [269, 270] in relation to the 
outcome of time-to-withdrawal of allocated treatment. Reference lists of the 37 studies 
published after 1998 were also checked for reference to the ILAE guidelines [249](or updated 
versions from 2006 [252]) and reference lists of all studies were checked for reference to any 
other citation relating to the definition of choice of outcomes in the study.  
Twenty-three studies (43%) cited one or both of the Mattson et al studies [269, 270] and ten 
studies cited the ILAE guidelines from 1998 [249] or 2006 [252], however only five of these 
33 citations seemed to be in relation to the definition of the outcome ‘time-to-withdrawal of 
allocated treatment.’ Citations were related to the results of the Mattson et al studies [269, 
270] or other aspects of study design or conduct. Three studies cited guidance published by 
the European Medicines Agency Committee for Proprietary Medicinal Products (CPMP) in 
2000 [255]  or an updated version published in 2010 [251]. Recommendation of primary 
outcomes was slightly different in this guidance to ILAE guidance [249, 252, 253]  (see 
Chapter 3.1.2 for further details) and the three studies citing these guidelines have employed 
the recommended primary efficacy outcome of proportion of patients remaining seizure-free 
for at least six months.  
Seventeen studies (31%) reported one or more outcomes in the results section of the study 
publication which are not defined in the methods section. Furthermore, three studies (5%) 
defined outcomes in the methods section which were not reported in the results section. Ten 
studies were not consistent in the definition of outcomes throughout the publication; e.g. 
use of terms ‘time-to-withdrawal of allocated treatment’ and ‘time-to-exit’ interchangeably.  
3.3.4  TTE outcomes reported in Epilepsy Monotherapy studies  
As stated in Chapter 3.3.3.4, 98 TTE outcomes were reported in 54 studies. Results are now 
expressed according at the level of outcomes rather than at the level of studies; all 
proportions are out of 98 outcomes (also see Table 2 for a summary of the reporting of 




3.3.4.1.  Number of participants and time origin 
For 93 out of 98 outcomes (95%), the numbers of participants contributing to the outcome 
was reported. For 72 outcomes (73%) the number of participants experiencing events for the 
outcome was reported and for 36 outcomes (38%) the number of participants censored was 
reported. For 53 outcomes (54%) the number of participants lost to follow-up were reported 
and for 25 outcomes (26%) the number of participants censored and lost to follow-up were 
reported separately. In 22 out of 98 outcomes (22%) the numbers of events, censored 
participants and those lost to follow-up were reported by treatment arm. 
For 59 outcomes (60%) the time origin of the outcome was reported; for 43 of these 59 
outcomes (73%) this was randomisation, for eleven outcomes (19%) this was the end of the 
titration period / start of the maintenance period, for three outcomes (5%) this was the first 
dose of study medication and for two outcomes (3%) this was enrolment in the study.  
3.3.4.2.  Definition of events and censoring 
For 85 out of 98 outcomes (87%), the event of the outcome was clearly defined and for 48 
outcomes (49%), the definition of a censored observation was clearly defined. All outcomes 
which clearly defined censoring also clearly defined an event. For 41 outcomes (42%), loss to 
follow-up was a censored observation, for 7 outcomes (9%) it was classed as an event and in 
23 studies (23%) it was unclear whether those lost to follow-up were treated as events or 
censored observations. For 27 outcomes (28%) censoring was not mentioned at all. Reporting 
of the definitions of events and censoring by outcome type is summarised in Table 4.   
Under the definition of the outcome ‘Time-to-withdrawal of allocated treatment’ as defined 
by the ILAE [249], if a participant withdraws from the study due to lack of efficacy (e.g. 
recurrence of seizures), poor tolerability (e.g. occurrence of adverse events) or a combination 
of the two then the withdrawal is classed as an event. If a participant withdraws for other 
reasons, including reasons not related to the study drug and losses to follow-up, or the 
participant completes the study without withdrawal then these participants are classed as a 
censored observation. Although for 29 out of 36 outcomes (78%), the event was well defined, 
only eight of the outcomes defined treatment withdrawal as in the ILAE definition [249]. The 
eight outcomes (22%) which did not clearly define an event referred to withdrawals from the 
study but did not specify which reasons for withdrawal were classified as events.  An event 
for the outcome ’Time-to-withdrawal due to adverse events’ was generally defined as “the 
occurrence of an adverse event leading to treatment withdrawal or premature 
discontinuation from the study” or similar. 
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An event for the outcome of ‘Time-to-first seizure’ was generally defined as the “occurrence 
of first seizure during the study” or similar. Twelve of these outcomes also specified the 
seizure type in the definition of the event (i.e. ‘occurrence of first generalised tonic-clonic 
seizure during the study’). An event for the outcomes of ‘Time-to-6, 12 or 24 month 
remission’ was generally defined as the “achievement of 6, 12 or 24 months of remission 
from seizures during the study” or similar. An event for ‘Time-to-exit from the study’ was 
generally defined according to listed protocol-defined exit criteria (e.g. occurrence of status 
epilepticus, increase in seizure rate, emergence of a more severe seizure type or intolerable 
adverse experience). Outcomes which enforce exit criteria based on seizure recurrence are 
thought to be of little clinical relevance and do not reflect routine clinical practice [252]. 
Three outcomes didn’t fall under any of our pre-specified definitions (see Chapter 3.2.4) and 
for two of these outcomes it was unclear if they had been analysed as TTE outcomes (see 
Chapter 3.3.2). One outcome seemed to be defined as ‘time-to-first, second, fifth and tenth 
seizure’ but analysed as ‘time-to-seizures;’ the definition of this outcome was not clear.  













allocated treatment (n=36) 29 (81%) 15 (42%) 12 (33%) 9 (25%) 
Time-to-first seizure (n=27) 25 (93%) 13 (49%)  6 (22%) 8 (30%) 
Time-to-6, 12 or 24 month 
remission (n=14)  13 (93%) 11 (79%) 1 (7%) 2 (14%) 
Time-to-exit from the study 
(n=10) 9 (10%) 5 (50%) 2 (20%) 3 (30%) 
Time-to-withdrawal due to 
adverse events (n=8) 7 (88%) 4 (50%) 2 (25%) 2 (25%) 
Other (n=3) 2 (66%) 0 (0%) 0 (0%) 3(100%) 
All outcomes (n=98) 85 (87%) 48 (49%) 23 (23%) 27 (28%) 
 
Overall, in only 28 outcomes (29%) was enough information provided regarding events and 
censoring to allow statistical analysis of the outcome to be replicated (i.e. numbers of events 
and censored observations provided and clear definitions for both). For three outcomes, the 
definition of the outcomes presented on the plots was not the same as the definition of the 
outcome in the text (two outcomes of time-to-first seizure and one outcome of time-to-
exiting the study).   
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3.3.4.3.  Statistical analysis and time-to-event statistics 
All 54 studies reporting at least one TTE outcome included details of statistical analysis within 
the methods section of the study publication, however the methods of TTE analysis used and 
the level of detail reported to describe statistical analysis conducted for each outcome in 
each study was variable. Furthermore, eight of the studies reporting more than one TTE 
outcome analysed the outcomes using different statistical methods. 
For 48 out of 98 outcomes (49%) due to lack of clear detail given in statistical analysis 
sections, it would not be possible to replicate statistical analysis. For 11 out of 98 outcomes 
(11%) no statistical analyses of any kind were reported at all for the outcome and for five 
outcomes (5%) no statistical analyses of a TTE nature were reported. It was reported that 
these five outcomes were to be analysed by methods for categorical data (see Chapter 3.3.2 
for further details). For 17 outcomes (17%) it was stated only that “methods of survival 
analysis” (or a similar description) were used and no further details were given.  Also, for 16 
outcomes, analyses were presented in the results sections which were not specified in the 
methods sections.   
For the 98 TTE outcomes, the following TTE statistics were reported (also see Table 2):  
 Survival probability is reported for 60 outcomes (61%) 
 Median survival time is reported for 19 outcomes (19%) 
 Hazard ratio and 95% confidence interval is reported for 31 outcomes (32%) 
 Odds or Risk Ratios and 95% confidence intervals are reported for 14 outcomes (14%) 
 Log-rank p-value is reported for 39 outcomes (40%) 
 Number of events and a log-rank p-value is reported for 27 outcomes (28%) 
 Other p-values (e.g. from Cox Proportional Hazards Model, Generalised Wilcoxon, chi-
squared, Fisher’s Exact) were reported for 28 outcomes (29%) 
 The Observed and Expected number of events is not reported for any of the outcomes 
 For ten outcomes (10%), none of the above statistics were reported  
 
Multivariable methods were used in 44 out of 98 outcomes (45%). Forty-two out of the 44 
outcomes (95%) used Cox multivariable regression models and one used logistic regression.  
Commonly specified variables used in multivariable models were gender (10 outcomes), 
baseline age (18 outcomes), baseline seizure type (25 outcomes), baseline seizure frequency 
(16 outcomes) country, region or centre (14 outcomes) and duration of epilepsy (5 
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outcomes). For 6 outcomes the only information given for adjusted variables is that they 
were “baseline characteristics” or “important prognostic variables.” Reasons for adjusting for 
specific variables were provided for 31 out of the 44 outcomes (70%) but for 13 outcomes 
(30%) only an adjusted effect size was presented (i.e. an unadjusted effect size for treatment 
effect only was not presented). Out of 42 outcomes analysed via Cox PH models, it was stated 
for only 8 of the outcomes (19%) that the assumption of PH had been checked. In fact, for 
three outcomes, the PH assumption was found to be violated yet HR and 95% confidence 
intervals from the model were still presented.  
Considering the 35 outcomes of ‘time-to-withdrawal of allocated treatment,’ for 26 
outcomes (74%), separate withdrawal rates due to lack of efficacy and poor tolerability are 
presented and for 11 outcomes, the composite nature of this outcome is taken account of in 
an analysis; for eight outcomes, separate analyses or subgroup analysis are presented for 
withdrawal for any reason, due to lack of efficacy and due to poor tolerability and for three 
outcomes a formal competing risks analysis is presented. It should be noted that subgroup 
analyses based on post-randomisation information are not generally recommended, and a 
competing risks analysis is a more appropriate way to analyse this composite outcome.  
For 29 out of 98 outcomes (30%) at least one subgroup analysis is reported; in total, 35 
subgroups analyses are reported for 29 outcomes. Subgroup analyses performed were by 
seizure type or epilepsy syndrome (18 outcomes), reason for treatment withdrawal (six 
outcomes, also see above paragraph), drug plasma concentration (5 outcomes), age (4 
outcomes), previous AED use at baseline (one outcome) and seizure frequency at baseline 
(one outcome). A significant difference in treatment effect between subgroups was 
demonstrated in 26 out of 35 subgroup analyses (74%).  
For 34 out of 98 outcomes (35%) a sensitivity analysis is reported; in total, 38 sensitivity 
analyses are reported for 34 outcomes. Sensitivity analyses performed were per protocol 
population only (compared to intention-to-treat population, 13 outcomes), exclusion or re-
classification of ‘uncertain’ seizure types (nine outcomes), exclusion of events in a specific 
period of the study (e.g. seizures during the titration period, seven outcomes), worst-case 
scenario analysis (i.e. all missing participants in one group are assumed to be non-responders 
and all missing participants in the other group are assumed to be responders, four 
outcomes), alternative definition of treatment failure (four outcomes), alternative variables 
in a multivariable model (one outcome). A significant difference in treatment effect was 
demonstrated in two out of 38 sensitivity analyses (5%). 
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3.3.4.4.  Survival plots 
For 74 out of 98 outcomes (75%) a survival plot was presented. Forty-nine out of 74 plots 
(70%) were described as ‘Kaplan-Meier’ plots, 6 were described as ‘actuarial’ plots’ (8%), 5 
were described as ‘cumulative-incidence’ plots (7%) and 14 (15%) were described as ‘survival’ 
plots or no definition was provided.  For 68 of the plots (92%), a step function was used.  
It has been recommended that plots with an upwards direction (i.e. a cumulative incidence 
plot) are more reliably informative, particularly in the situation of low event rates [241], 
however methods for the indirect estimation of HR from survival plots require a downwards 
direction [6, 13]. For 62 out of 74 plots (84%) the plot had a downwards direction and the 
remaining 12 (16%) had an upwards direction.  
For 32 plots (43%) a HR or a p-value was displayed on the graph and in 11 (15%) a measure 
of precision (e.g. confidence interval of the HR) was displayed on the graph. For twelve plots 
(16%) effective numbers at risk were reported on or underneath the plots and for ten plots 
(10%), effective numbers at risk were reported or could be deduced from the text of the 
publication. For nine plots (12%) censored observations were clearly marked on the plot; for 
five of these plots, the only marked censoring was at the end of follow-up time.  
For 64 plots (86%) different line types were clearly used for multiple curves. For eight plots, 
coloured lines were used to distinguish between curves however it would be difficult to 
distinguish between these line colours on a grayscale copy of the publication. For two plots, 
it was not possible to distinguish between the lines.  For 66 plots (89%) a clear legend was 
provided for the graph and for seven plots no legend was provided but labels were written 
next to the lines or underneath the graph. For one plot, no legend or labels were provided. 
It is not necessarily recommended to display the entire vertical axis of a survival plot and to 
do so may “inhibit the ability to discriminate between treatments.” It is also not necessarily 
recommended to present the whole extent of follow-up for studies with long durations and 
that the horizontal axis should be “halted once the proportion of patients free of an event, 
but still in follow-up, becomes unduly small [241]” However, enlarging any differences 
between the lines on the graph by presenting only part of the axis could lead to erroneous 
conclusions regarding importance and significance of the lines, particularly at later follow-up 
times with fewer participants, if not also presented with an effective number at risk and / or 
a measure of statistical uncertainty on the plot [31].  
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For 17 plots (23%) the vertical axis did not extend from 0 to 1 (survival probability), the 
smallest proportion of the vertical axis displayed was 0 to 0.15. For nine plots from study of 
duration of 12 months or less, the entire study duration is not displayed on the plot and for 
two plots from studies of two to five years duration, only a subset of the follow-up time is 
displayed on the plot. Only three of these plots do present numbers at risk which would aid 
with interpretation of the graphs. 
For eight plots (11%) the vertical axis scale was inappropriate; in other words, a plot with a 
downward direction and an increasing ‘cumulative’ axis (or vice-versa). Another seven plots 
(9%) had unlabelled or unclear labels on either the vertical or horizontal axis. Five plots (7%) 
were presented without any title or label therefore the content of the graph had to be 
deduced from the text of the publication.  
3.4  Discussion 
While an IPD approach to analysis is considered to be the ‘gold-standard,’ particularly for 
synthesis of TTE outcomes [6, 23, 24], such an approach is time consuming and resource 
intensive; therefore an analysis of AD may be considered as an alternative. Reviews of 
epilepsy monotherapy treatments have been conducted using an IPD approach by the 
Cochrane Epilepsy Group [59-67, 69], partly justified by the expectation that the AD required 
for such an approach to analysis would not be adequately and consistently reported in the 
relevant publications. 
This chapter systematically examines all trials of an epilepsy monotherapy design (whether 
included in a Cochrane Epilepsy IPD review or not) in terms of the reporting of important TTE 
outcomes of interest in relation to their inclusion in an AD synthesis.  
3.4.1  Summary of key results and implications 
This systematic review considers the reporting of 98 TTE outcomes in 54 epilepsy 
monotherapy RCTs published between 1978 and 2012 in a range of speciality and general 
medical journals. In total, half of the studies considered reported to have analysed at least 
one TTE outcome. However, definitions and methodology for analysing such outcomes 
greatly varied in detail, to the extent that it was not completely clear if outcomes had been 
defined and analysed appropriately as TTE outcomes in 8 out of the 54 trials (15%). 
The majority of studies described study and participant characteristics well relating to design, 
eligible population and source of funding. However, at least one reporting inadequacy in 
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participant numbers, time frames and definitions of outcomes in different sections of the 
same trial publication was identified in 38 out of the 54 studies (70%); within half of the 14 
studies which were completely or partially publically funded, 20 out of 29 (69%) studies which 
were industry funded and all of the 11 studies without a source of funding declared. 
Less than half of the outcomes considered (49%) were clearly defined, in terms of the 
definition of event, of censoring and of the time origin of the analysis. For most of the 
outcomes which were not clearly defined, it was definition of censoring which was not 
mentioned or not clear; in fact for 28% of TTE outcomes, censoring was not mentioned at all 
throughout the study publication, despite the fundamental methodological importance of 
censoring to TTE analysis. Although two-thirds of the studies reported the ILAE 
recommended outcome of ‘time-to-withdrawal of allocated treatment’ [249], only eight of 
these outcomes followed the ILAE definition and others differed in their definitions of events 
and censored observations in analysis (for example, whether all withdrawals were analysed 
as events or only those related to the allocated treatment).  
Further inadequacies relating to reporting of statistical analysis methods were noted with 
sufficient details to replicate analyses provided for only 49% of outcomes. There was also 
potential indication of selective reporting of subgroup analyses, with 74% of subgroup 
analyses reported showing significant results compared to only 5% of sensitivity analyses. 
From an evidence synthesis perspective, HRs and 95% CIs were presented for only 32% of 
outcomes. Considering the other 68% of outcomes, indirect estimation of HRs [6, 13] would 
be possible for only a small minority with observed and expected number of events 
presented for no outcomes, number of events and a log-rank p-value presented for 18 
outcomes and a survival plot with expected number at risk and/or minimum and maximum 
follow-up reported for only six outcomes (see Table 2 for full details). Furthermore, given the 
variability in definition of events and censoring for the outcomes of interest such as time-to-
withdrawal of allocated treatment as mentioned above; it likely that the synthesis of 
aggregate HRs from these studies would not be appropriate and standardisation of outcome 
definition via IPD analysis would be preferred.  
In summary; findings of this review imply that screening for eligible studies for an AD-MA of 
epilepsy monotherapy studies would be feasible with the majority of studies clearly reporting 
features relating to design and participant population. However, the necessary summary 
statistics needed to perform an AD-MA tend to be reported for only around one in three 
outcomes, and it may not be appropriate to synthesise this data due to variation in outcome 
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definition.  Overall, the results of this review confirm the assumption made by the Cochrane 
Epilepsy group that re-analysing IPD is the only feasible approach for meta-analysis of 
epilepsy monotherapy treatment.  
3.4.2  Strengths and limitations  
At the time of writing, we do not know of any other review which systematically considers 
the reporting of TTE data in a context other than oncology. Previous reviews have considered 
a subset of studies from a specific time period or from specific journals whereas no date or 
journal restriction was made in this review. Therefore results reflect the reporting standards 
across 35 years and 24 speciality and general medicine journals.  
While the focus of this review was to examine the reporting of published TTE data in relation 
to inclusion of AD in epilepsy monotherapy reviews rather than to examine differences over 
time or across journals, no clear differences were apparent by year or journal of publication. 
This was not examined statistically so it cannot be ruled out that such differences in reporting 
by year or publication journal may exist. However given that a systematic review would 
generally not make exclusions based on year or journal of publications, any differences are 
of little relevance to this review. 
Furthermore, some of the trials were reported before the introduction of CONSORT 
minimum reporting standards in 1996 [244]. However as discussed in Chapter 3.1.1, the 
CONSORT statement makes very little reference to reporting of TTE analyses and statistics 
specifically so while reporting of general information in the epilepsy monotherapy trials may 
have improved following the introduction of the CONSORT statement, it is unlikely that such 
guidelines will have had much impact on the reporting of TTE analyses.  
To minimise the number of references to screen for this work, only a single source was 
searched to identify eligible studies for this review. This is potentially a limitation as multiple 
electronic databases and grey literature are usually searched for a systematic review. 
However the Cochrane Epilepsy Group Specialised register is compiled from regular 
electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and 
MEDLINE along with hand searches of relevant epilepsy journals and conference abstract 
booklets. All epilepsy monotherapy studies that had been included in Cochrane reviews and 
all monotherapy studies known by clinical expert (AGM) up to 2012 at were identified by the 
search therefore it is unlikely that any studies relevant to the review were missed. 
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An additional limitation is that external information to the publication of each study was not 
taken into account for the review (e.g. if a previous publication was referenced in relation to 
a sample size calculation, it was recorded that a sample size calculation was not recorded in 
the given publication). In reality when conducting a systematic review and meta-analysis, all 
relevant information would be considered and original trial authors may be contacted to 
request unpublished data. Therefore, some of the results presented here may be 
underestimated (reflecting a worst-case scenario), where information may be available from 
related sources. It does however seem unlikely that a TTE outcome would be defined in one 
(non-protocol based) publication and results presented in another; therefore it is unlikely 
that reporting rates of summary statistics and other results have been underestimated by 
not considering related publications. 
3.4.3  Comparison to previous work  
Chapter 3.1.1, Table 1 and Table 2 summarise the findings of previous reviews of aggregate 
TTE data. It should be noted that previous reviews have varied in characteristics, inclusion 
criteria and objective (such as examining change in reporting standards over time [242], 
assessing potential impact on health technology assessment [243] and determining feasibility 
of indirect estimation methods [144]), therefore all comparisons made between the reviews 
and the current review are informal and narrative and results of each should be interpreted 
within the context and objective of the review. 
Table 2 demonstrates a wide variability in the results across all of the reviews regarding the 
reporting of measures of follow-up time, sample size calculations and effect sizes and 
measures of precision; particularly HRs and 95% CIs required for synthesis of TTE data 
reported in between 3% and 87% of reviewed articles. Reporting of other summary statistics 
such as survival probability, log-rank p-values and median survival times was also very 
variable; reporting rates ranged from 2% to 97% of reviewed articles. Consistently, the 
majority of studies reviewed (86% to 100%) presented survival curves, a useful graphical 
representation of TTE outcomes. However the number of studies presenting the effective 
number at risk, essential for properly interpreting such plots, ranged from 8% to 66% and 
other reporting inadequacies such as inappropriate axes or legends and poor graphical 
quality were noted. 
Results of this review agree with previous work that the statistics required for indirect 
estimation of TTE measures required for AD-MA published statistics [6, 13] are not commonly 
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reported either [141, 144, 160, 161]. Michiels et al [160]  argue that meta-analysis can be 
conducted using the difference in median survival rather than HRs as the former measure is 
more commonly presented. However, in this review median survival was actually reported 
less frequently than HRs (26 % of outcomes compared to 32% of outcomes). 
Poor reporting of outcome definitions was also consistently noted across the reviews.  While 
over 70% of reviewed studies clearly define an event of interest; between 45% and 75% 
specified the number of events, 30% to 58% defined which individuals would be censored in 
analysis and 26% to 56% described how losses to follow-up were handled in analyses. 
Previous reviews of oncology trials [236, 237] have commented on the impact of differently 
defined endpoints on the ability to conduct in meta-analysis. Arguably commonly used 
endpoints in oncology such as overall survival have fairly intuitive definitions (i.e. deaths 
during the trial are events and individuals who do not die are censored at their last follow-
up), whereas the commonly used TTE outcome in epilepsy monotherapy trials such as ‘time-
to-withdrawal of allocated treatment,’ have more complex and potentially variable 
definitions, resulting in further difficulties in conducting an AD meta-analysis of such 
outcomes is even more difficult in this context.  
Recent work has also noted that the lack of statistical detail, particularly relating to validation 
of statistical assumptions for TTE analyses and how unvalidated summary statistics can be 
interpreted for secondary analyses including meta-analysis [242, 243]. This review shows 
similar results with confirmation of the PH assumptions for less than 20% of outcomes 
analysed by a Cox PH model. These findings provide further justification of why an AD 
approach is not feasible for reviews of epilepsy monotherapy treatment. 
All previous reviews have concluded that an improvement is needed in the quality of the 
reporting of aggregate TTE data and both the first review [31] and one of the most recent 
reviews [242] have proposed guidelines for the reporting of survival analyses. Abraira et al 
[242]  noted in 2013 that the EQUATOR (Enhancing the QUAlity and Transparency of health 
Research) network [272], an initiative to promote transparent and accurate reporting of 
health research publications, did not report any recommendations specific to survival 
analysis at the time. Up to May 2017, the EQUATOR network online database 
(http://www.equator-network.org) provides 320 different reporting guidelines relating to 
many areas and many different designs of clinical studies, but still no recommendations for 
the reporting of TTE analyses.  
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3.4.4  Concluding remarks 
In conclusion, in line with all previous work conducted in this area, the current systematic 
review has shown concerning reporting inadequacies relating to the definition, analysis and 
reporting of TTE outcomes in epilepsy monotherapy trials and the results of this review are 
sufficient to confirm that an AD-MA based on the published information presented in these 
trials would not be feasible or recommended to inform clinical practice.  
Results of this review are perhaps not surprising given conflicting advice within guidelines, 
both epilepsy specific guidelines [249, 251-253, 255] and also analysis and reporting 
guidelines [244-246]. Recommendations specific to epilepsy trials also place a lot of emphasis 
on study design features, particularly blinding of studies, rather than the accuracy and quality 
of statistical analysis and reporting in studies; essential aspects for the synthesis of trial 
results to inform clinical practice and future research. 
Findings of this systematic review suggest that consistency of recommendations, supported 
by clinical reasoning, is needed within epilepsy specific guidelines in addition to further 
emphasis on the transparent reporting of published results. 
Findings of this review also further highlight calls from previous reviews for the urgent 
development of minimum reporting standards for TTE analyses. In the continuing absence of 
the development of such standards, use of the suggested guidelines from previous work [31, 
242] by journal editors and peer reviewers when considering study publications using TTE 
analyses would greatly improve reporting rates and in turn facilitate the conduct of AD-MAs 
and syntheses with TTE endpoints.  
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Chapter 4: IPD retrieval: A systematic review of 
individual participant data meta-analyses (IPD-MA) 
4.1  Introduction 
IPD-MA is widely regarded as the gold-standard approach to the synthesis of clinical trial data 
with many documented advantages over traditional AD-MA. Recent years have shown a 
sharp increase in the number of published IPD-MAs [33-35]. An average of 49 were published 
each year between 2005 and 2009 [34] and recent estimates suggest an increase of around 
four published IPD-MAs per year [35].  IPD-MAs have been shown recently to directly 
influence the design and conduct of clinical trials [29] and clinical practice guidelines [30].   
While IPD-MAs may offer many advantages, it is well recognised that greater resources are 
required to conduct them [22-24] and the use of IPD in meta-analyses does not guarantee 
freedom from biases. IPD-MAs are subject to a risk of selection bias and ‘availability bias;’ in 
that they may only include studies for which IPD is made available, which may not be 
representative of the whole evidence base [24, 40, 51].  IPD-MAs may be delayed or 
abandoned owing to unclear data requesting procedures or barriers to accessing IPD [89, 
273-275]. Review articles have shown that around a quarter of IPD-MAs published up to 2001 
[32], up to 2005 [40] and even as recently as 2012 [35] obtained IPD for less than 80% of 
eligible participants. These reviews also reveal poor reporting particularly in regard to the 
amount of included IPD, with between 10 and 20% of IPD-MAs not clearly stating how many 
studies and participants were eligible, requested and included in analysis [32, 33, 35, 40]. The 
most recent of these reviews found that reasons for unavailability of IPD were reported in 
only 23% of a sample of 100 IPD-MAs [33]. 
Despite a growing increase in the popularity of IPD-MAs [34, 35]; in the context of all 
published meta-analyses, an IPD approach is still taken in only a small minority [33] with 
meta-analysts reporting lack of resources, lack of time and difficulty of such an approach as 
barriers to conducting an IPD meta-analysis [276]. Another barrier to IPD-MA experienced 
within our own research group [277], has been the direction in which to address IPD requests, 
particularly for studies involving a pharmaceutical sponsor.  
The culture of clinical trial data sharing has changed in recent years. Authors of published 
trials have reported an increased willingness to share data in surveys conducted in 2011 [77, 
88] compared to an empirical study conducted in 2009 [89]. The publication of data 
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transparency strategies and policies by the Institute of Medicine [84] and the European 
Medicines Agency [85], a proposed policy by the International Committee of Medical Journal 
Editors [86, 87] and initiatives across the wider research community as a whole [77-80] may 
go some way to improving the sharing of IPD. Indeed, the launch of data sharing initiatives 
such as Clinical Study Data Request (CSDR)[91], a platform allowing researchers to request 
IPD from nearly 3000 clinical trials of thirteen pharmaceutical sponsors, should make access 
to IPD easier and faster. However, researchers have reported mixed experiences of using 
data sharing portals such as CSDR suggesting that the increased safeguards may have an 
unintended negative impact on the conduct of IPD-MA [110-113].  
The aim of this Chapter is to examine whether the shift in attitudes and awareness, and the 
increased number of options available for accessing IPD, is reflected by a positive impact on 
IPD-MA. This Chapter presents a systematic review of all published IPD-MAs to assess 
whether availability of IPD has improved over time, and explore characteristics associated 
with the retrieval of IPD. The primary aim of this systematic review was to investigate 
whether the success rate of retrieving IPD for the purpose of IPD-MA has increased over time. 
The secondary aim of the systematic review was to explore the characteristics associated 
with IPD retrieval.  
The work contained in this Chapter has been published in the British Medical Journal [278]. 
4.2  Methods 
4.2.1  Systematic search methods 
The following databases were searched: MEDLINE, Central, SCOPUS, Web of Science, CINAHL 
Plus and PsycINFO. The search strategies for each database are described in Appendix 7 and 
were based on a systematic search strategy of an earlier review of Riley et al 2007 [40]. 
Databases were searched from June 2005 (end date of the Riley et al 2007 [40] search) up to 
June 2014 initially and all systematic searches were updated in August 2015. The reference 
lists of two previous large reviews of IPD-MAs were also consulted; reference list of Riley et 
al 2007 [40] was provided by the first author on request and the reference list of Huang et al 
2014 [35] was available as an online appendix to journal publication of the review. 
Articles identified from electronic databases and the reference lists of the previous reviews 
were exported to Endnote version X7, lists merged and duplicates removed. One reviewer 
(SJN) performed title, abstract and full-text screening of articles identified in electronic 
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searches according to Eligibility Criteria described in Chapter 4.2.2. The principle reason for 
exclusion was recorded for relevant articles. Any uncertainties were discussed with CTS and 
resolved. For accuracy, two authors (BD and SR) also screened a random sample of between 
50 and 100 identified articles for eligibility; agreement between the independent screening 
(SJN and BD or SR) was good and any discrepancies were discussed and resolved. 
4.2.2  Eligibility criteria 
IPD-MAs of studies of all types (randomised, observational, diagnostic etc.) and all clinical 
areas published in English were eligible for inclusion. Articles were included if IPD was 
requested from original study investigators, if IPD was already available to review authors or 
if review authors were able to extract IPD from published articles.   
Methodological articles, conference abstracts, review protocols and non-clinical reviews (e.g. 
engineering articles etc.) were excluded. Articles including the analysis of IPD from a single 
study as a supplement to an AD-MA or articles in which the primary objective of the analysis 
was not to estimate a pooled effect size (e.g. prognostic model validation studies, cost-
effectiveness analysis) were excluded as inclusion criteria of studies in such analyses are 
generally selective and related to the objective of the analysis (e.g. an estimate of prognosis 
or cost is provided) rather than the availability of IPD. Where duplicate publications relating 
to the same IPD-MA were identified (e.g. identical publication across multiple journals) the 
most recently published article was retained.  Updates of analyses (e.g. updated Cochrane 
Reviews) were included if at least one new eligible study was identified for the analysis.  
4.2.3  Data extraction 
Information was extracted from eligible IPD-MAs using a piloted data extraction form (see 
Appendix 8). The data extraction form was piloted by three reviewers (SJN, BD and SR) 
extracting information from a sample of IPD-MAs referenced in the Riley et al 2007 [40]; 
following pilot extractions, content of the data extraction form was discussed and the final 
data extraction form (Appendix 8) was used to extract information from all IPD-MAs 
identified in the searches described in Chapter 4.2.1. 
Information extracted from IPD-MAs was year of publication, authorship policy, source of 
funding, clinical area, type of studies, type of analysis, number of eligible studies providing 
IPD or AD, reasons for IPD not being provided and details of any additional or sensitivity 
analyses performed to account for missing IPD.  
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Reasons for IPD not being provided and sensitivity analyses were recorded as free text by all 
reviewers and later classified into broad categories. Clinical area was also recorded as free 
text and later classified in broad categories based on the clinical areas covered by the review 
groups of the Cochrane Collaboration.  All classification of extracted free text was performed 
by one author (SJN). Type of analysis was classified as follows on extraction:  
 Systematic IPD-MA; where a systematic search aiming to identify all eligible studies was 
performed.  
 Pooled or ‘opportunistic’ analysis [33]; where an existing IPD database or IPD of a 
collaborative group was analysed without an attempt to systematically identify all 
eligible studies. Such analyses, by definition, used 100% of eligible IPD in analysis.  
 Other analysis; any other approach to IPD-MA which does not fit into either of the above 
definitions.  
 
Where published articles presented multiple IPD-MAs addressing different research 
questions with different eligible cohorts for IPD-MAs, information was extracted for each 
IPD-MA. If multiple analyses were presented for the same IPD-MA (e.g. analysis of several 
outcomes), information was extracted on the maximum amount of IPD provided, even if all 
IPD provided were not used in IPD-MA. 
One author (SJN) extracted information from all eligible articles and three authors (BD, SR, 
LW) independently extracted from a subset of around 40% of the eligible articles. Agreement 
between authors was good and any discrepancies were resolved by discussion.  
4.2.4  Statistical analysis and presentation of results 
The primary aim of analysis was to examine the IPD retrieval rate (i.e. the number of 
participants IPD was provided for divided by the number of participants identified as eligible 
for analysis) over time and the secondary aim was to explore the characteristics associated 
with IPD retrieval. 
Multivariable logistic regression was performed to examine associations between IPD-MAs 
characteristics and proportion of IPD retrieved. Proportion of IPD retrieved (dependent 
variable of interest) was highly skewed, despite attempts at transformation, as few IPD-MAs 
retrieved a very small proportion of data (i.e. less than 20% of IPD retrieved). It was therefore 
deemed most appropriate to dichotomise this variable to:  
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 Complete IPD retrieval rate (100% compared to less than 100% or unknown 
proportion of IPD provided) 
 High IPD retrieval rate (at least 80% compared to less than 80% or unknown 
proportion of IPD provided) 
Dichotomisation cut-off (i.e. 80% compared to less than 80%) was chosen to allow 
comparison with retrieval rates in previous reviews [32, 33, 35, 40]. The following variables 
were included in the model and results for all variables included in the model are presented 
regardless of statistical significance; no model selection techniques were used: 
 Age of publication of the IPD-MA  (calculated as years before 2016, log transformed due 
to skew, let this variable be 𝑥1) 
 Number of participants eligible for inclusion in IPD-MA (log transformed due to skew, 𝑥2) 
 Study design (inclusion of randomised studies only in IPD-MA versus  other study designs; 
non-randomised studies, diagnostic test accuracy studies or a combination of 
randomised and non-randomised studies, 𝑥3) 
 Cochrane IPD-MA (IPD-MA performed as a Cochrane Review compared to non-Cochrane 
IPD-MA, 𝑥4) 
 Authorship policy (individual authorship for those providing IPD or collaborative group 
versus no authorship policy, 𝑥5) 
 Source of funding (IPD-MA with a commercial source of funding (pharmaceutical or 
manufacturer) versus other funding: non-commercial sources of funding only, no funding 
or no information regarding funding provided, 𝑥6) 
 
In other words, let 𝑍𝑗  be the dependent variable in the 𝑗
th IPD-MA such that 𝑍𝑗 = 1 if 100% 
of IPD was retrieved and 𝑍𝑗 = 0 if less than 100% of IPD was retrieved (or equivalently,  𝑍𝑗 =
1 if at least 80% of IPD was retrieved and 𝑍𝑗 = 0 if less than 80% of IPD was retrieved) and 




) = 𝛽1(𝑙𝑜𝑔(𝑥1𝑗)) + 𝛽2(log (𝑥2𝑗)) + 𝛽3𝑥3𝑗 + 𝛽4𝑥4𝑗 + 𝛽5𝑥5𝑗 + 𝛽6𝑥6𝑗 (Equation 27) 
Where 𝑥1𝑗…𝑥6𝑗 are the explanatory variables of the 𝑗
th IPD-MA (see above) and 𝛽1…𝛽6 are 
the resulting regression coefficients associated with each of the explanatory variables.  
 
Results of multivariable regression are presented as odds ratios and 95% confidence 
intervals. Other numerical results are presented as medians and ranges or numbers and 
percentages as appropriate.  
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4.2.5  Additional and sensitivity analyses 
Additional and sensitivity analyses were conducted to investigate the assumptions made in 
the primary multivariable logistic regression: 
1) Univariable analysis was performed to examine the effect of each variable independently 
on IPD retrieval rate. 
2) Further examination of the association of authorship policy on IPD retrieval; authorship 
policy redefined as no authorship policy (reference), individual authorship or 
collaborative group. 
3) Inclusion of the variable ‘Type of Study’ (defined as drug or device (interventional, 
reference), non-drug (interventional), diagnostic test accuracy or epidemiological study) 
in the multivariable model. 
4) Exclusion of IPD-MAs from analysis with no information regarding funding reported. 
5) Assuming the following scenarios for 257 IPD-MAs for which the proportion of IPD 
retrieved could not be calculated: 
a. Less than 80% of IPD was retrieved 
b. 80% or more IPD was retrieved 
c. 100% of IPD was retrieved 
An additional analysis was also performed to examine characteristics associated with 
non-reporting of the proportion of IPD retrieved for IPD-MA. 
6) Use of fractional logistic regression with proportion of IPD retrieved (dependent variable) 
expressed as a fraction between 0 and 1 as an alternative to logistic regression [279].  
Under this approach, rather than constraining dependent variable 𝑍𝑗  to take a value of 1 
or 0, 𝑍𝑗  is modelled as a fraction within the interval (0, 1). Papke and Wooldridge [279] 
demonstrate the Bernoulli log-likelihood function for a fractional logit model:  
log(𝜷) = 𝑍𝑗𝑙𝑜𝑔 (
exp (𝑿𝒋𝜷)
1+ exp (𝑿𝒋𝜷)
) + (1 − 𝑍𝑗)𝑙𝑜𝑔 (1 − (
exp (𝑿𝒋𝜷)
1+ exp (𝑿𝒋𝜷)
))  (Equation 28) 
Where 𝑿𝒋  is a vector of explanatory variables (𝑥1𝑗…𝑥6𝑗 are the explanatory variables of 
the 𝑗th IPD-MA in this example) and 𝜷 is a vector of the resulting regression coefficients 
associated with each of the explanatory variables (𝛽1…𝛽6 in this example).  
7) Multivariable logistic regression of the proportion of study data retrieved (i.e. the 
number of studies IPD was provided for divided by the number of studies identified as 
eligible for analysis). 
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4.3  Results 
4.3.1  Results of the search 
Systematic searches (outlined in Chapter 4.2.1) identified 1278 eligible articles describing 
1280 IPD-MAs published to August 2015. See Figure 3 for study flow diagram of the searching 
and screening process and a reference list of eligible articles is available as an online 
Appendix to Nevitt et al [278]). 
A non-systematic method of identifying studies for inclusion (IPD-MA defined as pooled 
analyses or other analyses, see Chapter 4.2.4) such as collaboration of a group of researchers 
with available IPD, had been used in 520 IPD-MAs. Within these 520 non-systematic IPD-MAs, 
the number of eligible studies was reported in 516 (99%) IPD-MAs with a median number of 
eligible studies of 7 (range 2 to 287). The number of eligible participants was reported in 501 
(96%) systematic IPD-MAs with a median of 3633 (range 16 to 2,051,158) participants.  
For the remaining 760 IPD-MAs, a systematic approach was taken to identify all eligible 
studies. The number of eligible studies was reported in 746 (98%) IPD-MAs with a median of 
14 (range 2 to 923) studies. The number of eligible participants within an IPD-MA was 
reported in 510 (67%) systematic IPD-MAs with a median of 2369 (range 16 to 33369) 
participants. In 14 (2%) of the 760 systematic IPD-MAs, it was unclear how many studies were 
eligible and in 250 (33%) it was unclear how many participants were eligible; mainly as the 
number of participants without available IPD excluded from analysis was not stated. 
These median values imply that while systematic IPD-MAs identify more eligible studies, non-
systematic IPD-MAs tend to identify and include more eligible participants.  
4.3.2  Characteristics of IPD-MAs 
Table 5 presents the characteristics of the 1280 included IPD-MA according to systematic or 
non-systematic design.  
Within 85 systematic IPD-MAs, IPD was extracted from study publications rather than 
requested from original study authors or sponsors. Characteristics of these 85 systematic 




Figure 3: Study Flow Diagram of identification of eligible IPD-MA 
 




Table 5: Characteristics of 1280 individual participant data reviews 
 
IPD-MA Characteristic Type of Analysis 
Systematic  
IPD-MAs 
(n and % of total) 
Non-systematic 
IPD-MAs 
(n and % of total) 
Total 
Total 760 (59%) 520 (41%) 1280 
Year of publication of IPD-MA 
1987 – 1995 20 (61%) 13 (39%) 33 
1996 – 2000    72 (65%) 39 (35%) 111 
2001 – 2005  116 (57%) 88 (43%) 204 
2006 – 2010  195 (56%) 152 (44%) 347 
2011 – 2015  357 (61%) 228 (39%) 585 
Clinical area of IPD-MA 
Breast Cancer  40 (62%) 25 (38%) 65 
Cancer (other)  53 (65%) 28 (35%) 81 
Cardiology  105(49%) 110 (51%) 215 
Central Nervous System, Neurology and 
Brain Injury   
50 (62%) 31 (38%) 81 
Cervical Cancer and Ovarian Cancer  16 (59%) 11 (41%) 27 
Diabetes and Endocrinology  30 (63%) 18 (37%) 48 
Gastroenterology, Colorectal and Gastric 
Cancer  
49 (56%) 39 (44%) 88 
Gynaecology, Pregnancy and 
Neonatology  
35 (88%) 5 (12%) 40 
Haematology, Leukaemia and Blood 
Cancer 
43 (72%) 17 (28%) 60 
Head and Neck Cancer 16 (64%) 9 (36%) 25 
Hepatitis and Liver Disease 19 (56%) 15 (44%) 34 
HIV  17 (55%) 14 (45%) 31 
Infection and Infectious Diseases  31 (70%) 13 (30%) 44 
Injuries and Wounds  21 (58%) 15 (42%) 36 
Lung Cancer  32 (76%) 10 (24%) 42 
Mental and Psychiatric Disorders  32 (48%) 35 (52%) 67 
Musculoskeletal and Pain 34 (52%) 32 (48%) 66 
Other1  26 (48%) 28 (52%) 54 
Otolaryngology , Ophthalmology and 
Periodontology  
22 (76%) 7 (34%) 29 
Renal and Urology  17 (61%) 11 (39%) 28 
Respiratory and Pulmonary  21 (60%) 14 (40%) 35 
Stroke, Thrombosis and Hypertension  51 (61%) 33 (39%) 84 
Design of included studies 
Randomised 405 (58%) 288 (42%) 693 
Non-Randomised 253 (57%) 194 (43%) 447 
Diagnostic Test Accuracy 34 (97%) 1 (3%)  35 
Both Randomised and Non-Randomised 68 (65%) 37 (35%) 105 
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Type of included studies 
Diagnostic Test Accuracy 34 (97%) 1 (3%) 35 
Drug or device 348 (54%) 291 (46%) 639 
Epidemiology / Risk Factor 185 (52%) 173 (48%) 358 
Non-drug (interventional) 193 (78%) 55 (22%) 248 
Type of IPD-MA 
Cochrane Review 64 (100%) 0 (0%) 64 
Non Cochrane Review 696 (57%) 520 (43%) 1216 
Authorship Policy 
Individual authorship 243 (42%) 337 (58%) 580 
Collaborative Group 264 (60%) 177 (40%) 441 
None2 253 (98%) 6 (2%) 259 
Source of Funding 
Non-commercial3 383 (64%) 218 (36%) 601 
Commercial4 72 (42%) 101 (58%) 173 
Mixed5 35 (36%) 62 (64%) 97 
No funding 77 (73%) 28 (27%) 105 
Not stated 193 (63%) 111 (37%) 304 
Number of eligible studies  
2 to 5 102 (32%) 214 (68%) 316 
6 to 10 174 (57%) 130 (57%) 304 
11 to 15 120 (63%) 72 (37%) 192 
16 to 20 87 (81%) 21 (29%) 108 
21 to 30 101 (77%) 31 (23%) 132 
31 to 40 50 (70%) 21 (30%) 71 
41 to 50 29 (85%) 5 (15%) 34 
over 50 83 (80%) 22 (20%) 105 
Not stated 14 (78%) 4 (22%) 18 
Number of eligible participants  
under 100 18 (86%) 3 (14%) 21 
101 to 200 20 (65%) 11 (35%) 31 
201 to 500 45 (56%) 35 (44%) 80 
501 to 1000 67 (56%) 52 (44%) 119 
1001 to 5000 198 (51%) 187 (49%) 385 
5001 to 10000 62 (53%) 54 (47%) 116 
over 10000 100 (39%) 159 (61%) 259 
Not stated 250 (93%) 19 (7%) 269 
1. Other defined as lifestyle, nutrition, emergency medicine, patient care, patient preference, 
Pharmacokinetics and Forensics 
2. Including 83 IPD-MAs where IPD was extracted from published study reports (IPD not 
requested from original study authors). See Appendix 8 for further details. 
3. Non-commercial sources included institutional, government, charity, research council or 
research foundation funding. 
4. Commercial sources were defined as pharmaceutical or manufacturer funding. 
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As ‘opportunistic’ IPD-MAs by design often differ in their objectives and inclusion criteria 
from systematic IPD-MAs [33]; no formal statistical comparison of the characteristics of these 
two types of IPD-MA was made. From visual comparison of Table 5, there did not seem to be 
any changes over time in approach (systematic or non-systematic) to IPD-MA and few clear 
differences by clinical area. A systematic approach was taken proportionally most often in 
the topics of Gynaecology, Pregnancy and Neonatology, Lung Cancer and Haematology, 
Leukaemia and Blood Cancer while a non-systematic approach was taken proportionally 
more often than a systematic approach in the topics of Cardiology, Mental and Psychiatric 
Disorders and other clinical areas (see Table 5). The majority of IPD-MAs of diagnostic test 
accuracy studies and studies of non-drug interventions took a systematic approach, as well 
as all Cochrane Reviews. The majority of non-systematic IPD-MAs had an authorship policy 
and the majority of IPD-MAs receiving commercial funding took a non-systematic approach. 
Table 5 also suggests that systematic IPD-MAs identify more eligible studies, while non-
systematic IPD-MAs tend to identify and include more eligible participants. 
4.3.3  IPD retrieval rate in systematic IPD-MA 
Non-systematic IPD-MAs were mostly conducted with only the IPD which was already 
available to the analysts; therefore IPD retrieval rate is not relevant in these 520 IPD-MAs.  
The following two sections report only on the 760 systematic IPD-MAs. 
Figure 4: Number of distinct systematic IPD-MA published to August 2015 and proportion 
of IPD provided
 
1. See Table 6 for proportion of systematic IPD meta-analyses providing 100%, 80-99%, less than 80% 
of IPD and the proportion of IPD not reported. 
2. Six IPD-MA were published from 1987 to 1993; one was provided with less than 80% of IPD, three 






Figure 5: Characteristics of systematic IPD-MA and proportion of IPD provided. 
 
1. See Table 6 for proportion of systematic IPD meta-analyses providing 100%, 80-99%, less than 80% of IPD and the proportion of IPD not reported.  
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Proportion of IPD retrieved for systematic IPD-MA  
(n and % of N) 
100% ≥80% <80% Unknown3 
Total 760 188 (25%) 324 (43%) 179 (24%) 257 (34%) 
Clinical area of IPD-MA 
Breast Cancer  40 8 (20%) 22 (55%) 7 (17%) 11 (28%)  
Cancer (other)  53 14 (26%) 27 (51%)  14 (26%) 12 (23%)  
Cardiology  105 30 (29%) 53 (51%) 17 (16%) 35 (33%)  
Central Nervous System,  
Neurology and Brain 
Injury 50 13 (26%) 20 (40%) 14 (28%) 16 (32%)  
Cervical Cancer and 
Ovarian Cancer  16 1 (6%) 7 (44%) 1 (6%) 8 (50%) 
Diabetes and 
Endocrinology  30 8 (27%) 13 (43%) 3 (10%) 14 (47%) 
Gastroenterology, 
Colorectal and Gastric 
Cancer  49 11 (22%) 17 (35%)  23 (47%) 9 (18%) 
Gynaecology, Pregnancy 
and Neonatology 35 13 (37%)  18 (51%)  9 (26%) 8 (23%) 
Haematology, Leukaemia 
and Blood Cancer  43 11 (26%) 20 (47%) 4 (9%) 19 (44%) 
Head and Neck Cancer  16 4 (25%) 8 (50%) 5 (31%) 3 (19%) 
Hepatitis and Liver 
Disease  19 7 (37%) 8 (42%) 3 (16%) 8 (42%) 
HIV  17 6 (35%) 8 (47%) 2 (12%) 7 (41%) 
Infection and Infectious 
Diseases  31 6 (19%) 9 (29%) 12 (39%) 10 (32%) 
Injuries and Wounds  21 2 (10%) 4 (19%)  13 (62%) 4 (19%) 
Lung Cancer  32 9 (28%) 15 (47%) 3 (9%) 14 (44%) 
Mental  and Psychiatric 
Disorders 32 7 (22%) 12 (38%) 7 (21%) 13 (41%) 
Musculoskeletal and Pain 34 9 (26%) 11 (32%) 5 (15%) 18 (53%) 
Other 26 5 (19%) 9 (35%) 12 (46%) 5 (19%) 
Otolaryngology, 
Ophthalmology and 
Periodontology  22 3 (14%) 5 (23%) 6 (27%) 11 (50%) 
Renal and Urology  17 3 (18%) 6 (35%) 5 (30%) 6 (35%) 
Respiratory and 
Pulmonary  21 7 (33%) 11 (52%) 3 (15%) 7 (33%) 
Stroke, Thrombosis and 
Hypertension  51 12 (24%) 21 (41%) 11 (22%) 19 (37%) 
Design of included studies 
Randomised 405 117 (29%) 222 (55%) 83 (20%) 100 (25%) 
Non-Randomised 253 58 (23%) 81 (32%) 56 (22%) 116 (46%) 
Diagnostic Test Accuracy 34 5 (15%) 9 (26%) 8 (24%) 17 (50%) 
Both Randomised and 
Non-Randomised 68 8 (12%) 12 (18%) 32 (47%) 24 (35%) 
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Type of included studies 
Diagnostic Test Accuracy 34 5 (15%) 9 (26%) 8 (24%) 17 (50%) 
Drug or device 348 102 (29%) 183 (53%) 73 (21%) 92 (26%) 
Epidemiological  185 38 (21%) 58 (31%) 44 (24%) 83 (45%) 
Non-drug (interventional) 193 43 (22%) 74 (38%) 54 (28%) 65 (34%) 
Type of IPD-MA 
Cochrane Review 64 10 (16%) 25 (39%) 27 (42%) 12 (19%) 
Non Cochrane Review 696 178 (26%) 299 (43%) 152 (22%) 245 (35%) 
Authorship Policy 
Individual authorship 243 84 (35%) 116 (48%) 39 (16%) 88 (36%) 
Collaborative Group 264 40 (15%) 119 (45%) 43 (16%) 102 (39%) 
None 253 64 (25%)  89 (35%) 97 (39%) 67 (26%) 
Source of Funding 
Non-commercial 383 70 (18%) 155 (40%) 94 (25%) 134 (35%) 
Commercial 72 26 (36%) 37 (51%)  14 (20%) 21 (29%) 
Mixed 35 8 (23%) 20 (57%) 7 (20%) 8 (23%) 
No funding 77 25 (32%) 34 (44%) 14 (18%) 29 (38%) 
Not stated 193 59 (31%) 78 (40%) 50 (26%) 65 (34%) 
Number of eligible studies 
2 to 5 102 72 (71%) 83 (81%) 10 (10%) 9 (9%) 
6 to 10 174 67 (39%) 98 (56%) 34 (20%) 42 (34%) 
11 to 15 120 16 (13%) 47 (39%) 27 (23%) 46 (38%) 
16 to 20 87 12 (14%) 29 (33%) 27 (31%) 31 (36%) 
21 to 30 101 6 (6%) 30 (30%) 28 (28%) 43 (42%) 
31 to 40 50 3 (6%) 11 (22%) 19 (38%) 20 (40%) 
41 to 50 29 2 (7%) 5 (17%) 9 (31%) 15 (52%) 
over 50 83 10 (12%) 19 (23%)   24 (29%) 40 (48%) 
Not stated 14 0 (0%)  2 (14%) 1 (7%) 11 (79%) 
Number of eligible participants 
under 100 18 14 (78%) 16 (94%) 1 (6%) 0 (0%) 
101 to 200 20 13 (65%) 16 (80%) 4 (20%) 0 (0%) 
201 to 500 45 21 (47%) 25 (56%) 19 (42%) 1 (2%) 
501 to 1000 67 35 (52%) 45 (67%) 22 (33%) 0 (0%) 
1001 to 5000 198 70 (35%) 134 (68%) 61 (31%) 3 (1%) 
5001 to 10000 62 13 (21%) 37 (60%) 23 (37%) 2 (3%) 
over 10000  100 22 (22%) 53 (53%) 46 (46%) 1 (1%) 
Not stated 250 0 (0%) 0 (0%) 0 (0%) 250 (100%) 
1. See Table 5 for full definitions of characteristics. 
2. See Figure 4 for proportion of IPD provided in IPD-MAs by year. 
3. Unknown as the number of eligible participants and/or the number of participants excluded 




IPD was provided from 100% of eligible studies in only 189 (25%) and from 100% of 
participants in only 188 (25%) out of 760 systematic IPD-MAs; one IPD-MA provided with IPD 
from 100% of studies received an incomplete dataset for one study. IPD from at least 80% of 
studies was retrieved in 375 systematic IPD-MAs (49%) and from 80% of participants in 324 
systematic IPD-MAs (43%). IPD was retrieved for less than 50% of studies in 136 systematic 
IPD-MAs (18%) and for less than 50% of participants in 71 systematic IPD-MAs (9%). One of 
the reviews was designed as an IPD-MA but no IPD was available [280].  
For 257 IPD-MAs, the proportion of IPD retrieved could not be calculated because the 
number of eligible participants and/or the number of participants excluded from IPD analysis 
due to lack of IPD was not reported. Figure 4 shows the number of IPD-MAs published by 
year and the proportion of IPD retrieved. 
Figure 5 and Table 6 and show the characteristics of the 760 systematic IPD-MA overall as 
well as separated according to IPD retrieval rate. 
4.3.3.1 Characteristics associated with IPD retrieval 
Table 7 presents the results of multivariable logistic regression (see Chapter 4.2.4 for further 
details). A total of 503 IPD-MAs were included in this analysis for which the proportion of IPD 
retrieved could be calculated (i.e. the number of participants eligible for analysis and the 
number of participants data was provided for was reported).  
Table 7: Multivariable logistic regression model results: Characteristics associated with 
retrieving 100% of IPD or receiving more than 80% of IPD in 503 IPD-MAs 
IPD-MA 
Characteristic 
100% of IPD retrieved compared 
to less than 100% of IPD 
At least 80% of IPD retrieved 
compared to less than 80% of IPD 
OR 95% CI P-value OR 95% CI P-value 
Age of publication1 1.081 0.885 to 1.320 0.445 1.153 0.938 to 1.418 0.177 
Number of eligible 
participants1 
0.851 0.800 to 0.904 <0.001 0.889 0.837 to 0.943 <0.001 
Includes randomised  
studies only 
1.415 0.919 to 2.182 0.115 2.735 1.755 to 4.262 <0.001 
Cochrane IPD-MA 0.402 0.189 to 0.859 0.019 0.427 0.218 to 0.835 0.013 
Authorship Policy2 1.667 1.074 to 2.585 0.022 3.366 2.183 to 5.190 <0.001 
Commercial source of 
funding3 
1.291 0.762 to 2.187 0.341 1.043 0.568 to 1.914 0.892 
1. Log transformation applied due to skewed distribution of data 
2. Authorship policy (individual authorship for those providing IPD or collaborative group) compared 
to no authorship policy 
3. Commercial source of funding (pharmaceutical or manufacturer) compared to non-commercial 
sources of funding only, no funding or no information regarding funding provided. 
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The odds of retrieving all IPD was significantly higher for IPD-MAs that were non-Cochrane, 
had a lower number of eligible participants and those with  an authorship policy. The odds of 
retrieving a high proportion (at least 80%) of IPD were also significantly higher for these 
factors but in addition for IPD-MAs of randomised trials only. There was no association 
between the IPD retrieval rate and source of funding or the date of publication of IPD-MAs. 
4.3.3.2 Additional and sensitivity analyses  
A range of additional and sensitivity analyses were conducted to investigate assumptions 
made within the primary multivariable logistic regression analysis, see Chapter 4.2.5 for 
further details. Results of each additional analysis is summarised below and tables of 
numerical results are presented in Appendix 9. 
1) Univariate logistic regression analysis (i.e. unadjusted analysis) (see Table 34) 
Results of this analysis were numerically similar to those of multivariable (adjusted) analysis 
presented in Table 7; the only difference in conclusions was that unadjusted analysis shows 
no association between complete IPD retrieval rate and an authorship policy (association 
between authorship policy and high retrieval rate was maintained in adjusted and 
unadjusted analysis).   
2) Association of authorship policy on IPD retrieval (see Table 35) 
Results of this analysis show that odds of retrieving at least 80% of IPD were significantly 
increased when either individual authorship or collaborative authorship policies were used 
but odds of retrieving at 100% of IPD were significantly increased only when an individual 
authorship policy was used. Other numerical results were similar to those in Table 7 and 
results unchanged.  
3) Inclusion of the variable ‘Type of Study’ in the multivariable model (see Table 36) 
The variable ‘Type of study’ (drug or device (interventional), non-drug (interventional), 
diagnostic test accuracy or epidemiological study) was not included in the model due to 
correlation between this variable and type of study (interventional studies were significantly 
more likely to be randomised, chi-squared p<0.001) and source of funding (drug or device 
studies were significantly more likely to be commercially funded, chi- squared p<0.001). 
Sensitivity analysis was conducted adding an additional variable to the multivariable logistic 
regression model. Results showed that this characteristic was not statistically significant; 
other numerical results were similar to those in Table 7 and conclusions were unchanged. 
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4) Exclusion of IPD-MA from analysis with no information regarding funding reported (see 
Table 37) 
Numerical results were similar to those in Table 7 and conclusions were unchanged. 
5) Assuming the following scenarios for 257 IPD-MA for which the proportion of IPD 
retrieved could not be calculated: 
a. Less than 80% of IPD was retrieved (see Table 38) 
b. 80% or more IPD was retrieved (see Table 39) 
c. 100% of IPD was retrieved (see Table 40) 
Results of these sensitivity analyses are varied compared to those reported in Table 7; for 
example scenario a. and scenario b. contradict Table 7 and suggest that the odds of complete 
or high IPD retrieval rate are significantly higher in IPD-MA without an authorship policy.  
These sensitivity analyses highlight the importance of reporting the proportion of IPD 
retrieved in IPD-MA. 
An additional analysis was also performed to examine characteristics of the 257 IPD-MA 
where proportion of IPD retrieved could not be calculated compared to the 503 IPD-MA were 
proportion of IPD-MA could be calculated (see Table 41). 
Results of this additional analysis indicate that the odds of the proportion of IPD retrieved 
being reported are significantly higher in more recently published IPD-MA, IPD-MA including 
RCTs only and IPD-MA without an authorship policy. There was no association between 
publication as a Cochrane IPD-MA and the source of funding on whether the proportion of 
IPD retrieved was reported.   
6) Use of fractional logistic regression as an alternative to logistic regression (see Table 42) 
Results of this analysis indicate that odds of retrieving a higher proportion of IPD are 
significantly associated with older IPD-MAs, IPD-MAs including only randomised studies, non-
Cochrane IPD-MAs and IPD-MAs with an authorship policy. There was no association 
between the number of eligible participants and source of funding on the proportion of IPD 
retrieved.  
7) Multivariable logistic regression of the proportion of study data retrieved (see Table 43) 
A total of 744 IPD-MAs were included in this analysis for which we could calculate the 
proportion of study data retrieved (i.e. the number of studies eligible for analysis and the 
number of studies data was provided for was reported). 
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Results of this sensitivity analysis are mostly similar to those reported in Table 7, however 
these results suggest that the odds of retrieving at least 80% of study data are significantly 
associated with older IPD-MA; suggesting that IPD retrieval rate on a study-level has got 
worse over time. 
In summary, numerical results of additional and sensitivity analyses are mostly similar and 
conclusions mainly unchanged indicating that the results of primary multivariable regression 
analyses are robust to assumptions made. Some results do, however, indicate that the 
proportion of IPD retrieved over time (including on a study-level) has got worse over time. 
The most variability in results was shown in the sensitivity analyses exploring a range of 
scenarios for the 257 IPD-MAs which did not report the proportion of IPD retrieved. Results 
of these sensitivity analyses varied and some were contradictory to the primary analysis, for 
example indicating that the odds of complete or high IPD retrieval rate are significantly higher 
in IPD-MAs without an authorship policy.  These sensitivity analyses highlight the importance 
of a reporting the proportion of IPD retrieved in IPD-MAs. 
Interestingly, when further considering the association of an authorship policy with IPD 
retrieval rate, results of this additional analysis show that odds of retrieving at least 80% of 
IPD were significantly increased when either individual authorship or collaborative 
authorship policies were used but odds of retrieving at 100% of IPD were significantly 
increased only when an individual authorship policy was used. 
4.3.4  Unavailability of IPD and the impact on analysis 
Out of the 571 systematic IPD-MAs that failed to retrieve 100% of the IPD, 201 (34%) had 
supplemented IPD with AD extracted from study publications. The additional AD had been 
included from a median of 5 (range 1 to 541) studies and a median of 683 (range 9 to 
1,180,505) participants. 
At least one study had been excluded from the meta-analysis due to lack of IPD or AD in 419 
(55%) systematic IPD-MAs. Across these, a median of 4 (range 1 to 342) studies and a median 
of 478 (range 8 to 1,792,339) participants were excluded from IPD-MAs but 241 systematic 
IPD-MA (32%) failed to state how many participants were excluded from analysis.  
Up to six reasons were reported for unavailability of IPD (Table 8); non-specific reasons, such 
as ‘data was not available for analysis’ were reported in 341 out of 571 systematic IPD-MAs 
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(58%). The most common specific reasons for not obtaining IPD were that investigators could 
not be contacted, investigators had declined to share data or that data had been lost or 
destroyed. In 24 systematic IPD-MAs it was reported that data was not requested for all 
studies; mainly due to the size or quality of these studies. 
Table 8: Reasons reported for unavailability of IPD in 571 systematic IPD-MA without 
100% of IPD retrieved 
Reasons reported for not retrieving 100% of eligible IPD  Number of IPD-MA1,2 
Data not available3 341 (60%) 
No contact could be made with study authors 104 (18%) 
Investigators declined but no reason given 74 (13%) 
Data lost or destroyed 65 (11%) 
Data could not be extracted4 55 (10%) 
Trial was still ongoing 42 (7%) 
Data quality issues 29 (5%) 
Failed to provide data in time for the IPD-MA 26 (5%) 
Data not requested 24 (4%) 
Ethical / ownership restrictions 15 (3%) 
Reason unclear 11 (2%) 
1. 189 IPD-MA with 100% of IPD provided not included in the table. 
2. Up to 6 reasons reported for unavailability of IPD. Therefore total number of reasons (and 
total percentages) sum to greater than 571 (100%)  
3. IPD was not available for a proportion of studies without any specific reason quoted. 
4. Applicable only in a small number of IPD-MAs where IPD were extracted from publications 
rather than requested. 
Table 9: Approach to accounting for missing IPD in 571 systematic IPD-MA without 100% 
of IPD retrieved 
Approach reported to account for missing IPD Number of IPD-MA1,2 
None stated  143 (25%) 
Separate meta-analyses are conducted including IPD only 
and IPD plus available AD  81 (14%) 
Stated that missing IPD is a limitation of the meta-analysis 
and / or that availability bias may be present 76 (13%) 
AD included in primary analysis  61 (11%) 
Sensitivity analysis with AD performed  57 (10%) 
Stated that the missing IPD is unlikely to change results  56 (10%) 
Results from the studies without IPD summarised narratively 48 (8%) 
Stated that the majority of data is included in analysis 47 (8%) 
Narrative comparison to an AD meta-analysis  18 (3%) 
Intend to include data in an update  14 (2%) 
1. 189 IPD-MA with 100% of IPD provided not included in the table. 
2. Up to three approaches described to account for missing IPD. Therefore total number of 




In 143 (25%) out of the 571 systematic IPD-MAs there was no acknowledgement of potential 
bias resulting from missing IPD. In 199 (34%) of the systematic IPD-MAs additional analyses 
using AD had been performed and in a further 66 (11%) systematic IPD-MAs, a narrative 
description of the studies without IPD or a narrative comparison to an aggregate data meta-
analysis had been provided. The remaining 183 (31%) systematic IPD-MAs make reference to 
the missing data, some acknowledging this may result in bias, without any further 
investigation of the implication on the conclusions of the review (Table 9). 
4.4  Discussion 
4.4.1  Summary of main results 
At the time of writing, this systematic review is believed to include the largest cohort of 
published IPD-MAs to date. Recent years have shown an increase in development of 
statistical methodology for the synthesis of IPD [36] (see also Chapter 2.3.3 of this thesis) as 
well as a rapid increase in the uptake of methods, with the number of systematic and non-
systematic IPD-MAs published per year increasing to an average of 105 published per year 
between 2009 and 2015 compared to 49 per year published between 2005 and 2009 [34]. 
However, these rapid increases do not seem to be mirrored by improved IPD retrieval rates, 
which may be due, in part, to the increasing uptake of IPD-MAs across a wide range of clinical 
areas and settings where IPD may be difficult to obtain.  
The findings of this systematic review showed that Cochrane reviews were less likely to 
retrieve all or a high proportion of IPD than systematic non-Cochrane reviews. This may be 
explained by the inclusion of thorough search methods within Cochrane reviews, as well as 
advances in systematic searching of larger electronic databases generally, leading to the 
identification of larger numbers of studies including more grey literature studies where IPD 
may be difficult to retrieve with the resources available to review authors, such as Cochrane 
review authors who usually undertake systematic reviews on a voluntary basis. Furthermore, 
the framework of a Cochrane review requires the registration of a protocol and publication 
of results regardless of the IPD retrieval rate; therefore, Cochrane IPD reviews with a low IPD 
retrieval rate may be less subject to review-level ‘publication bias’ than non-Cochrane IPD 
reviews with a low IPD retrieval rate.  
On the other hand, results also showed that IPD-MAs with an authorship policy (individual 
authorship or collaborative group authorship) were associated with retrieving a high 
proportion of IPD but it was only the IPD-MAs offering individual authorship which were 
 89 
 
associated with 100% retrieval of IPD (see Table 35). This is an important finding as the 
implementation of an authorship policy as an incentive to participate in an IPD-MAs, as a 
feature of a well-designed project, is a factor which is in control of the IPD-MAs team; even 
where other characteristics such as study design and number of eligible participants for IPD-
MA are constrained by the research question. 
4.4.2  Strengths and weaknesses 
The aim of this systematic review was to systematically identify all published IPD-MAs 
regardless of use of a systematic design to identify studies, resulting in a large cohort of 
nearly 1300 IPD-MAs. Inclusion criteria were wide and reasons for exclusion were 
documented for all references identified in electronic searches. Ninety abstracts which could 
not be matched to full-text articles, despite best efforts, were excluded from the systematic 
review. Due to the size of the cohort of this study, double reference screening and data 
extraction was performed on only a subset of the articles. Agreement between double 
extractions was good and all discrepancies were minor and easily resolved, therefore any 
errors made in screening and extraction would have been minimal and unlikely to influence 
the overall findings of the study. 
It was not possible to systematically investigate the IPD retrieval methods employed within 
the IPD-MAs; such as the number of attempts to contact investigators to request data etc., 
due to the lack of published detail regarding such processes. Data collection methods are 
likely to be an important factor influencing the proportion of IPD retrieved and clearer 
reporting of approaches to IPD collection, would be valuable to those planning new IPD-MAs.   
The primary analysis approach taken in this study involved dichotomising the dependent 
variable (proportion of IPD retrieved) and performing multivariable logistic regression 
analysis. The limitations of dichotomisation should be noted and further approaches to 
modelling IPD retrieval rate which takes account of the bimodal distribution of the 
dependent variable could be considered as future research. However, we believe that any 
loss of information will be reduced by the size of the cohort included in analysis and a range 
of sensitivity analyses have been presented to investigate all assumptions made in the 
primary analysis, demonstrating overall consistency and robustness of results. 
This systematic review examines associations between IPD retrieval rate and characteristics 
of the IPD-MA. Arguably, it would have been more informative to consider the association 
between IPD retrieved (yes or no) and characteristics of the individual studies within the IPD-
MA, particularly when considering whether there has been any changes over time in IPD 
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retrieval rates. However, it was not possible to systematically examine the characteristics of 
the studies providing or not providing IPD within the 760 IPD-MAs due to lack of specific 
information reported at the study-level. For example, 125 out of 760 IPD-MAs (16%) did not 
provide any information at all regarding the years of publication of studies not providing IPD, 
and many of the IPD-MAs provided only year ranges of eligible studies and/or studies 
providing IPD. Therefore, modelling the probability of a study providing IPD was not deemed 
appropriate. This is a limitation of this analysis but it should be noted for future IPD-MAs that 
it is essential to clearly describe the characteristics of the eligible studies which do and also 
eligible studies which do not contribute to the IPD analysis. Reporting of such information on 
a study-level allows a judgement of ‘availability bias’ within the IPD-MA; in other words, 
whether the provision of IPD may be associated with characteristics of the eligible studies.   
4.4.3  Relation to other studies and implications 
Present results have shown that a quarter of systematic IPD-MAs published since 1987 
retrieved all IPD for analysis and only half retrieved at least 80% of relevant IPD. This latter 
finding is higher than previous results which reported that around 25% of IPD-MAs had 
included less than 80% of IPD [32, 33, 35, 40]. However previous work has been based on 
smaller cohorts of IPD-MAs, has mostly focused on IPD-MAs of RCTs only and has been 
conducted over smaller time frames.  
In line with previous work [32, 33, 35, 40], present results show that important inadequacies 
around conduct and reporting of IPD-MAs remain. Non-systematic methods, mostly based 
on the known availability of IPD, had been used to select eligible studies for inclusion in 41% 
of the initial cohort of IPD-MAs identified. It was outside the scope of this study to further 
examine the design of these analyses; however, it is recommended that non-systematic 
pooling of IPD is conducted in the framework of a prospective meta-analysis [281] and that 
the conclusions of such analyses must take the inevitable selection bias into account.   
Furthermore in around 5% of the systematic IPD-MAs, IPD was not requested from a subset 
of the eligible studies (Table 8), often due to the small size or study quality in relation to the 
other eligible studies.  It is arguably acceptable to exclude studies of poor quality which may 
impact on the overall IPD-MA [282], however such exclusions should be specified a priori and 
investigated via sensitivity analysis to avoid introducing selection bias to reviews of a 
systematic nature [51]. 
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Present results highlight the importance of clear reporting of study and participant numbers 
contributing to different stages of the IPD-MA with an adequate investigation of the reasons 
for lack of data and discussion of the potential for ‘availability bias.’ The total number of 
eligible participants and the total number of participants’ data requested was unclear in 34% 
of published IPD-MAs; in 58% of the IPD-MAs that failed to retrieve 100% of eligible IPD, 
there were no specific reasons provided for the unavailability of data, making interpretation 
of IPD-MAs results and conclusions in the presence of potential ‘availability bias’ difficult. In 
a quarter of IPD-MAs unable to retrieve 100% of IPD, there was a complete lack of discussion 
or acknowledgement of ‘availability bias’. A systematic investigation of the impact of 
'availability bias’ on IPD-MAs conclusions was outside the scope of this review and is specific 
to the clinical context in question. Despite this, further efforts are recommended by 
researchers conducting an IPD-MA to thoroughly investigate and report the impact of data 
availability [51].    
Proper uptake of new PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) IPD guidelines for the conduct and reporting of IPD-MA [283], in addition to 
guidance on the use of IPD-MA to synthesise the results of RCTs [282], should lead to 
improved conduct and reporting in IPD-MAs. In particular, transparent reporting of the 
number of eligible studies and participants, how much data was requested and obtained with 
clear reasons for non-availability of IPD, preferably via a flow diagram, and data collection 
methods.  Discussion of limitations and impact on conclusions due to missing IPD is essential. 
4.4.4  Concluding remarks 
IPD-MAs are resource demanding, time consuming and methodologically challenging but 
when conducted well [282], ideally following a registered protocol [284] and adhering to the 
PRISMA-IPD guidance [283], can provide more detailed and potentially more reliable results 
than a meta-analysis of aggregate data. Meta-analysts must carefully consider the 
appropriateness of an IPD analysis and demonstrate awareness of potential biases induced 
by missing IPD. Only one in four published systematic IPD-MAs have had access to all IPD; we 
hope that this proportion will grow in future years with the growing awareness of data 
sharing and transparency in the pharmaceutical industry and beyond [77-80, 84, 85].  
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Chapter 5: Individual participant data requests: 20 
years’ experience of the Cochrane Epilepsy Group  
5.1  Introduction 
The Cochrane Epilepsy Group has been making IPD requests to the authors of AED 
monotherapy trials since the mid-1990s with eight reviews for IPD-MA of pair-wise AED 
comparisons published to date since 2000 [59-67]. The group have also previously published 
an IPD-NMA including participants randomised to one of eight AEDs [285]. See Chapter 1.2 
for further discussion of the clinical setting and the rationale of these IPD reviews.  
Since the publication of the original NMA in 2007, additional AEDs have been used in clinical 
practice and additional clinical trials have been conducted which has prompted the need for 
an updated analysis. Plans to conduct a Cochrane Review and IPD-NMA of 10 AEDs began in 
2010 (see Figure 6), with the submission for project funding via a Cochrane programme grant 
in October 2010 and beginning in June 2011. 
Figure 6: Timeline of IPD requests for Cochrane Epilepsy IPD-NMA  
 
This chapter outlines the data requesting process for the current IPD-NMA, further details of 
which can be found in the Cochrane review [69]. This chapter also reflects upon the 
experiences of the Cochrane Epilepsy Group in requesting IPD prior to the current IPD-NMA 
and changes over time following 20 years of data requesting.  
The work contained in this Chapter relating to IPD requesting and IPD retrieval for Cochrane 
Epilepsy reviews has been published in the British Medical Journal [278] and the IPD-NMA 
has been published on the Cochrane Database of Systematic Reviews [69]. 
 93 
 
5.2  Selection of studies for IPD-NMA 
5.2.1. Inclusion criteria 
5.2.1.1  Study Design 
Randomised controlled trials (RCTs) of a parallel design in which the unit of analysis is the 
individual (i.e. cluster randomised trials were excluded). RCTs may be blinded (double-blind, 
single-blind etc.) or open label and may use either an adequate method of allocation 
concealment (e.g. sealed opaque envelopes) or a quasi-method of randomisation (e.g. 
allocation by date of birth).    
Trials of a monotherapy design only were included; i.e. participants are randomised to 
treatment with a single drug throughout the trial period. Trials with an add-on, poly-therapy, 
transitional or withdrawal to monotherapy periods of any length were excluded. 
Trials of a cross-over design were excluded as such as design is inappropriate for measuring 
primary outcome 'time-to-withdrawal of allocated treatment' as withdrawal during the first 
treatment period would prevent cross-over into the second period, resulting in incomplete 
outcome data. Furthermore, the use of cross-over designs is no longer recommended in 
epilepsy trials of a monotherapy design [286].  
5.2.1.2  Participants 
Children or adults with partial-onset seizures (simple partial, complex partial, or secondarily 
generalised tonic-clonic seizures) or generalised-onset tonic-clonic seizures (with or without 
other generalised seizure types) with a new diagnosis of epileptic seizures or who had had a 
relapse of seizures following antiepileptic monotherapy withdrawal. 
Trials recruiting only participants with other generalised seizure types alone (e.g. participants 
recruited with absence seizures alone without generalised tonic clonic seizures) as guidelines 
for the first-line treatment of other generalised seizure types are different from the 
guidelines for generalised tonic-clonic seizures [74] and due to documented evidence that 
certain drugs of interest may exacerbate some generalised seizure types [287, 288].  




5.2.1.3  Interventions 
Ten AEDs currently licensed and commonly used as monotherapy in at least one country 
were included in the treatment network [72, 73]: 
 carbamazepine (CBZ)  
 phenobarbitone (PHB)  
 phenytoin (PHT)  
 sodium valproate (VPS)  
 lamotrigine (LTG)  
 oxcarbazepine (OXC)  
 topiramate (TPM)  
 gabapentin (GBP)  
 levetiracetam (LEV)  
 zonisamide (ZNS) 
Clinical profiles and mechanisms of action of these ten drugs are detailed in the Cochrane 
Epilepsy IPD-NMA [68, 69]. 
Included trials must make at least one pairwise comparison between at least 2 of the 10 
antiepileptic drugs included in the network. For trials with three treatment arms or more, 
only treatment arms of the ten AEDs listed above are included and any treatment arms not 
included in the network were excluded from analysis. Trials with multiple arms (doses) of the 
same drug were included as long as at least one arm of another drug from our network was 
included (e.g. multiple doses of GBP compared to CBZ) [289]. Multiple dose arms of the same 
drug are pooled in analysis; dose comparisons were outside the scope of this analysis.  
5.2.2  Study selection 
5.2.2.1  Systematic Search methods 
The following databases were searched with no language restrictions: the Cochrane Epilepsy 
Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via 
the Cochrane Register of Studies Online (CRSO), MEDLINE, SCOPUS, ClinicalTrials.gov and 
World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). 
Search strategies are published in the Cochrane Epilepsy IPD-NMA [69]. 
Systematic searches were performed on the following dates: 
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 23rd  November 2011 
 14th September 2012 
 29th July 2013 
 9th September 2014 
 27th July 2016 
Hand-searching was performed of relevant conference proceedings and reference lists of 
retrieved trials. Experts in the field were also contacted for details of any ongoing or 
unpublished trials. 
5.2.2.2  Screening of studies 
One reviewer (SJN) screened all titles and abstracts of all records identified by the electronic 
searches according to the pre-specified inclusion criteria (see Chapter 5.2.1). Subsequently, 
two reviewers (SJN and AGM) independently assessed full-text publications according to the 
same inclusion criteria. Disagreements were resolved by discussion or by consulting a third 
reviewer (CTS). 
5.2.2.3  Results of the systematic search 
Electronic searching identified 6762 records and a further three records were found by hand-
searching and checking reference lists of included trials. Following removal of 3032 duplicate 
records, 3733 records were screened (title and abstract) and 3591 clearly irrelevant records 
were excluded. Full-text articles were accessed and screened for the remaining 142 records 
and 31 trials (described in 32 full-text articles) were excluded. In addition to the excluded 
trials, seven records were identified as ongoing trials and eight records were classified as 
‘awaiting assessment’ as translation into English or further information was required to 
assess eligibility of the trials.  
Figure 7 shows a study flow diagram of the screening process, including reasons for exclusion 
of full-text articles. In total, 77 trials (described in 95 full-text-articles) were included in the 
Cochrane review (see Appendix 10 for references of the primary publication of each trial). 
One full-text article reported on a cohort of participants which were recruited into two 
separate trials [290]; these two trials are treated separately in analysis as ‘Brodie 1995a’ and 
‘Brodie 1995b.’ It was unknown at the time of data request that the cohort of participants 
reported on were recruited in two separate trials, therefore Brodie 1995 is treated as a single 
data request in subsequent sections of this Chapter. 
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Figure 7: Study Flow Diagram: Selection of studies for Cochrane Epilepsy Individual 
Participant Data Network Meta-Analysis 
 
5.2.3.4  Characteristics of included trials 






Table 10: Characteristics of trials included in Cochrane review and IPD-NMA 
Trial reference1 
Characteristics of included trials6 
Trial AEDs  
Seizure 
type(s)7 Previous AED use permitted? Ages 
Single  or 
Multi Centre 




Aikia 1992 PHT; OXC Both No Adults   Not stated Academic No 
Banu 2007 CBZ; PHB Both No Children   Single   Academic Yes 
Baulac 2012 CBZ; ZNS Partial only No Adults   Multi   Pharmaceutical Yes 
Bidabadi 20092 CBZ; PHB Partial only Not stated Children   Single   Academic No 
Bill 1997 PHT; OXC Both No Adults   Multi   Pharmaceutical Yes 
Biton 2001 LTG; VPS Both Not stated All ages Multi   Pharmaceutical Yes 
Brodie 1995a3 CBZ; LTG Both No All ages Multi   Pharmaceutical Yes 
Brodie 1995b3 CBZ; LTG Both No All ages Multi   Pharmaceutical Yes 
Brodie 1999 CBZ; LTG Both No Elderly   Multi   Pharmaceutical Yes 
Brodie 2002 GBP; LTG Both Not stated Adults   Multi   Pharmaceutical No 
Brodie 2007 CBZ; LEV Both No Adults   Multi   Pharmaceutical Yes 
Callaghan 1985 CBZ; PHT; VPS Both No All ages Single   Academic No 
Capone 20084 CBZ; LEV Not stated New onset post-stroke seizures Adults   Single   Academic No 
Castriota 20084 CBZ; LEV Partial only No Adults   Single   Academic No 
Chadwick 1998 CBZ; GBP Partial only Relapsed seizures permitted All ages Multi   Pharmaceutical Yes 
Chen 1996 CBZ; PHB; VPS Both No Children   Single   Academic No 
Cho 2011 CBZ; LEV Partial only No All ages Single   Academic No 
Christe 1997 OXC; VPS Both No Adults   Multi   Pharmaceutical No 





Cossu 19844 CBZ; PHB Partial only No Adults   Single   Academic No 
Craig 1994 PHT; VPS Both No Elderly   Single   Pharmaceutical Yes 
Czapinski 19972 CBZ; PHB; PHT; VPS Partial only No Adults   Not stated Academic No 
Dam 1989 CBZ; OXC Not stated No Adults   Multi   Academic No 
de Silva 1996 CBZ; PHB; PHT; VPS Both No Children   Multi   Academic Yes 
Dizdarer 2000 CBZ; OXC Partial only Not stated Children   Single   Academic Yes 
Donati 2007 CBZ; OXC; VPS Partial only No Children   Multi   Pharmaceutical No 
Eun 2012 CBZ; LTG Partial only No Children   Multi   Academic Yes 
Feksi 1991 CBZ; PHB Both No All ages Single   Pharmaceutical No 
Forsythe 1991 CBZ; PHT; VPS Not stated No Children   Single   Academic No 
Fritz 20062 LTG; OXC Not stated Not stated Adults   Not stated Academic No 
Gilad 2007 CBZ; LTG Partial only New onset post-stroke seizures Adults Single   Academic No 
Guerreiro 1997 PHT; OXC Both No Children   Multi   Pharmaceutical Yes 
Heller 1995 CBZ; PHB; PHT; VPS Both No Adults   Multi   Academic Yes 
Jung 20159 CBZ; LEV Partial only No Children   Multi   Academic No 
Kalviainen 20022 CBZ; LTG Both No Not stated Multi   Pharmaceutical No 
Kopp 20072 CBZ; LEV; VPS Both No Not stated Single   Academic No 
Korean Lamotrigine 
Study Group 20082,9 CBZ; LTG Both No All ages Multi   Pharmaceutical No 
Kwan 2009 LTG; VPS Both Relapsed seizures allowed Adults   Multi   Academic Yes 
Lee 2011 CBZ; LTG Partial only No Adults   Multi   Academic Yes 
Lukic 20052 LTG; VPS Both No Adults   Single   Academic No 
Mattson 1985 CBZ; PHT; PHB Partial only Under-treated seizures allowed  Adults   Multi   Government Yes 





Mitchell 1987 CBZ; PHB Partial only No Children   Single   Academic No 
Miura 1990 CBZ; PHT; VPS Both No Not stated Single   Academic No 
Motamedi 20139 LEV; LTG Both No Elderly   Single   Academic No 
NCT014988222,9 OXC; LEV Partial only No Adults   Multi   Pharmaceutical No 
NCT019541212,9 CBZ; LEV Partial only No Adults   Multi   Pharmaceutical No 
Nieto-Barrera 2001 CBZ; LTG Partial only No All ages Multi   Pharmaceutical Yes 
Ogunrin 2005 CBZ; PHT; PHB Both No Adults   Single   Academic Yes 
Pal 1998 PHB; PHT Both No Children   Single   Academic Yes 
Placencia 1993 CBZ; PHB Both No All ages Single   Academic Yes 
Privitera 20035 CBZ; TPM; VPA Both No All ages Multi   Pharmaceutical Yes 
Pulliainen 1994 CBZ; PHT Both No Adults   Single   Academic No 
Ramsey 1983 CBZ; PHT Both No Adults   Multi   Government No 
Ramsey 1992 PHT; VPA GTC only No All ages Multi   Government Yes 
Ramsey 20072 CBZ; LEV Partial only Under-treated seizures allowed Elderly   Multi   Academic No 
Ramsey 2010 PHT; TPM Both Under-treated seizures allowed All ages Multi   Pharmaceutical Yes 
Rasgoti 1991 PHT; VPS Both Not stated All ages Single   Academic No 
Ravi Sudhir 1995 CBZ; PHT Both No Adults   Single   Academic No 
Resendiz 20044 CBZ; TPM Partial only No Children   Multi   Academic No 
Reunanen 1996 CBZ; LTG Both Relapsed seizures allowed All ages Multi   Pharmaceutical Yes 
Richens 1994 CBZ; VPS Both Relapsed seizures allowed Adults   Multi   Pharmaceutical Yes 
Rowan 2005 CBZ; GBP; LTG Both Under-treated seizures allowed Elderly   Multi   Government No 
Saetre 2007 CBZ; LTG Not stated No Elderly   Multi   Pharmaceutical No 
SANAD A 2007 
CBZ; GBP; LTG; OXC; 







SANAD B 2007 LTG; TPM; VPS GTC only Relapsed seizures allowed All ages Multi   Academic Yes 
Shakir 1981 PHT; VPS Both Relapsed seizures allowed All ages Multi   Academic No 
So 1992 CBZ; VPS Partial only Under-treated seizures allowed Adults   Not stated Academic No 
Steiner 1999 LTG; PHT Both No Adults   Multi   Pharmaceutical Yes 
Steinhoff 20055 CBZ; LTG; VPS Both No All ages Multi   Pharmaceutical No 
Stephen 2007 LTG; VPS Both No All ages Single   Academic Yes 
Suresh 20159 CBZ; LEV Partial only No Adults   Single   Academic No 
Thilothammal 1996 PHB; PHT; VPS GTC only No Children   Single   Academic No 
Trinka 20135 CBZ; LEV; VPS Both No Adults   Multi   Pharmaceutical Yes 
Turnbull 1985 PHT; VPS Both No Adults   Single   Academic Yes 
Verity 1995 CBZ; VPS Both Relapsed seizures permitted Children   Multi   Pharmaceutical Yes 
Werhahn 2015 CBZ; LEV; LTG Partial only No Elderly   Multi   Pharmaceutical Yes 
1. See Appendix 10 for reference of the primary publication of each trial and Chapter 5.2.1.3 for abbreviations of drugs. 
2. Available only as abstract, online summary or clinical trial summary report. 
3. Two trials reported in a single publication. 
4. Translated from Italian or Spanish 
5. Trials designed in two strata based on whether recommended treatment would be CBZ or VPS.  
6. Further details of characteristics (e.g. proportions of each seizure type, specific age ranges recruited, geographical locations of centres etc.) are available in the published 
Cochrane IPD-NMA [69]. 
7. GTC: Generalised tonic clonic seizures with or without other generalised types. ‘Both’ – indicates individuals with partial seizures and individuals with GTCs recruited. 
‘Not stated’ indicates that the proportion of each seizure type recruited was not stated.  
8. Academic defined as study conducted within a university or hospital setting without clear government or pharmaceutical sponsorship or involvement. 




Most of the trials (63 out of 77 trials (82%)) had been published in at least one full-text article 
in English; seven trials were available in abstract form only, two trials were available only as 
an online summary on ClinicalTrials.gov and one trial was available in English only as a clinical 
trial summary report (full-text article published in Korean). Three trials published as a full-
text article in Italian and one trial published as a full-text article in Spanish were translated.   
One published full-text article (Brodie 1995) reported on two separate trials. Furthermore, 
three trials were designed in strata based on whether clinician recommended treatment 
would be CBZ or VPS. Within the two strata, participants were randomised to an 
experimental AED (TPM, LTG or LEV) compared to the clinician recommended treatment. To 
ensure that randomised comparisons are made, the strata in these trials were considered 
separately in this review (i.e. IPD would be analysed in a CBZ branch and a VPS branch). 
Forty-five trials (58%) were multicentre, 28 trials (36%) were single centre and the number 
of centres was not stated for four trials (6%). Trials were conducted globally across North 
America, Europe, South America, Africa and Australasia. Twenty-nine studies (38%) were 
pharmaceutical sponsored (defined as pharmaceutical studies herein), five studies were 
government sponsored (6%, defined as government studies herein) and the remaining 43 
studies (56%) conducted within a university or hospital setting without clear pharmaceutical 
or government sponsorship or involvement (defined as academic studies herein).  
All trials recruited individuals of both genders. Twenty trials recruited individuals of all ages 
(26%), fifteen trials (19%) recruited children only; with the age limits ranging from under 12 
years to under 18 years of age; 32 trials (41%) recruited adults only, with the age limits 
ranging from over 13 years to over 18 years of age; seven trials (9%) recruited elderly 
participants only, with age limits ranging from over 60 years to over 65 years of age; and 
three trials (5%) did not state age ranges of eligible participants.   
Twenty-five trials (32%) were designed to recruit individuals with partial seizures only and 
three trials (4%) were designed to recruit individuals with generalised tonic clonic seizures 
with or without other generalised seizure types or unclassified seizure types only. The 
remaining 49 trials (64%) were designed to recruit individuals with partial or generalised tonic 
clonic seizures with or without other generalised seizure types. However, five of these trials 
did not state the proportion of individuals with each seizure type recruited.  
All trials recruited individuals with new onset seizures; within three trials individuals with 
new onset seizures following stroke were recruited. Fifty-four trials (70%) recruited only 
individuals with no previous AED treatment and fourteen trials also permitted the 
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recruitment of individuals with relapsed or ‘under-treated’ seizures (18%). The remaining six 
trials did not state whether previous AED use was permitted for inclusion.  
5.2.3.5  Methodological quality of included studies 
Methodological quality of the included studies was assessed in all included studies using the 
Cochrane Collaboration’s tool for assessing risk of bias [248]. The following methodological 
criteria are assessed according to this tool: 
 Domain 1: Selection bias (sequence generation) 
 Domain 2: Selection bias (allocation concealment) 
 Domain 3: Performance bias (blinding of participants and personnel) 
 Domain 4: Detection bias (blinding of outcome assessment) 
 Domain 5: Attrition bias (incomplete outcome data) 
 Domain 6: Reporting bias (selective outcome reporting) 
 Domain 7: Other bias (any issues not covered by above domains) 
Risk of bias assessments were made using information in all published reports of trials in 
addition to any unpublished information provided following IPD requests. Table 11 
summarises the methodological quality of the 77 trials eligible for inclusion in the NMA and 
further discussion of the risk of bias assessment can be found in the Cochrane IPD-NMA [69]. 
All trials were described as randomised but 37 trials (48%) did not provide details of how the 
random sequence was generated so were judged to be at unclear risk of selection bias. The 
remaining trials provided details of randomisation methods; in 38 trials (49%) this was judged 
to be adequate and at low risk of selection bias and two trials using alternate randomisation 
(2%) were judged to be at high risk of selection bias. In 28 trials (36%), an adequate method 
of allocation concealment was described (low risk of selection bias), in two trials (3%) it was 
stated that allocation was not concealed for some or all participants (high risk of selection 
bias) and in 47 trials (61%), no details were provided regarding allocation concealment 
(unclear risk of selection bias). 
Twenty-seven trials (35%) were double-blinded (low risk of performance bias), 32 trials (42%) 
were open label (high risk of performance bias) and it was not stated whether participants 
and personnel were blinded in the remaining 18 trials (23%, unclear risk of performance bias). 
Twelve trials (16%) also stated that outcome assessors were blinded (low risk of detection 
bias), 27 trials (35%) stated that outcome assessment was not blinded (high risk of detection 
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bias) and it was not stated whether outcome assessment was blinded in the remaining 38 
trials (49%, unclear risk of detection bias). 
Table 11: Methodological quality of studies included in the Cochrane Epilepsy Review and 
IPD-NMA 
Trial Reference1 
Risk of bias domain2,3 
1 2 3 4 5 6 7 
Aikia 1992 Unclear Unclear Low Unclear High Low Low 
Banu 2007 Unclear Low Low Unclear Low Low High 
Baulac 2012 Low Low Low Low Low Low Low 
Bidabadi 2009 Unclear Unclear Unclear Unclear Unclear Unclear Low 
Bill 1997 Low Low Low Unclear Low Low Low 
Biton 2001 Low Unclear Low Low Low Low Low 
Brodie 1995a Low Low Low Unclear Low Low Low 
Brodie 1995b Low Low Low Unclear Low Low Low 
Brodie 1999 Low Low Low Unclear Low Low Low 
Brodie 2002 Low Unclear Low Unclear Low Low Low 
Brodie 2007 Low Low Low Unclear Low Low Low 
Callaghan 1985 Unclear Low Unclear Unclear Low Low Low 
Capone 2008 Unclear Unclear Unclear Unclear Low Unclear Low 
Castriota 2008 Unclear Unclear High High Unclear Unclear Low 
Chadwick 1998 Low Low High Unclear Low Low Low 
Chen 1996 Low Unclear Unclear Low Unclear Low Low 
Cho 2011 Unclear Unclear Unclear Low Unclear Low Low 
Christe 1997 Unclear Unclear Low Unclear High Low Low 
Consoli 2012 Low Unclear High High High Low High 
Cossu 1984 Unclear Unclear Low Unclear Low Unclear High 
Craig 1994 Low Low High Low Low Low Low 
Czapinski 1997 Unclear Unclear Unclear Unclear Unclear Unclear Low 
Dam 1989 Unclear Unclear Low Unclear High Low Low 
de Silva 1996 Low Low High High Low Low Low 
Dizdarer 2000 High High High High Low Low Low 
Donati 2007 Low Low High High High Low Low 
Eun 2012 Low Unclear High High Low Low Low 
Feksi 1991 Low Low Unclear Unclear High Low High 
Forsythe 1991 High Unclear High Low Low Unclear Low 
Fritz 2006 Unclear Unclear Unclear Unclear Unclear Unclear Low 
Gilad 2007 Unclear Unclear High High Low Low Unclear 
Guerreiro 1997 Low Low Low Unclear High Low Low 
Heller 1995 Low Low High High Low Low Low 
Jung 2015 Low Low High Low High Low Low 
Kalviainen 2002 Unclear Unclear Unclear Unclear Unclear Unclear Low 




Study Group 2008 Unclear Unclear High High High Low Low 
Kwan 2009 Unclear Unclear High High Low Low Low 
Lee 2011 Low Unclear High High Low Low Low 
Lukic 2005 Unclear Unclear High High Unclear Unclear Low 
Mattson 1985 Unclear Unclear Low Unclear Low Low Low 
Mattson 1992 Low Low Low Unclear Low Low Low 
Mitchell 1987 Unclear Unclear High High Low Low High 
Miura 1990 Unclear Unclear Unclear Unclear Low Unclear Low 
Motamedi 2013 Low Unclear Low Unclear High Low Low 
NCT01498822 Unclear Unclear High High High Low Low 
NCT01954121 Unclear Unclear High High High High Low 
Nieto-Barrera 2001 Low Low High High Low Low Low 
Ogunrin 2005 Low Low Low Low Low Low Low 
Pal 1998 Low Unclear High Low Low Low Low 
Placencia 1993 Low High Unclear Unclear Low Low High 
Privitera 2003 Low Unclear Low Unclear Low Low Low 
Pulliainen 1994 Unclear Unclear Unclear Low High Unclear Low 
Ramsey 1983 Unclear Unclear Low Unclear High Low Low 
Ramsey 1992 Low Unclear High High Low Low Low 
Ramsey 2007 Unclear Unclear Low Unclear Unclear Unclear Low 
Ramsey 2010 Unclear Unclear Low Low Low Low Low 
Rasgoti 1991 Unclear Unclear Unclear Unclear Unclear Low Low 
Ravi Sudhir 1995 Unclear Unclear Unclear Unclear High Unclear Low 
Resendiz 2004 Low Unclear High High High Low Low 
Reunanen 1996 Low Low High High Low Low Low 
Richens 1994 Low Low High High Low Low Low 
Rowan 2005 Low Low Low Unclear Low Low Low 
Saetre 2007 Unclear Unclear Low Unclear Low Low Low 
SANAD A 2007 Low Low High High Low Low Low 
SANAD B 2007 Low Low High High Low Low Low 
Shakir 1981 Low Low Unclear Unclear Low Low Low 
So 1992 Unclear Unclear Low Unclear High Low Low 
Steiner 1999 Unclear Unclear Low Low Low Low Low 
Steinhoff 2005 Unclear Unclear High High High Low Low 
Stephen 2007 Unclear Unclear High High Low Low High 
Suresh 2015 Unclear Unclear High High Unclear High Low 
Thilothammal 1996 Low Unclear Unclear Unclear Low Low Low 
Trinka 2013 Unclear Low High High Low Low Low 
Turnbull 1985 Unclear Unclear Unclear Unclear Low Low Low 
Verity 1995 Low Low High High Low Low Low 
Werhahn 2015 Low Low Low Unclear Low Low Low 
1. See Appendix 10  for reference of the primary publication of each trial 
2. See Chapter 5.2.3.5 for definitions of the domains of risk of bias. 
3. See Cochrane IPD-NMA for full details of risk of bias assessments [69].  
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In theory, a review using IPD should overcome issues of attrition bias and reporting bias as 
unpublished data can be provided, unpublished outcomes calculated and all randomised 
participants can be analysed by an ITT approach. Forty seven trials (61%, including all trials 
providing IPD) were at low risk of attrition bias, as attrition rates were reported and an ITT 
approach was used for analysis. Eighteen trials (23%) were judged to be at high risk of 
attrition bias as participants were excluded from analysis and/or an ITT approach was not 
used. For the remaining 12 trials, mostly those without full-text publications available, were 
judged to be at unclear risk of attrition bias as insufficient information was available to make 
a judgement. Sixty one trials (79%, including all trials providing IPD) were at low risk of 
reporting bias. Two trials (6%) were judged to be at high risk of reporting bias as results were 
not provided for all listed outcomes and for the remaining 14 trials, mostly without full-text 
publications available, were judged to be at unclear risk of reporting bias as insufficient 
information was available to make a judgement. 
Another source of bias was detected in eight trials (10%). Inconsistencies between IPD 
provided and published results were found in four trials which could not be resolved by 
original trial authors. For one trial, too many inconsistencies were present for this data to be 
usable. Three trials were likely to be statistically underpowered and in one trial it was unclear 
if all participants were receiving AED monotherapy treatment.   
5.3  IPD request methodology and preparation of IPD for network 
meta-analysis 
5.3.1  IPD requests prior to 2012 
As described in Chapter 5.2.2.3, 77 trials were identified as eligible for the current IPD-NMA. 
Two of the trials, recruiting 2437 participants, were conducted within the Clinical Trials 
Research Centre at the University of Liverpool, therefore IPD was available on site and did 
not need to be requested [264, 265]. Thirty of these trials reported in 29 publications (see 
Chapter 5.2.2.3 for details of two trials within Brodie 1995 publication) had been identified 
previously by the Cochrane Epilepsy Group for inclusion in IPD-MA or IPD-NMA and IPD 
requests had been initiated between the years of 1995 and 2005 approximately. 
Many of the data requests were initiated at a time when IPD-MA was a relatively novel design 
and when e-mail was not commonly used. Exchanges were conducted by letter, fax, 
telephone and face-to-face meetings with trial investigators. Some datasets supplied had 
never been computerised. Due to the informal nature of many of these requests, no data 
sharing agreements were exchanged and very little documentation was retained regarding 
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the time-to-complete data requests (Professor Anthony Marson (Co-ordinating Editor – 
Cochrane Epilepsy Group), personal communication, January 2012). A summary of the results 
of these 29 IPD requests made is provided in Chapter 5.4.1. 
5.3.2  IPD requests from 2012 to 2015 
IPD requests for newly identified trials were initiated from January 2012 following the first 
systematic search in November 2011. Further requests were initiated in February 2013 and 
December 2013 following updated searches in 2012 and 2013 (see Figure 6). In total, 
requests for IPD from 39 eligible trials were initiated over this time frame. 
For all trials meeting inclusion criteria, a data request letter and a data request form were 
sent to the first or corresponding author of the trial or to the trial sponsor(s) as appropriate. 
The recipients of IPD requests are referred to as data providers herein. Data request letters 
and data request forms were sent by as many methods as possible (e-mail, postal mail, fax).  
A copy of a template request letter and the data request form can be found in Appendix 11. 
The data request form asked data providers if the following information was available:   
 Trial methods: 
o method of generation of random list 
o method of concealment of randomisation 
o stratification factors 
o blinding methods 
 Participant covariates: 
o sex and age 
o seizure types 
o epilepsy status (newly diagnosed / relapsed seizures following drug withdrawal) 
o time between first seizure and randomisation 
o number of seizures prior to randomisation (with dates) 
o presence of neurological signs 
o electroencephalography (EEG) results, computed tomography (CT) and/or 
magnetic resonance imaging (MRI) results 
o aetiology of seizures (if known) 
 Follow-up data: 
o treatment allocation 
o date of randomisation and dates of follow-up 
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o dates of seizures post randomisation or seizure frequency data between follow-
up visits 
o dates of treatment withdrawal and reason(s) for treatment withdrawal 
o starting dose of treatment 
o dates of dose changes 
o adverse events reported. 
The request also included any available, related documents such as case report forms, trial 
protocols, clinical summaries etc. Following the return of the data request form, data 
providers were asked to provide the data indicated to be available; data was accepted in any 
computerised format. 
In the event of no response to the request, a follow-up letter, e-mail and/or fax (as previously 
sent) was sent to the same data provider first contacted. If no response was received 
following the second communication, an alternative trial author or sponsor was contacted if 
their contact details could be sourced. All data requests were considered ongoing until IPD 
was provided or a data provider confirmed that IPD could not be made available. Where IPD 
could not be made available, the quoted reason for non-availability was recorded and an 
additional request for any unpublished AD related to the outcomes of interest of the review 
was made if appropriate.  
Any outstanding data requests were considered unsuccessful at the end of 2015; at this 
point, the database was closed to begin analysis (see Figure 6). Where IPD was not available 
for analysis (confirmation from data provider that IPD could not be provided or no responses 
received to any requests), an assessment was made by one reviewer (SJN) of whether any 
relevant and appropriate AD had been reported in the publication or could be indirectly 
estimated for inclusion in a combined IPD and AD analysis.  
5.3.3  Preparation of IPD for analysis 
All IPD provided (prior to 2012 or in requests made from 2012 to 2015) was stored on a 
secure, dedicated network drive which was accessible only to the statisticians performing 
analysis (SJN, MS, CTS) and the Computer Services Department of the University of Liverpool 
for maintenance purposes. All provided data was checked for consistency and prepared for 
analysis according to a pre-specified procedure which is detailed in Appendix 12.    
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The procedure was designed to ensure a standardised and consistent approach to 
preparation of all data for the IPD-NMA. However given differences in format and content of 
the datasets provided, the procedure serves as a guidance document rather than a direct 
algorithm for the preparation of IPD for analysis. The procedure was piloted firstly by SJN on 
a dataset provided prior to 2012 and secondly on the first dataset received from the 2012-
2015 requests by SJN and MS independently and results were compared. Updates were made 
accordingly following piloting and the procedure outlined in Appendix 12 was applied to all 
newly provided datasets and the remaining datasets provided prior to 2012. Stages of the 
procedure were ignored if not applicable to the dataset in question and additional steps were 
added in on a case-by-case basis if deemed necessary.  
Time to check and prepare a dataset for analysis following the procedure outlined in 
Appendix 12 (including time required for data providers to provide clarification of 
inconsistencies) was monitored approximately, but not recorded precisely. Due to different 
formats and content of IPD provided, resulting in varying numbers and extents of checks 
required, a comparison of total data checking and preparation time across all datasets was 
not deemed appropriate. Furthermore, datasets provided prior to 2012 had been checked 
and prepared for analysis by different statisticians working on the original Cochrane Reviews 
and IPD-MAs [67, 285, 291-296] and it is unlikely that a standardised procedure was used. 
Applicable sections of the procedure were applied to the original datasets provided to 2012 
by SJN where possible (replication of published results, calculation TTE outcomes etc.). 
However, contact with original data providers had not been maintained, therefore 
clarification of any inconsistencies was not possible. 
5.3.3.1  Consistency checking 
Appendix 12 provides full details of relevant consistency checks. In summary, after basic 
checks on the content of the IPD provided has been performed, IPD was cross-checked 
against any published reports of the trial and published results reproduced where possible. 
Also where possible, a review was also conducted of the chronological randomisation 
sequence by checking the balance of prognostic factors, taking account of factors stratified 
for in randomisation procedure. Where any missing data, errors or inconsistencies were 
found, data providers were contacted for clarification. If large or major inconsistencies were 
present which could not be resolved by data providers, the data was not included in any 
analyses. If minor inconsistencies were present, data was included in analysis and sensitivity 
analyses were conducted to test the robustness of results [68]. 
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5.3.3.2  Calculation of time-to-event outcomes 
The following outcome measures were of interest in the IPD-NMA (see Chapter 3.1.2 for 
further discussion of the clinical relevance of these outcomes). Reporting of these outcomes 
in the original trial report was not an eligibility requirement for the Cochrane IPD-NMA.  
 Primary outcome 
o Time-to-withdrawal of allocated treatment (retention time) 
 Secondary Outcomes 
o Time-to-12-month remission after randomisation 
o Time-to-6-month remission after randomisation 
o Time-to-first seizure post randomisation 
Outcomes were calculated from IPD provided following consistency checks and resolution of 
inconsistencies as far as possible (see Chapter 5.3.3 and Appendix 12 for further details). 
Outcomes for all datasets provided from 2012-2015 were calculated by one statistician (SJN 
or MS) and verified by the other. Outcome data which had been previously prepared for the 
original Cochrane IPD-MAs was verified by SJN (see Chapter 5.3.3 for further details). 
For the analysis of ‘time-to-withdrawal of allocated treatment,’ an 'event' was defined as 
either the withdrawal of the allocated treatment due to poor seizure control or adverse 
events or both. Non-compliance with the treatment regimen or the addition of another 
antiepileptic drug were also be classed as 'events'. The outcome was censored if treatment 
was withdrawn because the individual achieved a period of remission, if a participant 
withdrew from allocated treatment for reasons not related to the treatment (such as loss to 
follow-up) or if the individual was still on allocated treatment at the end of follow-up. Two 
authors (SJN and AGM) independently reviewed reasons for treatment withdrawal for 
classification as events or censored observations, and disagreements were resolved by 
discussion or by involving a third author (CTS). 
Calculation of secondary outcomes required seizure dates after randomisation. If seizure 
data were provided in terms of the number of seizures recorded between clinic visits rather 
than specific dates of seizures, to enable the calculation of TTE outcomes, linear interpolation 
was applied to estimate dates of seizures between follow-up visits. For example, if the trial 
recorded 4 seizures between 2 visits that occurred on 1 March 2010 and 1 May 2010 (interval 
of 61 days), then the date of first seizure would be approximately 13 March 2010.  
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Time-to-6-month and 12-month remission were calculated from the date of randomisation 
to the date (or estimated date) the individual had first been free of seizures for six or 12 
months respectively. If the person had one or more seizures during the trial, a six-month or 
12-month seizure-free period could also occur between the date of two seizures during the 
trial (or between the date of the last seizure and date of last follow-up). Time-to-first seizure 
was calculated from the date of randomisation to the date (or estimated date) that their first 
seizure occurred.  
If seizure data were missing for a particular visit, these secondary outcomes were censored 
at the previous visit. These outcomes were also censored if the individual died or if follow-
up ceased prior to the occurrence of the event of interest. Under an ITT approach, individuals 
who withdrew from allocated treatment but did not withdraw from follow-up (e.g. those 
who remained in the trial on an alternative treatment) were not censored at the date of 
withdrawal from treatment and remained ‘at risk’ for the secondary seizure outcomes. 
5.4  Results of IPD Requests 
At the end of 2015 the IPD database was closed to begin analysis and any outstanding 
requests at that point were considered to be unsuccessful. An additional systematic search 
was carried out in July 2016 in line with Methodological Expectations of Cochrane 
Intervention Reviews that published reviews must be as up-to-date as possible [297]. This 
search identified six eligible trials (recruiting 1460 participants). IPD requests have been 
initiated for each of these trials (via methods described in Chapter 5.3.2) and any IPD 
provided from these trials will be included in an update of the Cochrane IPD-NMA. 
5.4.1  IPD requests prior to 2012 
As outlined in Chapter 5.3.1, 30 unique trials reported in 29 publications were identified 
previously by the Cochrane Epilepsy Group for inclusion in IPD-MA or IPD-NMA and IPD 
requests had been initiated between the years of 1995 and 2005 approximately. According 
to the type of study sponsorship, fifteen of these studies are defined as academic studies, 
ten are defined as pharmaceutical studies and four are defined as government studies (see 
Chapter 5.2.3.4 for further details of definitions). 
IPD was requested for a total of 5887 participants from these 30 trials (29 requests) and IPD 
was provided for 4703 (80%) participants from 18 (62%) of these 29 requests. IPD was 
provided from trials published between 1985 and 2001.  Over 90% of IPD requested from 
pharmaceutical and government sponsored studies was successfully received (data provided 
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for 3695 out of 4084 participants from 12 out of 14 studies (86%)). However, only 56% of IPD 
(from 1008 out of 1803 participants) requested from 6 out of 15 academic sponsored studies 
(40% of studies) could be retrieved (see Table 12). IPD was not retrieved from a total of 11 
eligible trials, published between 1981 and 1997, recruiting 1184 participants (38% of all 
eligible trials); for the majority of these trials, data had been lost or was no longer available 
due to the time elapsed since the trial (Table 12).  
5.4.2  IPD requests from 2012-2015 
As outlined in Chapter 5.3.2, 39 IPD requests were initiated between 2012 and 2015. 
According to the type of study sponsorship, 24 of these studies are defined as academic 
studies, 14 are defined as pharmaceutical studies and one is defined as a government study 
(see Chapter 5.2.3.4 for further details of definitions). 
IPD was requested for a total of 8177 participants from these 39 trials. Four of the requests 
for pharmaceutical studies were made via data sharing portal ClinicalStudyDataRequest.com 
(CSDR) (or original platform ‘GSK Share’ between May 2013 and January 2014, see Chapter 
1.3 for further details of data sharing portals). All other requests were made directly to the 
relevant sponsor.  
At the close of the database at the end of 2015, IPD had been received for 5251 participants 
(64% of the total requested) from 15 (38%) trials requested from 2012 to 2015 (Table 12).  
Figure 8 shows the duration and outcome of the 39 IPD requests. For the fifteen successful 
requests, the median time from initial request to receiving data was similar between 24 
academic studies (343 days (range 154 to 861 days)) and 14 pharmaceutical studies (363 days 
(range 280 to 725 days)). The time taken to receive IPD for a single trial via CSDR was 364 
days, but it must be noted that the request was first submitted in June 2013 when the 
platform was newly initiated and processes still under development so this may not reflect 
current timelines to providing data in CSDR. 
IPD was not retrieved from a total of 24 eligible trials published between 1989 and 2012. For 
11 trials recruiting 1537 participants, the data provider confirmed that IPD was not available 
(i.e. a negative response to the data request). The median time from initial request to 















Table 12: Outcome of individual participant data requests conducted between approx. 1995 to 2005 and 2012 to 2015.  
Number of studies and 
participants requested1,2 
Original requests (approx. 1995 – 2005) New requests (2012-2015) All requests (approx. 1995-2015) 
Ac Go Ph Total Ac Go Ph Total Ac Go Ph Total 
Eligible studies requested 15 4 10 293 24 1 14 39 39 5 24 68 

























Eligible participants requested 1803 1178 2906 5887 1813 593 5771 8177 3616 1771 8677 14084 


























Reason data was not available: Number of studies (n (%)) 
Data lost  5 (33%) 1 (25%) 0 (0%) 6 (21%) 3 (13%) 0 (0%) 0 (0%) 3 (8%) 8 (21%) 1 (20%) 0 (0%) 9 (13%) 
Relevant data not recorded 2 (13%) 0 (0%) 0 (0%) 2 (7%) 1 (4%) 0 (0%) 0 (0%) 1 (3%) 3 (8%) 0 (0%) 0 (0%) 3 (4%) 
Unable to make contact with 
an author / sponsor 1 (7%) 0 (0%) 0 (0%) 1 (3%) 11 (46%) 0 (0%) 0 (0%) 11 (28%) 12 (31%) 0 (0%) 0 (0%) 12 (18%) 
Positive response but no data 
received 1 (7%) 0 (0%) 0 (0%) 1 (3%) 1 (4%) 1 (100%) 0 (0%) 2 (5%) 2 (5%) 1 (20%) 0 (0%) 3 (4%) 
Incomplete dataset provided 
which could not be used 0 (0%) 0 (0%) 1 (10%) 1 (3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 1 (1%) 
Local authority / ethical 
restrictions 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 1 (3%) 1 (3%) 0 (0%) 0 (0%) 1 (1%) 
“Data not available”4  0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (21%) 3 (8%) 0 (0%) 0 (0%) 3 (13%) 3 (4%) 
Costs of providing data are 
prohibitive 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (14%) 2 (5%) 0 (0%) 0 (0%) 2 (8%) 2 (3%) 
Country specific restrictions 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (7%) 1 (3%) 0 (0%) 0 (0%) 1 (4%) 1 (1%) 
Total 9 (60%) 1 (25%) 1 (10%) 11 (38%) 17 (61%) 1 (100%) 6 (43%) 24 (62%) 26 (67%) 2 (40%) 7 (29%) 35 (51%) 




1. In addition, we had IPD available from our own ‘SANAD’ trial [264, 265], the largest ever 
in epilepsy at the time, which randomised 2437 participants 
2. An additional search was conducted in July 2016 and six eligible trials (recruiting 1460 
participants) were identified. IPD requests for these trials have been initiated and any 
IPD made available will be included in an update of the Cochrane IPD-NMA (see Chapter 
5.4.2 for further details). 
3. In total, 29 data requests were made, one request resulted in the provision of data from 
two trials (reported in a single publication). These two trials are treated as a single 
request in this table. 
4. Refers to a non-specific reason (data not available for secondary analysis with no further 
reason provided). 
 
Reasons for negative response were: 
(i) country specific restrictions over anonymisation of data (one request submitted to 
CSDR for a pharmaceutical study conducted in 2005) 
(ii) cost of retrieving and preparing data prohibitive due to age of study (two requests 
submitted to CSDR for pharmaceutical studies conducted in 2002 and 2007) 
(iii) data cannot be made available, no more specific details provided (three requests 
directly to pharmaceutical sponsors for studies conducted between 1997 and 2007) 
(iv) concerns regarding ethical approval for sharing data (one academic author, study 
conducted 2011) 
(v) the data requested were not recorded (one academic author, study conducted 2005)   
(vi) data were lost (three academic authors of studies conducted between 1992 and 
2012; one of which provided additional unpublished summary data) 
For the remaining 13 trials, two (one government and one academic) had indicated an initial 
positive response to data requests but data was not provided by the close of database, whilst 
for 11 trials (nine academic and two pharmaceutical) no response was received to any 
communications. These 13 data requests were closed at a median of 972 (range 640 to 1448 
days) after initial request (Figure 8). If response is received to any of these 13 data requests 
following the close of database and IPD is subsequently provided, it will be included in an 
update of the Cochrane IPD-NMA.  
It must be emphasised when interpreting the timelines of the requests between 2012 and 
2015, that data sharing policies and platforms were under development, and that all of the 
pharmaceutical sponsors contacted directly at the time of request have since committed to 
CSDR or an equivalent data sharing platform such as YODA [298].  
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5.4.3  Total IPD available for Cochrane IPD-NMA 
At the close of database at the end of 2015, the total number of participants data provided 
from IPD requests was 9954 out of 14084 participants (71% of total eligible participants 
requested) from 33 out of 68 trials (49% of eligible trials requested, Table 12).  
As outlined in Chapter 5.3.1, IPD for two trials recruiting 2437 participants were available on 
site at the University of Liverpool (data requests not required) and a single data request 
resulted in provision of data from two separate trials. Further, IPD requests for six trials, 
recruiting 1460 participants, identified and initiated following the close of database did not 
provide any IPD for the current Cochrane IPD-NMA (but any IPD provided will be included in 
an update of the IPD-NMA, see Chapter 5.4 for further details). 
Therefore, IPD for 12,391 out of a total of 17,961 eligible participants (69% of total data) from 
36 out of the 77 eligible trials (47%) was provided for the current Cochrane IPD-NMA. The 
statistical analyses and results of the Cochrane IPD-NMA are presented in Chapter 6. 
Data were available for the following participant characteristics (percentage of 12,391 
participants with data available): sex (99.5%, data missing for 75 participants), seizure type 
(96%, data missing for 555 participants), drug randomised (99.9%, data missing for 11 
participants), age at randomisation (99%, data missing for 98 participants), number of 
seizures in six months prior to randomisation (83%, data missing for 2135 participants), and 
time since first seizure to randomisation (37%, data missing for 7820 participants).Thirteen 
trials provided the results of neurological examinations for 5367 participants (43%). 
Seventeen trials provided electroencephalographic (EEG) results for 2990 participants (24%). 
Fifteen trials provided computerised tomography/magnetic resonance imaging (CT/MRI) 
results for 2083 participants (16%). 
Sufficient IPD was provided to calculate all four outcomes (see Chapter 5.3.3.2) for 20 of the 
36 trials. Time-to-12-month remission could not be calculated for nine trials as the duration 
of the trial was less than 12 months and for a further four trials, neither time-to-12-month 
remission or time-to-6-month remission could be calculated as the duration of the trial was 
less than 6 months. For one additional trial, only the date of first seizure recurrence after 
randomisation was provided (dates of subsequent seizures not available), therefore only 
time-to-first seizure could be calculated and remission outcomes could not. For four trials, 
time-to-withdrawal of allocated treatment could not be calculated; for three trials, 
insufficient information was available regarding dates or reasons for withdrawal and for one 
trial, all participants completed the twelve week follow-up without treatment withdrawal. 
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Table 13 shows the number of participants randomised to each of the 10 drugs, split 
according to the trials for which IPD were available and not available. 
Table 13: Number of participants randomised to each drug for trials with IPD provided or 
not provided 
 
Trials providing IPD 
Trial \ Drug1 CBZ PHB PHT VPS LTG OXC LEV TPM GBP ZNS Total5 
Banu 2007 54 54 0 0 0 0 0 0 0 0 108 
Baulac 2012 301 0 0 0 0 0 0 0 0 282 583 
Bill 1997 0 0 144 0 0 143 0 0 0 0 287 
Biton 2001 0 0 0 69 66 0 0 0 0 0 136 
Brodie 1995a 66 0 0 0 70 0 0 0 0 0 136 
Brodie 1995b 63 0 0 0 61 0 0 0 0 0 124 
Brodie 1999 48 0 0 0 102 0 0 0 0 0 150 
Brodie 2007 291 0 0 0 0 0 288 0 0 0 579 
Chadwick 
1998 
74 0 0 0 0 0 0 0 218 0 292 
Craig 1994 0 0 81 85 0 0 0 0 0 0 166 
de Silva 1996 54 10 54 49 0 0 0 0 0 0 173 
Dizdarer 2000 26 0 0 0 0 26 0 0 0 0 52 
Eun 2012 41 0 0 0 43 0 0 0 0 0 84 
Guerreiro 
1997 
0 0 94 0 0 99 0 0 0 0 193 
Heller 1995 61 58 63 61 0 0 0 0 0 0 243 
Kwan 2009 0 0 0 44 37 0 0 0 0 0 81 
Lee 2011 53 0 0 0 57 0 0 0 0 0 110 
Mattson 1985 155 155 165 0 0 0 0 0 0 0 475 
Mattson 1992 236 0 0 244 0 0 0 0 0 0 480 
Nieto-Barrera 
2001 
202 0 0 0 420 0 0 0 0 0 622 
Ogunrin 2005 19 18 18 0 0 0 0 0 0 0 55 
Pal 1998 0 47 47 0 0 0 0 0 0 0 94 
Placencia 
1993 
95 97 0 0 0 0 0 0 0 0 192 
Privitera 
2003 (CBZ)2 
129 0 0 0 0 0 0 266 0 0 395 
Privitera 
2003 (VPS)2 
0 0 0 78 0 0 0 147 0 0 225 
Ramsey 1992 0 0 50 86 0 0 0 0 0 0 136 
Ramsey 2010 0 0 128 0 0 0 0 133 0 0 261 
Reunanen 
1996 
121 0 0 0 230 0 0 0 0 0 351 
Richens 1994 151 0 0 149 0 0 0 0 0 0 300 
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SANAD A 2007 378 0 0 0 378 210 0 378 377 0 1721 
SANAD B 2007 0 0 0 238 239 0 0 239 0 0 716 
Steiner 1999 0 0 95 0 86 0 0 0 0 0 181 
Stephen 2007 0 0 0 109 117 0 0 0 0 0 227 
Trinka 
2013 (CBZ)2 
503 0 0 0 0 0 493 0 0 0 999 
Trinka 
2013 (VPS)2 
0 0 0 353 0 0 350 0 0 0 703 
Turnbull 1985 0 0 70 70 0 0 0 0 0 0 140 
Verity 1995 130 0 0 130 0 0 0 0 0 0 260 
Werhahn 2015 121 0 0 0 118 0 122 0 0 0 361 
Total 3372 439 1009 1765 2067 478 1253 1163 595 282 12391 
Trials not providing IPD 
Trial \ Drug CBZ PHB PHT VPS LTG OXC LEV TPM GBP ZNS Total1  
Aikia 1992 0 0 18 0 0 19 0 0 0 0 37 
Bidabadi 2009 36 35 0 0 0 0 0 0 0 0 71 
Brodie 2002 0 0 0 0 151 0 0 0 158 0 309 
Callaghan 
1985 
59 0 58 64 0 0 0 0 0 0 181 
Capone 2008 17 0 0 0 0 0 18 0 0 0 35 
Castriota 2008 14 0 0 0 0 0 13 0 0 0 27 
Chen 1996 26 25 0 25 0 0 0 0 0 0 76 
Cho 2011 15 0 0 0 0 0 16 0 0 0 31 
Christe 1997 0 0 0 121 0 128 0 0 0 0 249 
Consoli 2012 66 0 0 0 0 0 62 0 0 0 128 
Cossu 1984 6 6 0 0 0 0 0 0 0 0 12 
Czapinski 1997 30 30 30 30 0 0 0 0 0 0 120 
Dam 1989 100 0 0 0 0 94 0 0 0 0 194 
Donati 2007 28 0 0 29 0 55 0 0 0 0 112 
Feksi 1991 152 150 0 0 0 0 0 0 0 0 302 
Forsythe 1991 23 0 20 21 0 0 0 0 0 0 64 
Fritz 2006 0 0 0 0 21 27 0 0 0 0 48 
Gilad 2007 32 0 0 0 32 0 0 0 0 0 64 
Jung 20153 64 0 0 0 0 0 57 0 0 0 121 
Kalviainen 
2002 
70 0 0 0 73 0 0 0 0 0 143 
Kopp 2007 6 0 0 3 0 0 6 0 0 0 15 
Korean LTG  
Study Group 
20083 
129 0 0 0 264 0 0 0 0 0 393 
Lukic 2005 0 0 0 38 35 0 0 0 0 0 73 
Mitchell 1987 15 18 0 0 0 0 0 0 0 0 33 





0 0 0 0 50 0 50 0 0 0 100 
NCT014988223 0 0 0 0 0 178 175 0 0 0 353 
NCT019541213 215 0 0 0 0 0 218 0 0 0 433 
Pulliainen 
1994 
23 0 20 0 0 0 0 0 0 0 43 
Ramsey 1983 42 0 45 0 0 0 0 0 0 0 87 
Ramsey 20074 ? 0 0 0 0 0 ? 0 0 0 37 
Rasgoti 1991 0 0 45 49 0 0 0 0 0 0 94 
Ravi Sudhir 
1995 
20 0 20 0 0 0 0 0 0 0 40 
Resendiz 2004 42 0 0 0 0 0 0 46 0 0 88 
Rowan 2005 198 0 0 0 200 0 0 0 195 0 593 
Saetre 2007 92 0 0 0 93 0 0 0 0 0 185 
Shakir 1981 0 0 15 18 0 0 0 0 0 0 33 
So 1992 17 0 0 16 0 0 0 0 0 0 33 
Suresh 20153 30 0 0 0 0 0 30 0 0 0 60 
Steinhoff 2005 
(CBZ)2 
88 0 0 0 88 0 0 0 0 0 176 
Steinhoff 2005 
(VPA)2 
0 0 0 30 33 0 0 0 0 0 63 
Thilothammal 
1996 
0 51 52 48 0 0 0 0 0 0 151 
Total 1721 315 374 538 1040 501 645 46 353 0 5570 
Grand total 5093 754 1383 2303 3064 979 1898 1209 948 282 17950 
 
IPD provided 66% 58% 73% 77% 66% 49% 66% 96% 63% 100% 69% 
1. See Appendix 10 for reference of the primary publication of each trial and Chapter 5.2.1.3 for 
abbreviations of drugs. 
2. Trials designed in strata based on clinician recommended treatment. Within the two strata, 
participants were randomised to TPM (Privitera 2003), LEV (Trinka 2013) or LTG (Steinhoff 
2005) or CBZ / VPS depending on the strata. Data analysed according to the separate strata.  
3. Trial identified in an updated search in 2016, following closure of database for analysis. IPD 
request initiated, any IPD provided will be included in an update of the Cochrane IPD-NMA. 
4. One trial provided the total number randomised but not the numbers randomised to each 
group. The 37 participants randomised are counted in the overall totals. 
5. Drug allocated missing for 11 participants in the IPD provided. 
 
Figure 9 shows the networks of trials with and without IPD provided. Specifically, IPD was 
provided for all direct pairwise comparisons in the overall network except for OXC compared 
to VPS and OXC compared to LEV. In fact, out of all drugs included in the network, the lowest 
proportion of data was received for OXC (49%, Table 13). Aside from the lack of IPD for the 
OXC / VPS and OXC / LEV comparisons, the networks of the trials with and without IPD appear 
visually similar (Figure 9).  
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Figure 9: Network plots of pairwise comparisons for all trials, for trials providing IPD and 
for trials not providing IPD for a network meta-analysis of 10 antiepileptic drugs 
  
See Table 12 and Table 13 for numbers of trials and participants providing and not providing 
IPD and Chapter 5.2.1.3 for abbreviations of drugs. 
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Figure 10: Characteristics of studies providing or not providing IPD 
 
 
1. See Chapter 5.2.3.4 for further details of the definitions of characteristics 
2. High risk of bias defined as at least one domain of the Cochrane Risk of Bias tool deemed to be 
at high risk of bias, see Chapter 5.2.3.5 for further details 
3. P-values calculated from Fishers Exact test due to small numbers in some categories of 
characteristics. 𝜒2 p-values were also calculated for completeness, conclusions were unchanged.  
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Further exploratory examination of the characteristics of the studies with and without IPD 
was carried out via graphical plots and using Fisher’s Exact Test (due to some small numbers 
in categories of characteristics); see Table 10 and Figure 10. Principally, due to additional 
communications with data providers regarding trial design for trials providing IPD compared 
to replying on published information only for trials without IPD; there were much fewer cases 
of a characteristic ‘not stated’ in trials providing IPD across all characteristics.  
There were no significant differences between trials with and without IPD in terms of ages 
and epilepsy type recruited and designs permitting participants with previous AED use. There 
was also no significant difference in terms of methodological quality of the trials with and 
without IPD (in terms of a least one domain of the Cochrane Risk of bias tool at high risk of 
bias, Table 11) or in terms of the date of publication of trials with and without IPD.  
There were significant differences between trials with and without IPD in terms of the design 
and source of funding of trials; with more multi-centre trials and more pharmaceutical trials 
providing IPD and more single centre trials and more academic trials not providing IPD. There 
were also significant differences in the sizes of trials with and without IPD; trials providing 
IPD tended to be larger than trials not providing IPD. This is also reflected in the proportion 
of participant data (69%) provided compared to the proportion of trials providing data (49%). 
These three significant characteristics are all related to the resources of the trial; larger multi-
centre pharmaceutical trials are likely to have more resources to prepare IPD than small, 
single centre academic trials (also see Table 12 for reasons IPD was not provided).  
The majority of studies not providing IPD did not report any of the outcomes of interest to 
the Cochrane review; this was not a criteria for inclusion in the review as the intention was 
to calculate these outcomes in a standardised manner using IPD. Therefore, it was difficult 
to examine whether ‘significant’ or ‘positive’ trial results were related to provision of IPD or 
conversely whether trials with ‘negative’ results were less likely to provide IPD. Figure 11 
shows a comparison-adjusted funnel plot of the trial-specific effect sizes for primary outcome 
‘Time-to-withdrawal of allocated treatment’ for the network of interventions, produced via 
the ‘netfunnel’ command in Stata version 14 [299]. 
Visual inspection of this network funnel plot and a test for asymmetry does not suggest that 
‘publication bias’ (i.e. bias from missing results from studies without IPD) is present for this 
outcome. However, an association between trial resources and provision of IPD may have 
implications for updates of this Cochrane IPD-NMA (and for systematic IPD-MA generally).  
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Figure 11: Comparison-adjusted network funnel plot of trial-specific ln HRs for time-to-
withdrawal of allocated treatment 
 
1. Produced via ‘netfunnel’ command in Stata 14 [299].  
2. Dotted line corresponds to the study effect sizes centred at the comparison-specific summary 
plotted against the standard error of the log hazard ratio. P-value corresponds to a t-test of 
the gradient of the line (difference from zero which would indicate asymmetry). 
5.5  Discussion 
5.5.1  Reflection of experiences Group and implications 
The first in the series of Cochrane Epilepsy Group IPD-MA was published in 2000 when such 
an approach was relatively novel and methodology limited [67]. This meta-analysis included 
IPD from 63% of total trials and 83% of total participants, a good retrieval rate in the wider 
context of all IPD-MAs (see Chapter 4). Success rate of the group of retrieving IPD has 
declined from 80% up to around 2005 to 65% between 2012 and 2015 (Table 12). It should 
be noted that this difference in IPD retrieval rate could be due to chance, nonetheless, the 
apparent decline in the proportion of IPD provided is of concern.   
Results of the systematic review outlined in Chapter 4 of this thesis showed that Cochrane 
reviews were less likely to retrieve all or a high proportion of IPD than non-Cochrane reviews. 
This may be explained by the inclusion of thorough search methods within Cochrane reviews, 
as well as advances in systematic searching of larger electronic databases generally, leading 
to the identification of larger numbers of studies including more grey literature studies where 
IPD may be difficult to retrieve with the resources available to review authors, such as 
Cochrane review authors who usually undertake systematic reviews on a voluntary basis. 
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Also of concern are changes in the reported reasons for lack of data availability. Table 12 
demonstrates that loss of datasets is an issue for academic trials and has been for many 
years, highlighting a need for better methods of data curation and solutions for long-term 
storage and access. As highlighted in Chapter 4, lack of specific reasons for unavailability of 
IPD remains an issue in the reporting of IPD-MA and Cochrane Epilepsy Group experiences of 
data requesting show that this issue is not restricted to the reporting of IPD-MA and also 
exists at the study request level; IPD from three out of 35 studies was ‘not available’ with no 
further reason stated (Table 12). During more recent requests, ‘prohibitive costs’ have 
prevented the sharing of pharmaceutical data. Additional costs and resources associated 
with IPD-MA are generally considered to be incurred by the meta-analysts [22-24]; however 
in this new era of commercial data sharing platforms [91] and requirement of high level data 
de-identification, costs to data providers have certainly increased and should be taken under 
consideration when planning an IPD-MA [300]. Collaboration, financial or otherwise, 
between meta-analysts and data providers may assist in sharing costs and resources, 
potentially maximising retrieval rates of IPD.  
Despite our highlighted concerns, recent changes in methods of data sharing have resulted 
in several benefits to our analyses. Our most common reason for not retrieving data, an issue 
only for academic trials, was due to failing to make contact with data providers. In our 
experience, facilities within pharmaceutical data sharing platforms allowed a clear and 
transparent pathway of communication between data requestors and providers; but the 
continued benefit of such facilities will require increasing uptake of such platforms from both 
data users and data providers, from both a pharmaceutical and non-pharmaceutical setting.  
In addition to improvements in Good Clinical Practice over time, resulting from regulations 
such as the European Union Clinical Trials Directive [298], a greater focus on data privacy and 
additional preparation required to share a dataset has resulted in ‘cleaner’ datasets provided 
in the most recent requests compared to earlier and previous requests. As described in 
Chapter 5.3.3, the exact time required to check and prepare datasets was not recorded but 
the most recent datasets provided (see Figure 8) required minimal to no clarification of 
inconsistencies, therefore reducing the relative time to prepare the dataset for analysis.  
While under the new framework of data sharing platforms, additional time and resources 
must allow for constructing a research proposal, independent scientific review, signing of 
data sharing agreements and de-identification of data; recent datasets provided have 
required much less data cleaning prior to analysis than in previous years, implying a shift in 
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the time required to perform an IPD-MA, rather than an increase. However, the research 
community must ensure that procedures to access IPD do not become over-burdensome, 
over-costly and prohibitive and that common sense and responsible risk proportionate 
approaches should be used [79, 84]. 
5.5.2  Relation to the wider context of clinical trial data sharing 
A summary of the development and processes of data sharing platforms such as CSDR and 
YODA is provided in Chapter 1.3. Both CSDR and the YODA project provide metrics related to 
submitted research proposals [91, 93]. Metrics provided by YODA relate to requests for de-
identified individual participant datasets and to de-identified clinical study reports (CSRs) 
combined whereas requests to CSDR relate only to individual participant datasets.  
To 31st May 2017, out of 291 research proposals submitted to CSDR and processed, 235 (81%) 
met initial requirements and 198 (68%) were approved (or approved with conditions) by the 
independent review panel. Out of 296 proposals submitted since January 2014, 50 (17%) 
were multi-sponsor proposals. Data sharing agreements have been signed for 163 proposals 
and de-identified datasets provided for 153 proposals. Results for eight data requests 
(provided with access to between one and fourteen datasets from a single sponsor) have 
been published to date [69, 100-103, 106-108] and one publication is listed to be in press 
according to CSDR [91] with other requests remaining ‘in process.’ 
According to metrics provided on the YODA project website, to 1st July 2017, all 65 fully 
reviewed research proposals were approved by YODA for Johnson & Johnson datasets or 
CSRs with a median of eight days for YODA project review. Data access (to IPD or CSRs) has 
been granted for 59 proposals and results of two proposals have been published to date [104, 
105]. Further partners of the YODA project are Medtronic Inc. and SI-Bone Inc. The YODA 
data sharing model was first put into practice via independently performed systematic 
reviews of the safety and efficacy of Medtronic’s recombinant human bone morphogenetic 
protein-2 product [301, 302]. Up to July 2017, no requests had been made via the YODA 
project to use SI-Bone data.  
Metrics are also provided for the number of ‘enquiries’ for non-listed studies on both the 
CSDR and YODA project websites. To 31st March 2017, out of 784 unique studies requested 
via enquiries on CSDR, following feasibility checks, a positive response was provided for 321 
studies (41%) (I.e. a researcher would be able to submit a research proposal for that study 
and the study would subsequently be listed on CSDR). A negative response was provided for 
the remaining 389 studies (59%) and access to data from the study would not be provided. 
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To 1st July 2017; out of 164 unique studies within answered enquiries to the YODA project, a 
positive response was provided for 100 studies (61%) and a negative response was provided 
for the remaining 64 studies (38%).  
Table 14: Reasons why access could not be provided to de-identified study data following 
enquiries to CSDR and YODA 
Reason why access cannot be provided to data1 Number of studies 
CSDR YODA2 Total 
Sponsor did not agree to share data from Phase I 
or Phase IV trials 
143 (31%) 25 (39%) 168 (32%) 
Interventional product not approved  / 
unapproved indication or terminated  
77 (16%) 11 (17%) 88 (17%) 
Considered out of scope as per the Sponsor 
Specific Information1 
75 (16%) 0 (0%) 75 (14%) 
Cannot be anonymised or likelihood of re-
identification 
53 (11%) 0 (0%) 53 (10%) 
Study ongoing or unpublished 33 (7%) 16 (25%) 49 (9%) 
Interventional product not or no longer owned 
by that sponsor 
43 (9%) 0 (0%) 43 (8%) 
Sponsor does not have legal authority to share 
the data 
15 (3%) 0 (0%) 15 (3%) 
Data sharing commitment with a development 
partner, partner does not agree to share 
1 (<1%) 10 (17%) 11 (2%) 
Foreign language studies or documentation not 
available in English 
7 (2%) 4 (7%) 11 (2%) 
Data unavailable 7 (2%) 0 (0%) 7 (1%) 
Costs / resources prohibitive to providing data 
due to age of studies 
5 (1%) 0 (0%) 5 (<1%) 
Beyond the period that sponsor retains study 
data and documentation 
2 (<1%) 0 (0%) 2 (<1%) 
Requested data is already publicly available 2 (<1%) 0 (0%) 2 (<1%) 
Data cannot be converted to electronic format 0 (0%) 1 (2%) 1 (<1%) 
Total  463 67 530 
Abbreviations: CSDR: ClinicalStudyDataRequest; YODA: Yale University Data Access 
1. Classified into 'general' reasons and merged for all sponsors, exact wording for each sponsor 
(including Sponsor Specific Information) can be found on CSDR and YODA websites [91, 93] 
2. Number of reasons listed (67) is greater than number of studies listed (64); assumed that 
more than one reason for a negative response can be given per study 
A summary of the list of sponsor reported reasons for a negative response to enquiries to 
CSDR and the YODA project is provided in Table 14. The majority of reported reasons (around 
70%) were related to the legal authority of the sponsor to share the requested data; e.g. data 
from early phase studies (a third of negative responses were requests for Phase I study data), 
from studies of unapproved or terminated intervention products, from ongoing studies and 
from studies with a development partner who does not agree to share data. Such reasons, 
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other than restrictions around ongoing or unpublished studies, would generally not be 
applicable in the context of IPD syntheses with the objective of establishing clinical 
effectiveness or safety of approved interventions. Research proposals or further objectives 
of projects for which early phase or off-licence product use were requested via enquiries to 
CSDR or the YODA project are not available; but would make an interesting comparison to 
the objective of the list of approved research proposals provided on the respective websites. 
As reflected in the Cochrane Epilepsy Group requests, a proportion (around 15%) of sponsor 
reported reasons listed on the CSDR website were non-specific such as ‘Data not available’ 
or ‘Considered out of scope as per the Sponsor Specific Information’ without further detail 
Furthermore, ‘Sponsor Specific Information’ for all sponsors states (in various wording) that 
studies with a risk of re-identification such as single centre studies, studies in rare diseases 
or studies with very small sample sizes will not be provided [91]. Documentation of the 
anonymisation standards employed by each sponsor are provided but details are not 
provided on any methodology employed by sponsors to quantify the re-identification risk 
[303] or criteria for judging when the risk of re-identification is too high to share data, even 
though this reason is listed for 9% of studies requested via enquires to CSDR. 
As outlined in Chapter 5.4.2, three out of the four requests made by the Cochrane Epilepsy 
Group via CSDR resulted in a negative response related to resources to fulfil the requests (i.e. 
prohibitive costs or facilities to translate documentation of foreign language studies). Such 
resource related reasons seem to have been specific to the studies under request for 
Cochrane Epilepsy reviews and are in the minority (around 2%) of sponsor reported reasons 
for all negative responses to enquires made to CSDR and the YODA project. Informal 
comparison of the IPD retrieval rate of the Cochrane Epilepsy Group for the conduct of 
systematic IPD-MAs and NMAs and reasons provided for unavailability of data to the 
researcher reported ‘approved research proposals’ and sponsor reported reasons for 
negative responses to data requests may provide some insight to the type of data requests 
and research projects suited to data request platforms. 
Considering the 161 approved research proposals published on the CSDR website up to July 
2017 (restricted to IPD requests, whereas requests to YODA may be for IPD or CSRs), 30 (19%) 
clearly describe a proposal for meta-analysis but only 12 (7% of total proposals) clearly 
describe a systematic approach to meta-analysis. Information provided on the CSDR website 
regarding research proposals is limited so a larger proportion may in fact intend to perform 
a systematic IPD-MA, however IPD-MA (systematic or not), are currently in minority of 
approved research proposals on CSDR. At the time of writing, two systematic IPD syntheses 
including data provided from a data sharing platform have been published [69, 108].  
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Results from Chapter 4 suggest as many as 105 new IPD-MAs per year are being published 
up to 2015, yet only 30 IPD-MA projects seem to have been submitted as research proposals 
on CSDR between October 2013 and July 2017. This could be for the simple reason that only 
a small proportion of the 3461 studies listed on CSDR have been identified as eligible for an 
IPD-MA, or this could indicate that authors conducting IPD-MA over recent years are not 
using data request platforms; perhaps due to lack of awareness of the existence of such 
platforms or perhaps because IPD-MA projects are not suited to data request platforms. In 
fact, up to July 2017, three projects, two identified as IPD-MAs within their research 
proposals, could not be completed due to the restrictions of the remote platforms preventing 
merging of individual participant datasets [93] 
The suitability and practicality of data request platforms and remote data access for the 
conduct of IPD-MA should become clear in future years as further research proposals are 
submitted and further research projects making use of the data available via data request 
platforms are published.  
5.5.3  Concluding remarks 
Twenty years of Cochrane Epilepsy IPD-MA and NMA have shown a decline in IPD retrieval 
rate from has declined from 80% in 2005 to 65% between 2012 and 2015. Recent years, in 
line with data transparency initiatives in the pharmaceutical industry and across the research 
community as a whole, have shown that provision of IPD seems to be related to the resources 
of the trial, with larger multi-centre pharmaceutical trials more likely to have more resources 
to prepare IPD than small, single centre academic trials.  However, resources alone do not 
guarantee provision of IPD with ‘prohibitive costs’ preventing sharing of some 
pharmaceutical data in recent years. On the other hand, loss of datasets continues to be an 
issue for academic trials and has been for many years, highlighting a need for better methods 
of data curation and solutions for long-term storage and access.  
Consideration of approved research proposals for access to IPD via CSDR show that less than 
20% of proposals have been for an IPD-MA, whether systematic or ‘opportunistic.’ IPD-MAs 
which are systematic may identify older studies, small studies and foreign language studies, 
many of which are outside of the scope of CSDR sponsors to provide data due to resources, 
restrictions and risks from re-identification. While data sharing platforms such as CSDR and 
YODA may be suitable for some objectives of secondary research, the implications of limited 
resources, increased costs and increased awareness of data privacy and risks from re-
identification may result in a decline in the amount of IPD made available from both a study 
and patient-level for systematic IPD-MA.   
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Chapter 6: Approaches to network meta-analysis of 
antiepileptic drug monotherapy  
6.1 Introduction 
The clinical setting and rationale of IPD-MAs and IPD-NMAs of AED monotherapy trials 
performed by the Cochrane Epilepsy Group is described in Chapter 1.2. There are strong 
clinical beliefs that some AEDs are more effective in certain seizure types than others and 
current NICE guidelines recommend different first-line treatments for individuals with partial 
seizures (carbamazepine or lamotrigine) and for individuals with generalised seizures 
(sodium valproate)[74]. Furthermore, some RCTs of AED monotherapy have built this clinical 
preference for certain drugs for different seizure types into their design by recruiting 
participants with different seizure types separately [264, 265] or by stratifying randomisation 
by ‘clinician choice’ of first-line treatment according to seizure type [304, 305].  
A previous IPD-NMA of AED monotherapy published in 2007 demonstrated results which are 
in line with current NICE guidelines for recommended first-line AED treatment for individuals 
with new onset partial or generalised seizures [74, 285] and the objective of the illustrative 
example of the IPD-NMA described throughout this thesis was to update the previous IPD-
NMA, including evidence from all trials published since 2007 and for two additional AEDs, 
licenced for epilepsy monotherapy treatment after 2007 (levetiracetam and zonisamide). 
The objective of this Chapter is to describe the approaches for the statistical methodology of 
an IPD-NMA of AED monotherapy, taking account of current clinical practice for treating 
individuals with partial onset and generalised onset seizures. IPD-NMA results for the 
different approaches described as also presented. 
6.2  Statistical methodology  
The outcomes of the IPD-NMA are outlined in Chapter 5.3.3.2 and details of data preparation 
is provided in Chapter 5.3.3. All preparation of data for analysis was performed in SAS 
statistical software (version 9.3) [306] and all syntheses were performed in Stata statistical 





Figure 12: Network plots of pairwise comparisons for all individuals, participants with 




11978 participants classified as experiencing partial seizures (66.7% of total), 4407 participants 
classified as experiencing generalised seizures (24.5% of total) and 1576 had an unclassified or missing 
seizure type (8.8% of total). Generalised tonic-clonic seizures with or without other seizure types was 
shortened to 'generalised seizures' for brevity. See Chapter 5.2.1.3 for abbreviations of drugs.
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Epilepsy type is classified according to the main seizure type an individual has experienced at 
baseline (partial-onset or generalised-onset). Partial seizures (simple or complex) and partial 
secondarily generalised seizures are classified as partial epilepsy. Primarily generalised tonic-
clonic seizures (with or without other seizure types) are classified as generalised epilepsy. 
Figure 12 presents the networks of evidence for participants with partial seizures and with 
generalised seizures (for all individuals eligible for inclusion in the review, not just those for 
whom IPD was provided for analyses). Overall and for individuals with partial seizures there 
are a total of 45 possible pairwise comparisons between the ten AEDs of interest. At the time 
of analysis, zonisamide (ZNS) had been randomised in one trial recruiting individuals with 
partial-onset seizures only [267], therefore ZNS does not feature in the network of evidence 
for generalised seizures. Hence, there are a total of 36 possible pairwise comparisons 
between the nine AEDs of interest in network of evidence for generalised seizures. 
As outlined in Chapter 6.1, current clinical practice treats different seizure types with 
different drugs, suggesting the existence of a ‘clinical’ treatment-by-epilepsy type (partial or 
generalised) interaction. If such an interaction is also present statistically, then the key 
assumption made in NMA of an exchangeable treatment effect across all included trials 
would be violated. Furthermore, it would be of little relevance to current and future medical 
decision making to perform an NMA ignoring the differences in the treatment of partial and 
generalised seizure types in ‘real-world’ clinical practice.  
Within this Chapter, several approaches are outlined with regard to the association between 
epilepsy type and treatment effect in IPD-NMA.  The NMA was performed in two stages. 
Firstly, trial-specific estimates of treatment effects relating to a reference AED were obtained 
by fitting a stratified Cox PH regression model (based on Equation 23, outlined in Chapter 
2.3.3) to the entire individual participant dataset. Secondly, the trial-specific estimates 
obtained from the ‘first-stage’ were synthesised in an NMA under a multivariate framework. 
The following sections describe the how epilepsy type was modelled in the ‘first-stage’ of 
each approach and the ‘second-stage’ multivariate approach to NMA. 
6.2.2 First-stage: IPD-NMA with separate models by epilepsy type 
In this approach, NMA is performed separately for individuals with partial seizures and for 
individuals with generalised seizures (i.e. no treatment-by-epilepsy type interaction term).  
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In the first-stage, for the 𝑖𝑡ℎ participant in the 𝑗𝑡ℎ trial, the following fixed-effects models, 
stratified by trial to preserved within-trial randomisation to the IPD datasets for individuals 
with partial and generalised seizures respectively: 
ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡)𝑒𝑥𝑝((𝛼2𝑗𝑥2𝑖𝑗 + …+ 𝛼10𝑗𝑥10𝑖𝑗)  (Equation 29) 
ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡)𝑒𝑥𝑝((𝛽2𝑗𝑥2𝑖𝑗 + …+ 𝛽9𝑗𝑥9𝑖𝑗)  (Equation 30)  
Where 𝑥2𝑖𝑗 …𝑥10𝑖𝑗 are indicator variables for each of comparator AED of interest in relation 
to reference treatment CBZ (first-line treatment for partial seizures, constrained to be 0) in 
Equation 29 and VPS (first-line treatment for generalised seizures, constrained to be 0) in 
Equation 30.  Note that treatment with ZNS (i.e.  𝑥10𝑖𝑗) is not included in  Equation 30 for 
individuals with generalised seizures as this treatment is not present in the network for 
generalised seizures (see Figure 12).  
Coefficients 𝛼2𝑗 …𝛼10𝑗 for individuals with partial seizures and 𝛽2𝑗…𝛽9𝑗 for individuals with 
generalised seizures correspond to trial-specific fixed effect estimates (i.e. the ln (𝐻𝑅)) of 
each AED compared to the reference treatment which will be synthesised in NMA. 
To facilitate NMA, the models described in Equation 29 and Equation 30 were applied by 
running the ‘stcox’ command in Stata via ‘mvmeta_make’ command. In other words, 
Equation 29 is fit using the following command for 𝑥2𝑖𝑗 …𝑥10𝑖𝑗: 
xi: mvmeta_make stcox _ x2 _x3 _x4 _x5 _x6 _x7 _x8 _x9 _x10, strata(trial) ppfix(none) nohr 
by(trial) names(y S) esave(N) keepmat saving(Partial1) replace   
This command outputs and saves a dataset ‘Partial1’ with trial-specific estimates 
(coefficients 𝛼2𝑗 …𝛼10𝑗 or equivalently 𝛽2𝑗…𝛽9𝑗 for generalised seizures), their associated 
variances and covariances if applicable (i.e. correlation between treatment effects for trials 
with more than two treatment arms)[308]. The subsequent dataset is within the correct 
format for the ‘mvmeta’ command to be run (see Chapter 6.2.5 for further details). 
6.2.3 First stage: IPD-NMA with treatment-by-epilepsy type interaction 
In this approach, in the first-stage a single Cox PH model is fitted to the IPD with a treatment-
covariate interaction.  In other words, for the 𝑖𝑡ℎ participant in the 𝑗𝑡ℎ trial, the following 
model, stratified by trial with treatment-by-epilepsy type interaction, was fitted to the entire 
individual participant dataset:  
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ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡)𝑒𝑥𝑝((𝛼2𝑗𝑥2𝑖𝑗 + …+ 𝛼10𝑗𝑥10𝑖𝑗) + 𝑧𝑖𝑗 (𝜋𝑗 + 𝛾2𝑗𝑥2𝑖𝑗 + … +  𝛾9𝑗𝑥9𝑖𝑗)) (Equation 31) 
Where 𝑥2𝑖𝑗 …𝑥10𝑖𝑗 are indicator variables for each of comparator AED of interest in relation 
to reference treatment CBZ constrained to be 0 and 𝑧𝑖𝑗  is an indicator variable for whether 
an individual has partial (𝑧𝑖𝑗 = 0) or generalised seizures (𝑧𝑖𝑗 = 1). 
Coefficients 𝛼2𝑗 …𝛼10𝑗 correspond to the trial-specific effect sizes (i.e. the ln (𝐻𝑅)) of each 
AED compared to CBZ for individuals with partial seizures, coefficient 𝜋𝑗 is the trial-specific 
effect size of generalised seizures compared to partial seizures (reference) and coefficients 
𝛾2𝑗…𝛾9𝑗  correspond to trial-specific interaction effects of each AED compared to the 
reference treatment CBZ (i.e. the additional effect of the drug in individuals with generalised 
seizures compared to individuals with partial seizures).  
It should be noted that under this approach, the treatment effect sizes for individuals with 
generalised seizures are calculated as follows. For example in the  𝑗𝑡ℎ  trial, let ?̂?2𝑗  and 
var (?̂?2𝑗)  be the estimates of 𝑙𝑜𝑔 (𝐻𝑅)  and variance for drug 2 compared to CBZ for 
individuals with partial seizures and let  𝛾2𝑗  and var (𝛾2𝑗) be the 𝑙𝑜𝑔 (𝐻𝑅) and variance for 
the treatment-epilepsy type interaction term for drug 2 compared to CBZ. To obtain the 
𝑙𝑜𝑔 (𝐻𝑅) and variance for individuals with generalised seizures, ?̂?2𝑗  and var (?̂?2𝑗)   : 
?̂?2𝑗   = ?̂?2𝑗 + 𝛾2𝑗      (Equation 32) 
var(?̂?2𝑗) = var(?̂?2𝑗) + var(𝛾2𝑗) + 2 𝑐𝑜𝑣𝑎𝑟(?̂?2𝑗, 𝛾2𝑗)      (Equation 33) 
Where 𝑐𝑜𝑣𝑎𝑟(?̂?2𝑗, 𝛾2𝑗) is the covariance between treatment effect ?̂?2𝑗  and interaction 
effect 𝛾2𝑗. As described above in Chapter 6.2.2, the model described in Equation 31 is fit by 
running the ‘stcox’ command in Stata via ‘mvmeta_make’ command to produce a dataset in 
correct format for ‘mvmeta’ (see Chapter 6.2.5 for further details). 
This approach was pre-specified in the protocol of Cochrane IPD-NMA, which was written in 
2014 [68] and detailed results of the Cochrane IPD-NMA [69], including investigation of 
heterogeneity and inconsistency, sensitivity analyses and clinical interpretation of the IPD-
NMA results are presented in Chapter 7 of this thesis. 
Recent work has highlighted the importance of the appropriate specification of one-stage 
IPD models with treatment-covariate interactions by separating within-study and across-
study interactions to avoid inadvertent ecological bias [25, 38, 41, 185], particularly within a 
TTE setting [25]. The most recent work in this area has illustrated this within the context of 
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epilepsy, showing that the magnitude and statistical significance of age as a treatment effect 
modifier is reduced when within-trial and across-trial interactions are separated in IPD-MA 
compared to the original IPD-MA where they are amalgamated [25]. Furthermore, the 
importance of separating within-study and across-study associations increases as the 
variability of the covariate value across the included studies increases [25, 41, 46]. In the 
present example, some studies recruit only individuals with partial seizures, some recruit 
only individuals with generalised seizures and the proportion of individuals with partial 
seizures within the studies designed to recruit both seizure types ranges from 18% to 86%, 
therefore, there is a risk of ecological bias in the approach presented above. 
An additional analysis was performed following the completion of main analysis for the 
Cochrane Review [69]. The additional analysis separates the within and across-study 
interactions in the Cox PH model (specified in Equation 31) by centering the treatment-by-
epilepsy type interaction:   
ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡)𝑒𝑥𝑝((𝛼2𝑗𝑥2𝑖𝑗 + …+ 𝛼10𝑗𝑥10𝑖𝑗) + (𝑧𝑖𝑗 − 𝑧?̅?)(𝜋𝑗 + 𝛾2𝑗𝑥2𝑖𝑗 + … + 𝛾9𝑗𝑥9𝑖𝑗)) 
          (Equation 34) 
Where 𝑧?̅? is the proportion of individuals with generalised seizures within each trial and 
other parameters are defined as in Equation 31. 
6.2.4 First stage: IPD-NMA via the ‘meta-analysis of interactions’ approach 
This approach is based on the ‘meta-analysis of interactions’ approach by Simmonds and 
Higgins [309]. In this approach, rather than a ‘complete’ IPD analysis, IPD is reduced to 
summary statistics with a treatment-by-epilepsy type interaction.  
In other words, a model of the structure outlined in Equation 31 (with a treatment-by-
epilepsy type interaction) is fitted separately to the IPD of each trial, producing separate 
summary statistics of treatment effect for individuals with partial seizures 𝛼2𝑗 …𝛼10𝑗 and 
individuals with generalised seizures 𝛽2𝑗…𝛽9𝑗 (calculated as described above in Equation 32 
and Equation 33).  
The summary statistics for each epilepsy type from each trial are then combined in separate 
NMAs by epilepsy type as if they were AD. This was achieved by producing a dataset of the 
summary statistics structured as a list of pairwise comparisons and converted from ‘pairs’ to 
‘augmented’ format via the ‘network’ command within Stata version 14 [310] (see Appendix 
13)  and NMA is performed via ‘mvmeta’ as described in Chapter 6.2.5.  
 134 
 
6.2.5 Second stage: IPD-NMA methods  
NMA was performed under a multivariate meta-analysis framework, where the pairwise 
treatment comparisons are treated as different outcomes and NMA is performed via 
multivariate meta-regression techniques [220]. 
Assume that each trial provides 𝑝 treatment effects of interest in relation to a reference 
treatment. This framework will be demonstrated assuming a simple example of a three-
armed trial which randomises participants of both seizure types to the reference treatment 
CBZ and two other AEDs (say drug 2 and drug 3). Using the notation outlined in Chapter 6.2.2 
and Chapter 6.2.3, in the 𝑗𝑡ℎ trial with 𝑖 participants, with reference CBZ (constrained to be 
0) and two other AEDs defined by indicator variables 𝑥2𝑖𝑗   and 𝑥3𝑖𝑗 , then the 𝑗
𝑡ℎ  trial will 
provide four effect estimates of interest (i.e. here 𝑝 = 4 ): 𝛼2𝑗  and 𝛼3𝑗 for individuals with 
partial seizures and 𝛽2𝑗  and 𝛽3𝑗  for individuals with generalised seizures. For trial 𝑗, the 𝑝 
effects of interest can be written as a (1 x 𝑝 ) vector 𝒚𝒋  and the within-trial variance-











𝑣𝑎𝑟(𝛼2𝑗 ) 𝑐𝑜𝑣(𝛼2𝑗 , 𝛼3𝑗 ) 𝑐𝑜𝑣(𝛼2𝑗 , 𝛽2𝑗 ) 𝑐𝑜𝑣(𝛼2𝑗 , 𝛽3𝑗 )
𝑐𝑜𝑣(𝛼3𝑗 , 𝛼2𝑗 ) 𝑣𝑎𝑟(𝛼3𝑗 ) 𝑐𝑜𝑣(𝛼3𝑗 , 𝛽2𝑗 ) 𝑐𝑜𝑣(𝛼3𝑗 , 𝛽3𝑗 )
𝑐𝑜𝑣(𝛽2𝑗 , 𝛼2𝑗 )
𝑐𝑜𝑣(𝛽3𝑗 , 𝛼2𝑗 )
𝑐𝑜𝑣(𝛽2𝑗 , 𝛼3𝑗 )
𝑐𝑜𝑣(𝛽3𝑗 , 𝛼3𝑗 )
𝑣𝑎𝑟(𝛽2𝑗)
𝑐𝑜𝑣(𝛽3𝑗 , 𝛽2𝑗 )




  (Equation 36) 
The aim of the multivariate analysis is to estimate the ‘network parameters’ which are 
unknown i.e. in this case the treatment effect of drug 2 in relation to CBZ and the drug 3 in 
relation to CBZ, for individuals with partial seizures and for individuals with generalised 
seizures across all trials and across the whole network of AEDs. These ‘network parameters’ 
can be written as (𝑝 x 1) matrix 𝝁. So in this example: 
𝝁 = (𝛼2 , 𝛼3 , 𝛽2 , 𝛽3)    (Equation 37) 
The general form of multivariate random-effects meta-regression for 𝑗 trials is [220]: 
𝒚𝒋~𝑁(𝝁 𝑿𝒋, Σ + 𝑆𝑗)    (Equation 38)
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Where 𝒚𝒋, 𝝁 and 𝑺𝒋 are defined as above for the 𝑝 treatment effects of interest in the 𝑗
𝑡ℎ 
trial, 𝑿𝒋 is a (𝑞 x 𝑝) matrix with all elements equal to 0 or 1 to indicate which treatment effects 
are present in each trial (up to a maximum of 𝑞 ‘network parameters’ to be estimated) and 
Σ is a (𝑞 × 𝑞) matrix of between-trials variance-covariance which is assumed to be the same 
for all trials. Various assumptions can be made about the structure of this variance-
covariance matrix; see White et al [220] for further discussion. Multivariate meta-regression 
under this framework can also be performed using fixed-effects, with Σ assumed to be a zero 
matrix (i.e. no heterogeneity). 
Therefore for the two separate models for individuals of each seizure type described in 
Chapter 6.2.2,  for individuals with partial seizures, the network parameters to be estimated 
are 𝝁 = (𝛼2  … , 𝛼10 ) (i.e. 𝑞 =9) and for individuals with generalised seizures the network 
parameters to be estimated are 𝝁 = (𝛽2… 𝛽9)  (i.e. 𝑞  =8). Similarly, for the approaches 
described in Chapter 6.2.3 and Chapter 6.2.4 where seizure types are considered within the 
same model via a treatment-by-epilepsy type interaction, the network parameters to be 
estimated are 𝝁 = (𝛼2…𝛼10 , 𝛽2…  𝛽9),  (i.e. 𝑞 = 17).   
Both fixed-effects and random-effects models were fitted via ‘mvmeta’ command in Stata 
using the default estimation method of restricted maximum likelihood estimation (REML) 
[220, 308]. Random-effects models were fitted assuming equal heterogeneity for all pairwise 
comparisons (i.e. between-trial-covariance structure (variance-covariance matrix Σ ) 
proportional to single unknown heterogeneity parameter 𝜏2  rather than allowing for 
heterogeneity to vary across the comparisons). It was necessary to make an assumption 
regarding the between-trial covariance structure as not all possible pairwise comparisons 
between the treatments of interest were present in the network (see Figure 9). This 
multivariate meta-regression approach requires that all studies report on a common 
reference treatment (in this example, CBZ or VPS depending on the ‘first-stage’ model 
approach). For studies that do not include this reference treatment, to allow this approach 
to be used a minimally informative reference arm (i.e. a very small treatment effect and 
variance) can be imputed via a data augmentation technique describe by White et al [308]. 
Due to the assumption made of ‘proportional’ heterogeneity, an 𝐼2  statistic cannot be 
directly calculated for the NMA. Alternatively, an R statistic can be estimated directly via the 
‘randfix’ option of ‘mvmeta’ which is a ratio measure of the standard errors in the random-
effects NMA model compared to the fixed-effects NMA model [311], and it has been shown 
that R can be used to calculate 𝐼2 as follows [312]: 
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𝐼2 = (𝑅2 − 1) 𝑅2⁄     (Equation 39) 
An 𝐼2  statistic was estimated for the whole treatment network for each NMA and the 
estimate of 𝜏2  from the random-effects NMA model was also used in interpreting the 
presence of any heterogeneity in the treatment network (with higher 𝐼2  and 𝜏2  values 
indicating more heterogeneity present). It should also be noted that the 𝑅  statistic and 
therefore this  𝐼2 statistic are dependent on the number of parameters in the NMA model. 
Therefore when seizure types are considered in separate NMA models (Chapter 6.2.2), these 
models have fewer network parameters to estimate than the models which consider the two 
seizure types via an interaction term (Chapter 6.2.3 and Chapter 6.2.4) so the models with 
the interaction terms are likely to have higher 𝑅 and 𝐼2  values which may be due to the 
number of parameters rather than necessarily due to increased variability in the model. For 
this reason, direct numerical comparisons of the  𝜏2 , 𝑅 and 𝐼2  statistics across the NMA 
models was not made and any relative comparisons were made in the context of the number 
of parameters included in each model. 
The estimated network parameters (matrix 𝝁  for each model) represent the relative 
treatment effects for each AED compared to reference treatment CBZ. To obtain a complete 
set of pairwise comparisons for the treatments, some algebraic manipulation was required 
in a similar manner to the calculations described above in Equation 32 and Equation 33.  
For example, let ?̂?2  and var (?̂?2) be the ‘network parameter’ estimates of 𝑙𝑜𝑔 (𝐻𝑅) and 
variance for drug 2 compared to CBZ (for individuals with partial seizures) and let ?̂?3  and 
var (?̂?3)  be the ‘network parameter’ estimates of 𝑙𝑜𝑔 (𝐻𝑅)  and variance for drug 3 
compared to CBZ. To obtain the ‘network parameter’ estimates of 𝑙𝑜𝑔 (𝐻𝑅) and variance for 
drug 3 compared to drug 2, ?̂?3𝑣𝑠.2  and var (?̂?3𝑣𝑠.2) : 
?̂?3𝑣𝑠.2   = ?̂?3 − ?̂?2        (Equation 40) 
var(?̂?3𝑣𝑠.2) = var(?̂?2) + var(?̂?3) + 2 𝑐𝑜𝑣𝑎𝑟(?̂?2, ?̂?3)      (Equation 41) 
Where 𝑐𝑜𝑣𝑎𝑟(?̂?2, ?̂?3) is the covariance between treatment effects ?̂?2𝑗  and ?̂?3.  Other 




6.3  Results  
The main focus of this Chapter is the consideration of different methodological approaches 
to modelling epilepsy type in this IPD-NMA of AED monotherapy. Therefore, for brevity, 
results for primary outcome ‘Time-to-withdrawal of allocated treatment’ only are reported 
in this Chapter. Further details of secondary outcomes, additional consideration of 
inconsistency and heterogeneity and clinical implications are presented in Chapter 7.  
6.3.1. IPD-NMA results according to the approach for modelling epilepsy type 
Table 15 and Table 16 show IPD-NMA results for individuals with partial seizures and with 
generalised seizures respectively according to the approach for modelling epilepsy type; see 
Chapter 6.2 for further details of all methods. 
Table 15: Fixed-effects IPD-NMA results for time-to-withdrawal of allocated treatment 
according to approach of modelling epilepsy type (individuals with partial seizures) 
Comparison1,2 Model for partial 
seizures only3  
Model with 
amalgamated 
interaction term4  
Model with 
separated 




CBZ vs PHB 1.57 (1.20 to 2.05) 1.55 (1.18 to 2.04) 1.56 (1.19 to 2.04) 1.58 (1.14 to 2.18) 
CBZ vs PHT 1.16 (0.93 to 1.45) 1.13 (0.92 to 1.38) 1.12 (0.92 to 1.36) 1.20 (0.89 to 1.62) 
CBZ vs VPS 1.10 (0.90 to 1.35) 1.04 (0.86 to 1.25) 0.90 (0.76 to 1.07) 0.90 (0.70 to 1.17) 
CBZ vs LTG 0.72 (0.63 to 0.83) 0.75 (0.65 to 0.86) 0.73 (0.64 to 0.85) 0.78 (0.61 to 0.98) 
CBZ vs OXC 1.07 (0.84 to 1.37) 1.09 (0.84 to 1.42) 1.09 (0.80 to 1.47) 1.34 (0.48 to 3.72) 
CBZ vs TPM 1.17 (0.99 to 1.38) 1.18 (0.98 to 1.43) 1.17 (0.94 to 1.47) 1.01 (0.50 to 2.05) 
CBZ vs GBP 1.18 (1.01 to 1.39) 1.20 (1.00 to 1.43) 1.18 (0.95 to 1.47) 1.12 (0.83 to 1.53) 
CBZ vs LEV 0.83 (0.70 to 0.99) 0.82 (0.69 to 0.97) 0.85 (0.70 to 1.02) 0.69 (0.51 to 0.95) 
CBZ vs ZNS 1.08 (0.81 to 1.44) 1.08 (0.79 to 1.48) 1.08 (0.75 to 1.55) 1.08 (0.81 to 1.44) 
PHB vs PHT 0.74 (0.49 to 1.11) 0.73 (0.55 to 0.96) 0.72 (0.54 to 0.95) 0.76 (0.44 to 1.31) 
PHB vs VPS 0.70 (0.50 to 0.99) 0.67 (0.48 to 0.92) 0.58 (0.43 to 0.78) 0.57 (0.37 to 0.88) 
PHB vs LTG 0.46 (0.34 to 0.62) 0.48 (0.35 to 0.66) 0.47 (0.35 to 0.64) 0.49 (0.33 to 0.73) 
PHB vs OXC 0.68 (0.48 to 0.98) 0.70 (0.48 to 1.03) 0.70 (0.47 to 1.04) 0.85 (0.28 to 2.54) 
PHB vs TPM 0.75 (0.54 to 1.02) 0.76 (0.55 to 1.06) 0.75 (0.53 to 1.07) 0.64 (0.29 to 1.41) 
PHB vs GBP 0.76 (0.55 to 1.03) 0.77 (0.55 to 1.07) 0.76 (0.54 to 1.07) 0.71 (0.46 to 1.11) 
PHB vs LEV 0.53 (0.39 to 0.73) 0.53 (0.38 to 0.73) 0.54 (0.39 to 0.75) 0.44 (0.28 to 0.69) 
PHB vs ZNS 0.69 (0.47 to 1.02) 0.70 (0.46 to 1.06) 0.69 (0.44 to 1.09) 0.69 (0.45 to 1.05) 
PHT vs VPS 0.95 (0.70 to 1.29) 0.92 (0.70 to 1.21) 0.81 (0.62 to 1.04) 0.76 (0.49 to 1.16) 
PHT vs LTG 0.62 (0.48 to 0.80) 0.66 (0.52 to 0.85) 0.66 (0.51 to 0.83) 0.65 (0.44 to 0.95) 
PHT vs OXC 0.92 (0.67 to 1.28) 0.97 (0.69 to 1.35) 0.97 (0.68 to 1.39) 1.12 (0.37 to 3.40) 
PHT vs TPM 1.01 (0.77 to 1.32) 1.05 (0.80 to 1.39) 1.05 (0.78 to 1.41) 0.85 (0.38 to 1.87) 
PHT vs GBP 1.02 (0.78 to 1.34) 1.06 (0.81 to 1.40) 1.05 (0.79 to 1.41) 0.94 (0.61 to 1.45) 
PHT vs LEV 0.72 (0.54 to 0.95) 0.73 (0.56 to 0.95) 0.76 (0.58 to 0.99) 0.58 (0.37 to 0.90) 
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PHT vs ZNS 0.93 (0.65 to 1.34) 0.96 (0.66 to 1.39) 0.97 (0.64 to 1.46) 0.90 (0.60 to 1.37) 
VPS vs LTG 0.65 (0.51 to 0.84) 0.72 (0.58 to 0.90) 0.81 (0.66 to 1.01) 0.86 (0.60 to 1.22) 
VPS vs OXC 0.97 (0.71 to 1.34) 1.05 (0.76 to 1.44) 1.21 (0.86 to 1.70) 1.48 (0.51 to 4.28) 
VPS vs TPM 1.06 (0.81 to 1.38) 1.14 (0.88 to 1.48) 1.30 (0.98 to 1.72) 1.12 (0.51 to 2.45) 
VPS vs GBP 1.07 (0.83 to 1.39) 1.15 (0.89 to 1.49) 1.31 (0.99 to 1.73) 1.24 (0.83 to 1.85) 
VPS vs LEV 0.76 (0.58 to 0.98) 0.79 (0.61 to 1.03) 0.94 (0.73 to 1.21) 0.77 (0.51 to 1.16) 
VPS vs ZNS 0.98 (0.69 to 1.39) 1.04 (0.73 to 1.50) 1.20 (0.80 to 1.79) 1.20 (0.82 to 1.76) 
LTG vs OXC 1.49 (1.10 to 2.02) 1.46 (1.11 to 1.92) 1.48 (1.08 to 2.03) 1.73 (0.60 to 4.95) 
LTG vs TPM 1.62 (1.27 to 2.06) 1.59 (1.29 to 1.95) 1.60 (1.26 to 2.03) 1.31 (0.61 to 2.78) 
LTG vs GBP 1.64 (1.29 to 2.09) 1.60 (1.31 to 1.96) 1.61 (1.27 to 2.04) 1.45 (0.99 to 2.13) 
LTG vs LEV 1.16 (0.92 to 1.45) 1.10 (0.89 to 1.35) 1.15 (0.92 to 1.44) 0.89 (0.58 to 1.38) 
LTG vs ZNS 1.50 (1.09 to 2.07) 1.45 (1.03 to 2.04) 1.47 (1.00 to 2.18) 1.40 (0.97 to 2.02) 
OXC vs TPM 1.09 (0.78 to 1.51) 1.09 (0.82 to 1.44) 1.08 (0.78 to 1.49) 0.76 (0.21 to 2.74) 
OXC vs GBP 1.10 (0.80 to 1.53) 1.10 (0.83 to 1.45) 1.09 (0.78 to 1.50) 0.84 (0.29 to 2.44) 
OXC vs LEV 0.78 (0.58 to 1.05) 0.75 (0.55 to 1.03) 0.78 (0.55 to 1.11) 0.52 (0.18 to 1.51) 
OXC vs ZNS 1.01 (0.69 to 1.47) 0.99 (0.66 to 1.49) 0.99 (0.62 to 1.59) 0.81 (0.28 to 2.33) 
TPM vs GBP 1.01 (0.78 to 1.32) 1.01 (0.82 to 1.25) 1.01 (0.77 to 1.31) 1.11 (0.51 to 2.41) 
TPM vs LEV 0.71 (0.56 to 0.90) 0.69 (0.54 to 0.89) 0.72 (0.54 to 0.96) 0.69 (0.31 to 1.49) 
TPM vs ZNS 0.93 (0.67 to 1.29) 0.91 (0.64 to 1.31) 0.92 (0.60 to 1.41) 1.07 (0.50 to 2.29) 
GBP vs LEV 0.70 (0.56 to 0.89) 0.69 (0.54 to 0.88) 0.72 (0.54 to 0.95) 0.62 (0.40 to 0.96) 
GBP vs ZNS 0.91 (0.66 to 1.27) 0.90 (0.63 to 1.30) 0.92 (0.60 to 1.40) 0.96 (0.63 to 1.47) 
LEV vs ZNS 1.30 (0.93 to 1.81) 1.32 (0.93 to 1.88) 1.28 (0.85 to 1.92) 1.56 (1.02 to 2.39) 
τ2 statistic 7 x 10-21 0.0037 7 x 10-13 2 x 10-20 
R statistic 1.000 1.064 1.131 1.000 
I2 statistic  0% 11.7% 21.8% 0% 
1. Order of drugs in the table: most commonly used drug first (CBZ), then drugs are ordered 
approximately by the date they were licenced as a monotherapy treatment (oldest first). 
2. HRs and 95% CIs are calculated from fixed-effects analyses. HR < 1 indicates an advantage to the 
second drug in the comparison; results in highlighted in bold are statistically significant. 
3. Results taken from the model outlined in Chapter 6.2.2 
4. Results taken from the models outlined in Chapter 6.2.3  
5. Results taken from the model outlined in Chapter 6.2.4  
 
For individuals with partial seizures for the majority of comparisons, the conclusions that 
would be drawn in terms of statistical significance are consistent across the four modelling 
approaches (i.e. either all statistically significant or non-significant). For eleven comparisons, 
there is variability across the modelling approaches in terms of the conclusions that would 
be drawn based on statistical significance, most notably for the important comparisons of 
CBZ vs LEV and VPS vs LTG (see Chapter 7 for further discussion of important AEDs); although 
the general direction of effect is consistent for all of the eleven comparisons. 
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Notably, when comparing the results of the two models described in Chapter 6.2.3 with the 
within-trial and across-trial interaction terms amalgamated or separated respectively, 
numerical results of these two models are mostly very similar (to one or two decimal places) 
and conclusions mostly the same. Also notably, for the comparisons of CBZ vs LEV and VPS 
vs LTG, the conclusions drawn in terms of statistical significance would be different, with the 
amalgamated interaction model showing a significant effect and the separated interactions 
model showing no statistically significant difference; although the direction of effect is the 
same for both comparisons across the two approaches and numerical results for the CBZ vs 
LEV comparison are the same to one decimal place. 
In comparison to the other modelling approaches, the ‘meta-analysis of interactions’ 
approach seems to produce the most different results to the other methods, particularly in 
terms of the precision of the results but also in terms of the numerical results (e.g. see 
comparisons of LTG vs OXC, TPM, GBP and ZNS in Table 15). The differences in results from 
this approach may have occurred for two reasons. Firstly, other approaches analyse IPD only 
in the ‘first-stage’ and this is the only method which reduces the IPD to aggregate data for 
each trial in the ‘first-stage’ and then performs the NMA as if the data was aggregate data. 
This aspect of the approach could have resulted in the loss of precision observed in the results 
in Table 15.  
Table 16: Fixed-effects IPD-NMA results for time-to-withdrawal of allocated treatment 
according to approach of modelling epilepsy type (individuals with generalised seizures) 
Comparison1,2 Model for 
generalised 
seizures only3  
Model with 
amalgamated 
interaction term4  
Model with 
separated 




CBZ vs PHB 1.63 (0.86 to 3.08) 1.47 (0.83 to 2.61) 1.27 (0.55 to 2.92) 0.76 (0.25 to 2.28) 
CBZ vs PHT 1.05 (0.73 to 1.52) 0.92 (0.59 to 1.42) 0.97 (0.54 to 1.75) 0.73 (0.32 to 1.63) 
CBZ vs VPS 0.83 (0.62 to 1.12) 0.70 (0.54 to 0.92) 0.70 (0.45 to 1.08) 0.63 (0.36 to 1.09) 
CBZ vs LTG 0.69 (0.48 to 1.01) 0.63 (0.45 to 0.89) 0.75 (0.47 to 1.19) 0.89 (0.49 to 1.61) 
CBZ vs OXC 0.83 (0.16 to 4.43) 1.00 (0.21 to 4.81) 0.90 (0.17 to 4.66) 0.73 (0.20 to 2.59) 
CBZ vs TPM 0.90 (0.42 to 1.93) 1.24 (0.90 to 1.71) 0.83 (0.42 to 1.63) 0.82 (0.40 to 1.68) 
CBZ vs GBP 0.92 (0.11 to 8.07) 0.90 (0.11 to 7.29) 0.76 (0.09 to 6.55) 0.65 (0.03 to 12.6) 
CBZ vs LEV 0.78 (0.43 to 1.42) 0.74 (0.44 to 1.23) 0.80 (0.48 to 1.32) 0.84 (0.45 to 1.58) 
PHB vs PHT 0.65 (0.30 to 1.39) 0.62 (0.32 to 1.24) 0.77 (0.30 to 1.97) 0.95 (0.22 to 4.20) 
PHB vs VPS 0.51 (0.24 to 1.09) 0.48 (0.27 to 0.86) 0.55 (0.23 to 1.33) 0.83 (0.22 to 3.11) 
PHB vs LTG 0.43 (0.20 to 0.89) 0.43 (0.22 to 0.83) 0.59 (0.23 to 1.52) 1.16 (0.32 to 4.28) 
PHB vs OXC 0.51 (0.09 to 3.06) 0.68 (0.13 to 3.60) 0.71 (0.11 to 4.48) 0.95 (0.16 to 5.57) 
PHB vs TPM 0.55 (0.20 to 1.49) 0.84 (0.44 to 1.60) 0.66 (0.22 to 1.92) 1.08 (0.27 to 4.25) 
PHB vs GBP 0.57 (0.06 to 5.43) 0.61 (0.07 to 5.34) 0.60 (0.06 to 6.03) 0.86 (0.04 to 20.7) 
PHB vs LEV 0.48 (0.20 to 1.15) 0.50 (0.23 to 1.09) 0.63 (0.24 to 1.67) 1.11 (0.31 to 4.03) 
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PHT vs VPS 0.79 (0.49 to 1.28) 0.77 (0.46 to 1.27) 0.72 (0.36 to 1.45) 0.87 (0.28 to 2.69) 
PHT vs LTG 0.66 (0.39 to 1.12) 0.69 (0.39 to 1.20) 0.77 (0.36 to 1.62) 1.22 (0.38 to 3.90) 
PHT vs OXC 0.79 (0.14 to 4.38) 1.09 (0.21 to 5.56) 0.92 (0.16 to 5.31) 1.00 (0.16 to 6.23) 
PHT vs TPM 0.85 (0.36 to 1.99) 1.35 (0.79 to 2.30) 0.85 (0.35 to 2.10) 1.13 (0.33 to 3.92) 
PHT vs GBP 0.88 (0.10 to 7.91) 0.98 (0.12 to 8.30) 0.78 (0.08 to 7.29) 0.90 (0.04 to 20.9) 
PHT vs LEV 0.74 (0.37 to 1.49) 0.80 (0.42 to 1.55) 0.82 (0.38 to 1.77) 1.16 (0.40 to 3.37) 
VPS vs LTG 0.83 (0.51 to 1.36) 0.90 (0.60 to 1.35) 1.07 (0.59 to 1.93) 1.41 (0.55 to 3.62) 
VPS vs OXC 1.00 (0.18 to 5.46) 1.42 (0.29 to 6.92) 1.28 (0.24 to 7.01) 1.15 (0.26 to 5.13) 
VPS vs TPM 1.08 (0.47 to 2.44) 1.76 (1.22 to 2.53) 1.19 (0.53 to 2.65) 1.30 (0.45 to 3.76) 
VPS vs GBP 1.11 (0.12 to 9.89) 1.28 (0.16 to 10.5) 1.09 (0.12 to 9.74) 1.04 (0.05 to 22.0) 
VPS vs LEV 0.93 (0.48 to 1.82) 1.05 (0.58 to 1.90) 1.14 (0.58 to 2.23) 1.34 (0.53 to 3.39) 
LTG vs OXC 1.20 (0.21 to 6.91) 1.58 (0.33 to 7.67) 1.20 (0.23 to 6.27) 0.82 (0.18 to 3.77) 
LTG vs TPM 1.29 (0.53 to 3.13) 1.96 (1.25 to 3.08) 1.11 (0.51 to 2.41) 0.93 (0.32 to 2.65) 
LTG vs GBP 1.33 (0.14 to 12.4) 1.42 (0.17 to 11.6) 1.02 (0.12 to 8.81) 0.74 (0.03 to 16.1) 
LTG vs LEV 1.12 (0.55 to 2.28) 1.17 (0.63 to 2.19) 1.07 (0.54 to 2.11) 0.95 (0.39 to 2.35) 
OXC vs TPM 1.07 (0.15 to 7.86) 1.24 (0.26 to 5.94) 0.93 (0.18 to 4.80) 1.13 (0.23 to 5.61) 
OXC vs GBP 1.11 (0.06 to 21.8) 0.90 (0.08 to 9.96) 0.85 (0.07 to 9.91) 0.90 (0.03 to 26.0) 
OXC vs LEV 0.93 (0.16 to 5.49) 0.74 (0.14 to 3.86) 0.89 (0.16 to 4.99) 1.16 (0.27 to 4.95) 
TPM vs GBP 1.03 (0.09 to 11.6) 0.73 (0.09 to 5.89) 0.92 (0.11 to 7.90) 0.8 (0.03 to 18.36) 
TPM vs LEV 0.87 (0.33 to 2.29) 0.60 (0.33 to 1.09) 0.96 (0.41 to 2.23) 1.03 (0.38 to 2.78) 
GBP vs LEV 0.84 (0.09 to 7.97) 0.82 (0.10 to 7.10) 1.05 (0.11 to 9.58) 1.29 (0.06 to 27.0) 
τ2 statistic 0.0701 0.0037 7 x 10-13 2 x 10-20 
R statistic 1.225 1.064 1.131 1.000 
I2 statistic  33.3% 11.7% 21.8% 0% 
1. See Table 15 for abbreviations and other footnote labels 
Secondly, the largest differences in the results of this approach compared to the other 
modelling approaches seem to occur within the pairwise comparisons where no direct 
evidence exists or only very limited direct evidence from a single study contributes to the 
network (see Figure 12 and Chapter 7.2 for further discussion of direct evidence contributed 
for each comparison). The ‘meta-analysis of interactions’ approach fits only within-trial 
interactions and does not take account of across-trial interactions. The differences in the 
results across the modelling approaches suggest that any association between treatment 
effect and epilepsy type may be different within the trials compared to across the trials; in 
other words that ecological bias may be present within the model with an amalgamated 
interaction. If this is the case, then an approach to NMA which does not allow for across-trial 
relationships is likely to produce different results, particularly in this example where within-




Table 16 shows that statistically significant differences between pairs of AEDs are rarely 
found across any of the methodological approaches for individuals with generalised seizures; 
in fact no differences between the drugs in any of the pairwise comparisons is found from 
the model with separated within-trial and across-trial interactions, or from the ‘meta-analysis 
of interactions’ model. There is also more variability in the numerical results across methods 
for individuals with generalised seizures and more changes in the statistical significance and 
direct of effect of numerical results. As for individuals with partial seizures, the ‘meta-analysis 
of interactions’ approach seems to produce the most numerically different results to the 
other methods. Overall, it is not surprising that a different approach to modelling the 
relationship between treatment and epilepsy type has had less impact on the numerical 
results and conclusions for individuals with partial seizures (the majority epilepsy type, 
around 70%) but a larger impact on the numerical results and conclusions for individuals with 
generalised seizures (the minority epilepsy type, around 25%).  
It is well documented that VPS is the most effective drug for controlling generalised seizures 
[69, 74]. However this AED is not suitable for all individuals, particularly females of 
childbearing age due to the potential teratogenic effects of the drug [74, 75].  Therefore 
interest lies in identifying AEDs which are suitable alternatives for VPS, rather than AEDs 
which are significantly better than VPS. This is starting to be reflected within clinical practice, 
with recent trials aiming to demonstrate non-inferiority of new AEDs compared to ‘standard’ 
treatments, rather than superiority [261, 262]. In terms of the important comparisons shown 
in Table 16 (see Chapter 7 for further discussion), consistently across all of the methods, 
despite some numerical differences in results and general direction of effect, no statistically 
significant differences are shown for the comparisons VPS vs LTG and VPS vs LEV, suggesting 
that LTG and LEV do not seem to be any worse than VPS in terms of retention which may 
make these two treatments potential alternatives to VPS.  
Another notable difference is that the conclusion that may be drawn for the comparison of 
VPS over CBZ for individuals with generalised seizures in terms of statistical significance 
differs according to the methodological approach. Despite this, the direction of effect for the 
comparison of VPS and CBZ is consistent across all approaches and the statistical significance 
(or lack thereof) of this comparison is unlikely to impact on clinical practice due to 




6.3.2 Additional consideration of treatment-covariate interaction 
Hua et al [25] note the risk of an interaction being missed or incorrectly interpreted where 
within-study and across-study interactions are amalgamated. While this is an important and 
valid concern when performing analysis to establish the existence of treatment-covariate 
interactions, within this context, the aim was not to test for a statistical interaction. Strong 
clinical evidence and current guidelines [74] assume that a clinical interaction between 
treatment and epilepsy type exists, hence within current clinical practice clinicians do tend 
to have a preference for specific drugs for different seizure types (see Chapter 1.2 and 
Chapter 6.1 for further details). Therefore for this IPD-NMA to be useful to future clinical 
practice, it was essential to provide results by seizure type and missing an ‘interaction’ was 
not a specifically a concern to this NMA.   
However, previous Cochrane IPD-MAs (e.g. [59, 67]) as well as the analysis of Hua et al [25] 
have shown mixed results regarding whether a statistical interaction between treatment and 
epilepsy type actually exists. It is possible that misclassification of seizure type has 
confounded the results of previous Cochrane IPD-MAs, with one of the Cochrane IPD-MAs 
showing a significant interaction between treatment and epilepsy type following 
reclassification [59]; see Chapter 7.1.3 for further details of additional analyses to account 
for misclassification of seizure type in this IPD-NMA.  
Within this example, due to the ‘two-stage’ nature of the methodology (see Chapter 6.2), 
statistical interactions could only be tested at the ‘first-stage’ of the modelling approach (see 
Chapter 6.2.3). A further analysis was performed for ‘Time-to-withdrawal of allocated 
treatment’ comparing results for the interaction terms of one-stage IPD-MA models (with 
amalgamated or separated interactions, of the structure of the models outlined in Equation 
31 and Equation 34) fitted to subsets of the IPD for the most important pairwise comparisons 
in this context; CBZ vs LTG, CBZ vs LEV, CBZ vs VPS and VPS vs LTG (see Chapter 7).  
Results of these analyses are presented in Table 17. It should be noted that these analyses 
are considered exploratory and that across-study interactions (the ?̂?𝐴 defined by Hua et al 
[25]) are not presented due to the computational complexity of estimating this parameter 
within the current framework.  
For the comparisons of CBZ vs LTG, CBZ vs LEV, CBZ vs VPS, results presented in Table 17 
show that the interaction term is not statistically significant (i.e. no evidence of a statistical 
interaction between treatment effect and epilepsy type for these particular AEDs). 
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Furthermore, the same conclusions regarding the interaction between treatment and 
epilepsy type would be drawn (based on the statistical significance), although the magnitude 
of the interaction appears numerically larger for CBZ vs LTG where interactions are 
amalgamated rather than separated (-0.433 compared to -0.313).  
Table 17: One stage meta-analysis results for time-to-withdrawal of allocated treatment 
according to approach of modelling treatment-by-epilepsy type interaction 
Comparison1 Parameter Amalgamated interaction Separated interactions2 
β SE P-value β SE P-value 
CBZ vs LTG 
N=1,889 
(8 trials) 
Drug -0.328 0.100 0.001 -0.402 0.091 <0.001 
Epilepsy type 0.248 0.174 0.154 0.195 0.191 0.308 
Interaction -0.433 0.241 0.072 -0.313 0.274 0.253 
CBZ vs VPS 
N=1,219 
(5 trials) 
Drug 0.020 0.120 0.869 -0.024 0.104 0.816 
Epilepsy type -0.178 0.179 0.32 -0.127 0.195 0.515 
Interaction -0.136 0.235 0.562 -0.238 0.279 0.395 
CBZ vs LEV 
N=1,818 
(3 trials) 
Drug -0.165 0.087 0.059 -0.181 0.082 0.028 
Epilepsy type -0.127 0.179 0.478 -0.079 0.177 0.655 
Interaction -0.105 0.252 0.676 -0.204 0.257 0.427 
VPS vs LTG 
N=774 
(3 trials) 
Drug -0.782 0.249 0.002 -0.028 0.138 0.84 
Epilepsy type -0.392 0.234 0.094 -0.237 0.268 0.376 
Interaction 1.108 0.300 <0.001 0.719 0.393 0.067 
Abbreviations: β = parameter estimate; CBZ = carbamazepine; LEV= Levetiracetam; LTG = 
lamotrigine; SE=standard error; VPS = sodium valproate 
1. The first drug in the comparison is the reference treatment 
2. For the separated interaction model, only the within-study interaction presented 
( ?̂?𝑊  of Hua et al [25]) due to computational time of estimating across study 
interaction (?̂?𝐴 of Hua et al [25]) within Stata version 14.  
For the comparison of VPS vs LTG, the interaction is highly significant from the amalgamated 
model (p<0.001) but the within-study interaction is not significant from the separated model 
(p=0.067). The magnitude of the interaction is also numerically reduced in the separated 
model compared to the amalgamated model (0.719 compared to 1.108). The differences 
across the modelling approaches shown for this comparison are in line with the results 




6.3  Discussion 
6.3.1 Summary of main results and implications 
This Chapter presents several methodological approaches for an IPD-NMA of AED 
monotherapy, taking account of current clinical practice for treating individuals with partial 
onset and generalised onset seizures. Results from the different approaches presented in this 
Chapter demonstrate that for individuals with partial seizures (the majority epilepsy type, 
around 70%), numerical results and conclusions that could be drawn from them are fairly 
robust to the approach of modelling epilepsy type (within a separate model or via interaction 
terms). However, across methodological approaches for individuals with generalised seizures 
(the minority epilepsy type, around 25%) some numerical results change quite substantially, 
as well as some changes in the statistical conclusions. 
Also of note, the ‘meta-analysis of interactions approach’ which reduces IPD to aggregate 
data and models the treatment-by-epilepsy type interaction separately within each trial 
(rather than also the interaction across-trials as the methods analysing the entire IPD dataset 
across all trials do) seems to produce the most numerically different results to the other 
methods, with these differences even more pronounced for individuals with generalised 
seizures where less data is available. This may be due to potential ecological bias originating 
from this approach. 
It should be noted that definition of the primary outcomes of the IPD-NMA considered in this 
Chapter ‘time-to-withdrawal of allocated treatment’ is complex as multiple reasons for 
treatment withdrawal that are possible for each individual and how these reasons may be 
classified as events or censored observations compared to the definition of planned 
secondary outcomes of the IPD-NMA such as ‘time-to-first seizure,’ (i.e. whether an 
individual experiences a seizure during the study or not). Where different modelling 
approaches were applied to an IPD-NMA of ‘time-to-first seizure,’ numerical results again 
were similar and conclusions mostly unchanged for both seizure types (results not shown for 
brevity).  For such complex outcomes, modelling of the association between treatment effect 
and epilepsy type on the individual patient level is even more important where outcome 
definitions may vary across trials (i.e. more withdrawal events in some trials may occur due 
to adverse events and due to lack of efficacy in other trials), whereas the definition of seizure 
recurrence is the same across all trials so the analysis of ‘time-to-first seizure’ is more robust 
to varying assumptions regarding the treatment-covariate relationships.  
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Further consideration of outcome definitions, particularly ‘time-to-withdrawal of allocated 
treatment’ which can be modelled under a competing risks framework and the impact on 
treatment-covariate relationships (including modelled as interactions) for both meta-analysis 
and NMA would be of interest for future research.    
Result of additional exploratory analyses within this Chapter have also shown no evidence of 
a statistical interaction between treatment effect and epilepsy type for several commonly 
used AEDs which are assumed within current clinical practice to be more effective for 
particular seizure types [74]. This may indicate that such an interaction does not actually 
exist, despite the clinical perception of this interaction. Alternatively, it is possible that the 
existence of a statistical interaction has been not been identified due to lack of power or due 
to confounding from misclassification of epilepsy type, as was the case within a Cochrane 
IPD-MA of phenytoin (perceived to be a better treatment for partial seizures) compared to 
sodium valproate (perceived to be a better treatment for generalised seizures) [59].  
Therefore to inform future clinical practice which assumes a ‘clinical’ interaction between 
AEDs and seizure type, it is essential that future trials reflect clinical practice and this 
‘interaction’ within their designs; by recruiting participants with different seizure types 
separately (e.g. [264, 265] ) or performing stratified randomisation and presenting results for 
each seizure type separately (e.g. [304, 305]). Accurate seizure classification (as far as 
possible) of individuals recruited into future trials is also of great importance to avoid 
confounding of any associations between specific AEDs and seizure types; further discussion 
of this implication can be found in Chapter 7.3.3.  
6.3.2 Strengths and weaknesses 
The use of IPD in these analyses allowed several approaches to consider the relationship 
between treatment effect and epilepsy type and allowed for results to be presented 
separately by epilepsy type in the context of the recommended first line treatment of the 
epilepsy type, such an approach which would not have been possible without the use of IPD. 
At the time of planning this analysis during 2014 [68], there were few methodological 
publications for IPD-NMA, and no work has been published which had considered IPD-NMA 
of TTE data with treatment-covariate interactions (amalgamated interactions or separated 
into within and across-trial interactions). To my knowledge at the time of writing, there are 
still no published methods which allow such a ‘one-stage’ model to be fitted. 
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Hence the proposed methodology was adapted from a previous IPD-NMA in epilepsy 
conducted by the group [285] and a ‘two-stage’ approach was taken for all of the analyses 
presented within this Chapter. Recent work has outlined scenarios where one-stage and two-
stage approaches to meta-analysis may produce different results depending on modelling 
assumptions and estimation methods, choice of fixed or random-effects, clustering within 
studies, correlation between model parameters and handling of treatment-covariate 
interactions [169]. It should be noted that two-stage approaches are methodologically 
accessible and generally extend to any type of synthesis or type of data [40]. 
Further investigation of whether any existing NMA methodology (e.g. [44, 158, 159]) can be 
extended or whether new methodology could be developed within the context of this IPD-
NMA, within either the present multivariate framework or alternative frameworks (such as 
hierarchical Bayesian frameworks), would be of interest for further work. 
A common approach for presenting NMA results is to present the ‘ranks’ of the treatments 
(i.e. the probability that each treatment in the network is the best)[313] which may be of 
interest to readers, particularly clinicians or participants facing a treatment choice. Within 
the present analysis of a complex and chronic condition (epilepsy) with multiple outcomes 
relating to efficacy and tolerability, including a complex composite primary outcome of ‘time-
to-withdrawal of allocated treatment’ to which the individual participant can make a 
contribution, it was not deemed appropriate to present ‘best’ treatment for each outcome. 
For some individuals with epilepsy, complete remission of seizures may be a priority whereas 
for others intolerable side effects may be deemed more unacceptable than an occasional 
seizure so what would be deemed the ‘best’ treatment for one individual would not be the 
‘best’ treatment for another. Further discussion of the clinical implications of the results and 
an informal ‘ranking’  by ordering according treatment effect sizes from the IPD-NMA 
compared to the reference treatment (e.g. better or worse than carbamazepine) and are 
presented graphically in Chapter 7 and in the Cochrane IPD-NMA [69]. 
It should be noted that for some of the present analysis approaches, if it had been deemed 
appropriate to present treatment ‘ranks,’ due to the treatment-by-epilepsy type interaction 
in this model, rankings separated by epilepsy type cannot be calculated directly. Not being 
able to present a clearly ‘best’ treatment from NMA results according to different covariate 
values (where appropriate) is a general limitation and future research which allows ranking 
treatments from models with treatment-covariate interactions would be of value. 
 147 
 
6.3.3 Concluding remarks 
Results across the statistical approaches outlined in this Chapter demonstrate that for 
individuals with partial seizures are fairly robust to the approach of modelling epilepsy type 
(within a separate model or via interaction terms) but results are more variable across the 
methodological approaches for individuals with generalised seizures.  
Current clinical practice assumes that a clinical interaction between treatment effect and 
epilepsy type exists, with clinician preference for certain drugs and current NICE guidelines 
recommend different first-line treatments for individuals with different seizure types [74]. 
Despite this perception, the statistical approaches investigated within this Chapter do not 
provide consistent evidence that such an interaction exists statistically. 
Nonetheless, it is essential for this IPD-NMA to be informative to future clinical practice of 
epilepsy monotherapy that separate inferences by seizure type can be made and that future 
trials of epilepsy monotherapy reflect clinical practice and this perceived ‘interaction’ within 
their designs. Such future designs would better allow for more accurate investigation of any 
true statistical interaction between treatment effect and epilepsy type as well as further 





Chapter 7: A Cochrane IPD-NMA of antiepileptic drug 
monotherapy: additional considerations 
Chapter 6 of this thesis presents detailed statistical methodology for several approaches to 
modelling the association between epilepsy type and treatment effect in IPD-NMA. 
Methodology outlined in Chapter 6.2.3 was pre-specified in the protocol of Cochrane IPD-
NMA, which was written in 2014 [68]. This Chapter presents the clinical results and 
implications of the Cochrane IPD-NMA [69] and additional methodological considerations 
including comparison of NMA results to direct evidence, investigation of heterogeneity and 
inconsistency, additional and sensitivity analyses.   
7.1  Additional methodological considerations 
7.1.1  Direct (pairwise) evidence 
Where pairwise evidence was available (see Figure 9 in Chapter 5 for network diagram of 
comparisons made between the ten AEDs of interest), the 𝑗𝑡ℎ trial, a  trial-specific 𝑙𝑛 (𝐻𝑅)𝑗  
and 𝑠𝑒(𝑙𝑛 (𝐻𝑅))𝑗  was estimated using methods outlined in Chapter 6.2.5 of this thesis. 
These trial specific estimates were then combined via the ‘metan’ command in Stata (inverse-
variance meta-analysis, see Equation 13 and Equation 14 in Chapter 2.3.2), resulting in a 
pooled 𝑙𝑛 (𝐻𝑅) and 𝑣𝑎𝑟 (𝑙𝑛 (𝐻𝑅)) for each available pairwise comparison.  
For each pairwise comparison where data could be synthesised for at least two trials, the 
presence of statistical heterogeneity was assessed using the Q test (P-value < 0.10 for 
significance) and the 𝐼2  statistic [314].  The presence of clinical heterogeneity was assessed 
by comparing trial design characteristics and participant demographics and by visual 
inspection of forest plots, particularly in terms of the magnitude and direction of effects. In 
the first instance, a fixed-effects model was to be used for all pairwise meta-analyses. If an 
important amount of heterogeneity (defined here as 𝐼2 > 50%) was found to be present 
which could not be explained by differences in trial or participant characteristics, pairwise 
meta-analyses would be repeated using a Der Simonanian-Laird random-effects model [12].  
It should be noted that this is a ‘two-stage’ method of IPD-MA which was performed to allow 
visual comparison forest plots to assess for clinical heterogeneity. Such an approach may be 
associated with some limitations compared to one stage IPD-MA but is unlikely to produce 
different results to a one-stage method as both approaches have otherwise made the same 
assumptions [169].  For completeness, one-stage IPD-MA was also performed fitting a one-
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stage stratified Cox PH model with fixed-treatment effects, treatment-by-epilepsy type 
interaction and stratified by trial for each pairwise comparison. Numerical results were very 
similar and conclusions unchanged for all pairwise comparisons (results not shown). 
7.1.2  Investigation of consistency  
As outlined in Chapter 1.1.2, the key assumption made in NMA is that average treatment 
effect is "exchangeable" across all included trials. Due to the clinical perception of a clinical 
(and potentially statistical) interaction between treatment effect and epilepsy type within 
this network, judgements of exchangeability were made separately by epilepsy type. 
In the context of the present network, transitivity requires that all treatments are "jointly 
randomisable;" given that all of the ten drugs within this network are licenced and commonly 
used as monotherapy treatments for individuals with newly diagnosed partial-onset seizures 
or generalised-onset tonic-clonic seizures (with or without other generalised seizure types) 
and have all been used within trials of similar designs, there were no concerns over 
transitivity in this network. 
The consistency assumption can be evaluated statistically comparing the difference between 
the direct treatment effect estimate and the indirect estimate for each loop of evidence. In 
general, methods for evaluating inconsistency take either a ‘local’ or ‘global’ approach; the 
former approach is loop specific, focusing on inconsistency within each specific treatment 
comparison while the latter approach evaluates the presence of inconsistency across the 
entire network of evidence [18]. A recent literature review of NMA methodology 
recommends the use of both ‘local’ and ‘global’ methods, where possible, to gain a better 
understanding of both the plausibility of the consistency assumption in the network as a 
whole and also the sources of possible discrepancies within the network [18]. 
Given the complexity of the network model fitted (with treatment-by-epilepsy type 
interaction) and the number of multi-arm trials included in analysis, two methods were used 
to evaluate inconsistency within this network. Firstly, node-splitting was performed via the 
‘network sidesplit’ command in Stata [310, 315]; this ‘local’ method separates evidence from 
a particular comparison (node) into direct and indirect, allowing for formal comparison of 
difference between direct (pairwise), indirect and NMA (direct and indirect evidence 
combined) estimates. Secondly, a ‘design-by-treatment’ inconsistency model was fitted via 
the ‘network meta inconsistency’ command in Stata [310, 316]; a ‘global’ method which 
evaluates both loop and design inconsistencies, particularly within multi-arm trials. For 
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example, the A versus B treatment effect in a study comparing only treatments A and B (i.e. 
an AB design) may vary from the A versus B effect in a three arm study of an ABC design [18].  
Here a ‘design’ was classified to reflect both the treatment comparisons made in the study 
and the epilepsy types recruited within the trial. For example, a trial of CBZ compared to LTG 
in individuals with partial-onset seizures only was considered to be a different design to a 
trial of CBZ compared to LTG recruiting individuals of both epilepsy types.  
For investigation of inconsistency via node-splitting, treatment effect estimates are 
presented graphically for direct evidence (pairwise meta-analysis from the trials which make 
direct comparisons of the pair of drugs), indirect evidence (from the node-splitting model 
which makes indirect comparisons from the trials which do not make a direct comparison of 
the pair of drugs) and direct plus indirect evidence (from NMA model of the whole network) 
for each pairwise comparison.   Numerical results for direct evidence, indirect evidence and 
NMA results for each pairwise comparison were examined, particularly the overlap of CIs of 
the estimate. It would be expected that numerical results for the NMA would be the most 
precise as the largest amount of data contributes to these analyses and due to the ‘borrowing 
of strength’ across the network. P-values and heterogeneity statistics are also presented 
from ‘design-by-treatment’ inconsistency models for each outcome. 
Potentially important inconsistency was noted to be present if the global test for 
inconsistency from the ‘design-by treatment’ model was statistically significant and/or where 
CIs of results from direct evidence and NMA results do not overlap (i.e. there is a statistically 
significant difference between pairwise and NMA results). If deemed present, potential 
origins of inconsistency were investigated. Also, while of less concern than the potential 
inconsistency described above, it was also noted where CIs of results from indirect evidence 
did not overlap with the CIs of the direct and NMA estimates and reasons for any numerical 
differences in results were considered. 
7.1.3  Additional analyses and sensitivity analyses 
As outlined in Chapter 5.3.2, a range of participant covariates (including age, sex, seizure 
history, EEG and scan results) were requested in addition to outcome data in all IPD requests 
in order to explore these covariates as potential modifiers of treatment effect and as 
potential sources of heterogeneity and/or inconsistency. However,  due to large proportions 
of missing data and variability in the definitions of data provided for most of these covariates 
(see Chapter 5.4.3 for further details), adjusted analyses with all covariates of interest was 
deemed not appropriate.  
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Age at randomisation was provided for the majority of participants (99% of total eligible 
participants) and previous Cochrane IPD-MAs have shown an association between age and 
treatment effect for commonly used drugs CBZ, VPS and LTG [61, 67]. Therefore, an 
additional analysis was performed adjusting for age at randomisation where an additional 
interaction term of treatment-by-age (centred by mean age of participants in each trial) was 
added to the initial Cox PH model (described in Chapter 6.2.3). NMA was repeated and results 
compared to those from the primary analysis (without age). 
A range of sensitivity analyses were conducted to examine the robustness of results to 
assumptions made in pairwise and NMA: 
 Trial-specific treatment effects were estimated via a Cox PH model (see Chapter 6.2.3). 
To assess the validity of the PH assumption, the statistical significance of time-varying 
covariates for all covariates in the model were tested. If there was indication that the 
PH assumption has been violated, in sensitivity analysis, for the 𝑖𝑡ℎ participant in the 𝑗𝑡ℎ 
trial, a parametric accelerated failure time (AFT) model, stratified by trial, was fitted to 
the entire individual participant dataset:    
ℎ𝑖𝑗(𝑡) = ℎ0𝑗(𝑡/exp (𝜑𝑖𝑗)𝑒𝑥𝑝(−𝜑𝑖𝑗)   (Equation 42) 
Where  𝜑𝑖𝑗 = (𝛼2𝑗𝑥2𝑖𝑗 + …+ 𝛼10𝑗𝑥10𝑖𝑗) + 𝑧𝑖𝑗 (𝜋𝑗 + 𝛾2𝑗𝑥2𝑖𝑗 + … + 𝛾9𝑗𝑥9𝑖𝑗) 
Other parameters are defined as in Equation 31, outlined in Chapter 6.2.3. NMA was 
repeated according to the methods outlined in Chapter 6.2.5 and results were compared 
to those from the primary analysis with the Cox PH model. 
 As outlined in Chapter 5.3.3, where minor inconsistencies remained in IPD provided 
following clarification from data providers, sensitivity analyses were conducted.  Details 
of inconsistencies identified in IPD and sensitivity analyses conducted to account for 
these inconsistencies are presented in Appendix 14. 
 Misclassification of epilepsy type is a recognised problem in epilepsy; whereby some 
individuals with partial seizures have been mistakenly classed as having generalised-
onset seizures and vice versa. Such a misclassification has impacted on results of 
previous Cochrane IPD-MAs [66, 67]. Clinical evidence suggests that individuals with 
generalised-onset seizures are unlikely to have an 'age of onset' greater than 25 to 30 
years [317]; out of the 12,371 participants with IPD provided for analysis, 1,164 (9%) 
were classified as experiencing generalised seizures and had an estimated age of onset 
as greater than 30 years.  Two sensitivity analyses were performed to investigate the 
impact of potential misclassification: 
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o Re-classification of 1,164 individuals with generalised seizures and age of onset over 
30 years as having partial-onset seizures. NMA was then repeated with the 
interaction term of treatment-by-epilepsy type with the reclassified epilepsy type. 
o Re-classification of 1,164 individuals with generalised seizure and age at onset over 
30 years and 574 participants with missing epilepsy type into an 'unclassified 
epilepsy type' group. NMA was then repeated with the interaction term of 
treatment-by-epilepsy type where epilepsy type is partial epilepsy compared to 
generalised or unclassified epilepsy.  
It was not possible to achieve convergence of NMA with a 'three-way' interaction (i.e. partial 
epilepsy compared to generalised epilepsy compared to unclassified epilepsy). This is likely 
due to small numbers of participants with unclassified epilepsy and with generalised epilepsy 
following reclassification) receiving some AEDs.  
7.2  Results  
For brevity, results for ‘Time-to-withdrawal of allocated treatment’ and ‘Time-to-first seizure’ 
only are reported within this Chapter. Numerical results for the two remission outcomes can 
be found in Appendix 15 of this thesis and further discussion of the clinical implications of 
these results within the published Cochrane IPD-NMA [69]. 
All tables and figures of NMA results indicate the proportion of the treatment effect estimate 
which is contributed by direct evidence (ranging from 0% where no direct comparison exists 
to 100% for the CBZ vs ZNS comparison which is disconnected from the rest of the network, 
see Figure 12). These proportions were determined from a ‘contribution plot’ (derived via 
the ‘netweight’ command in Stata version 14), described by Chaimani et al [299].  It should 
be noted that due to a limited amount of evidence for individuals with generalised seizures 















CBZ PHB PHT VPS LTG OXC TPM GBP LEV ZNS Total 










































































































































































































































































































24 7 1 26 12 8 14 11 0 0 103 
Total5 
 
3258 320 863 1680 1978 478 1158 595 1253 282 11,865 
 
1. Other treatment related reasons included: Physician’s decision, drug-related death, pregnancy or perceived remission or non-specific (drug related) reason. 
2. Other non-treatment related reasons included: epilepsy diagnosis changed, participants developed other medical disorders including neurological and psychiatric 
disorders or non-specific (non-drug related) reason. 
3. Proportions for specific reasons indicate proportion of total events or total censored. Proportion for total events and total censored indicate the proportion of total 
participants. 
4. Those with missing reason for withdrawal were primarily classified as censored in analysis and performed a sensitivity analysis treating these individuals as having 
withdrawal 'events.' Results of sensitivity analysis were practically identical and conclusions unchanged. 
5. Four studies did not contribute to analysis of time-to-withdrawal of allocated treatment.  
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7.2.1  Primary outcome: Time-to-withdrawal of allocated treatment 
11,865 out of 12,391 participants (96%) contributed to analysis of 'Time-to-withdrawal of 
allocated treatment'. Withdrawal information was not available for three trials and all 
participants completed follow-up in one trial so 'Time-to-withdrawal of allocated treatment' 
could not be calculated for four trials (4% of participants with IPD provided).   
Table 18 shows the reported reasons for premature withdrawal from the trial and these 
reasons were classified in analysis. In some instances, participants many have withdrawn 
from treatment for a combination of reasons. For the purpose of analysis a judgement was 
made regarding the primary reason for withdrawal (see Chapter 5.3.3.2 for further details of 
classification). It should be noted that the information reported in Table 18 does not take 
account of randomisation within trials and should be interpreted as exploratory. 
Out of 11865 individuals, 4058 (34%) prematurely withdrew and 7704 were censored in 
analysis (65%). For 103 participants, reason for withdrawal was missing (ranging by drug from 
0 participants (LEV and ZNS) to 26 participants (VPS)). We treated those with missing reason 
for withdrawal as censored in analysis and performed a sensitivity analysis treating these 
individuals as having withdrawal 'events'. Results of sensitivity analysis were practically 
identical and conclusions unchanged (results not presented for brevity), therefore these 
individuals are censored in results presented.  
7.2.1.1  Direct evidence 
Table 19 (individuals with partial seizures) and Table 20 (individuals with generalised 
seizures) show the number of trials and participants contributing direct evidence for each of 
the pairwise comparisons in the network. Results highlighted in bold indicate statistically 
significant results and HR <1 indicates an advantage to the second drug in the comparison. 
All results presented are calculated with fixed-effects. 
Twenty out of 45 comparisons had no direct evidence for individuals with partial seizures. 
Thirteen out of 36 comparisons had no direct evidence for individuals with generalised 
seizures and eight comparisons for individuals with generalised seizures had less than 20 
individuals contributing direct evidence resulting in wide CIs around the treatment effect 
estimate. Comparisons with the most participants contributing to analysis were CBZ vs LTG 
and CBZ vs LEV (partial seizures) and VPS vs LEV and VPS vs TPM (generalised seizures). 
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Table 19: Pairwise and network meta-analysis results - Time-to-withdrawal of allocated 
treatment for individuals with partial seizures 
Comparision1 Direct Evidence  
(Pairwise meta-analysis) 





HR (95% CI)2,3 I² (%) Proportion 
of direct 
evidence5 
HR (95% CI)2,3 
CBZ vs PHB 4 (520) 1.57 (1.16 to 2.13) 0% 52.50% 1.55 (1.18 to 2.04) 
CBZ vs PHT 3 (428) 1.03 (0.74 to 1.42) 63.6% 12.80% 1.13 (0.92 to 1.38) 
CBZ vs VPS 5 (814) 0.94 (0.73 to 1.19) 0% 40.10% 1.04 (0.86 to 1.25) 
CBZ vs LTG 9 (2268) 0.76 (0.61 to 0.95) 39.3% 28.90% 0.75 (0.65 to 0.86) 
CBZ vs OXC 2 (562) 4.62 (0.95 to 22.4) 0% 5.70% 1.09 (0.84 to 1.42) 
CBZ vs TPM 2 (937) 1.04 (0.52 to 2.07) 0% 7.40% 1.18 (0.98 to 1.43) 
CBZ vs GBP 2 (954) 1.14 (0.84 to 1.55) 0% 87.10% 1.20 (1.00 to 1.43) 
CBZ vs LEV 3 (1567) 0.70 (0.52 to 0.94) 0% 37.90% 0.82 (0.69 to 0.97) 
CBZ vs ZNS 1 (583) 1.08 (0.81 to 1.44) NA4 100% 1.08 (0.79 to 1.48) 
PHB vs PHT 3 (404) 0.67 (0.50 to 0.91) 65% 15.20% 0.73 (0.55 to 0.96) 
PHB vs VPS 2 (75) 0.68 (0.34 to 1.36) 23% 8.80% 0.67 (0.48 to 0.92) 
PHB vs LTG No direct evidence 0% 0.48 (0.35 to 0.66) 
PHB vs OXC No direct evidence 0% 0.70 (0.48 to 1.03) 
PHB vs TPM No direct evidence 0% 0.76 (0.55 to 1.06) 
PHB vs GBP No direct evidence 0% 0.77 (0.55 to 1.07) 
PHB vs LEV No direct evidence 0% 0.53 (0.38 to 0.73) 
PHB vs ZNS No direct evidence 0% 0.70 (0.46 to 1.06) 
PHT vs VPS 4 (168) 1.00 (0.60 to 1.64) 58.5% 9% 0.92 (0.70 to 1.21) 
PHT vs LTG 1 (90) 1.10 (0.57 to 2.14) NA 11.60% 0.66 (0.52 to 0.85) 
PHT vs OXC 2 (325) 0.65 (0.32 to 1.32) 0% 40.40% 0.97 (0.69 to 1.35) 
PHT vs TPM 1 (53) 0.77 (0.38 to 1.57) NA 10.90% 1.05 (0.80 to 1.39) 
PHT vs GBP No direct evidence 0% 1.06 (0.81 to 1.40) 
PHT vs LEV No direct evidence 0% 0.73 (0.56 to 0.95) 
PHT vs ZNS No direct evidence 0% 0.96 (0.66 to 1.39) 
VPS vs LTG* 3 (221) 1.40 (1.00 to 1.96) 45.1% 5.10% 0.72 (0.58 to 0.90) 
VPS vs OXC No direct evidence 0% 1.05 (0.76 to 1.44) 
VPS vs TPM 2 (111) 1.66 (1.24 to 2.23) 48.1% 33.70% 1.14 (0.88 to 1.48) 
VPS vs GBP No direct evidence 0% 1.15 (0.89 to 1.49) 
VPS vs LEV 1 (190) 1.14 (0.73 to 1.75) NA 17.20% 0.79 (0.61 to 1.03) 
VPS vs ZNS No direct evidence 0% 1.04 (0.73 to 1.50) 
LTG vs OXC 1 (506) 0.69 (0.12 to 4.14) NA 4.40% 1.46 (1.11 to 1.92) 
LTG vs TPM 1 (648) 1.18 (0.86 to 1.62) NA 20.90% 1.59 (1.29 to 1.95) 
LTG vs GBP 1 (659) 0.62 (0.06 to 6.01) NA 1% 1.60 (1.31 to 1.96) 
LTG vs LEV 1 (240) 0.86 (0.58 to 1.28) NA 23.70% 1.10 (0.89 to 1.35) 
LTG vs ZNS No direct evidence 0% 1.45 (1.03 to 2.04) 
OXC vs TPM 1 (496) 0.87 (0.16 to 4.73) NA 4.90% 1.09 (0.82 to 1.44) 
OXC vs GBP 1 (507) 0.90 (0.08 to 9.96) NA 2.30% 1.10 (0.83 to 1.45) 
OXC vs LEV No direct evidence 0% 0.75 (0.55 to 1.03) 
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OXC vs ZNS No direct evidence 0% 0.99 (0.66 to 1.49) 
TPM vs GBP 1 (649) 1.04 (0.12 to 9.33) NA 1.10% 1.01 (0.82 to 1.25) 
TPM vs LEV No direct evidence 0% 0.69 (0.54 to 0.89) 
TPM vs ZNS No direct evidence 0% 0.91 (0.64 to 1.31) 
GBP vs LEV No direct evidence 0% 0.69 (0.54 to 0.88) 
GBP vs ZNS No direct evidence 0% 0.90 (0.63 to 1.30) 
LEV vs ZNS No direct evidence 0% 1.32 (0.93 to 1.88) 
1. Order of drugs in the table: most commonly used drug first (CBZ), then drugs are ordered 
approximately by the date they were licenced as a monotherapy treatment (oldest first). 
2. HRs and 95% CIs are calculated from fixed-effects analyses.  
3. HR<1 indicates an advantage to the second drug in the comparison; results in highlighted in bold 
are statistically significant. 
4. NA - heterogeneity is not applicable as only one study contributes direct evidence. 
5. Proportion of the estimate contributed by direct evidence (see Chaimani et al [299]) . 
Comparisons marked with a *, confidence intervals of direct evidence and network meta-analysis do 
not overlap indicating the inconsistency may be present in the results. 
Table 19 and Table 20 also show heterogeneity in the direct treatment effects. No substantial 
heterogeneity was present (I2 greater than 50%) for any comparison for individuals with 
generalised seizures. For three comparisons for individuals with partial seizures, substantial 
heterogeneity was present (I2 greater than 50%). The heterogeneity in these comparisons 
seemed to originate from difference in trial designs contributing to the pooled result; i.e. 
pooling of trials recruiting children only, adults only or elderly participants only and pooling 
of double-blind and open label trials (previous pairwise Cochrane Epilepsy IPD reviews in this 
series have discussed the importance of blinding to the outcome of time-to-withdrawal of 
allocated treatment) [61, 318]. Repeating analysis with random-effects did not change 
conclusions for two of the comparisons (CBZ vs PHT and PHT vs VPS) but for one comparison 
(PHB vs PHT), when repeating analysis with random-effects there was no longer a statistically 









Table 20: Pairwise and network meta-analysis results - Time-to-withdrawal of allocated 
treatment for individuals with generalised seizures 
Comparision1 Direct Evidence  
(Pairwise meta-analysis) 





HR (95% CI)2,3 I2 (%) Proportion 
of direct 
evidence5 
HR (95% CI)2,3 
CBZ vs PHB 3 (156) 1.21 (0.51 to 2.86) 11.8% 27.30% 1.47 (0.83 to 2.61) 
CBZ vs PHT 2 (118) 2.68 (0.95 to 7.57) 0% 11.30% 0.92 (0.59 to 1.42) 
CBZ vs VPS 4 (405) 1.26 (0.73 to 2.20) 6.6% 27.30% 0.70 (0.54 to 0.92) 
CBZ vs LTG 7 (302) 1.23 (0.72 to 2.10) 0% 39.20% 0.63 (0.45 to 0.89) 
CBZ vs OXC 1 (9) 0.39 (0.03 to 4.35) NA4 3.90% 1.00 (0.21 to 4.81) 
CBZ vs TPM 2 (101) 1.10 (0.51 to 2.36) 0% 23.20% 1.24 (0.90 to 1.71) 
CBZ vs GBP 1 (6) 0.49 (0.03 to 7.90) NA 8.50% 0.90 (0.11 to 7.29) 
CBZ vs LEV 2 (251) 1.22 (0.74 to 2.02) 0% 57% 0.74 (0.44 to 1.23) 
PHB vs PHT 2 (95) 1.56 (0.49 to 4.99) 0% 16.10% 0.62 (0.32 to 1.24) 
PHB vs VPS 2 (94) 0.56 (0.20 to 1.54) 0% 19.40% 0.48 (0.27 to 0.86) 
PHB vs LTG No direct evidence 0% 0.43 (0.22 to 0.83) 
PHB vs OXC No direct evidence 0% 0.68 (0.13 to 3.60) 
PHB vs TPM No direct evidence 0% 0.84 (0.44 to 1.60) 
PHB vs GBP No direct evidence 0% 0.61 (0.07 to 5.34) 
PHB vs LEV No direct evidence 0% 0.50 (0.23 to 1.09) 
PHT vs VPS 3 (326) 0.66 (0.30 to 1.45) 22.6% 19.30% 0.77 (0.46 to 1.27) 
PHT vs LTG 1 (91) 1.11 (0.42 to 2.94) NA 14.90% 0.69 (0.39 to 1.20) 
PHT vs OXC 2 (155) 1.05 (0.44 to 2.52) 0% 37.90% 1.09 (0.21 to 5.56) 
PHT vs TPM 1 (150) 1.68 (0.49 to 5.69) NA 11.20% 1.35 (0.79 to 2.30) 
PHT vs GBP No direct evidence 0% 0.98 (0.12 to 8.30) 
PHT vs LEV No direct evidence 0% 0.80 (0.42 to 1.55) 
VPS vs LTG 3 (387) 0.46 (0.22 to 0.97) 0% 14.80% 0.90 (0.60 to 1.35) 
VPS vs OXC No direct evidence 0% 1.42 (0.29 to 6.92) 
VPS vs TPM* 2 (443) 0.53 (0.27 to 1.07) 48.5% 22.40% 1.76 (1.22 to 2.53) 
VPS vs GBP No direct evidence 0% 1.28 (0.16 to 10.5) 
VPS vs LEV 1 (512) 0.68 (0.30 to 1.59) NA 18.60% 1.05 (0.58 to 1.90) 
LTG vs OXC 1 (10) 2.09 (0.34 to 12.8) NA 7.60% 1.58 (0.33 to 7.67) 
LTG vs TPM 1 (14) 1.10 (0.42 to 2.89) NA 7.30% 1.96 (1.25 to 3.08) 
LTG vs GBP 1 (7) 2.63 (0.27 to 25.7) NA 13.80% 1.42 (0.17 to 11.6) 
LTG vs LEV No direct evidence 0% 1.17 (0.63 to 2.19) 
OXC vs TPM 1 (14) 1.31 (0.24 to 7.32) NA 9% 1.24 (0.26 to 5.94) 
OXC vs GBP 1 (7) 1.26 (0.11 to 14.1) NA 12.70% 0.90 (0.08 to 9.96) 
OXC vs LEV No direct evidence 0% 0.74 (0.14 to 3.86) 
TPM vs GBP 1 (11) 0.96 (0.11 to 8.67) NA 14.60% 0.73 (0.09 to 5.89) 
TPM vs LEV No direct evidence 0% 0.60 (0.33 to 1.09) 
GBP vs LEV No direct evidence 0% 0.82 (0.10 to 7.10) 
1. See Table 19 for details of footnotes 
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7.2.1.2  NMA results (direct plus indirect evidence) 
Figure 13 shows how each AED performs compared to first-line treatment CBZ for individuals 
with partial seizures (ordered by treatment effect estimate); LTG and LEV are significantly 
better than CBZ and CBZ is significantly better than GBP and PHB. Figure 14 shows how each 
AED performs compared to first-line treatment LTG for individuals with partial seizures 
(ordered by treatment effect estimate); LTG is significantly better than all AEDs except for 
LEV. Figure 15 shows how each AED performs compared to first-line treatment VPS for 
individuals with generalised seizures (ordered by treatment effect estimate); VPS is 
significantly better than CBZ, TPM and PHB. 
Table 19 and Table 20 (above) show treatment effect estimates for all pairwise comparisons 
in the network combining direct with indirect evidence (NMA). In addition to the 
performance of the AEDs compared to the first-line treatments (as described above), for 
individuals with partial seizures, LEV seems to perform better than most other AEDs and for 
individuals with generalised seizures, LTG seems to perform better than most other AEDs. 
For both individuals with partial seizures and individuals with generalised seizures, PHB 
seems to perform worse than most other AEDs. 
Figure 13: All AEDs compared to carbamazepine (CBZ) for time to treatment withdrawal, 





Figure 14: All AEDs compared to lamotrigine (LTG) for time to treatment withdrawal, 
individuals with partial seizures 
 
Figure 15: All AEDs compared to sodium valproate (VPS) for time to treatment 





As described in Chapter 6.2.5., an I2 statistic could not be directly calculated for the NMA but 
could be estimated. The estimated I2 statistic was 11.7% and when repeating NMA with 
random-effects, calculated the τ2 statistic was 0.0037. Numerical results for treatment effects 
were very similar (the same to one decimal place, results not presented) and conclusions 
remained unchanged. Therefore, if any heterogeneity is present within this NMA, the impact 
upon results is negligible. 
7.2.1.3  Investigation of inconsistency  
The ‘design-by-treatment’ inconsistency model was fitted to 17 variables and regressed on 
23 designs, five of which were multi-arm trials (up to five treatment arms). Accounting for 
the multi-arm trials, this resulted in a 𝜒2 test for inconsistency with 36 degrees of freedom 
which was not significant: (𝜒2 (36) = 45.6, p-value = 0.131, heterogeneity (τ) = 5.65 x 10-10). 
Notably, for most pairwise comparisons, numerical results of direct evidence and NMA are 
similar, mostly in the same direction and CIs of estimates overlap. For all pairwise 
comparisons, results from NMA are more precise than results from direct evidence (in some 
cases, much more precise where limited direct evidence exists, for example, see CBZ 
compared to OXC, Appendix 16, Figure 36).  For the following comparisons, conclusions 
drawn from direct evidence and from NMA are different (see Table 19 and Table 20): 
 Direct evidence shows a significant advantage to one of the AEDs and the NMA results 
show no significant difference between the AEDs: VPS vs TPM (partial seizures) 
 Direct evidence shows no significant difference between the AEDs and NMA shows a 
significant advantage for one of the AEDs: CBZ vs GBP, LTG vs OXC, LTG vs TPM, LTG vs 
GBP (all partial seizures); CBZ vs VPS, CBZ vs LTG, PHB vs VPS, VPS vs TPM, LTG vs TPM 
(all generalised seizures) 
 No direct evidence exists between the AEDs while NMA shows a significant advantage 
for one of the AEDs: PHB vs LTG, PHB vs LEV, LTG vs ZNS, TPM vs LEV, GBP vs LEV (all 
partial seizures); PHB vs LTG (generalised seizures) 
For the following comparisons; CIs for the results from indirect evidence do not overlap with 
(see Appendix 16): 
 Direct evidence: CBZ vs PHT (generalised seizures), PHB vs PHT (generalised seizures). 




For the following comparisons; CIs for the results from direct evidence and from NMA do not 
overlap which indicates potential inconsistency is present (see Table 19 and Table 20, results 
marked with *): VPS vs LTG (partial seizures), VPS vs TPM (generalised seizures). 
For the comparison of VPS vs LTG for individuals with partial seizures, from direct evidence 
only, there is a statistically significant advantage to VPS (HR 1.40 (1.00 to 1.96), however from 
the NMA results, the direction of effect changes to a statistically significant advantage to LTG 
(HR 0.72 (0.58 to 0.90)). However, for this comparison, only 5.1% of the network estimate is 
contributed from direct evidence and a moderate amount of heterogeneity is present in this 
estimate (I2=45%), likely due to variability in the trial design of the three trials contributing 
to this estimate (for example, one trial was designed to only recruit individuals with 
generalised or unclassified seizures but did recruit a small number of individuals with partial 
seizures who contribute to this outcome) [264].  
For the comparison of VPS vs TPM for individuals with generalised seizures, from direct 
evidence, there is no significant difference between the drugs (HR 0.53 (0.27 to 1.07)), 
however from the NMA results, a statistically significant advantage is shown for VPS (HR 1.76 
(1.22 to 2.53)). As above, for this comparison, only 22.4% of the network estimate is 
contributed from direct evidence and a moderate amount of heterogeneity is present in this 
estimate (I2=48.5%). Again, this heterogeneity is likely due to difference in trial design of the 
two trials contributing direct evidence (see characteristics of Privitera et al [304] for details 
of stratification). 
Furthermore, the 'design-by treatment' inconsistency model does not show any significant 
evidence of inconsistency within the network. Therefore, we are not concerned about any 
impact of this observed inconsistency of numerical results on the conclusions of the review. 
7.2.2  Secondary outcome: Time-to-first seizure after randomisation 
12,152 out of 12,391 participants (98%) contributed to analysis of 'Time-to-first seizure post-
randomisation.' For 239 participants (2%) seizure dates after randomisation were missing so 




7.2.2.1  Direct evidence 
Table 21 (individuals with partial seizures) and Table 22 (individuals with generalised 
seizures) show the number of trials and participants contributing direct evidence for each of 
the pairwise comparisons in the network. Results highlighted in bold indicate statistically 
significant results and HR <1 indicates an advantage to the second drug in the comparison. 
All results presented are calculated with fixed-effects. 
Twenty out of 45 comparisons had no direct evidence for individuals with partial seizures. 
Thirteen out of 36 comparisons had no direct evidence for individuals with generalised 
seizures and eight comparisons for individuals with generalised seizures had less than 20 
individuals contributing direct evidence resulting in wide CIs around the treatment effect 
estimate. Comparisons with the most participants contributing to analysis were CBZ vs LTG 
and CBZ vs LEV (partial seizures) and VPS vs LEV and VPS vs TPM (generalised seizures). 
Table 21: Pairwise and network meta-analysis results - Time-to-first seizure for individuals 
with partial seizures 
Comparision1 Direct Evidence  
(Pairwise meta-analysis) 





HR (95% CI)2,3 I² (%)  Proportion 
of direct 
evidence5 
HR (95% CI)2,3 
CBZ vs PHB 6 (581) 0.99 (0.78 to 1.26) 54.3% 21% 0.79 (0.64 to 0.97) 
CBZ vs PHT 4 (432) 0.91 (0.72 to 1.16) 16.1% 27.10% 0.98 (0.85 to 1.13) 
CBZ vs VPS 5 (813) 1.01 (0.86 to 1.19) 32% 34.60% 1.20 (1.06 to 1.37) 
CBZ vs LTG 9 (2252) 0.98 (0.75 to 1.27) 0% 40.70% 1.29 (1.17 to 1.42) 
CBZ vs OXC 2 (555) 1.47 (0.57 to 3.81) 57.3% 4.80% 1.09 (0.89 to 1.32) 
CBZ vs TPM 2 (925) 1.03 (0.51 to 2.08) 69.3% 1.50% 1.12 (0.97 to 1.29) 
CBZ vs GBP 2 (943) 1.64 (1.14 to 2.36) 17.7% 49% 1.44 (1.25 to 1.66) 
CBZ vs LEV 3 (1552) 1.18 (0.85 to 1.65) 0% 26.20% 1.14 (0.99 to 1.30) 
CBZ vs ZNS 1 (581) 1.30 (0.97 to 1.73) NA4 100% 1.30 (0.97 to 1.73) 
PHB vs PHT 5 (463) 1.07 (0.83 to 1.37) 27.7% 33.60% 1.24 (0.99 to 1.56) 
PHB vs VPS* 2 (80) 0.71 (0.43 to 1.17) 9.10% 12.80% 1.53 (1.20 to 1.94) 
PHB vs LTG No direct evidence 0% 1.63 (1.30 to 2.06) 
PHB vs OXC No direct evidence 0% 1.38 (1.04 to 1.83) 
PHB vs TPM No direct evidence 0% 1.42 (1.11 to 1.83) 
PHB vs GBP No direct evidence 0% 1.83 (1.42 to 2.35) 
PHB vs LEV No direct evidence 0% 1.44 (1.12 to 1.85) 
PHB vs ZNS No direct evidence 0% 1.64 (1.15 to 2.35) 
PHT vs VPS 5 (245) 0.96 (0.72 to 1.29) 0% 25.40% 1.23 (1.02 to 1.48) 
PHT vs LTG 1 (90) 0.77 (0.38 to 1.54) NA 6% 1.31 (1.10 to 1.57) 
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PHT vs OXC 2 (318) 1.46 (0.88 to 2.44) 23.9% 36.10% 1.11 (0.87 to 1.41) 
PHT vs TPM 1 (53) 2.32 (0.95 to 5.70) NA 4% 1.14 (0.93 to 1.40) 
PHT vs GBP No direct evidence 0% 1.47 (1.20 to 1.80) 
PHT vs LEV No direct evidence 0% 1.16 (0.95 to 1.41) 
PHT vs ZNS No direct evidence 0% 1.32 (0.96 to 1.82) 
VPS vs LTG 3 (215) 1.57 (1.23 to 2.00) 39.4% 10% 1.07 (0.92 to 1.24) 
VPS vs OXC No direct evidence 0% 0.90 (0.72 to 1.14) 
VPS vs TPM 2 (111) 1.18 (0.93 to 1.50) 0% 70.20% 0.93 (0.77 to 1.13) 
VPS vs GBP No direct evidence 0% 1.20 (0.99 to 1.44) 
VPS vs LEV 1 (190) 1.27 (0.94 to 1.72) NA 31% 0.94 (0.77 to 1.15) 
VPS vs ZNS No direct evidence 0% 1.08 (0.78 to 1.48) 
LTG vs OXC 1 (499) 0.87 (0.23 to 3.25) NA 5.50% 0.84 (0.69 to 1.03) 
LTG vs TPM 1 (636) 0.73 (0.57 to 0.93) NA 2.30% 0.87 (0.75 to 1.01) 
LTG vs GBP 1 (647) 0.63 (0.07 to 5.42) NA 4.40% 1.12 (0.96 to 1.30) 
LTG vs LEV 1 (229) 0.84 (0.53 to 1.35) NA 15.90% 0.88 (0.75 to 1.04) 
LTG vs ZNS No direct evidence 0% 1.01 (0.74 to 1.36) 
OXC vs TPM 1 (487) 0.55 (0.15 to 2.06) NA 5.40% 1.03 (0.84 to 1.27) 
OXC vs GBP 1 (498) 0.73 (0.08 to 6.49) NA 4.60% 1.32 (1.08 to 1.63) 
OXC vs LEV No direct evidence 0% 1.05 (0.83 to 1.32) 
OXC vs ZNS No direct evidence 0% 1.19 (0.84 to 1.69) 
TPM vs GBP 1 (635) 1.31 (0.15 to 11.2) NA 3.50% 1.28 (1.09 to 1.51) 
TPM vs LEV No direct evidence 0% 1.01 (0.83 to 1.23) 
TPM vs ZNS No direct evidence 0% 1.15 (0.84 to 1.59) 
GBP vs LEV No direct evidence 0% 0.79 (0.65 to 0.96) 
GBP vs ZNS No direct evidence 0% 0.90 (0.65 to 1.24) 
LEV vs ZNS No direct evidence 0% 1.14 (0.83 to 1.57) 
1. See Table 19 for details of footnotes 
Table 21 and Table 22 also show heterogeneity in the direct treatment effects. For three 
comparisons for individuals with partial seizures and for three comparisons for individuals 
with generalised seizures, substantial heterogeneity was present (I2 greater than 50%). The 
heterogeneity in these comparisons seemed to originate from differences in trial designs 
contributing to the pooled result; i.e. pooling of trials recruiting different age groups and 
pooling trials with or without treatment strata (see Chapter 5.2.3.4 for further details).  
For the comparisons for individuals with partial seizures, none of the treatment effects with 
substantial heterogeneity present were statistically significant so conclusions would not 
change if random-effects were applied. For the comparisons for individuals with generalised 
seizures, repeating analysis with random-effects did not change conclusions for two of the 
comparisons (CBZ vs VPS and PHT vs VPS) but for one comparison (CBZ vs PHB), when 
repeating analysis with random-effects there was no longer a statistically significant 
advantage to PHB: HR 0.59 (0.27 to 1.26). 
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Table 22: Pairwise and network meta-analysis results - Time-to-first seizure for individuals 
with partial seizures 
Comparision1 Direct Evidence  
(Pairwise meta-analysis) 





HR (95% CI)2,3 I² (%) Proportion 
of direct 
evidence5 
HR (95% CI)2,3 
CBZ vs PHB 5 (237) 0.55 (0.33 to 0.92) 50.4% 35.50% 1.10 (0.80 to 1.51) 
CBZ vs PHT 3 (150) 0.88 (0.51 to 1.54) 0% 26.60% 0.76 (0.59 to 0.98) 
CBZ vs VPS 4 (411) 1.37 (0.98 to 1.92) 84.1% 10.40% 0.88 (0.76 to 1.03) 
CBZ vs LTG 7 (302) 1.49 (0.94 to 2.35) 0% 0.30% 0.98 (0.70 to 1.37) 
CBZ vs OXC 1 (9) 1.55 (0.38 to 6.31) NA4 9% 1.09 (0.36 to 3.36) 
CBZ vs TPM 2 (101) 1.19 (0.56 to 2.50) 62% 9% 1.15 (0.89 to 1.48) 
CBZ vs GBP 1 (6) 2.83 (0.31 to 25.5) NA 10.70% 0.79 (0.10 to 6.08) 
CBZ vs LEV 2 (251) 1.04 (0.65 to 1.64) 0% 44.90% 1.19 (0.78 to 1.83) 
PHB vs PHT 4 (161) 1.41 (0.76 to 2.62) 46.9% 20.30% 0.69 (0.48 to 1.00) 
PHB vs VPS 2 (98) 1.87 (0.87 to 4.00) 69.8% 6.50% 0.80 (0.57 to 1.12) 
PHB vs LTG No direct evidence 0% 0.89 (0.56 to 1.42) 
PHB vs OXC No direct evidence 0% 1.00 (0.31 to 3.20) 
PHB vs TPM No direct evidence 0% 1.05 (0.70 to 1.56) 
PHB vs GBP No direct evidence 0% 0.72 (0.09 to 5.68) 
PHB vs LEV No direct evidence 0% 1.09 (0.64 to 1.85) 
PHT vs VPS 4 (394) 1.11 (0.71 to 1.74) 0% 36.40% 1.16 (0.88 to 1.53) 
PHT vs LTG 1 (91) 1.00 (0.40 to 2.46) NA 16.20% 1.29 (0.85 to 1.97) 
PHT vs OXC 2 (154) 0.60 (0.33 to 1.10) 49.7% 25.20% 1.44 (0.46 to 4.56) 
PHT vs TPM 1 (150) 0.63 (0.18 to 2.26) NA 9.80% 1.51 (1.06 to 2.15) 
PHT vs GBP No direct evidence 0% 1.05 (0.13 to 8.14) 
PHT vs LEV No direct evidence 0% 1.57 (0.96 to 2.58) 
VPS vs LTG 3 (377) 0.64 (0.37 to 1.11) 23.2% 31.30% 1.11 (0.77 to 1.60) 
VPS vs OXC No direct evidence 0% 1.24 (0.40 to 3.84) 
VPS vs TPM* 2 (441) 0.42 (0.23 to 0.80) 46.4% 21% 1.30 (1.01 to 1.68) 
VPS vs GBP No direct evidence 0% 0.90 (0.12 to 6.92) 
VPS vs LEV 1 (512) 0.82 (0.48 to 1.40) NA 34% 1.35 (0.86 to 2.13) 
LTG vs OXC 1 (10) 0.94 (0.25 to 3.57) NA 12.20% 1.12 (0.36 to 3.48) 
LTG vs TPM 1 (14) 0.61 (0.28 to 1.30) NA 13.10% 1.17 (0.78 to 1.77) 
LTG vs GBP 1 (7) 1.72 (0.20 to 14.9) NA 11.90% 0.81 (0.11 to 6.25) 
LTG vs LEV No direct evidence 0% 1.22 (0.71 to 2.10) 
OXC vs TPM 1 (14) 1.90 (0.50 to 7.19) NA 13.60% 1.05 (0.34 to 3.24) 
OXC vs GBP 1 (7) 1.83 (0.20 to 16.5) NA 13.30% 0.73 (0.08 to 6.49) 
OXC vs LEV No direct evidence 0% 1.09 (0.33 to 3.62) 
TPM vs GBP 1 (11) 0.96 (0.11 to 8.29) NA 13.20% 0.69 (0.09 to 5.32) 
TPM vs LEV No direct evidence 0% 1.04 (0.63 to 1.71) 
GBP vs LEV No direct evidence 0% 1.50 (0.19 to 12.0) 
1. See Table 19 for details of footnotes 
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7.2.2.2  NMA results (direct plus indirect evidence) 
Figure 16 shows how each AED performs compared to first-line treatment CBZ for individuals 
with partial seizures (ordered by treatment effect estimate); PHB is significantly better than 
CBZ and CBZ is significantly better than VPS, LTG and GBP. Figure 17 shows how each AED 
performs compared to first-line treatment LTG for individuals with partial seizures (ordered 
by treatment effect estimate); PHB, PHT and CBZ are significantly better than LTG. Figure 18 
shows how each AED performs compared to first-line treatment VPS for individuals with 
generalised seizures (ordered by treatment effect estimate); VPS is significantly better than 
TPM. 
Table 21 and Table 22 (above) show treatment effect estimates for all pairwise comparisons 
in the network combining direct with indirect evidence (NMA). In addition to the 
performance of the AEDs compared to the first-line treatments (as described above); for 
individuals with partial seizures, PHB and PHT seems to perform better than most other drugs 
and for individuals with generalised seizures, PHT seems to perform better than most other 
drugs. There were few notable differences between the newer drugs (OXC, TPM, GBP, LEV 
and ZNS) for either individuals with partial seizures or generalised seizures. 
Figure 16: All AEDs compared to carbamazepine (CBZ) for time-to-first seizure, individuals 










Figure 18: All AEDs compared to sodium valproate (VPS) for time-to-first seizure, 






As described in Chapter 6.2.5, an I2 statistic could not be directly calculated for the NMA but 
could be estimated. The estimated I2 statistic was 0% and when repeating NMA with random-
effects, calculated the τ2 statistic was 9 x 10-21. As no heterogeneity was present and τ2 was 
negligible, numerical results for treatment effects and conclusions were identical. 
7.2.2.3  Investigation of inconsistency  
The ‘design-by-treatment’ inconsistency model was fitted to 17 variables and regressed on 
23 designs, seven of which were multi-arm trials (up to five treatment arms). Accounting for 
the multi-arm trials, this resulted in a 𝜒2 test for inconsistency with 43 degrees of freedom 
which was not significant (𝜒2 (43) = 38.2, p-value = 0.680, heterogeneity (τ) = 0.094). 
Notably, for most pairwise comparisons, numerical results of direct evidence and NMA are 
similar, mostly in the same direction and CIs of estimates overlap. For all pairwise 
comparisons, results from NMA are more precise than results from direct evidence (in some 
cases much more precise where limited direct evidence exists, for example see LTG 
compared to GBP, Appendix 16, Figure 39).  For the following comparisons; conclusions 
drawn from direct evidence and from NMA are different (see Table 21 and Table 22): 
 Direct evidence shows a significant advantage to one of the AEDs and the NMA results 
show no significant difference between the AEDs: VPS vs LTG (partial seizures); CBZ vs 
PHB (generalised seizures). 
 Direct evidence shows no significant difference between the AEDs and NMA shows a 
significant advantage for one of the AEDs: CBZ vs PHB, CBZ vs VPS, CBZ vs LTG, PHB vs 
VPS, PHT vs VPS, PHT vs LTG, OXC vs GBP (all partial seizures), CBZ vs PHT, PHB vs PHT 
(generalised seizures). 
 No direct evidence exists between the AEDs while NMA shows a significant advantage 
for one of the AEDs: PHB vs LTG, PHB vs OXC, PHB vs TPM, PHB vs GBP, PHB vs LEV, PHB 
vs ZNS, PHT vs GBP, GBP vs LEV (all partial seizures). 
CIs for the results from indirect evidence overlapped with the CIs from direct evidence and 
from NMA for all comparisons.  
For the following comparisons, CIs for the results from direct evidence and from NMA do not 
overlap which indicates potential inconsistency is present (see Table 21 and Table 22, results 
marked with *): PHB vs VPS (partial seizures), VPS vs TPM (generalised seizures). 
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For the comparison of PHB vs VPS for individuals with partial seizures, from direct evidence, 
there is no significant difference between the drugs (HR 0.71 (0.43 to 1.17)), however from 
the NMA results, a statistically significant advantage is shown for PHB (HR 1.53 (1.20 to 1.94)). 
For the comparison of PHB vs VPS for individuals with partial seizures, from direct evidence, 
there is no significant difference between the drugs (HR 0.71 (0.43 to 1.17)), however from 
the NMA results, a statistically significant advantage is shown for PHB (HR 1.53 (1.20 to 1.94)). 
For this comparison, only 12.8% of the network estimate is contributed from direct evidence 
and only 80 individuals contribute to this estimate. This small sample size and imprecision for 
the direct evidence is likely because VPS is not considered to be a first line treatment for 
partial seizures and although PHB is a broad spectrum agent for the treatment of many 
seizure types, it is no longer used as a first line treatment [68, 74].  
For the comparison of VPS vs TPM for individuals with generalised seizures, from direct 
evidence only, there is a statistically significant advantage to TPM (HR 0.42 (0.23 to 0.80)), 
however from the NMA results, the direction of effect changes to a statistically significant 
advantage to VPS (HR 1.30 (1.01 to 1.68)). Furthermore, for this comparison, only 21% of the 
network estimate is contributed from direct evidence and a moderate amount of 
heterogeneity is present in this estimate (I2=46%). The same two trials contribute evidence 
to this outcome as ‘time-to-withdrawal of allocated treatment’; see Chapter 7.2.1.3 for 
discussion of the differences in design of these trials. 
Furthermore, the 'design-by treatment' inconsistency model does not show any significant 
evidence of inconsistency within the network. Therefore, we are not concerned about any 
impact of this observed inconsistency of numerical results on the conclusions of the review. 
7.2.3  Additional analyses and sensitivity analyses 
Chapter 7.1.3 and Appendix 14  provide for full details and rationale of all additional analyses 
and sensitivity analyses conducted. For all additional analyses and sensitivity analyses, as in 
primary analysis, 95% CIs were very wide for some treatment comparisons for individuals 
with generalised seizures, due to small numbers of participants with generalised seizures 
randomised to some AEDs (such as GBP). 
Additional and sensitivity analyses (where appropriate) were also conducted on the two 
remission outcomes. There were no changes in conclusions following any of these analyses, 
see the Cochrane IPD-NMA for further discussion [69].  
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7.2.3.1  Age adjusted analysis 
An additional analysis was performed also adjusting for age in the original Cox PH model.  
Numerical results of these analyses were similar to results of the primary analysis; mostly the 
same to one or two decimal places for both individuals with partial seizures and individuals 
with generalised seizures.  There were some changes in direction of effect size and some 
changes in the order or 'rank' of AEDs compared to the reference treatment and there were 
a few changes in conclusions following this sensitivity analysis, most notably (see Appendix 
14; Figure 19 and Figure 20 for all numerical results): 
 For individuals with partial seizures, LEV was no longer significantly better than CBZ and 
CBZ became significantly better than TPM for ‘Time-to-withdrawal of allocated 
treatment.’  
 For individuals with generalised seizures, CBZ was no longer significantly better than LTG 
and VPS (but CBZ became significantly better than TPM) for ‘Time-to-withdrawal of 
allocated treatment.’ 
It should be noted that associations between age and treatment effect for commonly used 
AEDs have been shown in earlier Cochrane pairwise IPD-MAs and that age is also known to 
be associated with epilepsy type (and in turn with misclassification of epilepsy type) [67, 296]. 
Therefore, the results of this sensitivity analysis are likely to overlap with the results 
described below in Chapter 7.2.3.4. 
7.2.3.2  Validity of proportional hazards assumption 
For both ‘time-to-withdrawal of allocated treatment’ and ‘time-to-first seizure,’ at least one 
time-varying covariate in the Cox PH model was significant, therefore a sensitivity analysis 
was conducted using a parametric accelerated failure time (AFT) model (see Chapter 7.1.3). 
For both outcomes, numerical results of these sensitivity analyses were similar to results of 
the primary analysis; mostly the same to one or two decimal places for both individuals with 
partial seizures and individuals with generalised seizures.  There were some changes in 
direction of effect size and some changes in the order or 'rank' of AEDs compared to the 
reference treatment and there were a few changes in conclusions following this sensitivity 
analysis, most notably (see Appendix 14, Figure 21 and Figure 22 for all numerical results): 
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 For individuals with partial seizures, LEV became significantly better than VPS and OXC 
for ‘Time-to-withdrawal of allocated treatment,’ making LEV significantly better than all 
other AEDs except for LTG.  
 For individuals with partial seizures, LTG became significantly better than GBP and PHB 
became better than PHT for ‘Time-to-first seizure,’ making PHB significantly better than 
all other AEDs.  
 For both individuals with partial seizures and individuals with generalised seizures VPS 
was no longer significantly better than TPM (or any other treatment) for ‘Time-to-first 
seizure’ and that LEV became significantly better than VPS.  
7.2.3.3  Inconsistencies in individual participant data provided 
Appendix 14 provides full details and rationale of the sensitivity analyses conducted around 
inconsistencies in IPD and results of these additional analyses. 
The IPD from one trial (Stephen 2007) was excluded from all analyses due to inconsistencies 
in provided data. Numerical results of these sensitivity analyses were similar to results of the 
primary analysis; mostly the same to one or two decimal places for both individuals with 
partial seizures and individuals with generalised seizures.  There were no changes in 
conclusions for individuals with generalised seizures. For individuals with partial seizures, 
there were some changes in direction of effect size and some changes in the order or 'rank' 
of AEDs compared to the reference treatment and there were a few changes in conclusions 
following this sensitivity analysis, mostly notably for ‘time-to-withdrawal of allocated 
treatment,’ CBZ became significantly better than TPM and for ‘time-to-first seizure,’ CBZ 
became significantly better than LEV and VPS became significantly better than GBP (see 
Appendix 14, Figure 23 and Figure 24 for all numerical results). 
The IPD from two trials, Reunanen 1996 and Placencia 1993, were each excluded (separately) 
from analysis of ‘time-to-withdrawal of allocated treatment’ due to the definition of 
withdrawal from allocated treatment. The IPD from one trial (Banu 2007), was excluded from 
analysis of ‘time-to-first seizure’ due to inconsistencies in provided data and IPD was also 
excluded from one trial from the analysis of ‘time-to-first seizure’ (Nieto-Barrera 2001) as 
seizure dates for the first four weeks of the trial were not provided. For all four of these 
analyses, numerical results were very similar compared to the primary analysis (the same to 
two decimal places for individuals with partial seizures and one or two decimal places for 
individuals with generalised seizures) and conclusions remained unchanged for the vast 
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majority of results. One notable change to conclusions was that LTG was no longer 
significantly better than CBZ for individuals with generalised seizures for ‘time-to-withdrawal 
of allocated treatment’ following the exclusion of the IPD from Reunanen 1996 (see Appendix 
14, Figure 25, Figure 26, Figure 27, and Figure 28).  
7.2.3.4  Misclassification of epilepsy type 
Sensitivity analyses were performed to investigate the possibility of generalised seizures 
being misclassified; in the first analysis those with generalised seizures and age of onset 
greater than 30 are reclassified as having partial-onset seizures and in the second analysis 
generalised seizure types and age at onset greater than 30 and those with missing epilepsy 
type into an 'unclassified epilepsy type' group (see Chapter 7.1.3 for further details).  
For ‘time-to-withdrawal of allocated treatment,’ for the first analysis, numerical results for 
individuals with generalised seizures were similar; there were some changes in direction of 
effect size and some changes in the order or 'rank' of AEDs compared to the reference 
treatment but no change in statistical significance for any estimate and no notable change to 
conclusions (Appendix 14, Figure 30). 
For individuals with partial seizures, most numerical results were similar but the most notable 
change was that PHT was now significantly better than all other AEDs (Appendix 14, Figure 
29). There was a large amount of heterogeneity present in this analysis; the estimated I2 
statistic was 98% and when repeating NMA with random-effects, calculated the τ2 statistic 
was 7.074 and CIs of all treatment effect estimates were very wide so that no significant 
differences were present between any effect sizes (Appendix 14, Figure 33). There is no clear 
explanation as to why this sensitivity analysis has introduced a large amount of heterogeneity 
into analysis for this outcome but not for the other outcomes. Due to this uncertainty, 
interpretation of the numerical values of this sensitivity analysis is not encouraged. 
For the second analysis of epilepsy type classification, for ‘time to withdrawal of allocated 
treatment, numerical results of this sensitivity analysis were very similar compared to the 
primary analysis (the same to two decimal places for individuals with partial seizures and one 
or two decimal places for individuals with generalised seizures) and conclusions remained 
unchanged (see Appendix 14, Figure 31 and Figure 32 for numerical results).   
For the ‘time-to-first seizure’, results of these sensitivity analysis were similar to the primary 




7.3.1 Summary of main results 
A total of 77 trials were identified in which 17,961 individuals with partial-onset or 
generalised-onset tonic clonic seizures (with or without other generalised types) were 
randomised to one of 10 AEDs commonly used as monotherapy. IPD was provided for at least 
one outcome of this review for 12,391 out of 17,961 eligible participants (69% of total data) 
from 36 out of the 77 eligible trials (47%); see Chapter 5 for further details of IPD requests.  
NMA provided a total of 45 pairwise comparisons for individuals with partial seizures and 36 
pairwise comparisons for individuals with generalised seizures (no participants with 
generalised seizures were randomised to ZNS). Direct estimates could be calculated for 
between half and two thirds of comparisons across the outcomes of the review. However for 
many of the comparisons data was contributed by only a single trial and/or by a small number 
of participants. Where synthesis of head-to-head data was possible, direct evidence was 
generally quite consistent and where substantial heterogeneity was present between trials 
(I2 > 50%), it is likely that the heterogeneity originated from variability in design of the trials 
such as synthesis of trials recruiting different age groups, synthesis of double-blind and open 
label trials and pooled of trials with and without treatment stratification. 
NMA showed that for the primary outcome, ‘time-to-withdrawal of allocated treatment,’ for 
individuals with partial seizures, LTG and LEV were significantly better than first line 
treatment CBZ, which was significantly better than GBP and PHB. LTG was significantly better 
than all treatments except LEV. For individuals with generalised-onset seizures, first line 
treatment VPS performed significantly better than CBZ, TPM and PHB. 
NMA also showed that for ‘time-to-first seizure’ for individuals with partial seizures, PHB was 
significantly better than both first line treatments CBZ and LTG; first line treatment CBZ 
performed significantly better than VPS, GBP and first line treatment LTG and PHT also 
performed significantly better than LTG. In general, the earliest licenced treatments (PHT and 
PHB) performed better than the other treatments for both epilepsy types. 
Results from NMA were more precise than results from head-to-head comparisons, often 
much more precise for comparisons where limited direct evidence exists, reflecting the 
added precision of NMA over pairwise meta-analysis. Across outcomes for the majority of 
pairwise comparisons, numerical results of direct evidence and NMA were similar, mostly in 
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the same direction and confidence intervals of estimates overlapped and there was little 
indication of inconsistency between direct and NMA results. For the few pairwise 
comparisons where confidence intervals of direct estimates and NMA estimates did not 
overlap, generally direct evidence was limited and contributed only a small proportion of 
evidence to the NMA estimates.  
Despite some methodological concerns in several trials contributing to analyses which may 
have induced bias into analyses or inconsistencies present within IPD, numerous additional 
and sensitivity analyses were performed to test the robustness of the results in the presence 
of these biases (see Chapter 5 and Chapter 7.2.3). Results of additional and sensitivity 
analyses were numerically similar and did not lead to any consistent changes to conclusions, 
therefore it is unlikely that any methodological inadequacies of individual trials has 
influenced the overall pooled NMA results. 
7.3.2 Strengths and weaknesses 
An IPD approach was taken to analysis due to the many advantages of such a ‘gold-standard’ 
approach. Particularly within this setting, an IPD approach allowed standardisation of 
definitions of outcomes across trials, and attrition and reporting biases were reduced from 
the re-analysis of unpublished data and calculation of additional outcomes which were not 
considered originally within trials. Furthermore, the use of IPD in this analysis allowed the 
consideration of the relationship between treatment effect and epilepsy type via an 
interaction term in the NMA and to present results separately according to epilepsy type in 
the context of the recommended first line treatment of the epilepsy type, such an approach 
which would not have been possible without the use of IPD. 
This analysis includes 69% of eligible IPD from 47% of the eligible trials. Across the ten drugs, 
between 49% and 100% of IPD was provided. Data for the remaining 5570 participants from 
41 trials could not be provided for a variety of reasons; see Chapter 5 for further discussion. 
Figure 9 in Chapter 5 shows network plots of pairwise comparisons in all included trials, trials 
providing IPD and trials without IPD. IPD was provided for all direct pairwise comparisons in 
the total network except for OXC compared to VPS and OXC compared to LEV. In fact, out of 
all drugs included in the network, the lowest proportion of IPD was received for OXC (49%) 
and the lack of data for these comparisons may have contributed to imprecision of some 
effect sizes relating to OXC (e.g. see Figure 15). Therefore, caution should be taken when 
interpreting results for OXC from these analyses. However, it should be noted that the 51% 
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of IPD missing for OXC mostly comes from trials for which we could not establish contact with 
an author or sponsor to request IPD. If additional data can be included in an update for OXC, 
the precision of these estimates to is likely to improve. 
It is inevitable that the exclusion of 31% of eligible participants may have introduced some 
bias into results of analyses; further discussion of differences between studies providing and 
not providing IPD are discussed in Chapter 5.4.3. However, it is likely that the 69% of IPD 
provided for analyses is a representative sample of the total participants included in all 
eligible trials and that the benefits of an IPD approach outweigh the limitations. 
The majority of IPD requested was provided directly but for one trial randomising 136 
participants [319], data was requested via data sharing portal CSDR [91] and was provided 
via a remote secure data access system which allowed analysis in SAS based statistical 
software and export of analysis results. IPD from this trial could not be included with the 
entire individual participant dataset to fit the models outlined in Chapter 6.2 , therefore the 
results exported from the data access system were treated as AD in an additional analysis 
(see Chapter 8 for further discussion and results).  
7.3.3 Clinical implications and relation to other studies  
The majority of participants recruited into these trials were classified as experiencing partial 
seizures (66.8% of participants in all trials and 67.5% of participants with IPD provided); this 
majority is emphasised in the visual similarity of the network plot for individuals with partial 
seizures compared to the plot of all participants and reflected in the relative precision of the 
results of this review for partial seizures compared to generalised seizures (Figure 12). While 
a majority of partial seizures compared to generalised seizures is reflective of clinical practice 
(around 60% of individuals with epilepsy experience partial seizures [320]), the proportion of 
individuals with partial seizures recruited to the trials in this review is even greater.  
The remaining participants were classified as experiencing generalised tonic-clonic seizures 
with or without other generalised seizure types (24.4% of participants in all trials and 26.5% 
of participants with IPD provided) or unclassified / missing epilepsy type (8.8% of participants 
in all trials and 6% of participants with IPD provided). Misclassification of epilepsy type is a 
recognised problem in epilepsy (whereby some individuals with generalised seizures have 
been mistakenly classed as having partial-onset seizures and vice-versa). The potential 
impact of this misclassification on results has been shown in our series of Cochrane IPD 
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reviews of monotherapy for epilepsy [59]. Investigation of misclassification within this 
analysis (reclassification of 1,164 participants with generalised seizures and age of onset of 
over 30 years, 36% of individuals originally classified at experiencing generalised seizures) did 
not show any important changes to treatment effect sizes and no changes to conclusions. 
This does not, however, indicate that misclassification of epilepsy type has not occurred in 
these trials; rather that the primary analysis results are robust to any misclassification. Trials 
included in this analysis were published between 1981 and 2015 and a proportion of trials 
classified generalised and partial-onset seizures according to the ILAE classification of 1981 
[321], rather than the revised classification in 1989 [322] or recently revised terminology 
[323], which may have led to misclassification. Furthermore, several trials were conducted in 
developing countries in Africa, Asia and Central or South America without access to the same 
facilities such as electroencephalograms (EEGs) or magnetic resonance image (MRI) scanners 
as trials conducted in the USA and Europe. Within these trials, it is likely that seizure type 
would have been classified clinically, which may have further contributed to misclassification.  
In reality, it is likely that fewer than 20% of participants recruited into all of these trials 
experienced generalised seizures (17% of participants included in IPD analysis were classified 
as having generalised seizures following reclassification in sensitivity analysis), which is a 
lower proportion than would be expected in clinical practice [320]. For this reason, treatment 
effect sizes for generalised seizures, particularly those which are imprecise, should be treated 
as less applicable than the treatment effect sizes for partial seizures. 
In order to provide more precise evidence, applicable to individuals with generalised 
seizures, it is important both ensure accurate seizure classification (as far as possible) and to 
increase the proportion of individuals with generalised seizures recruited into trials of AEDs 
to better reflect the ‘real world’ ratio of partial to generalised seizures. Increased recruitment 
of may not be straightforward, particularly as those with new onset generalised seizures are 
expected to be children and adolescents and recruitment of children into clinical trials comes 
with difficulties [324]. However, if targeted recruitment strategies could be implemented and 
the evidence base for individuals with generalised seizures increased this may better inform 
treatment decisions for this population, particularly for those of childbearing potential, for 
whom first line treatment sodium valproate may not be appropriate [74].  
An NMA was published by representatives of the Cochrane Epilepsy Group in 2007 including 
IPD for over 6418 patients from 20 trials (also included in the current review) comparing 
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direct and indirect evidence from CBZ, PHB, PHT, VPS, LTG, OXC, TPM and GBP [285]. Results 
of this NMA showed for partial-onset seizures, LTG performed better than all other drugs in 
terms of treatment withdrawal but may not perform better than CBZ in terms of seizure 
control. PHB performed better than other drugs in terms of seizure control but at the expense 
of increased treatment failure. Overall for individuals with partial seizures; LTG, CBZ and OXC 
seemed to provide the best balance of seizure control and treatment failure. As in the current 
review, data for individuals with generalised seizures was limited and results suggested that 
VPS or PHT may provide the best combination of seizure control and treatment failure. 
The present analysis was designed to update the information in the previous NMA with new 
evidence from trials published since 2007 and including evidence for two drugs which were 
licensed for use as monotherapy after 2007 (LEV and ZNS) [68]. The results of the present 
analysis generally agree with the results of the previous NMA in addition to providing 
evidence of the comparative effectiveness of the two new drugs within the spectrum of 
commonly used AEDs and further highlight that nearly 10 years on, data for individuals with 
generalised seizures is still limited. 
7.3.4 Concluding remarks 
Results of this analysis demonstrate that generally the earliest licenced AEDs such as PHT and 
PHB provide increased seizure control, in terms of delaying recurrence of first seizure and 
earlier remission, compared to newer AEDs. However, this comes at the expense of earlier 
treatment failure and it is newer AEDs such as LTG and LEV that perform the best in terms of 
treatment retention. Considering the optimum balance of efficacy (seizure control) and 
tolerability (treatment retention), for individuals with partial seizures, CBZ, LTG and LEV seem 
to be the best treatment options whereas for individuals with generalised tonic-clonic 
seizures (with or without other seizure types); VPS, LTG and LEV seem to be the best 
treatment options. ZNS, the most recently licenced AED for monotherapy treatment, may be 
an effective treatment option for individuals with partial-onset seizures; however further 
evidence from randomised controlled trials is needed and the effectiveness of this drug has 
yet to be evaluated in a published clinical trial for individuals with generalised seizures. 
Overall, these results support the NICE guidelines that CBZ and LTG are suitable first-line 
treatments for individuals with partial-onset seizures and also demonstrates that LEV may be 
a suitable alternative. Results also support the use of VPS as the first-line treatment for 
individuals with generalised tonic-clonic seizures (with or without other seizure types) and 
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also demonstrates that LTG and LEV would be suitable alternative first-line treatments, 
particularly for those of child bearing potential, for whom VPS may not be an appropriate 
treatment option. Evidence for the relative effectiveness of other AEDs for individuals with 
generalised seizures is limited and of moderate quality; further evidence from randomised 
controlled trials is needed. 
This review highlights the need for the design of future AED monotherapy trials that are well 
powered to detect a difference between particular AEDs while recruiting a sample of 
individuals’ representative of the wider population in terms of age and seizure type. An 
approach to best reflect and inform clinical practice, as well as being statistically powerful, 
would be to recruit heterogeneous populations for whom epilepsy syndromes have been 
adequately defined, with testing for interaction between treatment and epilepsy syndrome. 
In view of potential problems of misclassification, syndromes will have to be well defined, 
with adequate checking mechanisms to ensure that classifications are accurate and a system 
to recognise uncertainty surrounding epilepsy syndromes in individuals within trials. 
The choice of outcomes at the design stage of a trial and the presentation of the results of 
outcomes, particularly of a TTE nature, require very careful consideration. While the majority 
of trials of a monotherapy design do record and report outcomes measuring efficacy and 
tolerability of AEDs, there is little uniformity between the definition of the outcomes and the 
reporting of the summary statistics related to the outcomes [325] (see Chapter 3 of this 
thesis) making an AD approach to meta-analysis in reviews of monotherapy trials impossible. 
Where trial authors cannot or will not make IPD available for analysis, excluding a proportion 
of relevant evidence from the review was unavoidable but will inevitably have some impact 
upon the interpretation of results of the review and applicability of the evidence and 
conclusions. The ILAE recommends that trials of a monotherapy design should adopt a 
primary effectiveness outcome of 'time-to-withdrawal of allocated treatment' and should be 
of a duration of at least 48 weeks to allow for assessment of longer-term outcomes, such as 
remission [249].  If trials followed these recommendations, an AD approach to meta-analysis 
may be feasible, reducing the resources and time required from an IPD approach.  
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Chapter 8: Combining individual participant data with 
aggregate data in network meta-analysis 
8.1  Introduction 
8.1.1  Individual participant level compared to aggregate level approaches 
to meta-analysis 
As outlined in Chapter 1.1.3, previous work has demonstrated that meta-analyses of the 
same studies taking IPD or AD approaches can produce different results [23, 43, 52-54]. A 
recent systematic review examined 39 meta-analyses with 190 comparisons taking both IPD 
and AD approaches for meta-analysis of the same studies [52]. Results of this systematic 
review showed that for 38 comparisons (20%) there was a disagreement in statistical 
significance between the IPD and AD approach to meta-analysis, with more IPD-MAs 
detecting a statistically significant result which was not confirmed in the AD-MA. 
Conclusions from this work recommend that before embarking upon a resource intensive IPD 
approach to analysis, researchers should carefully consider the added benefits of IPD to their 
clinical question, and consider whether a less resource intensive AD-MA could provide an 
adequate (and mathematically equivalent) answer to the question [52, 53].  
Specifically from a TTE setting, Haines and Hill [53] have demonstrated that in the context of 
repeated-measures data of accidental falls, a range of approaches may be taken to the 
statistical analysis at a trial level which influence the standard errors of the results and hence 
would influence the pooled result should these estimates be combined in AD-MA. The 
authors therefore argue that IPD-MA and AD-MA would fundamentally produce difference 
results in this setting and question whether AD-MA would ever be appropriate.  
Similarly, Duchateau et al [164, 165] note differing results for TTE outcomes from IPD-MAs 
and AD-MAs in head and neck cancer, concluding that the most likely reason for the 
differences is due to IPD-MAs being based on exact TTE analyses whereas AD-MAs are based 
on mortality as a specific time point. The authors also note that where AD results may have 
been indirectly estimated from a Kaplan-Meier (KM) curve, the estimated number of events 
is likely to be an over-estimation of the true number of events reflected in the IPD, with the 
extent of overestimation increasing as an increasing number of patients are censored. 
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It is argued that where treatment-covariate interactions are of interest to meta-analysis that 
an IPD approach (i.e. modelling the interaction as a parameter within an IPD model) is 
generally superior to an AD approach (i.e. meta-regression) due to limitations of the latter 
approach such as low statistical power and ecological biases. In other words, study-level 
associations may not accurately reflect individual-level associations [26, 309, 326, 327]. 
Simmonds and Higgins [309] define three approaches for the investigation of treatment-
covariate interactions in meta-analysis; a full IPD approach incorporating a treatment-
covariate interaction term into a model, a meta-regression approach (i.e. a fully AD 
approach) and an intermediate ‘meta-analysis of interactions’ approach which uses IPD to 
estimate within-study treatment-covariate interactions and then combines the separate 
estimates for each study using standard meta-analysis techniques. The authors demonstrate 
that theoretically if the IPD model is specified correctly and assuming normally distributed 
participant responses, a full IPD approach will always have at least as much statistical power 
to detect treatment-covariate interactions as meta-regression or meta-analysis of 
interactions. Furthermore, the power of the latter two approaches depends on the 
distribution and heterogeneity of the covariate of interest. The authors also derive a series 
of 𝑄  statistics based on the distributions and heterogeneity of covariates to allow 
comparison of the power of the three approaches for detecting treatment-covariate 
interaction and potentially guiding a choice between the methodological approaches. 
Although an IPD approach is still relatively rare within network meta-analysis (NMA) 
compared to an AD approach [18, 19, 44-47], several authors have highlighted the benefits 
of an IPD approach to NMA, particularly where detailed examination of heterogeneity, 
inconsistency and treatment-covariate interactions are of interest [19-21, 44-47, 328]. 
8.1.2  Combining IPD and AD in meta-analysis 
As an alternative approach to performing either a complete IPD analysis or a complete AD 
analysis, methods have been developed which allow the combination of IPD and AD in meta-
analysis [38-41, 329, 330] and network meta-analysis [19, 20, 44-46]; the latter are further 
discussed in Chapter 8.1.3. 
Such methods have generally been developed for two general reasons; firstly, to increase the 
power and precision of an AD-MA by incorporating participant-level information from IPD 
[19, 39, 46] or secondly for the scenario when an IPD approach to analysis was intended but 
IPD is not available from a subset of trials for analysis. Where AD is available for some or all 
of these trials, this AD could supplement the IPD in analysis, allowing a larger (and more 
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complete) proportion of the relevant evidence base to be included in analysis [40]. These 
methods are particularly appealing where there is a concern that unavailability of IPD for a 
study may be related to the results of that study, hence potentially introducing bias into IPD-
MA [24, 51]. It should, however, be noted that published AD may be prone to bias and not of 
the same quality as IPD [51, 331] so while incorporation of additional AD may increase 
precision, it may not necessarily improve the reliability of the overall analysis results. It is 
therefore recommended that sensitivity analyses are conducted comparing analyses of IPD 
only and IPD combined with AD in meta-analysis and consideration is given to potential 
reasons for unavailability of IPD and the relative quality of any published AD [36, 41, 51]. 
A systematic review of methods employed in IPD-MA conducted by Riley et al [40] showed 
that out of 199 applied IPD-MA identified, 33 published articles combined IPD and AD in 
meta-analysis and 30 clearly described the methods used to do this. In the majority of articles 
(27 out of 33 meta-analyses, 82%), IPD and AD were combined via a two-stage method to 
meta-analysis [32, 141, 142]; in other words, IPD were reduced to AD and combined with 
additional AD using standard meta-analytic techniques (see Chapter 2.3.2 for further 
description). Two-stage approaches have the potential disadvantage of losing participant-
level information provided within the IPD, but as discussed further in Chapter 2.3.2, two-
stage approaches and one-stage approaches often do produce the same results.   
Further, specifically within a TTE setting, it has been shown that employing a two-stage 
method to combine IPD and AD in meta-analysis, where feasible, can have advantages over 
an IPD only approach such as increasing precision of resulting pooled estimates [141, 142].  
Where treatment-covariate interactions are of interest, reducing IPD to AD for meta-analysis 
has the potential for ecological bias. In this case, the two-stage ‘meta-analysis of interactions’ 
approach defined by Simmonds and Higgins [309] may be applicable (see Chapter 6.2.4  and 
Chapter 8.1.1 for further details). The authors argue that this approach which remains within 
familiar meta-analysis frameworks may be more readily understood than complete IPD 
approaches; however, this approach would not readily extend to incorporation of AD with 
IPD, unless treatment-covariate interaction at an AD-level is available. 
The remaining three articles identified by Riley et al [40] combined IPD and ‘partially 
reconstructed IPD’ which could be extracted from published literature, i.e. reconstruction of 
2 x 2 tables for binary outcomes [41] or estimated survival times from KM curves for TTE 
outcomes [153, 157]. Messori et al [153] demonstrate that reconstructed IPD from KM  
curves can act as a good ‘intermediate’ method with advantages over an AD approach where 
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IPD is not available for every study or where resources to take a fully IPD approach are not 
available. The illustrative example of Messori et al [153] shows good correlation between 
estimated IPD and true IPD; however, it must be noted that reconstructed IPD may be less 
reliable than original IPD and may still be prone to ecological biases [40].  
Although not used in any of the articles identified in Riley et al [40], multi-level or ‘hierarchical 
related’ regression modelling approaches allow for IPD and AD to be combined in the same 
meta-analysis model [38-41, 326, 329, 330, 332]; some examples were developed in the 
context of combining summary (e.g. geographic area) level and individual-level data from 
ecological studies rather than in a clinical context [326, 332]. However, such methodology is 
also applicable to evidence synthesis from a clinical setting. 
This modelling approach allows the simultaneous or joint estimation of the likelihood from 
related regression models of each data source (IPD or AD) and a multi-level structure which 
allows the incorporation of AD alongside IPD via dummy variables to indicate the data source 
[38, 40, 329]. Such a structure allows for both data sources to contribute to overall treatment 
effect and any study-level covariates of interest but ensures that only studies providing IPD 
contribute to any participant-level covariates [40]. Simultaneous hierarchical estimation of 
related models for IPD and AD sources, which typically share common parameters, allows for 
both data sources to inform the common parameters which has the advantage of potentially 
reducing biases from both data sources; i.e. the inclusion of IPD may reduce ecological biases 
arising from AD and the combined analysis of IPD and AD together may increase statistical 
power, which may be particularly beneficial  where only a small proportion of IPD is available 
[40, 326, 332]. However, it should be noted that applying models of the same form with 
treatment-covariate interactions to IPD and AD sources will only result in valid estimates of 
treatment effect according to the level of covariate if all individuals in the study have the 
same covariate value or if the relative effect modification of the covariate is the same at the 
individual and aggregate-level [19, 41].  
Ravva et al [330] note that applying the same non-linear model to both IPD and AD sources 
to define common parameters may lead to ‘aggregation bias,’ a type of ecological bias where 
between-study effects are incorrectly interpreted as within-study effects. The authors 
describe a hierarchical linearization modelling technique and an application to 
pharmaceutical drug development (dose-response) to address this issue of aggregation bias 
by allowing AD model parameters to retain their original definition with respect to 
treatment-covariate interactions at the individual-level. 
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Specifically, meta-analysis models for combining IPD and AD have been developed for binary 
outcomes, modelling IPD and AD ‘event-risk’ responses as Bernoulli and Binomial 
distributions respectively [39, 41]. Such models provide pooled ‘event-risk’ estimates across 
studies, while accounting for within-study variability due to interactions between ‘event-risk’ 
and participant-level covariates of interest and can be applied within a Frequentist or 
Bayesian framework [39, 41]. 
Meta-analysis models for combining IPD and AD have also been developed by Goldstein et al 
[329], modelling a continuous response variable via multi-level linear or quadratic regression. 
Riley et al [38] build on the approach of Goldstein et al [329] and outline a series of one and 
two-step meta-analysis models to combine IPD and AD for continuous outcomes and 
demonstrate how these models can be used to incorporate participant-level covariates to 
estimate treatment-covariate interactions in relation to pooled treatment effect and 
between-study heterogeneity. The general framework of the one-step approach also extends 
to other data types (such as TTE data), multiple covariates, multiple correlated outcomes, 
non-linear interaction effects and incorporation of treatment-covariate interactions from the 
trials providing AD. 
Recent work emphasises the importance of parameter specification when fitting one-stage 
meta-analysis models, whether analysing IPD only or incorporating IPD and AD, to ensure 
that within-study and between-study associations are separated to avoid inadvertent 
ecological biases [25, 38, 41]. 
8.1.3  Combining IPD and AD in network meta-analysis 
As described in Chapter 8.1.2 for ‘traditional’ pairwise meta-analysis, a range of methods 
have been developed and described for combining AD with IPD in meta-analysis of various 
data types, allowing for the incorporation of treatment-covariate interactions. However, at 
the time of writing, methodology to combine IPD and AD in NMA across different data types 
and scenarios has been less widely researched. Such methods are arguably even more 
important in this setting, where more treatment comparisons are made across more eligible 
studies, the scope for unavailable IPD from a subset of studies is potentially larger [46]. 
Saramago et al [45]  and Donegan et al [46] have described similar models for combining IPD 
and AD which extend the methodology of Sutton et al [39] for meta-analysis of a binary 
outcome to NMA of a binary outcome. Both approaches are performed in a Bayesian 
framework and extend to fixed or random-effects.  
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Saramago et al [45] describe NMA models for a binary outcome for scenarios where only IPD, 
only AD or a combination of IPD and AD are available for NMA. These models also allow the 
incorporation of individual or aggregate-level covariate data as treatment-covariate 
interactions and to explore within-study and across-study interactions. 
Donegan et al [46] describe an approach for the joint synthesis of IPD and AD within NMA for 
a binary outcome via a ‘shared parameter model’ [46, 333], where available IPD and AD are 
entered as two separate datasets in a single model which allows both datasets to contribute 
to the shared model parameters. The model also extends to include multi-arm trials, 
treatment-covariate interactions and to explore within-study and across-study interactions 
(assuming independent, exchangeable or common treatment-covariate interactions for each 
treatment comparison). However, the authors experienced problems with model 
convergence when applying the proposed methods to explore within-study and across-study 
interactions to an illustrative example examining treatment success in malaria with a 
treatment-by-age interaction, likely due to the similarity in mean age across sites. 
Both Saramago et al [45]  and Donegan et al [46] conclude that the synthesis of IPD and AD 
to include as much available evidence as possible increases precision and the use of IPD in 
NMA has advantages over the usual AD approach to NMA. 
Jansen and Cope [20] present an aggregate-level approach to NMA which allows for the 
incorporation of study-level covariates to adjust for confounding bias due to heterogeneity 
and inconsistency. This method is an extension of a method described in Chapter 2 [158] for 
NMA of TTE data, which is a multi-dimensional approach which does not require a PH  
assumption. The authors note the limitations of this AD approach that the methods described 
do not reflect individual level-effect modification. In a related publication, Jansen [19] 
hypothetically demonstrates the potential differences in NMA results without covariate 
adjustment, with covariate adjustment using AD and with covariate adjustment using IPD. 
Jansen [19] presents two methods for the incorporation of IPD and AD in NMA for a binary 
outcome using non-linear models in the presence of a participant-level covariate. The first 
method can be considered an extension of the methods of Sutton et al [39] (outlined in 
Chapter 8.1.2) to NMA (combined with the methods of Cooper et al  [21]). The second 
method uses a ‘hierarchical related regression’ as introduced by Jackson et al [326, 332] (also 
outlined in Chapter 8.1.2) which derives the AD model by integrating the underlying IPD 
model over the joint within-study distribution of covariates. Results of a simulation study 
show that under the majority of scenarios, the NMA models incorporating IPD and AD were 
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less associated with confounding bias than the NMA models using AD alone and generally 
the hierarchical related regression approach to combining IPD and AD in NMA was associated 
with less confounding bias than the extended approach of Sutton et al [39]. Jansen [19] 
concludes that the incorporation of even a small proportion of IPD into an AD-NMA to model 
participant-level covariates has values, particularly where there are concerns regarding 
heterogeneity, inconsistency or confounding bias. 
Saramago et al [44] describe methodology for combining IPD and AD in NMA in a TTE setting; 
which extends the work of Sutton et al [39] and Saramago et al [45] for binary outcomes. 
Specifically the methods proposed by Saramago et al [44] combine individual event-time data 
with aggregated count data under the assumption that by specifying a parametric TTE 
distribution which can allow for HRs to be generated from the original count AD by estimating 
the cumulative hazard in each trial arm reporting count data for a given follow-up time [221]. 
The methods described also allow for the incorporation of treatment-covariate interactions 
from both IPD and AD sources. 
8.1.4  Objective 
The first objective of this Chapter is to directly extract aggregate TTE data for the outcomes 
of interest to the Cochrane Epilepsy IPD-NMA (outlined in Chapter 7) from the trials not 
providing IPD or to determine whether suitable AD can be estimated from other published 
summary statistics (as outlined in Chapter 2.3.2). 
The second objective of this Chapter is to perform a combined NMA of IPD and any extracted 
or estimated AD and to compare results to those of the IPD-NMA. The principle aim of the 
combined analysis is to investigate whether the incorporation of AD changes the results and 
conclusions of the IPD-NMA, which could indicate that the 69% of IPD obtained for the NMA 
may not be representative of the entire evidence base. 
8.2  Methods 
8.2.1  Extraction of aggregate data from epilepsy studies  
As outlined in Chapter 5 and Table 13, IPD was not provided from 5570 participants from 41 
trials which were eligible for the Cochrane NMA (31% of total participant data). As noted in 
Chapter 5.3.2, if IPD was not available, any unpublished AD related to the outcomes of 
interest of the review was requested and would have been used in a combined analysis if any 
useable unpublished AD had been provided. 
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For each trial without IPD available, published literature (journal articles, clinicaltrials.gov 
entries etc.) were examined to determine whether any relevant AD could be extracted from 
this literature either directly or indirectly estimated (as described in Chapter 2.3.2 of this 
thesis). Aggregate data was extracted and/or estimated in the following order of preference:  
 direct numerical estimates (e.g. a HR and measure of precision could be extracted 
for one or more outcomes of interest) 
 indirect numerical estimates (see Chapter 2.3.2.1) 
 indirect graphical estimates with numbers at risk provided (see Chapter 2.3.2.2) 
 indirect graphical estimates without numbers at risk provided but estimated 
according to methods of Parmar et al [6] (see Chapter 2.3.2.2) 
For graphical estimation, survival proportions were extracted by hand by SJN from an 
enlarged version of the published curve at an appropriate range of time points, according to 
the extent of follow-up of the trial or the intervals at which numbers at risk were reported. 
Indirect estimation was performed by entering extracted summary statistics or survival 
proportions into the macro-enabled spreadsheet developed by Tierney et al [128]. 
As outlined in Chapter 7.3.2, IPD was provided for one trial randomising 136 participants 
(referred to as Biton 2001 [319]) via a remote secure data access system which allowed 
analysis in SAS based statistical software and export of analysis results. IPD from this trial 
could not be included with the entire individual participant dataset to fit the models outlined 
in Chapter 6.2, therefore the results exported from the data access system were treated as 
AD in an additional analysis. 
None of the 41 studies reported AD of any kind for the outcomes of time-to-12-month or 
time-to-6 month remission and none of the studies appeared to have measured either of the 
outcomes. The trial duration of 19 trials was less than 12 months and less than 6 months for 
five trials, therefore these remissions outcomes were not in the scope of the trials. 
Furthermore, the range of follow-up was not reported in seven trials so it was unclear 
whether time-to-12-month or time-to-6 month remission could have been measured. For 
one study (Biton 2001), AD for time-to-6 month remission for all participants and by epilepsy 
type could be calculated from IPD provided within the remote data access system. Results of 
combining AD from this single study to the IPD for time-to-6-month remission did not change 
conclusions and for brevity, results are not reported here.  This trial was of less than a year 
duration so time-to-12-month remission was not in scope.   
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Table 23 and Table 24 summarise the aggregate data which could be extracted for the 
outcomes of interest to the Cochrane Epilepsy IPD-NMA.  
Table 23: Aggregate data available for time-to-withdrawal of allocated treatment 











Summary HR and 95% CI available (SAS 
remote data analysis system) 
Brodie 2002 291 99 Summary HR and 95% CI available 
Christie 1997 249 93 Graphical (no numbers at risk) 
Forsythe 1991 64 22 Extracted approximate IPD (Table) 
Gilad 2007* 64 
(all partial) 
11 Extracted approximate IPD (Graphical) 
Rowan 2005 590 314 Graphical (partial numbers at risk 
available at yearly time points) 
Saetre 2007 184 55 Summary HR and 95% CI available 




Extracted approximate IPD (Table) 




Graphical (no numbers at risk) 
AD = aggregate data; G=generalised seizures; P = partial seizures, * = AD available by epilepsy type 
1. See Appendix 10 for reference of the primary publication of each trial  
2. Number of participants in the evaluable population or included in analysis for the outcome; 
for Biton 2001; epilepsy type was missing for eight participants 
3. For 32 out of 41 trials (3720 participants, 21% of total participant data), ‘time-to-withdrawal 
of allocated treatment’ was not reported as an outcome of the trial so no AD was available. 
 
For the outcome ‘time-to-withdrawal of allocated treatment,’ nine trials reported AD for 
1850 participants across a range of drug comparisons; mostly of CBZ, LTG and VPS but also 
GBP, OXC and PHT. For ‘time-to-first seizure,’ six trials reported AD for 1369 participants 
across a range of drug comparisons; mostly CBZ and LTG but also GBP, LEV and VPS. For three 
trials, a summary HR and 95% CI were available for both outcomes and for one trial, summary 
statistics were estimated for both outcomes from published survival curves with partial 
numbers at risk available at yearly intervals).  
For ‘time-to-withdrawal of allocated treatment,’ summary statistics could be estimated from 
two further studies with published survival curves without published numbers at risk. For the 
remaining trials, approximate IPD could be estimated from tables or graphs and used to 
calculate a summary HR and 95% CI. In two studies, due to the small number of events and 
very clear graphics, approximate event times could be extracted for each participant for both 
outcomes (Gilad 2007) or for time-to-first seizure (Consoli 2012). 
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Table 24: Aggregate data available for time-to-first seizure  









Summary HR and 95% CI available (SAS 
remote data analysis system) 
Brodie 2002 291 1383 Summary HR and 95% CI available 
Consoli 2012 104 9 Extracted approximate IPD (Graphical) 
Gilad 2007* 64 
(all partial) 
26 Extracted approximate IPD (Graphical) 
Rowan 2005 590 3053 Graphical (partial numbers at risk available at 
yearly time points) 
Saetre 2007 184 84 Summary HR and 95% CI available 
AD = aggregate data; G=generalised seizures; P = partial seizures, * = AD available by epilepsy type 
1. See Appendix 10 for reference of the primary publication of each trial  
2. Number of participants in the evaluable population or included in analysis for the outcome; 
for Biton 2001; epilepsy type was missing for eight participants 
3. For two trials, the number of events was not reported and was estimated based on the 
reported proportions seizure free at the end of the study. 
4. For 32 out of 41 trials (3022 participants, 17% of total participant data), ‘time-to-first seizure’ 
was not reported as an outcome of the trial so no AD was available. 
5. For 3 out of 41 trials (1179 participants, 7% of total participant data), a ‘time-to-first seizure’ 
outcome was defined but was reported as mean or median time-to-first seizure or number 
of events only with no further statistical analysis so no usable AD was available. 
 
Two studies presented times at which allocated drug was withdrawn and the reason for 
withdrawal in a table. Shakir 1981 presented 'time on trial drug' in months for each 
participant; therefore to calculate 'time-to-withdrawal of allocated treatment,' it was 
assumed, for example, that if 'time spent on trial drug' was five months, the individual spent 
five full months (152 full days) on the trial drug before withdrawal. Forsythe 1991 presented 
'withdrawal and time of occurrence by month’ and therefore to calculate 'Time-to-
withdrawal of allocated treatment’ we assumed that, for example, if withdrawal occurred 
during the fifth month, that withdrawal occurred halfway between the fifth and sixth month 
(i.e. participants spent 167 full days on treatment before withdrawal). This approach to 
analysis of these trials was taken in a pairwise IPD-MA including these two trials [59]; within 
that IPD-MA, sensitivity analysis was conducted examining the assumptions made of the 
withdrawal times in these trials. Results were similar following sensitivity analysis, therefore 
it was assumed that these assumptions were reasonable for the NMA.  
It should be noted that the ‘approximate’ IPD which could be extracted could have been 
included as IPD in the complete IPD approach to the NMA. However, given the potential for 
ecological bias as noted by Riley et al [40], compared to IPD which was provided directly and 
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consistency checked (see Chapter 5), the ‘approximate’ IPD was reduced to a summary HR 
and 95% CI and treated as AD for the purpose of this analysis. 
In relation to the findings of Chapter 3, the majority of trials did not report the TTE outcomes 
of interest for the Cochrane IPD-NMA (rather than outcomes were reported inconsistently). 
No trials reported remission as a TTE outcome in the trial publication. For the 32 trials which 
did not report relevant information for ‘time-to-withdrawal of allocated treatment’ (21% of 
total participant data), withdrawal information was generally reported as the proportion of 
participants withdrawing, rather than as a TTE outcome. Also, for 32 trials without any AD 
for ‘time-to-first seizure’ (17% of total participant data), the outcome was reported as the 
proportion of participants with seizure freedom or the change in seizure frequency rather 
than as a TTE outcome. However, for three trials (Korean LTG Study Group 2008, 
NCT01498822 and NCT01954121, recruiting 7% of total participant data), a ‘time-to first 
seizure’ outcome was defined but reported as the mean or median time-to-first seizure or 
the number of events only.  Therefore this published data could not be used.  
8.2.2  Methods for combining IPD and AD in NMA 
As outlined in the objective (Chapter 8.1.4), the principle aim was to allow comparison of an 
NMA of combined IPD and AD to an NMA of IPD only to investigate whether the IPD-NMA is 
representative of the evidence base and to examine the robustness of results. To allow this 
comparison, methods for combining IPD and AD must use the same framework as the IPD 
only analysis (see Chapter 6.2). Use of a different approach to modelling (e.g. via a Bayesian 
framework [45]) would likely produce different numerical results to the IPD-NMA due to 
methodological differences, which may confound the impact of the AD on the IPD results.  
Table 23 and Table 24 show that for four of the trials, aggregate summary statistics could be 
extracted or estimated according to epilepsy type but none of these aggregate summary 
statistics came from statistical models accounting for a treatment-by-epilepsy type 
interaction.  Methods described in Chapter 6.2 of this thesis require that the epilepsy type of 
each individual was available, so, it would not be appropriate to combine summary statistics 
for all participants (regardless of epilepsy type) with IPD in these models. 
Therefore the following approach was taken to allow IPD and AD to be combined in an NMA 
under a multivariate framework. Firstly, IPD was reduced to summary statistics separately by 
epilepsy type. In other words, models of the structures outlined in Equation 29 and Equation 
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30 (see Chapter 6.2.2) are fitted separately to each trial, producing separate trial-specific 
summary statistics of treatment effect for individuals with partial seizures and individuals 
with generalised seizures. 
The summary statistics for each epilepsy type from each trial (estimated from the IPD) are 
then combined in separate NMAs by epilepsy type. This was achieved by producing a dataset 
of the summary statistics structured as a list of pairwise comparisons and converted from 
‘pairs’ to ‘augmented’ format via the ‘network’ command within Stata version 14 [310] (see 
Appendix 13) and NMA is performed via ‘mvmeta’ as described in Chapter 6.2.5.  
Secondly, these separate trial-specific summary statistics of treatment effect for individuals 
with partial seizures and individuals with generalised seizures estimated from the IPD are 
also combined with additional summary statistics extracted or estimated from published 
study reports. These summary statistics (estimated from the IPD and combined with 
additional AD) are then synthesised as described in the previous paragraph.  
The results of this NMA using IPD only and the NMA with IPD and AD combined for each 
seizure type are then compared. For completeness, these results are also compared to the 
results of the IPD-NMAs from the models outlined in Chapter 6.2.2. 
Table 23 and Table 24 also show that the majority of aggregate summary data available 
related to all participants in the trial, rather than separated by epilepsy type (see Chapter 8.3 
for further discussion). Therefore to allow further investigation of any ‘availability bias’ in the 
results of the IPD-NMA, to incorporate as much additional published AD as possible, an 
additional analysis was conducted without separating epilepsy type. 
In this approach, IPD was reduced to summary statistics without accounting for epilepsy type.   
In other words, a model of the structures outlined in Equation 29  (see Chapter 6.2.2) was 
fitted separately to each trial, producing separate trial-specific summary statistics of 
treatment effect for all individuals (regardless of epilepsy type).  These summary statistics 
(firstly those estimated from the IPD only and secondly those estimated from the IPD 
combined with additional AD) are then synthesised in an NMA as described above. 
It should be noted that results that do not accounting for epilepsy type, are of little clinical 
relevance given the known differences between AEDs in different epilepsy types and current 




As described in Chapter 6.2, 11,865 participants (66% of eligible participant data) contributed 
to the main analysis of ‘time-to-withdrawal of allocated treatment’ with a total of 4109 
withdrawal events and 12,152 participants (68% of eligible participant data) contributed to 
the main analysis of ‘time-to-first seizure’ with a total of 6453 first seizure events. 
An additional 336 participants (85 events) with partial seizures from four trials and an 
additional 128 participants (31 events) with generalised seizures from two trials contributed 
to ‘time-to-withdrawal of allocated treatment.’ In other words, an additional 2% of data was 
contributed by AD for individuals with partial seizures and an additional 0.7% of data for 
individuals with generalised seizures. An additional 146 participants (53 events) with partial 
seizures from two trials and an additional 46 participants (27 events) with generalised 
seizures from one trial contributed to for ‘time-to-first seizure.’ In other words, an additional 
0.8% of data was contributed by AD for individuals with partial seizures and an additional 
0.3% of data for individuals with generalised seizures. An additional 1850 participants (697 
events) from nine trials contributed to ‘time-to -withdrawal of allocated treatment’ (i.e. an 
additional 10% of data) and an additional 1369 participants (633 events) from six trials 
contributed to ‘time-to-first seizure’ (i.e. an additional 8% of data).   
NMA results compared to reference treatments and most commonly used treatments are 
discussed in the remainder of this section; results from all methods for all pairwise 
comparisons for both outcomes are available in Appendix 17. 
8.3.1. Individuals with partial seizures 
Results for all AEDs compared to reference treatment CBZ from NMAs of IPD only and IPD 
combined with AD (as outlined in Chapter 8.2.2) are presented in Table 25 and Table 26 
respectively for ‘time-to-withdrawal of allocated treatment’ and ‘time-to-first seizure.’ 
Comparing the results of the NMA which combines IPD and AD to the NMAs with IPD only, 
NMA results are very numerically similar, except for one change to statistical significance 
when incorporating AD to the comparison of CBZ vs TPM for ‘time-to-withdrawal of allocated  
treatment’ even though no additional AD for this comparison directly was added.  It should 
also be noted that the results of all models for this comparison are the same to two decimal 
places. Overall, incorporating AD with IPD in NMA has had very little impact and the lack of 
notable difference is not surprising given the small amount of additional AD available by 
seizure type, i.e. adding AD contributes only up to an extra 2% of data to the outcomes. 
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Table 25: Network meta-analysis results also incorporating aggregate data: Time-to-
withdrawal of allocated treatment for individuals with partial seizures. 
Comparison1 IPD only1,2 IPD reduced to AD1,3 IPD reduced to AD, plus AD1,3 
CBZ vs PHB 1.57 (1.20 to 2.05) 1.58 (1.21 to 2.07) 1.58 (1.21 to 2.07) 
CBZ vs PHT 1.16 (0.93 to 1.45) 1.18 (0.94 to 1.48) 1.19 (0.95 to 1.49) 
CBZ vs VPS 1.10 (0.90 to 1.35) 1.09 (0.90 to 1.32) 1.05 (0.88 to 1.25) 
CBZ vs LTG 0.72 (0.63 to 0.83) 0.72 (0.63 to 0.83) 0.73 (0.65 to 0.84) 
CBZ vs OXC 1.07 (0.84 to 1.37) 1.02 (0.81 to 1.28) 1.02 (0.82 to 1.28) 
CBZ vs TPM 1.17 (0.99 to 1.38) 1.17 (0.99 to 1.38) 1.17 (1.00 to 1.38) 
CBZ vs GBP 1.18 (1.01 to 1.39) 1.18 (1.00 to 1.38) 1.18 (1.01 to 1.39) 
CBZ vs LEV 0.83 (0.70 to 0.99) 0.84 (0.71 to 0.99) 0.84  (0.71 to 0.99) 
CBZ vs ZNS 1.08 (0.81 to 1.44) 1.08 (0.81 to 1.44) 1.08 (0.81 to 1.44) 
1. Results presented are HR and 95% CIs, See Chapter 5.3.2 for abbreviations of drugs. Results 
highlighted in bold italics show a difference in statistical significance when published AD is 
combined with IPD compared to both of the IPD only models. 
2. Results taken from the model outlined in Chapter 6.2.2 
3. Results taken from the model outlined in Chapter 8.2.2 
Table 26: Network meta-analysis results also incorporating aggregate data. Time-to-first 
seizure for individuals with partial seizures. 
Comparison1 IPD only1,2 IPD reduced to AD1,3 IPD reduced to AD, plus AD1,3 
CBZ vs PHB 0.77 (0.60 to 0.99) 0.80 (0.63 to 1.01) 0.79 (0.60 to 1.02) 
CBZ vs PHT 0.97 (0.80 to 1.16) 1.05 (0.87 to 1.26) 1.03 (0.84 to 1.27) 
CBZ vs VPS 1.19 (1.00 to 1.43) 1.28 (1.10 to 1.49) 1.21 (1.02 to 1.43) 
CBZ vs LTG 1.20 (1.02 to 1.40) 1.22 (1.07 to 1.40) 1.22 (1.05 to 1.42) 
CBZ vs OXC 1.06 (0.78 to 1.44) 1.01 (0.81 to 1.26) 1.01 (0.77 to 1.31) 
CBZ vs TPM 0.99 (0.78 to 1.27) 1.05 (0.86 to 1.28) 1.02 (0.81 to 1.30) 
CBZ vs GBP 1.41 (1.10 to 1.81) 1.41 (1.15 to 1.73) 1.42 (1.10 to 1.83) 
CBZ vs LEV 1.19 (0.94 to 1.51) 1.21 (1.01 to 1.46) 1.20 (0.96 to 1.51) 
CBZ vs ZNS 1.30 (0.86 to 1.95) 1.30 (0.91 to 1.84) 1.30 (0.85 to 1.98) 
See Table 25 for abbreviations, definitions and footnotes. 
8.3.2  Individuals with generalised seizures 
Results for all AEDs compared to reference treatment VPS from NMAs of IPD only and IPD 
combined with AD (as outlined in Chapter 8.2.2) are presented in Table 27 and Table 28 
respectively for ‘time-to-withdrawal of allocated treatment’ and ‘time-to-first seizure.’  
When comparing the results of the NMA which combines IPD and AD to the NMAs with IPD 
only, numerical results are mostly quite similar apart from one change to statistical 
significance when incorporating AD to the important comparison of VPS vs CBZ for ‘time-to-
first seizure’ even though no additional AD for this comparison directly was added.  Aside 
from this one change in conclusion, the lack of notable difference is not surprising given the 
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small amount of additional AD available by seizure type, i.e. adding AD contributes only up 
to an extra 0.8% of data to the outcomes. 
Table 27: Network meta-analysis results also incorporating aggregate data. Time-to-
withdrawal of allocated treatment for individuals with generalised seizures. 
Comparison1 IPD only1,2 IPD reduced to AD1,3 IPD reduced to AD, plus AD1,3 
VPS vs CBZ 1.20 (0.89 to 1.62) 1.50 (1.08 to 2.07) 1.46  (1.07 to 1.98) 
VPS vs PHB 1.95 (0.92 to 4.16) 2.12 (0.98 to 4.58) 2.09 (0.98 to 4.42) 
VPS vs PHT 1.26 (0.78 to 2.04) 1.10  (0.57 to 2.15) 1.13 (0.59 to 2.15) 
VPS vs LTG 0.83 (0.51 to 1.36) 0.97 (0.55 to 1.72) 0.94 (0.54 to 1.65) 
VPS vs OXC 1.00 (0.18 to 5.46) 0.77 (0.30 to 1.98) 0.78 (0.31 to 1.97) 
VPS vs TPM 1.08 (0.47 to 2.44) 1.27 (0.68 to 2.39) 1.26 (0.69 to 2.33) 
VPS vs GBP 1.11 (0.12 to 9.89) 1.20 (0.14 to 10.44) 1.19 (0.14 to 10.25) 
VPS vs LEV 0.93 (0.48 to 1.82) 1.16 (0.62 to 2.18) 1.15 (0.63 to 2.10) 
See Table 25 for abbreviations, definitions and footnotes. 
Table 28: Network meta-analysis results also incorporating aggregate data. Time-to-first 
seizure for individuals with generalised seizures. 
Comparison1 IPD only1,2 IPD reduced to AD1,3 IPD reduced to AD, plus AD1,3 
VPS vs CBZ 1.21 (1.05 to 1.40) 1.20 (0.97 to 1.48) 1.22 (1.01 to 1.49) 
VPS vs PHB 1.36 (0.95 to 1.95) 1.34 (0.86 to 2.08) 1.37 (0.89 to 2.10) 
VPS vs PHT 1.06 (0.81 to 1.39) 0.93 (0.61 to 1.42) 1.10 (0.73 to 1.65) 
VPS vs LTG 1.52 (1.16 to 1.99) 1.34 (0.86 to 2.07) 1.48 (0.96 to 2.29) 
VPS vs OXC 1.67 (0.51 to 5.44) 1.59 (0.85 to 2.99) 1.64 (0.88 to 3.02) 
VPS vs TPM 1.15 (0.58 to 2.30) 1.15 (0.73 to 1.80) 1.19 (0.78 to 1.83) 
VPS vs GBP 0.58 (0.07 to 4.91) 0.55 (0.06 to 4.70) 0.58 (0.07 to 4.93) 
VPS vs LEV 1.45 (0.93 to 2.28) 1.34 (0.86 to 2.09) 1.34 (0.88 to 2.05) 
See Table 25 for abbreviations, definitions and footnotes. 
8.3.3  All individuals (regardless of epilepsy type) 
Results for all AEDs compared to commonly used treatment CBZ from NMAs of IPD only and 
IPD combined with AD (as outlined in Chapter 8.2.2) are presented in Table 29 and Table 30 
respectively for ‘time-to-withdrawal of allocated treatment’ and ‘time-to-first seizure.’ 
Comparing the results of the NMA which combines IPD and AD to the NMAs with IPD only, 
NMA results are very numerically similar and there are no changes in conclusions (i.e. the 
statistical significance of the results) across any of the comparisons of CBZ to the other AEDs. 
Although more AD for all individuals is available to incorporate into analysis than for analyses 
separated by epilepsy type, the proportion of AD incorporated compared to the amount of 
IPD available is still small, i.e. adding AD contributes only up to an extra 10% of data to the 
outcomes. Furthermore, as noted in Chapter 8.2.2, results produced by these methods 
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without accounting for epilepsy type are of little clinical relevance given the known 
differences between AEDs in different epilepsy types and current clinical practice. 
Table 29: Network meta-analysis results also incorporating aggregate data. Time-to-
withdrawal of allocated treatment for all individuals (regardless of epilepsy type) 
Comparison1 IPD reduced to AD1,2 IPD reduced to AD, plus AD1,2 
CBZ vs PHB 1.50 (1.14 to 1.96) 1.50 (1.14 to 1.97) 
CBZ vs PHT 1.02 (0.83 to 1.26) 1.03 (0.84 to 1.27) 
CBZ vs VPS 0.90 (0.76 to 1.05) 0.88 (0.76 to 1.02) 
CBZ vs LTG 0.74 (0.64 to 0.86) 0.73 (0.65 to 0.83) 
CBZ vs OXC 0.91 (0.70 to 1.18) 0.91 (0.72 to 1.16) 
CBZ vs TPM 1.09 (0.92 to 1.30) 1.07 (0.90 to 1.27) 
CBZ vs GBP 1.13 (0.91 to 1.39) 0.99 (0.82 to 1.18) 
CBZ vs LEV 0.83 (0.69 to 1.00) 0.82 (0.68 to 1.00) 
CBZ vs ZNS 1.08 (0.76 to 1.55) 1.08 (0.74 to 1.57) 
1. Results presented are HR and 95% CIs, See Chapter 5.3.2 for abbreviations of drugs. Results 
highlighted in bold italics show a difference in statistical significance when published AD is 
combined with IPD 
2. Results taken from the model outlined in Chapter 8.2.2 
Table 30: Network meta-analysis results also incorporating aggregate data. Time-to-first 
seizure for all individuals (regardless of epilepsy type) 
Comparison1 IPD reduced to AD1,2 IPD reduced to AD, plus AD1,2 
CBZ vs PHB 0.88 (0.73 to 1.05) 0.87 (0.71 to 1.05) 
CBZ vs PHT 1.00 (0.87 to 1.14) 0.99 (0.85 to 1.15) 
CBZ vs VPS 1.06 (0.96 to 1.16) 1.01 (0.90 to 1.13) 
CBZ vs LTG 1.22 (1.11 to 1.33) 1.24 (1.11 to 1.38) 
CBZ vs OXC 1.05 (0.89 to 1.23) 1.04 (0.86 to 1.27) 
CBZ vs TPM 1.09 (0.97 to 1.22) 1.10 (0.95 to 1.27) 
CBZ vs GBP 1.39 (1.21 to 1.59) 1.36 (1.16 to 1.59) 
CBZ vs LEV 1.21 (1.07 to 1.38) 1.19 (1.01 to 1.40) 
CBZ vs ZNS 1.30 (0.97 to 1.73) 1.30 (0.92 to 1.82) 
See Table 29 for abbreviations, definitions and footnotes. 
8.4 Discussion 
8.4.1 Summary of results and clinical implications 
This Chapter presents approaches for combining IPD and AD in NMA, with or without 
accounting for epilepsy type. The principle aim of this Chapter was to investigate whether 
the incorporation of AD changes the results and conclusions of an NMA approach based on 
IPD only, which could indicate that the 69% of IPD obtained for the NMA may not be 
representative of the entire evidence base. 
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Nine trials reported AD for up to 1850 participants for the outcome ‘time-to-withdrawal of 
allocated treatment’ and six trials reported AD for up to 1369 participants for the outcome 
‘time-to-first seizure.’ For three trials, a summary HR and 95% CI could be extracted directly 
for both outcomes and for two trials, summary statistics could be estimated from published 
survival curves for one or both outcomes using the methods described in Chapter 2.3.2.2. For 
the remaining trials, IPD could be approximately reconstructed from tables or survival curves 
and used to estimate an aggregate HR and 95% CI.  
Out of 17,961 participants eligible for the IPD-NMA, 66% of IPD was available for the analysis 
of ‘time-to-withdrawal of allocated treatment’ and 68% was available for the analysis of 
‘time-to-first seizure.’ The additional extracted or estimated AD contributed an extra 3.5% 
and 1% respectively for individuals with partial seizures, 1% and 0.5% respectively for 
individuals with generalised seizures and 13% and 10% respectively for all individuals, 
regardless of seizure type. Therefore, for both outcomes, even with additionally extracted 
AD, around 20% of participants are still missing from the NMA.  
For all analyses, there seems to be very little impact of incorporating AD with IPD in NMA. 
The lack of notable difference compared to the IPD-only approach to the NMA is not 
surprising given the small amount of additional AD available by epilepsy type. 
Of note in the context of this analysis is that for one of the trials which contributed AD to the 
combined IPD and AD-NMA for both outcomes (Biton 2001), IPD was provided for this trial 
but could not be treated as IPD within the analysis. IPD for Biton 2001 was requested via data 
sharing portal CSDR and provided via a remote data access system which allowed analysis in 
SAS-based statistical software and export of analysis results but prohibited exporting of the 
dataset. Therefore, it was not possible to combine this IPD with the other datasets to perform 
the IPD only analyses (described in Chapter 6 and Chapter 7 of this thesis) and the only option 
was to treat results exported from the data access system as AD in analysis.  
As described above, there seems to be little impact on results following the addition of AD 
to the IPD analyses, therefore the restricted access format of this single trial does not seem 
to have impacted on the results of the NMA. However, it is a concern for updates of this NMA 
in particular and for future IPD syntheses in general, that the provision of data in different 
formats and the increased use of remote access systems may restrict the analyses that it is 
possible to perform across all eligible datasets and subsequently impact on results of 
syntheses and the scope of clinical questions that are able to be addressed. 
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8.4.2 Limitations of the methodological approach and future work 
It was assumed for the purpose of these analyses that the AD extracted was reliable and 
consistent in outcome definition with the IPD. It was anticipated from the results of Chapter 
3 that a limited amount of AD would be available for analysis and results of this Chapter show 
that at the most, data for 1850 out of 5570 participants (33%) from 10 out of 41 trials (24%) 
not providing IPD could be extracted or estimated. Further, for all 10 studies for which AD 
could be extracted or estimated, there were concerns regarding definitions of the outcomes 
(particularly for ‘time-to-withdrawal of allocated treatment,’ see Chapter 3 for further 
discussion), definitions of censoring, time origins of the outcomes or statistical analyses 
performed to estimate summary statistics or graphical figures. For the two studies, with 
approximate IPD provided in tables, assumptions had to be made about event times 
(examined in sensitivity analysis, see Chapter 7.2) and for data extracted graphically, graphs 
were generally of poor quality and without numbers at risk provided which will affect the 
precision of these estimated results.  
Additionally, digitisation of survival curves was not used due to the low quality of some 
graphics from older publications and it was preferred for the aim of this analysis to use a 
consistent method across all studies for the extraction of graphical data. It should be noted 
that for practical rather than methodological objectives, where graphical quality allows 
digitisation of curves, such a method may result in more accurate estimates. 
In this context, it can certainly be argued that the extracted or estimated AD was of lower 
quality than the IPD which has been consistency checked and prepared for analysis according 
to a pre-specified procedure to ensure consistency of outcome definition (see Chapter 5.3.3). 
Previous work has argued that incorporation of AD into IPD-MAs may only be justified where 
the amount of missing IPD is large and/or reasons for missing IPD are thought to be 
informative [38-41, 309]; in fact, methods for incorporating IPD and AD within NMA have 
generally been developed in the context of adding a small amount of IPD (from say one or 
two studies) to improve the precision of an AD-NMA [19, 44-46] rather than vice-versa, as 
was the objective of this Chapter.  Sutton et al [39] have argued ‘that even if IPD is available 
from only a selection of studies, assuming no selection bias in which studies have provided 
IPD, IPD analysis to explore treatment – covariate interactions may produce more reliable 
estimates than a more complete AD meta-regression.’ 
Although restricting analysis to IPD only when a subset of AD is available goes against the 
general principle of systematic reviewing of including ‘all available evidence’ [40], it is 
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questionable whether there was any benefit at all in this context of incorporating the small 
amount of AD available with the IPD in analysis, given the relative quality of the two sources, 
the small amount of additional AD available for analysis and no evidence of informative 
missingness when comparing studies with and without IPD (see Chapter 5.4.3).  
Riley et al [38, 40] warn that a joint analysis of IPD and AD may ‘distort the truth’ where AD 
is far less reliable than IPD, and that careful consideration of the approach to synthesis is 
needed within each individual setting. Results described in this Chapter show very few 
notable differences for an NMA incorporating IPD and AD compared to IPD only analyses in 
the same framework and no evidence of an increase in heterogeneity or inconsistency when 
incorporating AD with IPD in the NMA. So within this context, the small amount of ‘lower 
quality’ AD does not seem to have ‘distorted the truth’ of the conclusions from the IPD-only 
analyses but it is unknown whether bias would have been introduced into the NMA if a larger 
proportion of AD had been available for a joint analysis.   
Based on previous work conducted by the Cochrane Epilepsy group [59-67], including an 
earlier IPD-NMA using a subset of the present data [285] and the work outlined in Chapter 3 
of this thesis, it was estimated that around 80% of IPD would be retrievable for analysis and 
very little useable AD would be available. Results of Chapter 5 to Chapter 7 of this thesis 
agree with these a priori assumptions that substantially more IPD than AD would contribute 
to a combined analysis, although the final retrieval rate of 69% of IPD was slightly lower than 
anticipated. Previous methods considering combined analyses of IPD and AD in NMA have 
generally been developed in the context of adding a small amount of IPD to improve the 
precision of an AD-NMA [19, 44-46] and such methods are more methodologically complex, 
requiring analysis within a Bayesian framework.  
Therefore, following consideration, it was felt that the gain to the analysis and precision of 
results would not outweigh the methodological complexity within this context, particularly 
for communicating clinical results to the readership of Cochrane reviews for whom 
interpretations of Bayesian statistics such as credible intervals are quite unfamiliar. Hence a 
two-stage approach to the analyses outlined this Chapter (i.e. reducing IPD to AD and 
combining with additional AD using methods for AD-NMA) was specified in order to 
investigate, as far as possible, the extent of missing IPD on the clinical results of the NMA.  
On the other hand, from a methodological point of view, it would be of interest in future 
work to investigate the benefits of a Bayesian framework as defined in previous work for this 
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example of combining IPD and AD, to determine if any further information can be gained 
throughout the ‘borrowing of strength’ of a Bayesian approach.  
Furthermore, shortly after the submission of the protocol of the present IPD-NMA for 
publication on the Cochrane Database of Systematic reviews [68], we became aware of novel 
methodology proposed by Saramago et al [44] for combining individual event-time data with 
aggregated count data. These methods were not applied within this Chapter due to the 
differences in model distribution (parametric rather than semi-parametric) and framework 
(Bayesian rather than Frequentist) which were outside of the scope of this Chapter, which 
aimed to investigate whether the IPD-NMA is representative of the evidence base and to 
examine the robustness of results.  
These methods perhaps hold the most potential for future work in the context of this 
example. As outlined above, a more accessible two-stage method was preferred over 
methodologically complex methods to combine up to 68% of IPD with up to 13% of AD, 
resulting in a combined IPD and AD-NMA which still had around 20% of eligible patients 
missing. The methods of Saramago et al [44], assuming a parametric distribution, allow for 
HRs to be generated from the original count AD by estimating the cumulative hazard in each 
trial arm reporting count data for a given follow-up time. The example illustrated by the 
authors relates to high compression treatments for venous leg ulcers and the time-to-event 
outcome of interest is time-to-healing (with corresponding aggregate count data outcome of 
number healed) and the authors have IPD for 841 participants from two trials (43% of total 
data) and AD for 1105 participants from 14 trials (57% of total data).  
Examination of the outcomes and summary statistics reported within the epilepsy 
monotherapy trials not providing IPD or any time-to-event AD showed that an additional 16 
trials (recruiting 2806 participants) reported the ‘number of participants seizure-free’ and an 
additional 13 trials (recruiting 2398 participants) reported the ‘number of participants 
withdrawing from treatment.’ Therefore, in principle, using the methods of Saramago et al 
[44] may allow for up to 93% of eligible data to be included in NMA for ‘time-to-withdrawal 
of allocated treatment’ and up to 91% of data for ‘time-to-first seizure.’  
However, before undertaking such an analysis, further consideration would have to be given 
to the follow-up times and the measurement times of the count data within each trial. For 
example, some trials report seizure freedom at a series of time points throughout the trial, 
other trials report only seizure freedom during the maintenance period etc. Additionally, in 
order to synthesise ‘time-to-withdrawal of allocated treatment’ and ‘number of 
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withdrawals,’ consideration would have to be given to reasons for withdrawals which may 
not be as clearly articulated within published reported compared to participant-specific 
withdrawal reasons provided within IPD. Furthermore, within this context where treatment-
epilepsy type interactions are of interest, while the methods of Saramago et al [44] do extend 
to the incorporation of treatment-covariate interactions, for the majority of studies, AD 
(whether TTE or count data) tends to be published for all individuals, rather than separated 
by epilepsy type or adjusted for a treatment-epilepsy type interaction.  
Therefore, as this Chapter has shown for the ‘simple’ two-stage methods incorporating up to 
an additional 2% of epilepsy-type specific AD has very little impact on numerical results 
compared to an IPD only approach, the added benefits of the more complex methodology 
described by Saramago et al [44] may also be very minimal for this example.    
8.4.3 Concluding remarks 
In conclusion, this Chapter demonstrates the numerical results and conclusions of the IPD-
NMA described in Chapter 6 and Chapter 7 seem robust to the incorporation of a small 
amount of additional published AD with IPD in the NMA model. 
Despite best efforts to include as much relevant evidence as possible, including published 
aggregate data, NMAs presented within this Chapter are still missing between 20 and 30% of 
eligible data which almost inevitably will result in bias to some extent and must be taken into 
account when interpreting clinical results. 
The provision of accessible, standardised and high-quality data (whether provided at the 
aggregate or IPD level) is essential to allow updates of this IPD-NMA as further information 
becomes available, particularly for recently licenced and future treatment options. 
It appears that two IPD-MA projects submitted to the YODA project have already been 
prevented due to the restrictive remote access to data [93]. It is of concern that the increased 
use of remote access systems for sharing IPD with researchers will further restrict the 
analyses that it is possible to perform across all eligible datasets and subsequently have even 
further impact on results of syntheses and the scope of clinical questions that are able to be 
addressed. Additional flexibility within data sharing platforms, such as the ability to 
temporarily download IPD from the remote systems to perform syntheses, under the 
additional protection of legal documents such as data sharing agreements to prevent misuse 
of data may offer a solution.  
 200 
 
Chapter 9: Discussion and Conclusions 
9.1 Summary of main findings of the thesis  
Evidence syntheses are highly regarded techniques for the quantitative summary of evidence 
from a number of sources [8, 34]. In comparison to traditional aggregate-level data 
approaches, an IPD approach to meta-analysis has been widely regarded as the ‘gold-
standard’ for many years [22, 23], with a sharp increase in the number of IPD-MAs published 
in the last decade [33-35]. Recent work has also shown the benefit of an IPD approach for 
NMA [19, 44-48, 328]. 
Within many clinical settings, outcomes of interest are measured as a time to an event. 
Synthesis of TTE data is particularly common in the field of oncology but also important in 
other settings, such as measuring the retention time on treatment or the remission time from 
seizures for people with epilepsy. A range of methods for the meta-analytic synthesis of TTE 
data have been proposed over several decades and applied to a wide range of clinical and 
methodological scenarios; Chapter 2 of this thesis presents a literature review of this 
methodology according to the level of data required for the approach (IPD or AD).  
It is well documented within the field of oncology that the necessary published information 
required to perform AD-MA of TTE data is often not reported or is reported inconsistently 
[31, 144, 160, 235-237]. Therefore, a range of accessible and user-friendly methods have 
been developed with the aim of making use of more commonly reported summary statistics 
and published survival curves to indirectly estimate HRs and associated variances [6, 128]. 
However, whether these methods can be used in practice has been questioned since many 
alternative summary statistics are also not reported or published graphical figures are of 
inadequate quality [6, 141, 144].  Chapter 3 of this thesis summarises previous investigations 
of the reporting of aggregate TTE data in oncology and presents a novel systematic review of 
the reporting of TTE outcomes and associated statistics in epilepsy monotherapy studies.  
This is believed to be the first systematic review of this topic outside of the field of oncology, 
reflecting reporting standards across 35 years and 24 speciality and general medicine 
journals. In line with previous work, results of this systematic review reveal concerning 
reporting inadequacies relating to the definition, analysis and reporting of TTE outcomes 
within these epilepsy monotherapy trials.  In fact, the findings for some areas of reporting, 
particularly relating to definitions of outcomes, seem to be worse than previous reviews in 
oncology. These results also support the rationale of the Cochrane Epilepsy Group of taking 
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an IPD approach to synthesis of AED monotherapy trials, with nine IPD-MAs [59-67] and two 
IPD-NMAs [68, 69, 285] published to date, as a fully AD approach to synthesis based only on 
the published information presented in these trials would not be feasible or recommended 
to inform clinical practice. 
Increasing popularity of IPD approaches to meta-analysis over the last decade has resulted 
in rapid development of methodology allowing questions of growing clinical, statistical and 
computational complexity to be addressed via IPD-MA models [36]; Chapter 2 of this thesis 
summarises IPD-MA methodology specific to TTE outcomes. There has also been a rapid 
increase in the uptake of methods; Chapter 4 of this thesis shows that the number of 
systematic and non-systematic IPD-MAs published per year has increased to an average of 
105 between 2009 and 2015 compared to 49 per year between 2005 and 2009 [34]. 
However, despite the benefits of an IPD approach to synthesis and the increased use of such 
an approach, in practice retrieving all IPD to perform a re-analysis can require a considerable 
amount of time, cost and personnel and can be computationally intensive in the case of large 
individual participant datasets [22, 49]. Furthermore, retrieval of all relevant IPD is not always 
possible for a variety of reasons (IPD may have been destroyed or lost, original investigators 
may be unwilling to collaborate etc.) and only a proportion of IPD may be available for re-
analysis. This leaves the IPD-MA at potential risk of ‘availability bias’ where the subset of IPD 
available is not representative of the evidence base. In this case, a combined synthesis of IPD 
and AD may be a feasible option to increase precision and reduce ‘availability bias;’ 
methodology for the combined synthesis of IPD and AD is summarised in Chapter 8. 
The culture of clinical trial data sharing has changed in recent years, with a shift in attitudes 
towards the support of data sharing and many calls for improved data transparency and data 
sharing initiatives introduced across the research community as a whole [77-87]. The way 
that pharmaceutical clinical trial data is shared for secondary research, such as syntheses, 
has also changed with the launch of data-sharing platforms such as CSDR, YODA and SOAR 
since 2013 [91, 93, 95]. Such platforms allow researchers to request access to IPD via a 
structured process of selecting studies of interest, submitting a scientific research proposal, 
signing of a data sharing agreement by the researcher and sponsor and finally access to de-
identified IPD and related documentation which can be analysed remotely in a SAS analytic 
environment and analysis results exported from the environment. While such initiatives and 
platforms should make access to IPD easier and faster, the impacts of these changes in 
attitudes and data sharing methods may not become clear for some time.  
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Chapter 4 presents a novel systematic review of data retrieval within IPD-MAs. Out of 760 
IPD-MAs using systematic methods to identify eligible studies published between 1987 and 
2015, only 188 (25%) retrieved 100% of the eligible IPD for analysis and only 324 (43%) 
retrieved at least 80% of relevant IPD. Chapter 4 also shows that up to 2015, there is no 
evidence of an improvement in IPD retrieval rates over time but that IPD-MAs that included 
only randomised trials, had an authorship policy, included fewer eligible participants and 
were conducted outside of the Cochrane Database of Systematic Reviews were associated 
with a high or complete IPD retrieval rate.  
Chapter 5 reflects upon the IPD requesting experiences of the Cochrane Epilepsy group over 
the last 20 years, from a time when IPD approaches to synthesis were relatively novel up to 
the end of 2016, throughout the new era of data sharing initiatives. Chapter 5 shows that the 
earliest Cochrane Epilepsy IPD-MA published in 2000 included IPD from 63% of total trials 
and 83% of total participants [67], a good retrieval rate in the wider context of all IPD-MAs 
as presented in Chapter 4; however the latest Cochrane Epilepsy IPD-NMA included IPD from 
47% of  total trials and 69% of total participants [69]. This reflects a decline in the IPD retrieval 
rate from requests made between 1995 and 2005 to requests made between 2012 and 2015.  
Chapter 4 also highlights that reporting inadequacies in IPD-MAs of all clinical contexts are 
not uncommon, with 257 out of the 760 IPD-MAs (34%) not reporting sufficient information 
to calculate the IPD retrieval rate and in 58% of IPD-MAs that failed to retrieve 100% of 
eligible IPD, there were no specific reasons provided for the unavailability of data. 
Furthermore, in around a quarter of IPD-MAs that failed to retrieve 100% of eligible IPD, 
there was a complete lack of discussion or acknowledgement of any biases that may have 
been introduced by the missing IPD.  
Chapter 6 presents the statistical methodology and Chapter 7 presents clinical results for an 
IPD-NMA of ten AEDs used in monotherapy for 12,391 participants from 36 clinical trials that 
IPD was successfully retrieved from, data for 69% of eligible participants from 47% of eligible 
trials as outlined in Chapter 5. Outcomes considered within this IPD-NMA included ‘time-to-
withdrawal of allocated treatment’ and ‘time-to-first seizure after randomisation’ and the 
NMA also incorporated a treatment-covariate interaction between the antiepileptic drug and 
epilepsy type (partial or generalised seizures). Clinical results of this IPD-NMA support 
current NICE guidelines [74] and suggest some alternative treatment options for those 
individuals for which the first-line recommended treatments are not suitable.  
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Chapter 8 presents methodological approaches for including AD with IPD in NMA for this 
example. As predicted by the results of the systematic review presented in Chapter 3, few of 
the epilepsy monotherapy studies without IPD available reported any suitable AD which 
could be extracted or indirectly estimated (numerically or graphically, via the methods 
outlined in Chapter 2). The additional extracted or estimated AD contributed only up to an 
extra 3.5% or 1% of data to the NMA for individuals with partial seizures and individuals with 
generalised seizures respectively and the incorporation of this additional AD with the IPD in 
NMA had a negligible impact on results.  
On the other hand, the methodological approach to the relationship between treatment and 
epilepsy type did have an impact on the results; while different approaches produced very 
similar numerical results and mostly identical conclusions for individuals with partial seizures 
(the majority epilepsy type, around 70%),  numerical results for individuals with generalised 
seizures (the minority epilepsy type, around 25%) change quite substantially, as well as some 
changes in the statistical conclusions, with difference analysis approaches for epilepsy type.     
9.2.  Implications for practice and research 
The implications of this thesis fall into three topics; the methodological implications of the 
findings around IPD retrieval and around conduct and reporting of IPD syntheses, and the 
clinical implications of the illustrative example of the IPD-NMA of antiepileptic drugs.  
9.2.1 Clinical implications 
The findings of this thesis are underpinned by the application of methodology to a large 
Cochrane IPD-NMA of ten AEDs and investigation of the treatment-by-epilepsy type (partial 
or generalised seizures) interaction.   
The results of the IPD-NMA demonstrate that, in line with current NICE guidelines [74], that 
CBZ and LTG are suitable first-line treatments for individuals with partial seizures but also 
adds new information that LEV may be a suitable alternative. Results for individuals with 
partial seizures are robust to additional and sensitivity analyses including investigation of 
different methodological approaches for modelling the relationship between treatment 
effect and epilepsy type, accounting for any observed inconsistencies in the IPD provided and 
following the incorporation of additional AD with IPD into the NMA model. 
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The majority of participants recruited into the trials included in the IPD-NMA were classified 
as experiencing partial seizures, which is reflective of clinical practice that around 60% of 
individuals with epilepsy experience partial seizures [320]. However, the proportion of 
individuals with partial seizures recruited to the trials in the IPD-NMA is greater than would 
be expected in clinical practice with 67.5% of included participants classified as experiencing 
partial seizures, around 26.5% of participants experiencing generalised seizures and the 
remaining 6% experiencing seizures of a type which is difficult to classify. Additionally, there 
was an indication that up to 36% of individuals classified as experiencing generalised seizures 
may have had their seizure type misclassified, so the true proportion of individuals 
experiencing generalised seizures within the IPD-NMA may be as small as 17%.  
Due to this imbalance in the two epilepsy types, results for individuals with generalised 
seizures were less precise and less robust to different approaches to statistical analysis. 
Results of the main analysis for individuals with generalised seizures are also in line with 
current NICE guidelines, supporting the use of VPS as a first-line treatment but also adds new 
information that LTG and LEV may be suitable alternative first-line treatments.  
The findings of this thesis and the IPD-NMA provide recommendations for the design and 
conduct of future AED monotherapy trials. It is essential that future trials are adequately 
powered to detect a difference between particular AEDs while recruiting a sample of 
individuals representative of the wider population in terms of age and epilepsy type. The 
latter is particularly important in order that future syntheses can provide more precise and 
robust evidence for individuals with generalised seizures as additional potential treatment 
options become available. Given that current clinical practice reflects a different selection of 
preferred treatment options of individuals with different epilepsy types [74], it is also 
recommended that future trials should incorporate interactions between treatment effect 
and epilepsy types within statistical analysis and clearly report treatment and interaction 
effects according to different epilepsy types within the trials. 
Furthermore within these trials, the choice of outcomes at the design stage and the 
presentation of the results of outcomes require careful consideration. The ILAE recommend 
that trials of a monotherapy design should adopt a primary effectiveness outcome of 'time-
to-withdrawal of allocated treatment’ and should be of a duration of at least 48 weeks to 
allow for assessment of longer-term outcomes, such as remission [249].  If trials followed 
these recommendations, an AD approach to meta-analysis may be feasible, reducing the 
resources and time required from an IPD approach. 
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In a wider clinical context, the findings of this thesis highlight the importance of an IPD 
approach when considering a clinically complex treatment-covariate interaction, in addition 
to the essential requirement of transparent reporting at all levels, whether at the trial 
publication level, IPD level or data request level (e.g. with respect to reasons why IPD are not 
available), to allow the appropriate conclusions to be drawn from the clinical question. 
9.2.2 Methodological implications: IPD retrieval rate 
Reviews of the literature conducted for this thesis indicate that in recent years, IPD 
approaches to synthesis are rapidly gaining in popularity, with the majority of new 
methodological work relating to meta-analysis requiring the analysis of IPD and it is now 
estimated that over 100 new IPD-MAs are being published each year. In parallel, initiatives 
to promote open and transparent sharing of clinical trial data continue to gain in momentum 
over recent years.   
However, the findings of this thesis show that these substantial changes in culture and 
methodological practice do not seem to be mirrored by improved IPD retrieval rates. This 
may be due, in part, to the increasing uptake of IPD-MAs across a wide range of clinical areas 
and settings and increasing use of sophisticated systematic searching methods, such as those 
employed by the Cochrane Collaboration, which uncover grey literature where IPD may be 
difficult to obtain. 
There has been a decline in the IPD retrieval rate from data requests made by the Cochrane 
Epilepsy group between 2012 and 2015 compared to requests made between 1995 and 2005. 
A concern is that ‘prohibitive costs’ have prevented the sharing of pharmaceutical data for 
recent requests made by the Cochrane Epilepsy group and there seems to be an emerging 
association between the resources of the data provider and the provision of IPD. 
Changes in methods of sharing pharmaceutical and the additional step of rigorous data 
checking and de-identification have anecdotally resulted in the provision of cleaner datasets 
compared to datasets provided in previous requests to the Cochrane Epilepsy group. While 
this is beneficial to the researcher, who is required to spend less time and resource checking 
data and resolving problems or inconsistencies, these changes are associated with additional 
costs and resources to the data provider.  
Recent work has demonstrated that preparation of academic clinical trial data for external 
sharing may take up to 50 hours and the associated cost may be as high as £3000 per trial 
[300]. Such time and financial costs may be even higher for older trials, or trials which are 
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particularly large or of a complex data structure. It can be argued that it is unreasonable for 
data providers to incur all of these costs, without discernible acknowledgement or reward, 
particularly for academic data providers for whom the intellectual property of their data may 
be of great value to the academic institution and to individuals within the institution.  
Furthermore, results of this thesis have also demonstrated that implementation of an 
authorship policy, an incentive to participate in IPD-MAs, is associated with a complete or 
high retrieval rate of IPD compared to IPD-MAs without an authorship policy. Therefore, 
collaboration between researchers and data providers, whether financial, shared authorship 
or otherwise, may assist in sharing costs and resources and also the benefits of any secondary 
research. In turn, collaboration of personnel and resources may potentially maximise 
retrieval rates of IPD.  
Of further concern in the present era of data transparency is the continued reporting of non-
specific reasons for unavailability of IPD. Three out of the 35 requests made by the Cochrane 
Epilepsy group between 2012 and 2015 received a negative response but no specific reason 
was given as to why data could not be provided and metrics available on the CSDR website 
also list non-specific reasons for why data could not be provided for 15% of requests. While 
it is inevitable that some IPD-MAs will not be able to include all relevant IPD for perfectly 
valid reasons, where a specific reason for the unavailability of IPD is not provided, it is difficult 
to make a judgement regarding the presence of availability bias which has implications for 
the interpretation of the results and conclusions of the synthesis.   
Findings of this thesis also suggest that the current format of the data sharing platforms such 
as CSDR and YODA may not be suitable for syntheses due to the restrictive access to the data 
provided and associated legal obligations which prevent collating all available data in a single 
location for analysis.  The impact that the current restrictions of data sharing platforms may 
have on future clinical and statistical analyses, potentially rendering some analysis 
approaches impossible within the framework, are of great concern. Additional flexibility 
within data sharing platforms, such as the ability for ‘approved’ researchers to temporarily 
download IPD to perform syntheses, may offer a solution. 
9.2.3 Methodological implications: conduct and reporting of IPD syntheses 
The findings of this thesis reveal concerning inadequacies of reporting in many areas which 
have implications to the conduct of evidence synthesis and many of which have contributed 
to the conduct of a large IPD-NMA in epilepsy. 
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Concerns regarding inadequate reporting of aggregate TTE data has been well documented 
since 1995 [31] and there does not seem to have been any improvement over time, with 
several other reviews of this topic within oncology trials, the most recent published in 2013 
[242], showing equally poor reporting. Findings of this thesis emphasise the calls from 
previous reviews [31, 242] for the urgent development of minimum reporting standards for 
TTE analyses. In the continuing absence of the development of such standards, use of the 
suggested guidelines from previous work [31, 242] by journal editors and peer reviewers 
when considering study publications using TTE analyses would greatly improve reporting 
rates and in turn facilitate the conduct of AD-MAs and syntheses with TTE endpoints. 
Findings of this thesis also demonstrate inadequacy of reporting in the published results of 
IPD-MAs, particularly regarding study and participant numbers contributing to different 
stages of the IPD-MA, reasons for unavailability of IPD and consideration of potential 
availability bias introduced by missing IPD. It is unknown whether the lack of discussion or 
additional analyses to investigate availability biases are due to inadequate or selective 
reporting, or whether meta-analysts simply were not aware that biases could have been 
introduced into their analyses by a missing subset of eligible IPD. 
A recent scoping review of published IPD-NMAs, a relatively new research field compared to 
IPD-MAs, has also revealed several recurrent areas of inadequate reporting, such as an 
evaluation of consistency assumptions, existence of a study protocol, and methods used to 
request, collect, and manage IPD and management of missing data [48].  
These findings highlight that improvements are needed in the conduct and reporting of IPD 
syntheses. It is highly recommended that all syntheses, whether of an AD or IPD level and 
whether systematic or prospective, follow a registered protocol [284] and that any deviations 
from the protocol are clearly described and justified. It is particularly important for IPD 
approaches of a systematic nature, that researchers demonstrate awareness that despite 
their best efforts, it may not be possible to obtain all eligible IPD for analysis and that it is 
clearly outlined how biases related to missing IPD will be evaluated.   
It is also absolutely essential that the number of eligible studies and participants, how much 
data was requested and obtained with clear reasons for non-availability of IPD, preferably 
via a flow diagram, are transparently reported. Such information is not only important for 
the interpretation of reported results and conclusions, but is also of value for future research; 
providing ‘best practice’ guidance for researchers embarking upon IPD synthesis. 
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Proper uptake of new PRISMA-IPD guidelines for the conduct and reporting of IPD-MA [283], 
in addition to guidance on the use of IPD-MA to synthesise the results of RCTs [282] should 
lead to improvements in the highlighted areas of conduct and reporting that are currently 
inadequate. There has also been a recent call for the development of PRISMA-IPD-NMA 
guidelines, based on the current PRISMA-IPD and PRISMA-NMA guidelines for the conduct 
and reporting of IPD-MAs and NMAs respectively [48]. Such guidelines would be a welcome 
addition to the evidence synthesis literature and may prevent inadequacies of reporting of 
IPD-NMAs becoming commonplace, as this research field continues to develop. 
While existing guidelines such as PRISMA, PRISMA-IPD and PRISMA-NMA provide a minimum 
set of reporting items within each synthesis design (i.e. AD, IPD or NMA); there are currently 
no formal recommendations, from PRISMA or from Cochrane methods groups, to guide 
authors when choosing the most appropriate synthesis approach to the clinical question and 
what information should be reported regarding the rationale for the analysis approach. 
Previous work has recommended that researchers should carefully consider the added 
benefits of IPD whether a less resource intensive AD-MA could provide an adequate (and 
mathematically equivalent) answer to the question [52, 53]. Ideally, the rationale for an IPD 
approach to synthesis should be clearly described and justified in a registered protocol. 
Previous work has also suggested that the additional methodological complexity of 
incorporating both IPD and AD sources within synthesis may not necessarily provide any 
additional benefit to analysis and in fact may introduce biases into the combined analysis 
where AD is of a lower quality than the IPD [38, 40]. Although relatively simple methodology 
was used to incorporate IPD and AD for the illustrative example outlined in this thesis, 
findings are in line with previous work and suggest that there was very little impact to 
incorporating IPD and AD in this context, given that the majority of evidence came from IPD 
sources compared to AD sources. Therefore, it should be recommended that researchers 
consider the added benefits of a combined IPD and AD analysis over an IPD-only approach, 
taking into account the relative quality and available proportion of each data source. Again, 
ideally, any planned methodology for combining IPD and AD in synthesis should be clearly 




9.3 Limitations and future work 
The specific limitations to each element of the work presented in this thesis have been 
discussed in detail in the relevant chapters. This section will focus on the overall limitations 
of the work presented in this thesis and make suggestions for future work which may be able 
to address some of the limitations. 
The first major limitation is that many of the findings from this thesis are based on published 
information; such as the results reported in epilepsy monotherapy trials, IPD retrieval rates 
and characteristics of IPD-MAs and metrics from the CSDR and YODA websites.  
Due to the size of the cohorts included in the novel systematic reviews presented in this 
thesis, particularly the systematic review of IPD-MAs, it was out of the scope of the work to 
contact original investigators individually to request additional or unpublished information.  
In the context of Chapter 3, where results showed inconsistent choices of outcomes and 
inadequate reporting of TTE analyses in epilepsy trials, it would be of value to gain further 
insight into potential reasons for these findings. For example, how the trial outcomes were 
selected and why so few trials report the primary outcome according to the definition 
recommended by the ILAE [249]; perhaps clinicians do not agree with current guidelines and 
find recommended outcomes too complex or prefer alternative outcomes? Such insights 
could help to provide updated guidelines that more trials may adhere to, hence improving 
the consistency of outcome reporting across trials and facilitating synthesis of trials.  
Furthermore, it was not possible within the systematic review of IPD-MAs in Chapter 4 to 
examine data requesting and collection methods in detail as this level of information was not 
provided within published journal articles. This is a great limitation of the work as the 
approach to collecting data is likely to be very influential on the proportion of data retrieved. 
Therefore gaining further insight into the approaches taken by different research teams with 
respect to the routes of communications to make data requests, wording of requests, 
number of attempts at a request, any deadline set for data to be provided etc. would be of 
great interest and would be valuable to inform the conduct of future IPD syntheses.  
While word limits of journals do not always allow for detailed descriptions of methodology, 
including data collection methods for IPD-MAs, such information could be provided as online 
appendices or published within registered protocols, for example via PROSPERO [284] where 
word limits are not as restrictive. The detailed data collection methods for the IPD-NMA 
described in this thesis are outlined in Chapter 5 and published in an article in the British 
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Medical Journal [278]. While the methods employed to collect data for this IPD-NMA may 
not necessarily reflect the ‘best practice’ to obtain the maximum amount of IPD as possible; 
we hope providing this additional level of practical information regarding our methodology 
may further aid with interpretation of the results of the IPD-NMA and may act as a starting 
point for research groups planning future IPD syntheses.  
The second main limitation of the work in this thesis is the relatively simplistic ‘two-stage’ 
approach to the IPD-NMA (Chapter 6) and the NMAs combining IPD and AD (Chapter 8). As 
discussed in Chapter 6.3.2, at the time that the IPD-NMA analysis was planned [68], 
methodology in this field was still relatively rare, therefore the proposed methodology was 
adapted from a previous IPD-NMA in epilepsy conducted by the group [285]. Although 
additional IPD-NMA methodology is now available and additional applied IPD-NMAs have 
been published [48], we are still not aware of any existing methodology which would allow 
for one-stage IPD-NMA of a TTE outcome with a treatment-by-covariate interaction, 
separated into within and across-study interactions which also allows the incorporation of 
AD within a single model.  
The majority of methods for NMA, particularly IPD-NMA and models which combine IPD and 
AD in NMA have been developed within a hierarchical Bayesian modelling framework. When 
planning this IPD-NMA, intended for a Cochrane readership, it was decided that analysis and 
presentation of results within a Frequentist framework would be preferable for accessible 
interpretation of results. It would be of interest for further work to investigate the benefits 
of Bayesian framework for this example; particularly whether any gain in precision in results 
for individuals with generalised seizures would be possible from the additional ‘borrowing of 
strength’ across the network of a Bayesian approach. Also it would be of interest to further 
research whether a Bayesian framework is the only feasible option to incorporate all 
requirements of this example together in a one-stage NMA approach (i.e. analysis of IPD only 
or the simultaneous analysis of IPD and AD, analysis of a TTE outcome, consideration of 
within and across-study treatment-covariate interactions).   
Important considerations for further work would also be whether existing IPD-NMA methods 
developed within a Bayesian framework could also be translated into a Frequentist 
framework; hence potentially making results of complex IPD-NMAs more accessible to a 





9.4 Concluding remarks 
The work of this thesis has provided a detailed insight into the conduct of an IPD-NMA in 
epilepsy and highlighted many inadequacies of the conduct and reporting of AD and IPD 
syntheses across a wide range of clinical disciplines. It is essential for clinical research of all 
sources, whether an original trial or synthesis, that the study is well-designed, following a 
registered protocol, adhering to any relevant recommendations or minimum reporting 
guidelines and that all results are reported transparently. Recommendations taken from 
previous work and from this thesis and improved conduct and reporting of clinical research, 
whether trials or syntheses, could have a valuable impact on evidence based medicine.  
The work of this thesis was undertaken during a time of great change within the research 
community regarding how clinical trial data is shared for secondary research. These changes 
will have substantial impacts on how IPD syntheses such as meta-analyses and network meta-
analyses can be conducted in the future. While the full extent of the impact of this new era 
of data transparency may not become apparent for some time, the work undertaken in this 
has identified some of the early benefits and importantly some of challenges and restrictions 
of new methods of sharing clinical trial data. If emerging limitations, particularly those 
related to restricted access to data, can be addressed while data sharing platforms are still 
relatively new and under development, in the future, data sharing platforms are likely to be 
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Appendix 1: Search strategies and reference list for Chapter 2 
Search strategy for Cochrane Methodology Register (searched up to July 2012)  
#1 (meta-analysis):ti,ab,kw in Methods Studies    
#2 (time-to-event):ti,ab,kw in Methods Studies    
#3 (survival analysis):ti,ab,kw in Methods Studies   
#4 (survival data):ti,ab,kw in Methods Studies     
#5 (survival studies):ti,ab,kw in Methods Studies  
#6 (failure time):ti,ab,kw in Methods Studies    
#7 (#2 or #3 or #4 or #5 or #6)      
#8 (#1 and #7)        
#9 (review methodology):ti,ab,kw in Methods Studies   
#10 (#8 and #9)        
#11 (longitudinal):ti,ab,kw in Methods Studies    
#12 (#10 and not #11) 
Search strategy for MEDLINE (searched from 1946 up to 24 January 2017)  
1     *Meta-Analysis as Topic/       
2     (meta-analysis or meta-analyses).ti,ab.     
3     1 or 2         
4     "time-to-event".ti,ab.       
5     (failure time or failure time data).ti,ab.     
6     (survival analys$ or survival data or survival study).ti,ab.   
7     *Survival Analysis/        
8     4 or 5 or 6 or 7        
9     3 and 8         
10     Models, Statistical/       
11     Proportional Hazards Models/      
12     10 or 11         
13     9 and 12     
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Appendix 2: Search strategies used in Chapter 3 
Search Strategy of Cochrane Epilepsy Group’s Specialised Register (search 
conducted 14/09/2012) 
#1 (Carbamazepine or Tegretol or Carbagen or CBZ or Clobazam or Frisium or Urbanol or 
Onfi or CLB or Eslicarbazepine or Zebinix or Exalief or Stedesa or ESL or Ethosuximide or 
Emeside or Zarontin or ESM or Gabapentin or Fanatrex or Gabarone or Neogab or Gralise or 
Neurontin or Nupentin or GBP or Lamotrigine or Lamict* or Lamotrine or Lamitrin or 
Lamogine or Lamitor or LTG or Levetiracetam or Keppra or LEV or Oxcarbazepine or 
Trileptal or OXC or Phenobarbit* or Luminal or PB or Phenytoin or Epanutin or Phenytek or 
Dilantin or Eptoin or Diphenin* or Diphenylhydantoin or PHT or Pregabalin or Lyrica or PGB 
or Primidone or Mysoline or Prysoline or Liskantin or Desitin or Resimatil or Mylepsinum or 
Sertan or PRM or Remacemide or Ecovia or RMC or Sultiam* or Sulthiam* or Ospolot or 
STM or Tiagabine or Gabitril or TGB or Topiramate or Topamax or TPM or Valpro* or 
Convulex or Depak* or Depacon or Valparin or Stavzor or Epilim or Epiject or Episenta or 
Epival or Orlept or Orfiril or Selenica or VPA or Vigabatrin or Sabril or VGB or Zonisamide or 
Zonegran or Excegran or ZNS) AND (INREGISTER) [REFERENCE] [STANDARD] 
#2 ((adjunct* or "add-on" or "add on") NOT monotherap*) AND (INREGISTER) [REFERENCE] 
[STANDARD] 





Appendix 3: Data extraction form used in Chapter 3 
Reporting of Time-to-Event outcomes and analyses in 
Epilepsy Monotherapy Studies 
Data Extraction Form 
STAGE 1 – OUTCOMES 
Name of reviewer:   Laura    Sarah   




Year of Study:    
Study ID (first author and year): 
List all outcomes reported in the study: 
 
Is at least one time-to-event outcome reported? Yes  No   
Unclear   If Unclear, why?  
IF YES OR UNCLEAR, CONTINUE TO STAGE 2: TIME-TO-EVENT STUDIES 
IF NO, EXCLUDE STUDY FROM STAGE 2 (DATA EXTRACTION IS COMPLETE)  
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STAGE 2- TIME TO EVENT OUTCOMES (STUDIES) 
Number of treatment arms: 
List of treatment arms (including doses for dose-controlled studies): 
 
Did the study receive pharmaceutical sponsorship/support or have pharmaceutical 
involvement (e.g. authors affiliated with pharmaceutical companies)?   
Yes   No    Unclear   
If yes, provide details of pharmaceutical involvement: 
 
Type of control: Placebo or no treatment  Other AED    
Dose-controlled (same AED)   
Other active control (specify)  
Study sponsorship: Pharmaceutical   Academic   
   Government    Other (specify) 
   Unclear    Details (if unclear): 
 
Blinding  Single-blind    Double-blind   
   Open-Label / Unblinded  Other blinding   
Unclear    





Design of study: Superiority*   Equivalence   
   Non-inferiority  Unclear   
*Superiority design for Epilepsy monotherapy studies as defined by ILAE 2006 guidelines 
Reference: Glauser T, Ben Menachem E, Bourgeois B, et al. ILAE Treatment Guidelines: 
Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial 
Monotherapy for Epileptic Seizures and Syndromes. Epilepsia 2006;47(7):1094-120) 
Details: 
 
Population (tick all that apply):  
Refractory/ drug resistant seizures    Newly diagnosed seizures  
Relapsed seizures (after AED discontinuation)   Unclear   
Other (specify):           
General information: are the following clearly reported? 
Number of participants randomised:    Yes  No   
Number of participants completing study:   Yes  No   
Number of participants excluded from the study / from analysis:  
Yes  No  
Details of any reasons for exclusions: 
 
Are all above participant numbers specified by treatment arms?  
Yes  No   




Time frame of the study: are the following clearly reported? 
Length of accrual period of participants (specify):    
Length of titration / baseline / dose-escalation period (specify):   
Length of maintenance period (specify):     
Study Duration (specify):        
Other study period: (e.g. pre-treatment period, open-label extension period etc.): 
 
Frequency / number of follow-up visits (e.g. monthly visits, 4 visits per participant 
etc.): 
 
Minimum follow-up time:    Yes  No   
Maximum follow-up time:    Yes  No   
Mean follow-up time:     Yes  No   
Median follow-up time:    Yes  No   
If yes, is the method used to calculate median follow-up time reported (specify): 
 
 








All primary / secondary outcomes: are the following clearly reported? 
Number of outcomes (specify): 
Number of time-to-event outcomes (specify): 
Are all reported outcomes clearly defined?   Yes  No   




Is a single primary outcome identified?   Yes  No   
If yes, specify this primary outcome (and whether the outcome is time-to-event, 
binary, continuous etc.): 
 
 
If yes, is a sample size calculation described relating to the primary outcome? 
        Yes  No   
Is time-to-withdrawal of allocated treatment (retention time) reported?  
Yes  No   
If yes, are competing risks taken into account (e.g. withdrawal due to poor seizure 
control and/or adverse events)    Yes  No   







Is at least one seizure outcome (efficacy) defined?  Yes  No   





Is at least one adverse event outcome (tolerability) defined?  
Yes  No   









Are outcomes reported consistently in both methods and results sections?  
Yes  No   





STAGE 3: TIME-TO-EVENT OUTCOME REPORTING  
Repeat STAGE 3 for each time-to-event outcome reported 
Number of time to event outcomes in the study: 
Time-to-event outcome (exact definition): 
 
Is the time origin of the outcome defined?  
Yes  No   Unclear  
Specify details (e.g. date of randomisation, date of first treatment dose etc.): 
 
Is the number of participants contributing to the outcome reported? 
Yes  No   
Is the number of events for the outcome reported?  Yes  No   
Is the definition of an event clear for the outcome?  Yes  No   
If yes, specify definition of event: 
 
Number of participants censored:    Yes  No   
Number of participants lost to follow-up:   Yes  No   
Is the definition of a censored observation clear for the outcome?  
Yes  No   
If yes, specify definition of censored observations: 
 
Are participants censored and participants lost to follow-up reported separately? 
        Yes  No   
Are events, censoring and losses to follow-up reported by treatment group? 




Statistical analysis: Are the following clearly reported?  
Survival probability / event rate:    Yes  No   
Median Survival time:      Yes  No   
Log-rank p-value:      Yes  No   
Other p-value (specify): 
Precision of p-value (e.g. ‘not significant,’ one decimal place etc.): 
 
Hazard ratio:       Yes  No   
Other effect size (specify): 
 
Standard deviation / standard error of effect size:  Yes  No   
Confidence interval of effect size:    Yes  No   
Observed and Expected number of events:   Yes  No   








Is it stated that all assumptions of statistical methods have been assessed? 







Are any multivariable methods /analyses used?  Yes  No   




Is a method of choosing variables described (specify)? 
 
 
Are variables measured at baseline?    Yes  No   
Are multivariable model coefficients reported?  Yes  No   
Are multivariable model confidence intervals reported? Yes  No   
Are multivariable model p-values reported?   Yes  No   
Has a statistical software package been used for analysis (specify including version)? 
 
 




Are methods reported in sufficient detail to replicate results? 
        Yes  No   
Are reported methods and results sections consistent?  
        Yes  No   




Survival plots  
Is a survival graph presented for the outcome? Yes   No   
Which type of graph is presented? Kaplan-Meier   Actuarial   
Other (specify)  Unclear   
Is a step function used for Kaplan-Meier plots? Yes   No   
Is the direction of the graph up or down?  Up   Down   
Are censored observations clearly marked?  Yes   No   
Are (effective) numbers at risk reported at regular intervals?  
Yes   No   
Are different line types clearly used for multiple curves?  
Yes   No   
Is a clear legend provided for the graph?  Yes   No   
Are the axes of the graph appropriate (e.g. intervals, scale etc.)?  
Yes   No   
Is an effect size (e.g. p-value/hazard ratio) displayed on the graph?  
Yes   No   
Are standard errors/confidence intervals displayed on the graph?  
Yes   No   






STAGE 4: OVERALL REPORTING  
Are published survival graphs consistent with published text?    
Yes  No   No graph(s)   
Are published tables consistent with published text?   
Yes  No   No tables(s)   
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Appendix 6: Additional results from Chapter 3 
Table 31: Outcomes reported in 54 epilepsy monotherapy studies without a time-to-
event outcome defined 




1. Neuropsychological assessment: general intelligence, verbal 





1. Cognitive and behavioural effects (intelligence, memory, 
attention, psychomotor speed, impulsivity) - difference 
between baseline, 6 weeks and 12 months 




1. The change in frequency of complex partial seizures per 8 
weeks between the baseline period and the monotherapy 
portion of the experimental period. 
2. The change in seizure frequency of simple partial seizures 
and secondarily generalized tonic-clonic seizures. 
3. The percent change in seizure frequency from baseline 
(responder rate) 





1. Seizure control  
2. Seizure frequency  
3. Serum drug concentration  
4. EEG results 







1. Response to treatment: complete remission, partial 
remission or no remission  
2. Serum levels of anticonvulsant drugs in relation to seizure 
control  








1. Seizure control: excellent, good, poor  
2. Number and duration of seizures  
3. EEG findings  
4. Side-effects. 
Chen 1996 Epilepsia 
1. Seizure frequency (low/moderate/high) and duration; 
2. Side-effects  
3. Psychometric tests (WISC-R and Bender-Gestalt), 
4. Neurophysiological data (P_300 recorded by EEG)  
5. AED levels  
6. Blood count; liver function test. 
Cho 2011 Seizure 
1. Change in overnight polysomnography (PSG) scores (sleep 
latency, REM sleep latency, total sleep time, sleep efficiency, 
percentage of each sleep stage, arousal index, and Wake 
time After Sleep Onset (WASO)) from baseline after 4-6 
weeks of treatment 
2. Change in Sleep questionnaires (sleep diaries, the Pittsburg 
Sleep Quality Index (PSQI), the Korean version of the Epworth 
Sleepiness Scale (KESS), Beck’s depression inventory-2 (BDI-2) 
and the Hospital Anxiety Scale (HAS)) and National Hospital 







1. Proportion of patients remaining seizure-free by treatment 
group:  lack of clinically observed seizures since the previous 
visit and lack of electroclinical seizures during ambulatory 24-
h EEG testing and a video-EEG session with hyperventilation. 






2. Incidence of adverse events 
Craig 1994 Epilepsia 
1. Psychological tests: verbal memory, digit symbol substitution, 
letter cancellation, digit recall, anxiety and depression, recall, 
visual reproduction, reaction time, motor speed and 
coordination 
2. Health profile questionnaire (neuropsychiatric and other 
adverse drug effects)  
3. Drug concentration in blood  
4. Adverse event frequency 




1. Changes in seizure frequency between baseline and the end 
of each maintenance period 
2. Changes in EEG tracings between baseline and the end of 
each maintenance period 
3. Global evaluation of therapeutic efficacy and tolerability by 
the investigator at the end of each maintenance period 
4. Side effects observed by patients and investigators each visit 
5. Laboratory tests (WBC counts and liver function tests, Blood 




1. Neuropsychological testing difference from baseline: 
Wechsler Adult Intelligence Scale revised (WAIS-R), Brief 
Psychiatric Rating Scale (BPRS), Profile of mood states 
(POMS), Washington Psychosocial seizure Inventory (WPSI), 
Lafayette Grooved Pegboard, Stroop, Benton Visual 
Retention, Controlled Oral Word Association, Mood Rating, 
Symbol Digit Modalities, Rey Auditory Verbal Learning, 
Wonderlic Personnel, and Digit Cancellation. 
2. Relief from seizures (>= 50% reduction in seizures, < 50% 




1. Cognitive testing: Computerized Visual Searching Task (CVST), 
assessing mental information processing speed and 
attention.  Rey Auditory Verbal Learning Test (AVLT) and 
Raven’s Standard 
2. Progressive Matrices for children: Psychomotor speed, 
alertness, memory and learning, and non-verbal intelligence. 
3. Percentage of patients remaining seizure-free throughout 
treatment 
4. Most common adverse events 




1. Mean reported percentage weight gain by treatment group 
2. Incidence of excessive body weight velocity (weight velocity 
defined as change in body weight over one year and 
excessive defined as body weight exceeding the 97th centile) 
Eun 2011 Seizure 
1. Seizure-free rate over 6 months (maintenance period) by 
treatment group 
2. Change in cognition (neuropsychological), behavior and 
quality of life from screening to the end of the maintenance 
phase by treatment group 






1. Seizure-freedom (seizure-free during 24-wk maintenance 
period after titration); 
2. Greater than 50% seizure reduction after treatment; 
3. Cognitive changes (FSIQ, VIQ, PIQ, verbal comprehension, 
perceptual organisation, attention, concentration); 
4. Behavioral changes (social competence, academic 
competence, total social competence, withdrawn, somatic 
complaints, depression/anxiety, social problem, thought 
problem, attention problem, delinquent behaviour, 
aggressive behaviour, internalizing problem, eternalizing 
problem, total behaviour problem, Conners [parent and 
teacher]); 




1. Responder status: percentage of patients free from clinical 
seizures on days 13 and 14 
2. Freedom from EEG seizures during standard EEG recording 
with hyperventilation and intermittent photic stimulation on 
day 14 
3. Percentage of patients free from clinical and EEG seizures 
lasting > 4 seconds on days 4-7 and days 11-14 
Percentage of patients free from clinical seizures days 1-14 
and free from EEG seizures lasting > 4 seconds on days 7 and 
14 
4. Percentage change (vs. baseline) in number and total 
duration of EEG seizures and spikewave discharges lasting >4 
s during the 24-h EEG on day 14  
5. Percentage of patients with at least 50% reduction (vs. 
baseline) in the total duration of EEG seizures lasting >4 
seconds during the 24-h EEG on day 14  
6. Safety and tolerability data (adverse events) 




1. Number of patients meeting escape criteria (doubling of 2-
day/monthly seizure frequency, worsening of seizure 
subtype, prolongation of seizure duration) 
2. Adverse events  
3. Lab variables (blood counts and urinalyses) 
4. Plasma drug concentration 
5. Vital sign data 
6. Body weights  
7. ECG findings. 
Feksi 1991 Lancet 
1. Seizure activity during therapy (freedom from seizures/ 
seizure frequency)  
2. Difference in drop-out rate  
3. Serum drug concentration  






1. Seizure time, duration and severity  
2. Side-effects  
3. Cognitive assessments (visual recall, auditory recall, visual 
scanning, concentration, speed of information processing, 




1. Reasons for failure of the initial drug in 223 patients during 
24 months following the onset of therapy 
Composite score (summation of seizure activity, systemic 
toxicity and neurotoxicity)  
2. Drug serum concentrations present at failure times by drug 
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Kang 2007 Epilepsia 
1. Change on a neuropsychological test battery after 28 weeks 
of treatment (Bender Gestalt Test (BGT) 
(correct copy and recall) and KEDI-WISC (Korean Educational 
2. Developmental Institute-Wechsler Intelligence Scale for 
Children) Full Scale Intelligence Quotient (FSIQ), Verbal 
Intelligence Quotient (VIQ), and Performance Intelligence 
Quotient (PIQ), and consists of 12 subtests: information, 
similarities, arithmetic, vocabulary, comprehension, picture 
completion, picture arrangement, block design, object 
assembly, coding, digit span, and maze. 
3. Evaluation for treatment-emergent adverse events 




1. Total number of treatment failures (discontinuation or 
modification to AEDs) in by group due to breakthrough 






1. Seizure type/frequency  
2. Psychopathology (anxiety, depression, mania, Bunney-





1. Difference in mean fasting serum insulin concentration at 12 
months between the two treatment groups 
2. Difference in mean changes from baseline at various time 
points in metabolic and endocrine measurements and body 
mass index (BMI) between the two treatment groups and by 
gender. 
3. Frequency of common adverse events experienced by at 
least %% of subjects by treatment group 
Lee 2011 Seizure 
1. Change of neuropsychological and cognitive scores from 
baseline: general intellectual ability, learning and memory, 
attention and executive function (group-by-time interaction) 
2. Frequency of psychological and health related quality of life 
symptoms 






1. Seizure reduction from baseline (response rates) 
2. Systemic toxicity and neurotoxicity scores (via 
questionnaires) 
3. Physician and patient evaluation of improvement 
4. Proportion of patients experiencing most common adverse 
events during randomised treatment 




1. Change in cognitive, intelligence (IQ), behavioural and 
psychometric scores between baseline, 6 and 12 months. 
2. Compliance, drug changes and withdrawal rates 






1. Effects of anticonvulsants on Rolandic discharges 




1. The relationship between trough valproate plasma levels and 
platelet counts 
2. Incidence of thromobocytopenia (and relationship with 
platelet counts) 
3. Incidence of adverse events (related to thrombocytopenia) 







1. Incidence of most common adverse events (occuring in more 
than two patients) 
2. Efficacy of anticonvulsants: changes in frequency of 
myoclonic jerks compared to myoclonic seizure frequency in 
the six months prior to commencement of treatment 
3. Seizure reduction by categories (all seizure types): Seizure-
freedom, more than 50% reduction, less than 50% reduction, 






1. Cognitive outcomes: visual and auditory reaction times, 




1. Change in neuropsychological test scores and cognitive 
performance from baseline 
2. Relationship between neuropsychological test scores and 
cognitive performance and ZNS dosage 
3. Frequency of cognitive and mood complaints between 
treatment groups 
4. Change in seizure frequency at one year from baseline 





1. Proportion seizure-free at 3, 6 and 12 month follow-ups 
2. Proportion seizure-free, with more than 50% seizure 
reduction and no change in seizure frequency in 6-12 month 
follow-up period. 




1. Change in neuropsychological scores (motor speed, 
coordination, attention, concentration, memory, learning and 
reasoning) and Profile of Mood States (POMS) between 
baseline, 6 and 12 months.  
2. Recurrence of seizures in study period 
3. Serum drug levels at 6 and 24 months 




1. Laboratory measures (WBC, platelet, blood drug levels, 
hematologic indexes etc.)  
2. Incidence of side effects (major and minor)  
3. Seizure control and treatment failures/discontinuations 
Rasgoti 
1991 




1. Reduction in frequency of seizures by seizure type 
(response)) 




1. Cognitive outcomes pre and post treatment: verbal and 
performance intelligence, visual organisation and visuomotor 
function, memory and dysfunction 






1. Seizure control (antiepileptic efficacy): seizure frequency 
during therapy (including exacerbation of seizures leading to 
treatment withdrawal) 
2. Incidence of side effects during the study (titration and 
maintenance phases). 







1. Improvements in health related quality of life during the 
study by treatment groups (mean change) via the Quality of 
Life in Epilepsy 89 (QOLIE 89) questionnaire 
2. Change in body weight during the study (pooled groups) 
3. Seizure frequency during the study (pooled groups) 
4. Psychological status (at the end of the study, pooled groups) 
measured by Profile of Mood States, Beck Depression 
Inventory and Cornell Dysthymia Rating Scale (self-report). 





1. Change from baseline to 40 weeks of therapy (mean values 
by treatment group) of electrocardiography (ECG) 
parameters via resting 12 lead ECG recording: QRS interval 
time, heart rate, PQ interval time and QTc interval. 
2. Incidence of abnormalities in ECG recordings at baseline and 





1. Change from baseline health related quality of life scores at 
12, 28 and 40 weeks (median by treatment group) assessed 
by the Side Effects and Life satisfaction (SEALS) inventory and 
Liverpool Adverse Event Profile (AEP) questionnaires 
2. Differences in SEALS and AEP scores for those who did not 
complete the study 





1. Seizure Recurrence during treatment 
2. Serum drug levels 




1. Proportion of patients free of complex partial seizures (CPS) 
during the maintenance period 





1. Seizure control based on percentage reduction of seizures: 
very good, good, mild, no effect (efficacy) 
2. Most frequently reported treatment adverse events (safety) 





1. Percentage of randomised patients achieving a minimum 
period of 12 months seizure-freedom. 
2. Percentage of randomised patients withdrawing due to 
adverse events 
3. Percentage of randomised patients with lack of efficacy at 
maximum tolerated dose 
4. Changes in levels of androgenic hormone levels 
(testosterone, androstenedione and SHBG levels) 





1. Seizure recurrence 
2. Incidence of side effects 
3. Relationship between serum AED levels and side effects 
Trudeau 
1996 
Journal of Child 
Neurology 
1. Absence seizure frequency change from baseline to end of 
double-blind treatment from ambulatory EEGs - response 
ratio and responder rate (efficacy) 
2. Frequency of treatment emergent adverse events (safety) 
3. Relationship between gabapentin dosage and plasma 
concentration 









1. Outcome of therapy (proportion seizure-free, recurrence of 
seizures, drug failure, drug withdrawal) by seizure type 
2. Compliance 





1. Change of cognitive scores (power of attention, continuity of 
attention, memory and recognition) from baseline 
2. Change of neuropsychological scores from baseline 
3. Seizure recurrence / total number of seizures 
4. Relationship between computerised and conventional 




1. Seizure control / recurrence of seizures (excellent / good / 
poor) 
2. Incidence of side effects 
3. Plasma levels of study drug 





1. Development of rash after start of phenytoin treatment  






1. Proportion of patients with relapse of seizures  
2. Frequency of adverse events (tolerability) 
1. Study ID corresponds to first author and year of publication. See Appendix 5 for references 
of the studies.  
Table 32: Outcomes reported in 54 epilepsy monotherapy studies with at least one time-
to-event outcome clearly or possibly defined 






1. Time-to-first partial-onset seizure or generalized-onset tonic 
clonic seizure during the double-blind phase (P) 
2. Seizure-free rate at 6 months and 1 year 




1. Behavioural side effects at 1 year (compared to baseline) (P) 
2. Seizure control (freedom of seizures during the last quarter 
of the 12 month follow-up) 
3. Time-to-first seizure 
4. Time-to-withdrawal due to adverse events 
Bast 20033 Epilepsia 
1. Rate of treatment failures per group (P) 





1. Proportion of patients who achieved seizure-freedom for 26 
weeks or more (maintenance period) in the per protocol 
population (P) 
2. Incidence of treatment emergent results 
3. Time to 26 week (6 months) remission  
4. Time to 52 week (12 month) remission 
5. Proportion of patients with no seizures for at least 52 weeks 





1. The percentage of patients meeting one of the exit criteria 
(P) 
2. Time to meeting one of the exit criteria 
3. Incidence of mild, moderate or severe adverse events 






1. The proportion of seizure-free patients who had at least one 
seizure during the maintenance period (P) 
2. Time to premature discontinuation due to adverse 
experiences (P) 
3. Rate of premature discontinuations for any reason (P) 
4. Overall assessments of efficacy and tolerability and 
therapeutic effect 
5. Individual adverse experiences 
6. Laboratory values 




1. Weight change (P) 
2. The proportion of patients seizure-free during the entire 
study 
3. Incidence of the most common drug related adverse events 




1. Time-to-first seizure after 6 weeks of treatment 
2. Time-to-withdrawal 
3. Proportion of randomised patients remaining seizure-free 
during the last 40 and 24 weeks of trial 





1. Time-to-first seizure after 6 weeks of treatment 
2. Time-to-withdrawal 
3. Percentage of patients reporting an adverse event 
4. Proportion of patients who were both seizure-free in the 





1. Time-to-exit (P) 
2. Percentage of completers / time-to-withdrawal for any 
reason 
3. Time-to-first seizure 
4. Percentage who remained seizure-free during the final 12 
weeks of the 30 week evaluation period 





1. Time-to-first seizure after 6 weeks dose titration (P) 
2. Time-to-treatment failure 
3. Time to second, third and fourth seizures after 
randomisation 
4. Proportion of patients remaining seizure-free after 6 and 12 
months of treatment 




1. Proportion of per protocol (PP) patients achieving at least 6 
months of seizure-freedom at the last evaluated dose (P) 
2. 1 year seizure-freedom rate 
3. 6 month and 1 year seizure-freedom rate by dose level 
4. Time to study withdrawal 




1. Retention on the study medication for 12 months (P) 
2. Seizure control 
3. Incidence of side effects 




1. Time-to-treatment failure (withdrawal because of lack of 
therapeutic effects or adverse events) (P) 
2. Time to 6-month remission of seizures 
3. Time-to-first seizure after initial dose stabilisation and 
4. Time-to-withdrawal due to adverse events 






1. Time-to-exit (P) 
2. Time-to-exit plus withdrawals because of adverse events 
3. Completion rate (percentage of patients attending end-of-
phase visit),  
4. Exit event rate (percentage of patients who experienced 
an exit event during the evaluation phase), 
5. Adverse event withdrawal rate (percentage of patients who 
withdrew because of adverse events during either titration 
or evaluation phases),  
6. Exit plus adverse event withdrawal rate (the sum of the exit 
rate plus the adverse event withdrawal rate). 





1. The proportion of seizure-free patients who had at least one 
seizure during the maintenance period (P) 
2. Time to premature discontinuation due to adverse 
experiences (P) 
3. Rate of premature discontinuations for any reason (P) 
4. Overall assessments of efficacy and tolerability and 
therapeutic effect 
5. Individual adverse experiences 




1. Time-to-first seizure after the start of treatment (P) 
2. Time to enter one year remission (P) 
3. Incidence of side effects leading to treatment withdrawal 
Edwards 
2001 
Epilepsy and  
Behaviour 
1. Change in depression scores (Beck Depression Inventory, 
the Cornell Dysthymia Rating Scale, and the Profile of Mood 
States) from screening to weeks 10 and 32 (P) 
2. Weight change 
3. Time-to-withdrawal from the study 
4. Incidence of adverse events 





1. The appearance of a second seizure under treatment or by 
finishing the 12 month follow-up without seizures (P) 
2. Tolerability: Incidence of adverse events 




1. Change in Health Related Quality of Life (HRQOL) from 
baseline according to the modified Side Effect and Life 
Satisfaction (SEALS) Inventory with subscales Worry, 
Temper, Cognition, Dysphoria, and Tiredness and the 
relationship between SEALS scores 




1. Proportion of patients in each treatment group meeting 
escape criteria any time after initiation of concomitant AED 
withdrawal (P) 
2. Time to escape  
3. Incidence of adverse events 




1. Time-to-exit (i.e., time to meeting a seizure-related exit 
criterion) (P) 
2. Seizure frequency distribution (i.e., the proportion of 
patients completing the trial seizure-free or experiencing 
one or two seizures) 
3. Time-to-first-seizure  
4. Association of plasma topiramate concentration with time-
to-first-seizure. 





Journal of Child 
Neurology 
1. Time-to-first partial-onset or generalized-onset tonic-clonic 
seizure during the double-blind phase (P) 
2. Probability of being seizure-free for patients remaining 
in the study at 6 months and at 1 year 






1. Freedom from treatment failure after 16 weeks (P) 
2. Attention dysfunction (Confidence Index of 0.60 or higher 
on the Conners’ Continuous Performance Test) 
3. Incidence of adverse events by treatment group 
4. Drug concentrations between treatment failures and 





1. The proportion of seizure-free patients who had at least one 
seizure during the maintenance period (P) 
2. Time to premature discontinuation due to adverse 
experiences (P) 
3. Rate of premature discontinuations for any reason (P) 
4. Overall assessments of efficacy and tolerability and 
therapeutic effect 
5. Individual adverse experiences 
6. Laboratory values 





1. Proportions of patients who showed improvement in 
depression symptoms and QOL at 3 months following 
randomization (P) 
2. Proportions of patients who showed improvement in 
depression symptoms and QOL at 12 months following 
randomization. 
3. Changes in HADS depression and anxiety scores and QOL 
scores at 3 months and 12 months  
4. Liverpool Adverse Events Profile (LAEP) scores at 3 months 
and 12 months 
5. Mean IntegNeuro cognitive function scores at 3 months  
6. Freedom from seizures (excluding those occurring during the 
drug titration period)  
7. Adherence to treatment (time on allocated drug) 







1. Time-to-first seizure after the start of treatment (P) 
2. Time to enter one year remission (P) 




1. Proportion of patients who remained seizure-free for 6 or 
more continuous months during the efficacy phase (P) 
2. Time-to-exit because of lack of efficacy, adverse events, or 
any reason  
3. Time to 6-month seizure-freedom 
4. Time-to-first seizure after the dose-escalation phase 
5. Number of seizures during the dose escalation phase 
6. Monthly seizure frequency for all patients 
7. Incidence of adverse events (severity and causal relation) 
8. Anxiety and depression on the Hospital Anxiety and 
Depression Scale (HADS) 







1. Percentage of patients with treatment success: completion 
of the 24-week Maintenance Phase (MP) without 
prematurely discontinuing study medication because of 
inadequate seizure control or unacceptable side effects (P) 
2. Mean time (days) to withdrawal from the study. 
3. Percentage of patients seizure-free during the last 8 weeks 
of the MP and during the 24-week MP. 
4. Mean percentage reduction in seizure frequency during MP. 
5. Percentage of patients with marked improvement on 
investigator ratings of clinical status, assessed at 
Monotherapy Week 24 (on a 7 point scale) 
6. Percentage of patients rating current study medication as 
better than previous treatment in a self-assessment 
administered at Monotherapy Week 24 (on a 5 point scale) 
7. Health-related quality of life assessed at screening and 
Monotherapy Week 24 with the QOLIE-31 
8. Percentage of patients with adverse events during the 




1. Time-to-treatment failure (P) 
2. Time to 1 year (12 month) remission (P) 
3. Time to 2 year remission 
4. Time-to-first seizure 
5. Health related quality of life via the NEWQOL (Newly 
Diagnosed Epilepsy Quality of Life Battery) 
6. Health economic assessment and cost effectiveness of the 
drugs 
(cost per QALY gained and cost per seizure avoided) 




1. Time-to-treatment failure (P) 
2. Time to 1 year (12 month) remission (P) 
3. Time to 2 year remission 
4. Time-to-first seizure 
5. Health related quality of life via the NEWQOL (Newly 
Diagnosed Epilepsy Quality of Life Battery) 
6. Health economic assessment and cost effectiveness of the 
drugs (cost per QALY gained and cost per seizure avoided) 






1. Patient retention (length of time that patient continued to 
take the randomly assigned drug) (P) 
2. Composite score (combined score for the control of seizures 
and incidence of adverse events) 
3. Total seizure control /Seizure rate 






1. Total number of seizures (of each type) during 12 months 
2. Number of seizures per month 
3. Percentage of patients with seizures completely controlled 
4. Time-to-first seizure 
5. Severity of seizures at 12 and 24 months 
6. Composite score (combined score for the control of seizures 
and incidence of adverse events) 
7. Incidence and severity of systemic and neurologic adverse 
events 






1. Percentage (of patients) free of seizures 
2. Number of treatment withdrawals 
3. Withdrawal time 
4. Number of seizures until time of treatment withdrawal 






1. Proportion of patients seizure-free during the last 16 weeks 
of treatment 
2. Efficacy success: proportion of patients who did not 
withdraw before the end of week 18 and were seizure-free 
in the last 16 weeks of the study 
3. Time-to-withdrawal from the study (proportion of patients 
completing the study) 
4. Proportion of patients experiencing adverse events 
5. Withdrawals due to adverse events 
Pal 1998 The Lancet 
1. Frequency of behavioural side effects (assessed by Conner's 
parent rating scale or pre-school behaviour screening 
questionnaire) at 12 months or at withdrawal (P) 
2. Incidence of side effects 
3. Time-to-first seizure after randomisation 






1. Time-to-exit (P) 
2. Time-to-first seizure  
3. Proportion of seizure-free patients during the last 6 months 
of double-blind treatment. 





1. Time-to-first generalised tonic-clonic seizure after initiation 
of therapy 
2. Six month seizure recurrence rate 
3. Frequency of adverse reactions (events) 




1. Time-to-first complex partial seizure or generalised tonic 
clonic seizure (P) 
2. Patient retention (time to discontinuation of treatment) 




1. Rate of treatment failure events per group (P) 
2. Individual change in EEG recordings over time 





1. Proportion completing seizure-free after 6 weeks treatment 
2. Time-to-first seizure 
3. Time-to-withdrawal 
4. Frequency of Adverse Events with at least 5% incidence in 







1. Remission analysis (time to 6, 12 and 24 month remission) 
2. Retention analysis (time-to-treatment failure) 
3. Adverse event incidence 
4. Incidence of treatment failures due to poor seizure control 




1. Retention in the trial for 12 months (P) 
2. Seizure-freedom at 12 months 
3. Time-to-first, second, fifth and tenth seizure (Time to 
seizures) 
4. Incidence of systemic and neurologic toxicities 
5. Serum drug levels and compliance 









1. Rate of seizure-free patients by treatment group in the first 
6 weeks after randomisation (P) 
2. Rate of seizure-free patients by treatment group in the last 
16 weeks of the trial (categorical) 
3. Retention time in the trial (randomisation to 26 weeks) 
4. Rate of seizure-free patients by treatment group in the 
whole treatment period (26 weeks) 
5. Seizure-free time (time-to-first seizure) 
6. Incidence of adverse events  






1. The number of patients in each treatment group who met 
escape criteria (P) 
2. Seizure frequency data (percentage improvement since 
baseline) 
3. Incidence of adverse experiences 




1. Time until exit (P) 
2. Clinical response to study medication (investigator and 
patient's global assessments) 
3. Reduction from baseline in average monthly seizure rate for 
patients completing the 16 week double-blind treatment 
phase (>50%, >75% or 100% reduction) 





1. Efficacy analysis: Time to meeting one of the exit criteria (P) 
2. Percentage of patients meeting one of the exit criteria 
3. Safety analysis: Incidence of adverse events rated as mild, 
moderate or severe  
4. Pharmacokinetic analysis: population-pharmacokinetic 




1. Retention in the trial (time-to-withdrawal of allocated 
treatment for any cause) (P) 
2. Seizure-freedom after week 4 
3. Seizure-freedom after week 20 
4. Time-to-first seizure 
5. Adverse event reports 




1. Percentage of patients remaining on treatment 
2. Percentage of patients remaining seizure-free in the last 24 
and last 16 weeks of treatment 
3. Number of seizures (percentage change from baseline) in 
the last 24 weeks and 16 weeks of treatment 
4. Time-to-first seizure after the first 6 weeks of treatment 
(dose-titration period) 
5. Time to discontinuation 
6. Incidence of adverse events and adverse events leading to 
discontinuation 
7. Quality of Life according to the Side Effects and Life 




1. Number of seizure-free patients during weeks 17-24 (P) 
2. "Leaving the study" (retention rates) 






1. Average frequency of all seizure types among study (P) 
completers during the 14-day evaluation period 
2. Average frequency of complex partial seizures, simple 
partial seizures and secondarily generalised seizures among 
study completers during the 14-day evaluation period 
3. Time to dropout  





1. Time to 24-month remission of seizures 
2. Time-to-first seizure 
3. Incidence of adverse events 






1. Remission analysis (time to 6, 12 and 24 month remission) 
2. Retention analysis (time-to-treatment failure) 
3. Adverse event incidence 
4. Rate of withdrawals and treatment failures 
Wheless 
2004 
Journal of Child 
Neurology 
1. Time-to-exit from the study for any reason (P) 
2. Time-to-first seizure 
3. Proportion of patients seizure-free in the last 6 months of 
treatment 
4. Frequency of most common adverse events 
1. Study ID corresponds to first author and year of publication. See Appendix 5 for references 
of the studies.  
2. Outcomes in Italics were considered to be TTE outcomes for further data extraction and 
outcomes marked with (P) were the study defined primary outcome. 




Appendix 7: Search strategies used in Chapter 4 
1 Cochrane Central Register of Controlled Trials (CENTRAL) via CRSO (search dates: 
12/06/2014 and 17/08/2015) 
#1 ("individual patient*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#2 ("individual participant data" OR ipd):TI,AB 
#3 ("individual subject*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#4 ("raw patient*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#5 ("raw subject*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#6 (idiopathic OR "immediate pigment darkening" OR "intermittent peritoneal dialysis" 
OR "invasive pneumococcal disease" OR "indirect photometric detection" OR 
"interaural phase disparity"):TI,AB 
#7 #1 OR #2 OR #3 OR #4 OR #5 
#8 #7 NOT #6 
#9 2004 TO 2014:YR NOT INMEDLINE 
#10 #8 AND #9 
 
2 MEDLINE (Ovid) (search dates: 10/06/2014 and 17/08/2015) 
1. (individual patient$ adj6 data).ti,ab. 
2. (individual patient$ adj6 report$).ti,ab. 
3. (individual patient$ adj6 outcome$).ti,ab. 
4. (individual patient$ adj6 level$).ti,ab. 
5. individual participant data.ti,ab. 
6. ipd.ti,ab. 
7. (individual subject$ adj6 data).ti,ab. 
8. (individual subject$ adj6 report$).ti,ab. 
9. (individual subject$ adj6 outcome$).ti,ab. 
10. (individual subject$ adj6 level$).ti,ab. 
11. (raw patient$ adj6 data).ti,ab. 
12. (raw patient$ adj6 report$).ti,ab. 
13. (raw patient$ adj6 outcome$).ti,ab. 
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14. (raw patient$ adj6 level$).ti,ab. 
15. (raw subject$ adj6 data).ti,ab. 
16. (raw subject$ adj6 report$).ti,ab. 
17. (raw subject$ adj6 outcome$).ti,ab. 
18. (raw subject$ adj6 level$).ti,ab. 
19. idiopathic.ti,ab. 
20. immediate pigment darkening.ti,ab. 
21. intermittent peritoneal dialysis.ti,ab. 
22. invasive pneumococcal disease.ti,ab. 
23. indirect photometric detection.ti,ab. 
24. interaural phase disparity.ti,ab. 
25. or/1-18 
26. or/19-24 
27. 25 not 26 
28. limit 27 to ed=20050601-20140610 
 
3. SCOPUS (search dates: 10/06/2014 and 18/08/2015) 
(((((TITLE-ABS-KEY("individual patient*" PRE/6 data)) OR (TITLE-ABS-KEY("individual 
patient*" PRE/6 report*)) OR (TITLE-ABS-KEY("individual patient*" PRE/6 outcome*)) OR 
(TITLE-ABS-KEY("individual patient*" PRE/6 level*)) OR (TITLE-ABS-KEY("individual 
participant data")) OR (TITLE-ABS-KEY(ipd)) OR (TITLE-ABS-KEY("individual subject*" PRE/6 
data)) OR (TITLE-ABS-KEY("individual subject*" PRE/6 report*)) OR (TITLE-ABS-
KEY("individual subject*" PRE/6 outcome*))) OR ((TITLE-ABS-KEY("individual subject*" 
PRE/6 level*)) OR (TITLE-ABS-KEY("raw patient*" PRE/6 data)) OR (TITLE-ABS-KEY("raw 
patient*" PRE/6 report*)) OR (TITLE-ABS-KEY("raw patient*" PRE/6 outcome*)) OR (TITLE-
ABS-KEY("raw patient*" PRE/6 level*)) OR (TITLE-ABS-KEY("raw subject*" PRE/6 data))) OR 
((TITLE-ABS-KEY("raw subject*" PRE/6 report*)) OR (TITLE-ABS-KEY("raw subject*" PRE/6 
outcome*)) OR (TITLE-ABS-KEY("raw subject*" PRE/6 level*)))) AND NOT ((TITLE-ABS-
KEY(idiopathic)) OR (TITLE-ABS-KEY("immediate pigment darkening")) OR (TITLE-ABS-
KEY("intermittent peritoneal dialysis")) OR (TITLE-ABS-KEY("invasive pneumococcal 
disease")) OR (TITLE-ABS-KEY("indirect photometric detection")) OR (TITLE-ABS-
KEY("interaural phase disparity")))) AND PUBYEAR > 2004) AND NOT (INDEX(medline)) AND 
( LIMIT-TO(SUBJAREA,"MEDI" ) OR LIMIT-TO(SUBJAREA,"BIOC" ) OR LIMIT-
TO(SUBJAREA,"NEUR" ) OR LIMIT-TO(SUBJAREA,"PHAR" ) OR LIMIT-TO(SUBJAREA,"IMMU" ) 
OR LIMIT-TO(SUBJAREA,"NURS" ) OR LIMIT-TO(SUBJAREA,"HEAL" ) OR LIMIT-




4 Epilepsy Specialized Register (CRS) (search dates: 12/06/2014 and 17/08/2015) 
#1 ("individual patient*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#2 ("individual participant data" OR ipd):TI,AB 
#3 ("individual subject*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#4 ("raw patient*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#5 ("raw subject*" ADJ6 (data OR report* OR outcome* OR level*)):TI,AB 
#6 (idiopathic OR "immediate pigment darkening" OR "intermittent peritoneal dialysis" OR 
"invasive pneumococcal disease" OR "indirect photometric detection" OR "interaural phase 
disparity"):TI,AB 
#7 #1 OR #2 OR #3 OR #4 OR #5 
#8 (#7 NOT #6) AND >2003:YR 
5. CINAHL Plus and PsycINFO (EBSCOhost) (search dates: 10/06/2014 and 18/08/2015) 
S9 S7 NOT S6  
Published: 20040601- 
S8 S7 NOT S6 
S7 S1 OR S2 OR S3 OR S4 OR S5 
S6 TX ( idiopathic OR "immediate pigment darkening" ) OR TX "intermittent peritoneal 
dialysis" OR TX "invasive pneumococcal disease" OR TX "indirect photometric 
detection" OR TX "interaural phase disparity" 
S5 "raw subject*" W6 (data OR report* OR outcome* OR level*) 
S4 "raw patient*" W6 (data OR report* OR outcome* OR level*) 
S3 "individual subject*" W6 (data OR report* OR outcome* OR level*) 
S2 "individual participant data" OR TX ipd 
S1 "individual patient*" W6 (data OR report* OR outcome* OR level*) 
 
6. Web of Science: Core Collection 1900- and BIOSIS Previews (Biological Abstracts) 
(search dates: 10/06/2014 and 18/08/2015) 
#12 #5 OR #4 OR #3 OR #2 OR #1 
Refined by: PUBLICATION YEARS: (2013 OR 2004 OR 2012 OR 2011 OR 2010 OR 
2009 OR 2008 OR 2007 OR 2005 OR 2006 OR 2014) AND Databases: (WOS OR 
BIOSIS) AND [excluding]:Databases: (MEDLINE) AND RESEARCH DOMAINS: 
(SCIENCE TECHNOLOGY) AND RESEARCH AREAS: (BEHAVIORAL SCIENCES OR 
OTORHINOLARYNGOLOGY OR PHARMACOLOGY PHARMACY OR PSYCHIATRY OR 
TRANSPLANTATION OR ONCOLOGY OR RHEUMATOLOGY OR ALLERGY OR 
CARDIOVASCULAR SYSTEM CARDIOLOGY OR ANESTHESIOLOGY OR PSYCHOLOGY 
OR DERMATOLOGY OR GENERAL INTERNAL MEDICINE OR REHABILITATION OR 
HEMATOLOGY OR ORTHOPEDICS OR REPRODUCTIVE BIOLOGY OR IMMUNOLOGY 
OR CRITICAL CARE MEDICINE OR NEUROSCIENCES NEUROLOGY OR 
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OPHTHALMOLOGY OR NUTRITION DIETETICS OR TROPICAL MEDICINE OR PUBLIC 
ENVIRONMENTAL OCCUPATIONAL HEALTH OR GASTROENTEROLOGY HEPATOLOGY 
OR DENTISTRY ORAL SURGERY MEDICINE OR OBSTETRICS GYNECOLOGY OR 
GERIATRICS GERONTOLOGY OR PATHOLOGY OR RADIOLOGY NUCLEAR MEDICINE 
MEDICAL IMAGING OR PARASITOLOGY OR SUBSTANCE ABUSE OR RESEARCH 
EXPERIMENTAL MEDICINE OR SURGERY OR RESPIRATORY SYSTEM OR 
DEVELOPMENTAL BIOLOGY OR HEALTH CARE SCIENCES SERVICES OR PHYSIOLOGY 
OR UROLOGY NEPHROLOGY OR VIROLOGY OR ENDOCRINOLOGY METABOLISM OR 
PEDIATRICS OR INFECTIOUS DISEASES OR NURSING OR MICROBIOLOGY OR 
TOXICOLOGY) AND [excluding]:DOCUMENT TYPES: (PATENT OR EDITORIAL)  
DocType=All document types; Language=All languages;  
#11 #5 OR #4 OR #3 OR #2 OR #1 
Refined by: PUBLICATION YEARS: (2013 OR 2004 OR 2012 OR 2011 OR 2010 OR 
2009 OR 2008 OR 2007 OR 2005 OR 2006 OR 2014) AND Databases: (WOS OR 
BIOSIS) AND [excluding]:Databases: (MEDLINE) AND RESEARCH DOMAINS: 
(SCIENCE TECHNOLOGY) AND RESEARCH AREAS: (BEHAVIORAL SCIENCES OR 
OTORHINOLARYNGOLOGY OR PHARMACOLOGY PHARMACY OR PSYCHIATRY OR 
TRANSPLANTATION OR ONCOLOGY OR RHEUMATOLOGY OR ALLERGY OR 
CARDIOVASCULAR SYSTEM CARDIOLOGY OR ANESTHESIOLOGY OR PSYCHOLOGY 
OR DERMATOLOGY OR GENERAL INTERNAL MEDICINE OR REHABILITATION OR 
HEMATOLOGY OR ORTHOPEDICS OR REPRODUCTIVE BIOLOGY OR IMMUNOLOGY 
OR CRITICAL CARE MEDICINE OR NEUROSCIENCES NEUROLOGY OR 
OPHTHALMOLOGY OR NUTRITION DIETETICS OR TROPICAL MEDICINE OR PUBLIC 
ENVIRONMENTAL OCCUPATIONAL HEALTH OR GASTROENTEROLOGY HEPATOLOGY 
OR DENTISTRY ORAL SURGERY MEDICINE OR OBSTETRICS GYNECOLOGY OR 
GERIATRICS GERONTOLOGY OR PATHOLOGY OR RADIOLOGY NUCLEAR MEDICINE 
MEDICAL IMAGING OR PARASITOLOGY OR SUBSTANCE ABUSE OR RESEARCH 
EXPERIMENTAL MEDICINE OR SURGERY OR RESPIRATORY SYSTEM OR 
DEVELOPMENTAL BIOLOGY OR HEALTH CARE SCIENCES SERVICES OR PHYSIOLOGY 
OR UROLOGY NEPHROLOGY OR VIROLOGY OR ENDOCRINOLOGY METABOLISM OR 
PEDIATRICS OR INFECTIOUS DISEASES OR NURSING OR MICROBIOLOGY OR 
TOXICOLOGY)  
DocType=All document types; Language=All languages;  
#10 #5 OR #4 OR #3 OR #2 OR #1 
Refined by: PUBLICATION YEARS: (2013 OR 2004 OR 2012 OR 2011 OR 2010 OR 
2009 OR 2008 OR 2007 OR 2005 OR 2006 OR 2014) AND Databases: (WOS OR 
BIOSIS) AND [excluding]:Databases: (MEDLINE) AND RESEARCH DOMAINS: 
(SCIENCE TECHNOLOGY)  
DocType=All document types; Language=All languages;  
#9 #5 OR #4 OR #3 OR #2 OR #1 
Refined by: PUBLICATION YEARS: (2013 OR 2004 OR 2012 OR 2011 OR 2010 OR 
2009 OR 2008 OR 2007 OR 2005 OR 2006 OR 2014) AND Databases: (WOS OR 
BIOSIS) AND [excluding]:Databases: (MEDLINE)  
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DocType=All document types; Language=All languages;  
#8 #5 OR #4 OR #3 OR #2 OR #1 
Refined by: PUBLICATION YEARS: (2013 OR 2004 OR 2012 OR 2011 OR 2010 OR 
2009 OR 2008 OR 2007 OR 2005 OR 2006 OR 2014) AND Databases: (WOS OR 
BIOSIS)  
DocType=All document types; Language=All languages;  
#7 #5 OR #4 OR #3 OR #2 OR #1 
Refined by: PUBLICATION YEARS: (2013 OR 2004 OR 2012 OR 2011 OR 2010 OR 
2009 OR 2008 OR 2007 OR 2005 OR 2006 OR 2014)  
DocType=All document types; Language=All languages;  
#6 #5 OR #4 OR #3 OR #2 OR #1  
DocType=All document types; Language=All languages;  
#5 TOPIC: ("raw subject*" NEAR/6 (data OR report* OR outcome* OR level*)) NOT 
TOPIC: (idiopathic OR "immediate pigment darkening" OR "intermittent peritoneal 
dialysis" OR "invasive pneumococcal disease" OR "indirect photometric detection" 
OR "interaural phase disparity")  
DocType=All document types; Language=All languages;  
#4 TOPIC: ("raw patient*" NEAR/6 (data OR report* OR outcome* OR level*)) NOT 
TOPIC: (idiopathic OR "immediate pigment darkening" OR "intermittent peritoneal 
dialysis" OR "invasive pneumococcal disease" OR "indirect photometric detection" 
OR "interaural phase disparity")  
DocType=All document types; Language=All languages;  
#3 TOPIC: ("individual subject*" NEAR/6 (data OR report* OR outcome* OR level*)) 
NOT TOPIC: (idiopathic OR "immediate pigment darkening" OR "intermittent 
peritoneal dialysis" OR "invasive pneumococcal disease" OR "indirect photometric 
detection" OR "interaural phase disparity")  
DocType=All document types; Language=All languages;  
#2 TOPIC: ("individual participant data" OR ipd) NOT TOPIC: (idiopathic OR 
"immediate pigment darkening" OR "intermittent peritoneal dialysis" OR "invasive 
pneumococcal disease" OR "indirect photometric detection" OR "interaural phase 
disparity")  
DocType=All document types; Language=All languages;  
#1 TOPIC: ("individual patient*" NEAR/6 (data OR report* OR outcome* OR level*)) 
NOT TOPIC: (idiopathic OR "immediate pigment darkening" OR "intermittent 
peritoneal dialysis" OR "invasive pneumococcal disease" OR "indirect photometric 
detection" OR "interaural phase disparity")  





Appendix 8: Data extraction form used in Chapter 4 
Individual Participant Data Meta-Analyses: Data Extraction Form 
Date of Extraction: 
Name of data extractor: 
Meta-analysis First Author: 
Meta-analysis Year: 
Meta-analysis Title: 
Journal or Source: 
Authorship policy (individual authorship, collaborative group, none): 
Source of funding: 
Clinical area (lung cancer, breast cancer, epilepsy, diabetes etc.): 
Design of studies included (Randomised / Non-randomised/ both / Other 
(diagnostic test accuracy etc.): 
Type of studies included (Drug / Device / Observational / Other (diagnostic test 
accuracy etc.): 
Type of pooled analysis: Systematic search performed or existing database of 
studies pooled/ collaboration? 
Number of studies eligible for meta-analysis: 
Number of participants in all eligible studies: 
Year range of eligible studies: 
Number of studies providing IPD: 
Number of participants IPD is provided for: 
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Number of studies providing aggregate data (AD): 
Number of participants AD is provided for: 
Number of studies excluded due to no IPD or AD available: 
Number of patients excluded due to no IPD or AD available: 
Year range of studies IPD is not available for: 
Any reported reasons that IPD was not provided (data no longer available, authors 
unwilling to collaborate)? 
 
Were any adjustments/ sensitivity analyses performed to account for missing IPD? 








1. Reasons for IPD not being provided and sensitivity analyses recorded as free text 
and later classified into broad categories.  
2. Source of funding recorded as free text and later classified as Commercial, Non-
Commercial, Mixed (Commercial and Non-Commercial), No funding, Not stated. 
3. Clinical area was also recorded as free text and later classified in broad categories 





Appendix 9: Additional results from Chapter 4 
Table 33 Characteristics of 85 reviews in which IPD was extracted from included studies 
IPD-MA Characteristic1 Number of IPD-MA2 
Year of publication of IPD-MA 
1987 – 1995 2 
1996 – 2000 3 
2001 – 2005 9 
2006 – 2010 22 
2010 – 2015 49 
Clinical area of IPD-MA 
Breast Cancer 1 
Cancer (other) 11 
Cardiology 9 
Central Nervous System, Neurology and Brain Injury 11 
Cervical Cancer and Ovarian Cancer 1 
Diabetes and Endocrinology 0 
Gastroenterology, Colorectal and Gastric Cancer 13 
Gynaecology, Pregnancy and Neonatology 3 
Haematology, Leukaemia and Blood Cancer 2 
Head and Neck Cancer 6 
Hepatitis and Liver Disease 1 
HIV 1 
Infection and Infectious Diseases 3 
Injuries and Wounds 1 
Lung Cancer 0 
Mental and Psychiatric Disorders 5 
Musculoskeletal and Pain 4 
Other 2 
Otolaryngology, Ophthalmology and Periodontology 5 
Renal and Urology 3 
Respiratory and Pulmonary  0 
Stroke, Thrombosis and Hypertension  3 
Design of included studies 
Randomised 8 
Non-Randomised 59 
Diagnostic Test Accuracy 8 
Both Randomised and Non-Randomised 10 
Type of included studies 
Diagnostic Test Accuracy 8 
Drug or device 20 
Epidemiology / Risk Factor 28 
Non-drug (interventional) 29 
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Type of IPD-MA 
Cochrane Review 2 
Non Cochrane Review 83 
Authorship Policy 
Individual authorship 0 
Collaborative Group 2 
None 83 




No funding 13 
Not stated 45 
Number of eligible studies 
2 to 5 2 
6 to 10 14 
11 to 15 7 
16 to 20 6 
21 to 30 10 
31 to 40 12 
41 to 50 8 
over 50 22 
Not stated 4 
Number of eligible participants 
under 100 10 
101 to 200 12 
201 to 500 17 
501 to 1000 12 
1001 to 5000 10 
5001 to 10000 2 
over 10000 0 
Not stated 22 
1. See Table 5 for full definitions of characteristics. 




Results of additional and sensitivity analyses 
See Table 7 in Chapter 4.3.3.1 for definitions of characteristics and footnotes of the tables 
Table 34: Results of univariate logistic regression analysis  
IPD-MA 
Characteristic 
100% of IPD retrieved compared 
to less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2 0.918 0.748 to 1.126 0.411 1.102 0.897 to 1.355 0.355 
Number of eligible 
participants2 
0.701 0.625 to 0.787 <0.001 0.872 0.789 to 0.965 0.008 
Includes randomised  
studies only 
1.113 0.768 to 1.613 0.571 2.517 1.729 to 3.666 <0.001 
Cochrane IPD-MA 0.365 0.179 to 0.746 0.006 0.471 0.264 to 0.839 0.011 
Authorship Policy3 1.225 0.840 to 1.786 0.292 3.123 2.132 to 4.577 <0.001 
Commercial source of 
funding4 
1.360 0.834 to 2.218 0.218 1.606 0.938 to 2.750 0.084 
 
Table 35: Multivariable logistic regression: further examination of authorship policy 
IPD-MA 
Characteristic 
100% of IPD retrieved compared 
to less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2 1.137 0.923 to 1.402 0.228 1.155 0.939 to 1.420 0.173 
Number of eligible 
participants2 
0.843 0.791 to 0.898 <0.001 0.889 0.838 to 0.943 <0.001 
Includes randomised  
studies only 
1.491 0.957 to 2.322 0.078 2.748 1.761 to 4.288 <0.001 
Cochrane IPD-MA 0.450 0.208 to 0.973 0.042 0.432 0.221 to 0.844 0.014 







1.729 to 4.519 








2.173 to 5.908 




Commercial source of 
funding4 
1.623 0.933 to 2.824 0.086 1.061 0.576 to 1.953 0.849 
 
Table 36: Multivariable logistic regression: inclusion of type of study 
IPD-MA 
Characteristic 
100% of IPD retrieved compared 
to less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2 1.068 0.874 to 1.306 0.520 1.138 0.924 to 1.402 0.224 
Number of eligible 
participants2 
0.845 0.794 to 0.898 <0.001 0.881 0.830 to 0.936 <0.001 
Includes randomised 
studies only 
1.220 0.756 to 1.971 0.415 2.253 1.372 to 3.670 0.001 
Drug or device 1.374 0.887 to 2.130 0.155 1.492 0.936 to 2.379 0.093 
Cochrane IPD-MA 0.403 0.189 to 0.862 0.019 0.429 0.219 to 0.841 0.014 
Authorship Policy3 1.710 1.101 to 2.658 0.017 3.491 2.252 to 5.413 <0.001 
Commercial source of 
funding4 








100% of IPD retrieved compared 
to less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2 1.029 0.804 to 1.318 0.818 1.094 0.848 to 1.411 0.490 
Number of eligible 
participants2 
0.847 0.789 to 0.909 <0.001 0.891 0.833 to 0.952 0.001 
Includes randomised  
studies only 
1.318 0.783 to 2.217 0.298 3.013 1.779 to 5.103 <0.001 
Cochrane IPD-MA 0.419 0.180 to 0.977 0.044 0.392 0.188 to 0.818 0.013 
Authorship Policy3 1.726 1.014 to 2.936 0.044 3.583 2.154 to 5.961 <0.001 
Commercial source of 
funding4 
1.544 0.885 to 2.694 0.126 1.003 0.529 to 1.902 0.992 
 
A sensitivity analysis was conducted including all 760 IPD-MAs, assuming the following 
scenarios for the 257 IPD-MAs for which the proportion of IPD retrieved was unknown: 
a. Less than 80% of IPD was retrieved 
b. 80% or more IPD was retrieved 
c. 100% of IPD was retrieved 
Table 38: Multivariable logistic regression results:  a. less than 80% of IPD was retrieved 
IPD-MA 
Characteristic 
100% of IPD retrieved compared 
to less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2  0.641 0.554 to 0.739 <0.001 0.713 0.624 to 0.816 <0.001 
Includes randomised 
studies only 
1.667 1.160 to 2.393 0.006 2.906 2.076 to 4.067 <0.001 
Cochrane IPD-MA 0.334 0.161 to 0.701 0.004 0.489 0.278 to 0.861 0.013 
Authorship Policy3 0.505 0.372 to 0.685 <0.001 0.842 0.635 to 1.115 0.230 
Commercial source of 
funding4 
1.102 0.687 to 1.767 0.687 0.994 0.642 to 1.541 0.980 
 
Table 39: Multivariable logistic regression results:  b. 80% or more IPD was retrieved  
IPD-MA 
Characteristic 
100% of IPD retrieved compared to 
less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2  0.641 0.554 to 0.739 <0.001 1.206 1.046 to 1.392 0.010 
Includes randomised 
studies only 
1.667 1.160 to 2.393 0.006 1.479 0.999 to 2.190 0.051 
Cochrane IPD-MA 0.334 0.161 to 0.701 0.004 0.428 0.233 to 0.784 0.006 
Authorship Policy3 0.505 0.372 to 0.685 <0.001 3.222 2.340 to 4.439 <0.001 
Commercial source of 
funding4 





Table 40: Multivariable logistic regression results:  C. 100% of IPD was retrieved 
IPD-MA 
Characteristic 
100% of IPD retrieved compared 
to less than 100% of IPD1 
At least 80% of IPD retrieved 
compared to less than 80% of IPD1 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2  1.109 0.975 to 1.392 0.114 1.206 1.046 to 1.392 0.010 
Includes randomised 
studies only 
0.682 0.492 to 0.947 0.022 1.479 0.999 to 2.190 0.051 
Cochrane IPD-MA 0.477 0.269 to 0.846 0.011 0.428 0.233 to 0.784 0.006 
Authorship Policy3 1.762 1.331 to 2.332 <0.001 3.222 2.340 to 4.439 <0.001 
Commercial source of 
funding4 
1.092 0.704 to 1.693 0.993 1.002 0.577 to 1.743 0.993 
 
Table 41: Multivariable logistic regression results: proportion of IPD known compared to 
proportion of IPD unknown 
IPD MA Characteristic Proportion of IPD retrieved unknown compared 
to proportion of IPD retrieved known  
OR 95% CI P-value 
Age of publication2  0.869 0.761 to 0.992 0.039 
Includes randomised studies only 0.361 0.256 to 0.508 <0.001 
Cochrane IPD-MA 0.658 0.332 to 1.303 0.231 
Authorship Policy3 1.397 1.043 to 1.869 0.025 
Commercial source of funding4 0.849 0.523 to 1.379 0.509 
 
Table 42: Results of fractional logistic regression 
IPD-MA Characteristic OR 95% CI* P-value 
Age of publication2  1.339 1.152 to 1.555 <0.001 
Number of eligible participants2  0.998 0.946 to 1.032 0.591 
Includes randomised studies only 2.432 1.775 to 3.333 <0.001 
Cochrane IPD-MA 0.446 0.288 to 0.691 <0.001 
Authorship Policy3 2.511 1.835 to 3.436 <0.001 
Commercial source of funding4 0.871 0.544 to 1.394 0.565 
*Calculated with robust standard errors. 
 
Table 43 Multivariate logistic regression by proportion of study data retrieved 
IPD MA 
Characteristic 
100% of study data retrieved 
compared to less than 100% of 
study data 
At least 80% of study data 
retrieved compared to less than 
80% of study data 
OR 95% CI P-value OR 95% CI P-value 
Age of publication2  1.172 0.961 to 1.431 0.116 1.235 1.050 to 1.454 0.011 
Number of eligible 
participants2  
0.498 0.428 to 0.576 <0.001 0.681 0.610 to 0.759 <0.001 
Includes randomised 
studies only 
1.555 1.050 to 2.304 0.028 1.301 0.936 to 1.807 0.117 
Cochrane IPD-MA 0.441 0.207 to 0.937 0.033 0.664 0.373 to 1.181 0.163 
Authorship Policy3 1.078 0.739 to 1.573 0.695 1.851 1.355 to 2.529 <0.001 
Commercial source of 
funding4 
1.339 0.819 to 2.187 0.244 1.227 0.781 to 1.927 0.375 
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Appendix 11: Template IPD request letter and data request form  
Cochrane Epilepsy Group 
Department of Molecular and Clinical Pharmacology 
Institute of Translational Medicine 
Room 2.28, Clinical Sciences Centre for Research and Education 









We are contacting you on behalf of the Cochrane Epilepsy Group. The Cochrane 
Collaboration is an international organisation dedicated to providing summaries of the best 
evidence about medical treatments in the form of systematic reviews. You can find more 
about the Collaboration and the Cochrane Epilepsy Group at www.epilepsy.cochrane.org  
 
We plan to carry out a Cochrane overview and network meta-analysis of studies comparing 
monotherapy for patients with epilepsy. The current overview (published 2007) which we 
wish to update as a Cochrane overview is enclosed: 
 
i) Time-to-withdrawal from treatment (retention time) 
ii) Time to 6 and 12 month remission (seizure-free period) 
iii) Time-to-first seizure post randomisation. 
iv) Adverse events 
 
Due to the complexity in definition of these outcomes, the review is an individual patient 
data review which allows the most reliable methods to be used for meta-analysis. As you will 
see, this approach has been used in a number of epilepsy monotherapy Cochrane Reviews. 
 
Following a recent search for reports for the review update, we believe your study may meet 
the criteria for inclusion in the review update: 
 
<Insert full citation of study> 
 
We would be grateful if you could provide some further information about your study so that 
we can confirm that it meets our inclusion criteria. 
 
If your study does meet the inclusion criteria we would like to ask if you would be willing to 
provide individual patient data from your trial. It would also be helpful if you could complete 
the attached form to indicate the data that you have for your study. 
 









Sarah Nolan, Statistician (sarah.nolan@liv.ac.uk) 
Dr Catrin Tudur Smith, Statistical Editor (cat1@liv.ac.uk) 
Professor Tony Marson, Co-ordinating Editor (a.g.marson@liv.ac.uk) 
 




Current Overview: Multiple treatment comparisons in epilepsy monotherapy trials 




     
Data request form 
Cochrane Epilepsy Network Meta-Analysis  





Would you be able to supply the following data for each individual patient in the study 
(delete as appropriate)? 
If data is unavailable, please indicate reasons (where possible) in comments section: 
Patient Characteristics 
 Patient Identifier       YES/NO 
 Age          YES/NO 
 Gender         YES/NO 
 Presence of neurological signs       YES/NO 
 EEG results (prior to randomization)     YES/NO 
 MRI / CT results (prior to randomisation)    YES/NO 
 Aetiology (known/unknown origin of seizures)    YES/NO 
 Number of seizures before randomisation    YES/NO 
 Dates of seizures before randomisation     YES/NO 
 Seizure type at randomisation      YES/NO 
o Partial: simple/complex partial or secondary generalised tonic-clonic 
o Generalised: generalised tonic-clonic  
o Other seizure type (myoclonic, absence etc.) 
 Patient  type        YES/NO 
o Newly onset epilepsy 
o Active Seizures 






 Date of randomisation       YES/NO 
 Name of drug randomised      YES/NO 
 Dose of drug randomised      YES/NO 
 Dates of follow-up       YES/NO 
 Dates of dose changes       YES/NO 
 Number of seizures after randomisation (at each follow-up)  YES/NO 
 Dates of seizures after randomisation  (at each follow-up)  YES/NO 
 Date of withdrawal of randomised treatment    YES/NO 
 Reason for withdrawal of randomised treatment   YES/NO 




 Method of randomisation (generation of random list)   YES/NO 
 Method of concealment of randomisation    YES/NO 
 Stratification factors       YES/NO 
 Blinding methods (if applicable)      YES/NO 
 Analysis approach       YES/NO 
o Intention to treat / per protocol / other 
Comments: 
 
Please indicate any further information you feel may be relevant: 
 
Please return completed form to:  
Professor A.G Marson, Co-ordinating Editor, Cochrane Epilepsy Group, Department of 
Molecular and Clinical Pharmacology, Institute of Translational Medicine,  Room 2.28, Clinical 






Appendix 12: Procedure for preparing a raw IPD dataset into an 
analysis ready dataset 
Context: Data is received via an e-mail attachment, CD, other portable device or via remote 
SAS data access system (ClinicalStudyDataRequest.Com) 
Stage 1: Initial general checks to make on the data in the format in which it 
is sent:  
1. Has all additional documentation required been provided with the data?  
o Documents: Protocols, Case Report Forms, Variable Labels or Formats etc. 
2. What format is/are the dataset(s) and accompanying documentation in?  
o Do the data and accompanying documents open?   
o Is any reformatting required? 
3. Is documentation and narrative text within the data written in clearly in English?  
o Translation may be required into English from authors or Cochrane translators.  
4. Has a single dataset been provided or multiple datasets?  
o If multiple datasets, how has the data been split? Can the datasets be linked with 
a Unique Identifier? 
5. Did the data provider previously complete an individual participant data request form to 
specify which data could be provided?  
a. If yes, does the data provider give data for all of the variables specified as 
available on the IPD request form or provide reasons why data is not available?  
b. Has sufficient data been provided to calculate outcomes? (i.e. randomisation 
date, withdrawal reason and date, last follow-up date, seizure dates following 
randomisation) 
6. Are variable labels with full and clear descriptions provided?  
o Does each column of data have a variable name and label? 
o Are clear labels given for coded/categorical variables?  
7. Is original or de-identified data provided? If data has been de-identified, are sufficient 
details provided of the de-identification?  
o For example, whether actual dates or offset dates are provided, do empty cells 
correspond to missing or redacted values?  
Action to take following checks 
 Contact with data providers will be required if: 
o Data does not open 
o Data is not in an appropriate format 
o Essential accompanying documentation is missing or if insufficient 
o Important data which was reported to be available is missing  
o Data is not clearly labelled or described. 
 Data which satisfies all of these checks (in the first instance or following contact with data 
providers) can now be imported into SAS and proceed with Stage 2 checking. 
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Stage 2: Checks on the content of the data (general): 
1. Has a unique identification number been provided for each participant in the dataset?  
o Is this the original randomisation number (or equivalent) or has a new number been 
produced for de-identification purposes?  
o If a new de-identified ID number is used, are details provided of how this number 
was generated? If not, no checks can be performed. 
o If the original number is used or a de-identified number has been produced which 
takes account of the original sequence: 
 Are any numbers missing from the sequence which may indicate excluded 
patients? 
 Does the randomisation sequence appear random? (i.e. no trends are present in 
participants being randomised to any of the drugs, baseline characteristics, 
prognostic factors are balanced across the allocations)  
2. For each variable start with exploratory analyses (range for continuous variables, 
frequencies in each category for categorical variable)  
o Are there any extreme (e.g. age of 100) or impossible (age of -1) values? 
o How much data is for missing each variable?  
o Will missing data for a given variable affect calculation of outcomes (e.g. missing 
seizure dates)?  
3. In comparison to any publications (journal article / clinical trials.gov entry etc.) or other 
related documents (protocols / clinical study reports etc.): 
o Is the same number of participants included in the publication / document provided 
in the dataset?  
o Does all information reported in publication/ document match what is provided in 
the data? For example 
 Inclusion and exclusion criteria 
 Enrolment / randomisation dates / other specified dates 
 Demographics and participant characteristics  
 Number of participants contributing to each outcome (exclusions etc.) 
 Number of participants randomised to each drug and doses started / achieved. 
o Can relevant results within the publication be recreated accurately (where possible 
with data provided)?  
 If not, why not? For example numerical differences between published results 
and IPD, unclear methods of analysis in publications etc.   
Action to take following checks 
 If data does not seem to follow a random sequence, enquire with the data provider 
regarding randomisation methods.  Data which is not truly random the data may not be 
able to be used.  
 If large amounts of missing data are present, particularly within variables needed to code 
outcomes, contact data provider for reasons of missingness:  
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o If missingness cannot be explained or data required cannot be provided for an 
outcome, the data cannot be included in the analysis of the outcome. 
 Contact data provider for clarification of numerical inconsistencies between published 
results and IPD or where published results cannot be recreated due to unclear 
methodology.  
 Make a list of ‘general’ inconsistencies (prioritising large numerical inconsistencies or 
those which influence calculation of outcomes) for the attention of the data provider.   
o This list will be combined with any queries or inconsistencies following Stage 3. 
Stage 3: Checks on the content of the data and initial coding of outcomes 
for the analysis dataset (clinically (epilepsy) specific): 
1. Checks to make on dates/ relative days (convert dates to relative days before and after 
randomisation if desired):  
o If provided, is date of birth the earliest date in the dataset? 
o If provided, is date of death the latest date in the dataset? 
o If provided, do all dates of seizures before randomisation occur before date of 
randomisation? 
o If provided, do follow-up dates / post randomisation visit dates occur after the date 
of randomisation?  
 Do follow-up dates occur in order? (E.g. follow-up 2 occurs after follow-up 1).  
 Do follow-up dates match (approximately) information reported in publications 
(e.g. follow-ups every six weeks)? 
 If any follow-up dates are missing, how is this recorded? For example if a 
participant misses follow-up visit 2 at 2 months but attends the third visit at 3 
months, is this visit recorded as visit 2 or visit 3 for this participant?  
o If provided, do all dates of seizures after randomisation occur after the date of 
randomisation?  
o If provided, does the date of withdrawal of allocated treatment occur after 
randomisation? 
 Is the date of withdrawal of allocated treatment also the last date in the dataset 
for all participants? If not, are dates recorded after treatment withdrawal (e.g. 
death, seizure dates for the participant on an alternative treatment)? 
2. Data provided relating to epilepsy diagnoses and seizure types: 
o Where results of pre-randomisation investigations are reported (EEG, CT, MRI, 
Neurological Signs): 
 Are results reported as normal / abnormal or are specific results given? 
 Where specific results are given are the results clearly described and clinically 
reasonable (consult AGM for assistance here if needed)? 
o Are all participants defined as ‘newly diagnosed’ (specified in dataset or 
publications)? 
 For trials also recruiting participants with relapsed seizures, are any concomitant 
antiepileptic drug treatments reported for these participants during the trial?   
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o Where seizures before randomisation are specified, did all participants have at least 
two seizures before randomisation or satisfy other specified diagnostic criteria of 
epilepsy?  
o Has the seizure type for all participants been classified before randomisation?  
 If applicable, are any participants over the age of 30 are classified as experiencing 
newly diagnosed generalised-onset seizures? 
 If types of seizures before randomisation are specified, do seizure types recorded 
before and after randomisation correspond?  
 Where generalised seizures are specified before randomisation, do all 
participants experience a generalised tonic clonic seizure with or without other 
generalised seizure types? Are other generalised seizure types only without 
other than tonic clonic seizures reported for any participants? 
3. Is sufficient information provided to calculate primary effectiveness outcome for all 
participants (time-to-withdrawal of allocated treatment)? 
o Date of withdrawal of allocated treatment / time spent on allocated treatment from 
randomisation.  
o Reason for withdrawal of allocated treatment in enough detail to allow a judgement 
whether the withdrawal was related to the allocated drug or not. 
4. Is sufficient information provided to calculate secondary efficacy outcomes for all 
participants (time-to-first seizure and time-to-6-month and 12 month remission)? 
o Dates / relative dates (e.g. study day) of seizure recurrences after randomisation 
(first seizure recurrence and subsequent seizure recurrences) 
o Numbers of seizures over a specific time period (between follow-up visits) 
o Total number of seizures during the follow-up period 
5. Adverse event / side effects (if provided) 
o How are adverse events recorded? Narratively as reported by participants or 
according to dictionary terms (e.g. MEDRA high level or low level terms)?  
o Are adverse events reported at each follow-up or overall across the whole study? 
o Is it specified when adverse events were ‘serious’ or led to treatment withdrawal? 
o Is it specified whether adverse events were likely to be directly caused by study drug? 
Action to take following checks 
 Enquire with data providers regarding any potentially wrong dates (e.g. follow-up data 
reported before randomisation or apparently outside the scope of the study) with 
inconsistencies of dates relating to outcomes (e.g. withdrawal or seizure dates) taking 
priority.  
 Enquire with data provider regarding any uncertainties regarding diagnosis of epilepsy 
and classification of seizure type. Particularly note where potentially:  
o Participants may not have had a certain diagnosis of epilepsy 
o Participants may not be treated with monotherapy  
o Participants were not experiencing either partial-onset or generalised-onset tonic 
clonic seizures with or without other seizure types 
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o Participants over the age of 30 were experiencing new onset generalised seizures or 
seizures of both partial and generalised types.  
 Is enough data provided for the calculation of appropriate outcomes? If not, enquire with 
data providers for additional information. 
 Enquire with data providers regarding any uncertainties or inconsistencies regarding 
adverse events, particularly serious adverse events and/or those resulting in treatment 
withdrawal. 
Make a list of specific inconsistencies (by order of magnitude and importance) for the 
attention of the data provider to be combined with any enquiries from Stage 2. In order of 
priority:  
1. Enquiries relating to variables used in the calculation of outcomes 
2. Large inconsistencies within other variables in the dataset (compared to 
publications) 
3. Any other enquiries 
Data which satisfies all checks and is sufficient for analysis (in the first instance or following 
clarification from data provider) can now be used to calculate outcomes for analysis. 
Note: If inconsistencies remain following clarification with data provider which cannot be 
resolved, discuss the magnitude of inconsistencies with AGM and CTS before proceeding to 
Stage 4. 
Stage 4: Coding of effectiveness and efficacy outcomes 
Primary outcome: Time-to-withdrawal of allocated treatment  
Two variables are to be calculated: 
 Time-to-withdrawal of allocated treatment = ‘withtime’ 
 Censoring indicator for withtime = ‘wcens’  
Coding ‘Time-to-withdrawal of allocated treatment’ 
1. The following reasons for withdrawal are classed as ‘events’ in time-to-event analysis 
(drug related withdrawals) and the censoring indicator wcens = 1; 
a. Recurrent seizures, lack of efficacy etc. 
b. Intolerable adverse events, side effects, poor tolerability etc. 
c. Combination of lack of efficacy and poor tolerability 
d. Non-compliance, poor compliance, patient choice etc. 
e. Any other reason described as related to the allocated drug 
If wcens=1 and both date of withdrawal and date of randomisation are not missing: 
Withtime = Date of withdrawal – Date of randomisation 
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2. The following reasons for withdrawal are classed as ‘censored’ in time-to-event analysis 
(withdrawals not related to the study drug) and the censoring indicator wcens = 0; 
a. Completed the study without withdrawing from treatment 
b. Loss to follow-up 
c. Remission of seizures 
d. Death (for reasons not related to study drug)  
e. Any other reason not related to the study drug 
If wcens=0 and participant completed the study without withdrawing (reason a):  
Withtime = Study duration  or   
Withtime = Date of last follow-up – Date of randomisation 
If wcens=0 and participant withdrew for a reasons not related to the study drug (reasons b 
to e): 
Withtime = Date of withdrawal/last follow-up – Date of randomisation 
Points to consider when coding this outcome 
 If all participants completed the study, time-to-withdrawal of allocated treatment cannot 
be calculated. 
 If reason for withdrawal, date of withdrawal / last follow-up or date of randomisation are 
missing (following clarification from data providers, see Stage 3), wcens and/or withtime 
are classed as missing for the participant   
 Where any minor inconsistencies exist between data and publication results (reported 
number of withdrawals or reasons) or unclear reasons for withdrawal are documented 
which could not be resolved by data provider in Stage 3; if assumptions are made (e.g. 
whether to class a reason for withdrawal as event or censored), perform sensitivity 
analysis to test robustness of results. 
Efficacy outcomes: Seizure and Remission outcomes  
Six new variables are to be calculated:  
 Time-to-first seizure after randomisation = ‘seztime’ 
 Censoring indicator for seztime = ‘scens’  
 Time-to-12-month remission = ‘remtime’ 
 Time-to-6-month remission = ‘remtime6’ 
 Censoring indicator for remtime = ‘rcens’  
 Censoring indicator for remtime6 = ‘rcens6’ 




Example (with seizure dates provided): 
ID Seizure1 Seizure2 Seizure3 Seizure4 Seizure5 Seizure6 
101       
102 01/01/2010 04/01/2010 22/01/2010 26/01/2010 05/06/2010 01/09/2010 
103 06/06/2010 01/01/2011 03/04/2011    
 
Example (no seizure dates provided): 
ID Visit1 Seizures Visit2 Seizures Visit3 Seizures 
111 01/02/2010 0 01/03/2010 0 01/06/2010 0 
112 22/01/2010 2 25/03/2010 1 02/07/2010 0 
113 01/06/2010 5 05/07/2010 1 01/12/2010 1 
 
Therefore data in “long” format (below) must be reshaped to “wide” format (use PROC 
TRANSPOSE in SAS, reshape in Stata or reshape() in R) 
Example (with seizure dates provided)  Example (no seizure dates provided)  
ID Seizuredate  ID Visitdate Seizures 
102 01/01/2010  111 01/02/2010 0 
102 04/01/2010  111 01/03/2010 0 
102 22/01/2010  111 01/06/2010 0 
102 26/01/2010  112 22/01/2010 2 
102 05/06/2010  112 25/03/2010 1 
102 01/09/2010  112 02/07/2010 0 
103 06/06/2010  113 01/06/2010 5 
103 01/01/2011  113 05/07/2010 1 
103 03/04/2011  113 01/12/2010 1 
 
Coding time-to-first seizure before randomisation  
If no seizure recurrence occurs at any point during follow-up, the participant is censored for 
this outcome and scens=0  
Seztime = Date of last follow-up – Date of randomisation 
If a seizure occurs at any point during follow-up, an event has occurred for this outcome and 
scens=1.  
1. Calculation of seztime if scens =1 and seizure dates are provided 
Sort seizure dates into ascending order and minimum date is the date of first seizure 




2. Calculation of seztime if scens =1 and seizure dates are not provided 
Calculation of the following variables is needed for the following steps 
 Total number of seizures in time period X = ‘totalsezX’ 
o Sum of all seizures in the time period (including if seizures split by seizure 
type) 
 Total number of seizures in the whole study = ‘totalsez’ 
o Sum of all seizures in the study (including if seizures split by seizure type) 
 Follow-up time in days of time period X = ‘fuX’ 
o fuX = Date of fu(X) – Date of Randomisation 
 Time between follow-up visits in days = ‘futimeX’ 
o futimeX= Date of fu(X) – Date of fu(X-1) where Date of fu(0) is date of 
randomisation 
o futimeX=Last day of fu(X) – first day of fu(X) 
 
a. Number of seizures over a specified time period X (e.g. between follow-up visits) is 
given  
 
o Calculate approximate seizure times during the time period X by assuming a uniform 
distribution of seizure times across time period X (rounded up to the nearest day): 
Days been seizures in time period X (sezrateX) = CEILING (futimeX / (totalsezX +1)) 
For example: over follow-up period 1 from 01/01/2010 to 17/01/2010 (16 days), 3 seizures 
occurred 
sezrate1 = CEILING (16/ (3+1))) = 4 days – i.e. a seizure occurred every 4 days 
o For n seizures occurring during time period X, the dates of the seizure i where i=1…n : 
sezdateX(i) = sezdateX(i-1)+sezrateX  where sezdateX(0) is the first day of time period X 
For example: over follow-up period 1 from 01/01/2010 to 17/01/2010 (16 days), 3 seizures 
occurred 
sezdate1(1) = 01/01/2010 + 4 days = 05/01/2010 
sezdate1(2) = 05/01/2010 + 4 days = 09/01/2010 
sezdate1(3) =09/01/2010 + 4 days = 13/01/2010 
o Date of first seizure (first seizure) is the minimum date across all time periods (1, 2, …, N)  
 
Firstsez = minimum (sezdate1(1), sezdate1(2), …, sezdateX(i))   
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Seztime = Date of first seizure after randomisation (firstsez) – Date of 
randomisation 
 
b. Total number of seizures across the whole study duration are given  
 
o Calculate approximate seizure times, assuming uniform distribution of seizure times 
across the whole study duration (rounded up to the nearest day): 
sezrate=CEILING (study duration / (totalsez +1)) 
For example over a 24 week study (168 days from 01/02/2011 to 19/07/2011), 3 seizures 
occurred 
sezrate=CEILING (168/ (3+1)) = 42 days – i.e. a seizure occurred every 42 days 
o For n seizures occurring over the study duration, the dates of the seizure i where i=1…n 
: 
sezdate(i) = sezdate(i-1)+sezrate  where sezdateX(0) is the first day of time period X 
For example over a 24 week study (168 days from 01/02/2011 to 19/07/2011), 3 seizures 
occurred 
sezdate(1) = 01/02/2011 + 56 days = 15/03/2011 
sezdate(2) = 15/03/2011 + 56 days = 26/04/2011 
sezdate(2) = 26/04/2011 + 56 days = 07/06/2011 
o Date of first seizure (first seizure) is the minimum date across all time periods (1, 2, …, N)  
 
Firstsez = minimum (sezdate(1), sezdate(2), …, sezdate(i))   
Seztime = Date of first seizure after randomisation (firstsez) – Date of 
randomisation 
 
c. If seizure recurrence status is reported over a specified time period X (e.g. seizure-free 
since last follow-up, yes or no) 
 
o Calculate approximate first seizure time (sezday) during time period X, assuming uniform 
distribution of seizure times across the time period X (rounded up to the nearest day): 
SezdateX= CEILING (fuX + (futimeX/2)) 
For example seizure-free up to 3 weeks (21 days between 01/09/2012 and 22/09/2012) and 
seizure recurrence happened in week 4 (7 days between 23/09/2012 and 30/09/2012). 
SezdateX=CEILING (21 + (7/2)) = 24days – i.e. on the 24/09/2012 
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o Date of first seizure (first seizure) is the minimum date across all time periods (1, 2, …, N)  
 
Firstsez = minimum (sezdate1, sezdate2, … , sezdateN)   
Seztime = Date of first seizure after randomisation (firstsez) – Date of 
randomisation 
 
Coding time to remission of seizures after randomisation (6 and 12 month remission). 
The following steps calculate 12 month remission but can also be extended to a remission 
period of 6 months or any other length by replacing 365 days with the required number of 
days of remission. 
Calculation of the following variable is needed: 
Follow-up time (maxfu) = Date of last follow-up – date of randomisation 
1. If participant has less than 12 months follow-up (i.e. maxfu < 365 days) 
The participant is censored for the outcome (cannot achieve 12 month remission); rcens=0 
and remtime=maxfu 
2. If participant has at least 12 months follow-up and no seizure recurrence during 
the trial 
The participant has an event for the outcome (immediate remission); rcens=1 and 
remtime=365 
3. If participant has at least 12 months follow-up and one-or-more seizures during the 
trial 
Using exact seizure dates / days provided (or estimates where number of seizures are 
provided using steps 2a – 2c described in the coding of ‘time-to-first seizure’) sorted into 
ascending order across all time periods, calculate the time between each seizure during the 
trial (i = 0…n, where n is the last seizure) : 
Time between seizures (sezdiff(i))=sezdate (i+1)- sezdate(i) 
Note that  sezdiff(0) = sezdate(1) – date of randomisation  
Note that sezdiff(n) = Maxfu – sezdate(n) 
Calculate the maximum difference (maxdiff) between seizure times: 
maxdiff = maximum (sezdiff(0), sezdiff(1)… sezdiff(n)) 
o If maxdiff less than 365 then the participant does not have a remission period of at least 
365 days during the trial; rcens=0 and remtime=maxfu 
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o If maxdiff is at least 365 then the participant does have a remission period of at least 365 
days; rcens=1 
 For each participant, identify the first time between seizures (sezdiff (i)) greater 
than 365; by sorting sezdiff (i) variables or by manual inspection. Let sezdiff(j) be 
the first time between seizures greater than 365: 
Remtime=sezdate(j)+365 
Points to consider when coding these outcomes (first seizure and reemission) 
 If no participants experienced seizure recurrence, time-to-first seizure cannot be 
calculated 
 If the duration of the study was less than 6 or 12 months, time to 6 and 12 month 
remission respectively cannot be calculated 
 If all data on seizure recurrence, all follow-up dates or date of randomisation is 
missing, the participant is excluded from analyses.  
 If relative study days are provided rather than dates (e.g. seizures occurred on day 5, 
10, 15 etc. of the study) then ‘firstsez’ and ‘seztime’ are equivalent. 
 If any minor inconsistencies exist between data and publication results (reported 
number of seizure recurrences etc.) which cannot be resolved by the data provider, 
or if seizure data required for the calculation of outcomes is missing, censor 
outcomes at the time of last follow-up. Consider sensitivity analysis excluding these 
participants from analysis and/or assuming seizure recurrence occurs during earlier 
or subsequent time periods. The presence of missing data may require visual 
inspection to judge whether remission occurred. 
 Where exact seizure recurrence dates are not available and seizure dates are 
estimated (using methods 2 a – 2c outlined above in the coding of ‘time-to-first 
seizure’, consider sensitivity analysis (for example, assuming seizure recurrence time 




Stage 5: Adding new data into the Epilepsy IPD master dataset 
The analysis ready dataset has the following variables, create an analysis dataset for the new 
data with as many of the following variables as possible: 
Note: Missing data is indicated by  `  .  ‘  for all variables.   
TRIALNO = Unique patient identifier for each participant in each trial (may be original or de-
identified ID provided with data, or a new unique ID created)  
TRIAL = Trial number assigned to each trial (see assignment list prepared by SJN) 
RAND = Date of randomisation 
DRUG= Randomised drug (labelled from 1 – 10)    
1= Carbamazepine (CBZ)    2= Phenobarbitone (PHB)    
3= Phenytoin (PHT)    4= Sodium Valproate (VPS)   
5= Lamotrigine (LTG)      6= Oxcarbazepine (OXC)   
7= Levetiracetam (LEV)     8= Topiramate (TPM)     
9= Gabapentin (GBP)     10 Zonisamide (ZNS)     
Outcome variables created in Stage 4 
WITHTIME = Time-to-withdrawal of allocated treatment     
WCENS = Withdrawal censoring indicator (1 = event, 0= censored)  
REMTIME = Time-to-12-month remission       
RCENS = 12 month remission censoring indicator (1 = event, 0= censored) 
REMTIME6= Time-to-6-month remission  
RCENS6 = 6 month remission censoring indicator (1 = event, 0= censored)   
SEZTIME = Time-to-first seizure after randomisation 
SCENS = First seizure censoring indicator (1 = event, 0= censored)  
Demographic variables (if data provided, further coding may be needed from original 
dataset) 
AGE = age at randomisation 
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SEX = Gender (1 = female, 0 = male) 
EPTYPE= Epilepsy Type (1 = partial, 0 = generalised)  
EPTYPE2 = Epilepsy Type Reclassified (participants with generalised seizures and age of 
onset over 30 years reclassified to partial - 1 = partial, 0 = generalised)     
EPTYPE3 = Epilepsy Type Reclassified (participants with generalised seizures and age of 
onset over 30 years and participants with missing seizure type reclassified to unknown 
seizure type – 2 – unknown,  1 = partial, 0 = generalised)   
NEURSIGN=Presence of Neurological Signs (1 = Yes, 0 = No)  
EEG = EEG results (1 = abnormal 0 = normal)   
SCAN= MRI / CT results (1 = abnormal 0 = normal)   
TIMESZD = Time from first (ever) seizure to nearest day to randomisation (calculated in a 
similar manner to ‘time-to-first seizure, see Stage 4)  
TIMESZY = Time from first (ever) seizure to nearest year to randomisation (calculated in a 
similar manner to ‘time-to-first seizure, see Stage 4)  
NUMSEIZ = Number of seizures 6 months prior to randomisation  
Example of analysis ready data  
 
Screenshot taken from SAS 9.3 of analysis ready data for Cochrane Epilepsy Individual 
Participant Data Network Meta-Analysis  
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Appendix 13: Example data structure for NMA in Chapter 6 
Method described in Chapter 6 and Chapter 8 reduce IPD to summary statistics, with the 
overall objective of being able to incorporate aggregate data with IPD in NMA. Summary 
statistics estimated from IPD from each study were then combined in separate NMAs by 
epilepsy type as if they were aggregate data.  
Table 44: Example structure of a dataset in ‘pairs’ format in Stata version 14.  
Id loghr seloghr drug1 drug2 eptype 
trial 1 0.651982 0.467607 CBZ PHB partial 
trial 1 0.235209 0.449843 CBZ PHB generalised 
trial 1 0.064524 0.490908 CBZ PHT partial 
trial 1 -1.21468 0.667371 CBZ PHT generalised 
trial 1 -0.05105 0.519561 CBZ VPS partial 
trial 1 0.140863 0.451576 CBZ VPS generalised 
trial 1 -0.58746 0.450693 PHB PHT partial 
trial 1 -1.44989 0.651693 PHB PHT generalised 
trial 1 -0.70303 0.484911 PHB VPS partial 
trial 1 -0.09435 0.427372 PHB VPS generalised 
trial 1 -0.11558 0.505825 PHT VPS partial 
trial 1 1.355542 0.651716 PHT VPS generalised 
trial 2 1.711753 0.60801 CBZ PHB partial 
trial 2 0.794814 0.592827 CBZ PHB generalised 
trial 2 0.241746 0.425658 CBZ PHT partial 
trial 2 -0.58901 0.548477 CBZ PHT generalised 
trial 2 0.227631 0.460312 CBZ VPS partial 
trial 2 -0.02997 0.479234 CBZ VPS generalised 
trial 2 -1.47001 0.590079 PHB PHT partial 
trial 2 -1.38382 0.673133 PHB PHT generalised 
trial 2 -1.48412 0.610886 PHB VPS partial 
trial 2 -0.82478 0.62 PHB VPS generalised 
trial 2 -0.01412 0.442092 PHT VPS partial 
trial 2 0.559036 0.573396 PHT VPS generalised 
trial 3 0.450873 0.177159 CBZ PHB partial 
trial 3 0.183851 0.179511 CBZ PHT partial 
trial 3 -0.26702 0.162971 PHB PHT partial 
trial 4 -0.03332 0.154534 CBZ VPS partial 
trial 5 0.190944 0.311932 CBZ VPS partial 
trial 5 -0.61638 0.353263 CBZ VPS generalised 
trial 6 -0.02297 0.353657 CBZ VPS partial 








This was achieved by producing a dataset of the summary statistics structured as a list of pairwise comparisons and converted from ‘pairs’ to ‘augmented’ 
format via the ‘network’ command within Stata version 14 [310]. In other words, the following code was applied to the data in Table 44 which produced a 
dataset of the format in Table 45: 
network import, tr(drug1 drug2) eff(loghr) study(id) stderr(seloghr) 
network convert augmented 
Table 45: Example structure of a dataset in ‘augmented’ format in Stata version 14.  
id eptype logvar _design loghr_2 loghr_3 loghr_4 _S_2_2 _S_2_3 _S_2_4 _S_3_3 _S_3_4 _S_4_4 
trial 1 partial 0.255859 1 2 3 4 0.651982 0.064524 -0.05105 0.218656 0.128262 0.126731 0.240991 0.127538 0.269944 
trial 1 generalised 0.424734 1 2 3 4 0.235209 -1.21468 0.140863 0.202359 0.111519 0.111816 0.445384 0.112285 0.203921 
trial 2 partial 0.195445 1 2 3 4 1.711753 0.241746 0.22763 0.369676 0.101334 0.104191 0.181185 0.098814 0.211887 
trial 2 generalised 0.328783 1 2 3 4 0.794813 -0.58901 -0.02997 0.351444 0.099581 0.098355 0.300827 0.100854 0.229665 






trial 4 partial 0.023881 1 4 
  
-0.03332 
     
0.023881 
trial 5 partial 0.097302 1 4 
  
0.190944 
     
0.097302 
trial 5 generalised 0.124795 1 4 
  
-0.61638 
     
0.124795 
trial 6 partial 0.125073 1 4 
  
-0.02297 
     
0.125073 
trial 6 generalised 0.149023 1 4 
  
0.306479 
     
0.149023 
Subsequently, NMA was performed via the ‘network meta’ command. 
 303 
 
Appendix 14: Additional analysis and sensitivity analyses of IPD-NMA 
performed to account for inconsistencies in IPD (Chapter 7) 
The following sensitivity analyses were performed where minor inconsistencies were 
identified when preparing IPD for analysis (see Chapter 5.3.3 and Appendix 12). See Chapter 
7.1.3 for full details of other additional and sensitivity analyses performed. 
 In Stephen 2007, there were minor inconsistencies between rates of seizure recurrence 
and reasons for withdrawal between the data provided and the publication, which could 
not be resolved with the original trial authors. Therefore, a sensitivity analysis was 
performed excluding Stephen 2007 from all analyses. 
 In Reunanen 1996, participants were considered to have completed the trial and hence 
treatment was withdrawn if they experienced a seizure after week six. This does not 
correspond with the treatment withdrawal definition used in this review and analysis 
(see Chapter 5.3.3.2). Therefore a sensitivity analysis was performed excluding Reunanen 
1996 for the analysis of 'Time-to-withdrawal of allocated treatment.' 
 In Banu 2007, there were minor inconsistencies between rates of seizure recurrence 
between the data provided and the published paper, which could not be resolved. 
Therefore, a sensitivity analysis was performed excluding Banu 2007 from analysis of 
'Time-to-first seizure.' (Data provided was insufficient to contribute to outcomes time-
to-6-month remission and time-to-12-month remission, see Chapter 5.4.3).  
 In Nieto-Barrera 2001, seizures that occurred during the first four weeks of the trial were 
not included in efficacy analyses and dates of seizures before week four were not 
provided. Therefore, ‘time-to-first seizure’ was calculated after week four rather than 
after randomisation and a sensitivity analysis was performed excluding Nieto-Barrera 
2001 from analysis of 'time-to-first seizure' (this trial was 24 weeks duration so did not 
contribute to outcomes time-to-6-month remission and time-to-12-month remission). 
 In Placencia 1993, there were minor inconsistencies between reasons for withdrawal 
between the data provided and the published paper. In the primary analysis, withdrawals 
were classified according to the reasons provided in IPD and a sensitivity analysis was 
performed for analysis of 'time-to-withdrawal of allocated treatment' with withdrawals 





Results of additional and sensitivity analyses 
Figure 19: Time-to-withdrawal of allocated treatment and time-to-first seizure adjusted 
for age (partial seizures) 
 
Figure 20: Time-to-withdrawal of allocated treatment and time-to-first seizure adjusted 













Figure 23: Time-to-withdrawal of allocated treatment and time-to-first seizure, Stephen 
2007 excluded (partial seizures) 
   
Figure 24: Time-to-withdrawal of allocated treatment and time-to-first seizure, Stephen 




Figure 25: Time-to-withdrawal of allocated treatment, Reunanen 1996 excluded (both 
seizure types) 
 





Figure 27: Time-to-first seizure, Banu 2007 excluded (both seizure types) 
 




Figure 29: Time-to-withdrawal of allocated treatment and time-to-first seizure, seizure 
type reclassification 1 (see Notes below, results for individuals with partial seizures) 
 
Figure 30: Time-to-withdrawal of allocated treatment and time-to-first seizure, seizure 





Figure 31: Time-to-withdrawal of allocated treatment and time-to-first seizure, seizure 
type reclassification 2 (see Notes below, results for individuals with partial seizures) 
 
Figure 32: Time-to-withdrawal of allocated treatment and time-to-first seizure, seizure 




Figure 33: Time-to-withdrawal of allocated treatment, seizure type reclassification 1 with 
random-effects (see Notes below, both seizure types) 
 
Notes 
See Appendix 10 for references of the trials included in the Cochrane IPD-NMA and Chapter 
5.2.1.3 for abbreviations of drugs. 
Results shown on all figures are those from NMA (direct and indirect evidence combined).  
Generalised tonic-clonic seizures with or without other seizure types is shortened to 
'Generalised seizures' for brevity 
Reclassification 1: Re-classification of 1,164 individuals with generalised seizures and age of 
onset greater than 30 years as having partial-onset seizures. 
Reclassification 2: Re-classification of 1,164 individuals with generalised seizure and age at 
onset greater than 30 years and 574 individuals with missing seizure type to 'unclassified 








Appendix 15: Additional results of the IPD-NMA: time to 12 month and time to 6 month remission 
















Appendix 16: Investigation of inconsistency in Chapter 7 
All figures present direct evidence (from pairwise meta-analysis), indirect evidence (from node-splitting) and NMA results. 














































































































































Appendix 17: Additional results from Chapter 7 
Figures presented within this Appendix show NMA results for all pairwise comparisons for 
the additional analyses described in Chapter 8.   
See Appendix 10 for references of the trials included in the Cochrane IPD-NMA and Chapter 
5.2.1.3 for abbreviations of drugs.  
Results shown on all figures are those from NMA (direct and indirect evidence combined).  
Generalised tonic-clonic seizures with or without other seizure types is shortened to 
'Generalised seizures' for brevity 



























Figure 59: NMA results of IPD reduced to summary statistics for all individuals regardless of 










Appendix 18: Published work from this thesis 
A full list of publications and presentations of work in this thesis is provided at the start of 
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